Strategies to improve vascular access outcomes in haemodialysis patients by Viecelli, Andrea Katharina
  
 
 
 
 
 
 
Strategies to Improve Vascular Access Outcomes in Haemodialysis Patients 
  
Andrea Katharina Viecelli 
MD, FRACP 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2019 
Faculty of Medicine 
 
I 
 
Abstract  
 
It is estimated that over 3 million people worldwide are currently treated for end-stage kidney 
disease, with most receiving haemodialysis (HD). A functioning vascular access (VA) provides a 
lifeline for patients requiring HD but VA dysfunction remains one of the leading causes of 
excessive morbidity, mortality and healthcare costs in this group. Despite increasing numbers of 
VA trials, successful interventions to improve VA outcomes have been sparse and compromised 
by highly variable, often selectively reported outcomes of limited relevance to patients and health 
professionals. 
This thesis aimed to establish strategies to improve VA outcomes by 1) determining whether fish 
oil or aspirin is effective in improving outcomes of newly created arteriovenous fistulas (AVFs); 
and, 2) establishing a standardised core outcome measure for VA based on the shared priorities of 
patients and health professionals to improve the consistency, reliability and relevance of VA 
research in HD.  
Aim 1 was addressed with an international, double-blind, randomised, placebo-controlled trial 
entitled, “omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal 
Disease” (FAVOURED). It included 567 adult participants planned for AVF creation who were 
randomised to fish oil (4g/d) or placebo. Of these, 406 participants were also randomised to aspirin 
(100mg/d) or placebo. Treatment started 1 day pre-surgery and was continued for 12 weeks. The 
primary outcome was AVF failure (a composite of thrombosis and/or abandonment and/or 
cannulation failure) at 12 months. Secondary outcomes included the primary outcome components, 
AVF interventions, and central venous catheter (CVC) requirement. The FAVOURED study 
revealed that 12 weeks of fish oil did not reduce the proportion of AVF failure compared to placebo 
(47% versus 47%, relative risk [RR] adjusted for aspirin use 1.03, 95% confidence interval [CI] 
0.86-1.23) or its outcome components. Low-dose aspirin was similarly ineffective. However, fish 
oil was effective in reducing AVF intervention rates (0.82 vs 1.14 interventions/1000 patient-days, 
incident rate ratio [IRR] 0.72, 95% CI 0.54-0.97), driven by a significant relative reduction in 
rescue interventions for thrombosis by 47%. Similarly, low-dose aspirin significantly reduced 
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rescue intervention rates by 55%. Neither fish oil nor aspirin reduced the frequency or duration of 
CVC requirements compared to placebo. 
FAVOURED trial results were then included in a meta-analysis of randomised controlled trials 
(RCTs) to determine the efficacy and safety of fish oil supplementation to prevent complications 
of arteriovenous fistulas and grafts. Based on meta-analysis of five RCTs (833 participants) 
comparing fish oil supplementation with placebo, fish oil prevented primary patency loss with 
moderate certainty (761 participants, RR 0.81, CI 0.68-0.98) but may have had little or no effect 
on other VA outcomes or mortality and uncertain effects on bleeding risk and gastrointestinal side-
effects. No treatment effect differences were observed between grafts and fistulas. 
Aim 2 was achieved through the global Standardised Outcomes in NephroloGy (SONG) Initiative, 
which aims to establish core outcomes that are critically important to patients with kidney disease 
and health professionals using a multi-step evidence- and consensus-based process. Vascular 
access was identified as one of four core outcome domains for haemodialysis along with 
cardiovascular disease, fatigue and death. The core outcome measure for VA was established by 
initially conducting a systematic review of 168 RCTs that identified 23 VA outcomes, based on 
more than 1400 outcome measures. Vascular access function was the most frequently reported 
outcome (81% of trials) followed by infection (38%). A subsequent multi-language survey 
completed by 873 participants (26% patients/caregivers and 74% health professionals) from 58 
countries confirmed function to be the top critically important outcome. Themes from this survey 
and an international multi-stakeholder consensus workshop indicated that function was considered 
the core outcome for VA based on its broad applicability to all access types and its critical impacts 
on quality of life, survival and various access-related outcomes. ‘The rate of interventions to 
maintain VA use for HD’ was considered a pragmatic and feasible outcome measure for VA 
function that was meaningful to patients and clinicians. The feasibility and reliability of this 
proposed core outcome measure will now be assessed in an international, prospective validation 
study to facilitate global implementation in research and clinical practice.  
In conclusion, the FAVOURED study found that neither fish oil nor aspirin significantly reduced 
the primary binary composite outcome of AVF failure, but that each agent may reduce intervention 
rates in newly created AVFs. Through the SONG initiative, function defined by intervention rate 
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was found to be the most important VA outcome based on the shared priorities of patients and 
health professionals. Consistent reporting of VA function in all studies in haemodialysis through 
global implementation of the SONG VA core outcome will maximise the opportunity to further 
explore and either confirm or refute the possible treatment benefits of fish oil or aspirin in 
improving VA function. It will also help to foster discovery of other effective interventions for 
improving VA function in HD patients.  
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1.1 Chapter overview 
It is estimated that more than 3 million people worldwide receive treatment for end-stage kidney 
disease (ESKD) and numbers are expected to rise sharply related to aging of the population and 
increasing prevalence of diabetes and cardiovascular comorbidities2. Haemodialysis (HD) remains 
the most common renal replacement therapy worldwide and requires functioning long-lasting 
vascular access. A functioning vascular access is an important determinant of the well-being and 
survival of patients on HD and has been referred to as both, the lifeline and Achilles’ Heel of 
HD3,4. Establishing and maintaining a functioning access, however, is one of the greatest 
challenges in caring for HD patients. Vascular access related complications are associated with 
increased patient morbidity and mortality and account for 20-25% of annual hospital admissions 
in these patients5-7. From a patient’s perspective, the experience and anticipation of vascular access 
complications are key sources of stress and can lead to anxiety about the potential for failure8. 
Improving vascular access outcomes is therefore considered a critical priority not only by patients, 
but also their caregivers and health professionals9-11.  
There is a paucity of evidence to guide best strategies to prevent vascular access failure and large-
scale clinical trials evaluating interventions to improve vascular access outcomes are urgently 
needed. There is also a need for global use of standardised outcome measures for vascular access 
complications that are relevant to patients, their families and clinicians to enhance the applicability, 
comparison and interpretation of trial results and to help guide clinical practice.  
The proposed research project aimed to establish: (i) strategies to improve vascular access 
outcomes by exploring systemic medical interventions to improve outcomes of newly formed 
arteriovenous fistulas (AVFs), the preferred long-term vascular access; and (ii) a standardised 
outcome measure for vascular access that is considered most critically important by patients and 
health professionals and ideally is reported in all clinical trials in HD to help improve the 
consistency, reliability, relevance and meaningfulness of research outcomes to guide patient-
centred care.  
This chapter provides context for this research project by describing the different HD vascular 
access types and their use, the pathophysiology of vascular access failure focusing on 
arteriovenous accesses (i.e. fistulas and grafts), and the reasons for and outcomes of systemic 
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medical interventions that have been trialled to prevent arteriovenous access failure. Additionally, 
this chapter will highlight the need for consistent reporting of vascular access outcomes that are 
important to patients and their clinicians to inform clinical practice in a meaningful way and 
introduce current initiatives that address this issue. Finally, the aims of this thesis will be detailed 
and an overview of the thesis structure provided.  
1.2 Included publication 
Sections 1.5 to 1.7 of this chapter were adapted from a narrative review published in the Seminars 
in Dialysis. 
Viecelli AK, Mori TA, Roy-Chaudhury P, Polkinghorne KR, Hawley CM, Johnson DW, Pascoe 
EM, Irish AB. The pathogenesis of hemodialysis vascular access failure and systemic therapies 
for its prevention: Optimism unfulfilled. Semin Dial. 2018;(3):244-257. Reproduced with 
permission. 
The candidate was the lead author of this narrative review. The candidate performed the literature 
search and review, data analysis and interpretation, designed tables and figures, drafted the 
manuscript and integrated feedback and revisions from co-authors into a final version. 
1.3 Haemodialysis access types 
Vascular access can be obtained by use of a native (autologous) AVF, a synthetic (most commonly 
polytetrafluroethylene [PTFE]) interposition graft between artery and vein (AVG) or a central 
venous catheter (CVC) as shown in Figure 1-1. 
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Figure 1-1: Haemodialysis vascular access types: Arteriovenous fistula (top left), arteriovenous 
graft (top right), and central venous catheter (bottom), reproduced with permission from ©Mike 
Austin, Internal Art Medical Illustration. 
5 
 
Based on national practice guidelines12-14, the sites of AVF placement in order of preference are 
(1) radiocephalic (wrist/forearm), (2) brachiocephalic (elbow), and (3) a transposed brachiobasilic 
fistula if the former two are not possible to create13,14 (Figure 1-2). If upper limb options are 
exhausted, an AVF in the lower limb may be considered15,16.  
If an AVF cannot be established, a synthetic graft is recommended with the preferred site and type 
being a curved looped radiocephalic graft followed by an upper arm straight graft. Forearm straight 
radial cephalic and looped thigh grafts are alternative, but less favoured options14,17. Placement of 
a CVC is least desirable for HD due to the highest associated complication rates, but necessary 
when an AVF or AVG has not been created, is not feasible, or not ready for use13,14,18. 
Radiocephalic AVF Brachiocephalic AVF 
Transposed brachiobasilic 
AVF 
  
 
Figure 1-2: The three basic sites of an arteriovenous fistula placement (adapted from Allon M and 
Robbin ML19 reproduced with permission) 
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1.4 Vascular access choice 
Arteriovenous fistulas are recommended as the preferred vascular access by national clinical 
practice guidelines and initiatives12-14,18,20-23 due to their longevity and lower rates of thrombosis, 
infection, interventions to maintain patency and overall mortality when compared with AVGs and 
CVCs24-26. However, AVFs require a longer maturation time before use and have a higher risk of 
early failure compared to AVGs27. Arteriovenous fistula maturation failure has been reported to 
range between 9% and 70% with a meta-analysis showing that 23% (95% confidence interval [CI] 
18% to 28%) of AVF never become suitable to support HD as a result of early thrombosis or 
maturation failure19,28-30. Compared to a functioning AVF, AVGs have a lower primary failure rate 
but have a higher risk of thrombosis and require more interventions to maintain patency27. More 
than half of all AVGs will thrombose within the first year after creation and over 75% will require 
a salvage procedure resulting in significant health costs31. Frequently, patients with AVF and AVG 
complications will require temporary placement of a CVC, which is the least desirable type of 
vascular access due to significantly higher rates of catheter-associated bacteraemia, fatal infections 
and cardiovascular events, inadequate solute clearance and all-cause mortality24,25,32,33.  
Arteriovenous access (i.e. AVF and AVG) failure remains a major barrier to decreasing the use of 
CVCs, particularly in patients initiating HD. In Australia, 86% of prevalent patients received HD 
via an arteriovenous access, yet the majority of patients initiated dialysis with a CVC (42-44%) 
between 2014 and 201634. Similarly, 68-73% of patients in New Zealand initiated HD with a CVC, 
while only 22% used a CVC long-term during the same time period34. Based on an international 
cross-sectional comparison of vascular access types in use in 2013 from the Dialysis Outcomes 
and Practice Patterns Study (DOPPS), Australia and New Zealand had some of the lowest 
proportions of CVC use, comparable to those of most European countries (e.g. the United 
Kingdom [UK], Turkey, Germany) and the United States [US] and less than a third of that seen in 
Canada35. In contrast, CVC use in the incident HD populations of Australia and New Zealand 
remained substantially higher compared to most European countries and Japan, where the 
proportions of CVC use within the first 60 days of HD initiation were as low as 11% (Japan)35. 
Over the last two decades, the promotion of a “fistula first and catheter last” approach through 
national initiatives and guidelines10-12,17,19-22 has led to a successful increase in AVF use and a 
concurrent decrease in CVC use in the prevalent dialysis population of countries with historically 
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lower AVF rates. For example, in the US, the use of AVFs increased from 24% in 1997 to 68% in 
201335. However, the proportion of patients initiating dialysis via an AVF, as opposed to a CVC, 
had not increased to the same extent. This highlighted the urgent need for optimisation of pre-
dialysis care and effective interventions to reduce early AVF failure to ensure timely usability of 
the AVF at dialysis initiation without the need of a CVC. 
Over the past four decades, significant progress has been made in the understanding of vascular 
access biology and techniques for creating and maintaining an arteriovenous access for HD. The 
following section will describe i) the current understanding of the pathogenesis of arteriovenous 
access failure; ii) the different biological effects of systemic therapies including antiplatelet agents, 
omega-3 polyunsaturated fatty acids (PUFAs), statins and renin-angiotensin-aldosterone system 
(RAAS) blockers (angiotensin converting enzyme inhibitors [ACEI] and angiotensin II type I 
receptor blockers [ARB]) that may be beneficial in improving vascular access outcomes; iii) results 
from clinical trials that have investigated the effect of these treatments on arteriovenous access 
outcomes; and, iv) identified evidence gaps that will be addressed in this thesis.  
1.5 Pathogenesis of vascular access failure  
In order to provide adequate dialysis, formation of a vascular conduit with the properties of easy 
cannulation, sufficient blood flow rate and low flow resistance is required. Failure of the 
arteriovenous access to achieve these properties is usually the result of a vascular stenosis with or 
without resulting thrombosis due to neointimal hyperplasia, inadequate vascular remodelling or a 
combination of the two36.  
 
Arteriovenous fistula failure  
Arteriovenous fistula maturation is a complex process involving the progressive increase in arterial 
and venous vessel diameter and blood flow following creation of an arteriovenous anastomosis37. 
Formation of an arteriovenous anastomosis leads to a sudden increase in blood flow, pressure and 
shear stress, which prompts compensatory vascular remodelling and vasodilation aimed at 
preserving the original level of shear stress37. Compensatory mechanisms include secretion of the 
endothelial-cell derived smooth muscle relaxants nitric oxide (NO) and prostacyclin, which 
promote vasodilation and inhibit thrombus formation, as well as smooth muscle migration and 
proliferation. Nitric oxide further combines with free radical oxygen to form peroxynitrite, which 
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stimulates matrix metalloproteinases (MMP-2 and MMP-9) and promotes further vasodilation. In 
addition, structural outward remodelling occurs via the breakdown of elastin fibres and vascular 
smooth muscle cell hypertrophy to increase the cross-sectional vessel wall diameter without 
compromising the vessel lumen. Resultant re-alignment of endothelial cells to the new vascular 
flow direction also takes place29,37-42.  
Maturation failure most commonly occurs because of luminal narrowing due to the combined 
impacts of neointimal hyperplasia and unfavourable remodelling (i.e. inward instead of outward 
remodelling with vasoconstriction instead of vasodilation)36. The characteristic pathology 
identified in primary non-functioning AVFs is a stenotic lesion due to neointimal hyperplasia 
commonly located at the juxta-anastomotic site43-45. Neointimal hyperplasia describes 
fibromuscular thickening of the vascular wall due to myofibroblasts and differentiated contractile 
smooth muscle cells that have migrated from the media into the intima where they proliferate to 
form a subintimal layer associated with increased extracellular matrix. Additional cell-types can 
include fibroblasts that migrate from the adventitia into the intima and transform into 
myofibroblasts, and bone marrow-derived smooth muscle cells. The presence of adventitial and 
neointimal microvessel formation is also characteristic36,43. 
Even in the absence of a stenotic lesion, AVF may fail to mature due to insufficient arterial or 
venous dilatation and inadequate outward vascular remodelling. This failure to mature may occur 
due to accessory veins that direct blood flow away from the venous segment of the fistula, thereby 
reducing flow and shear stress-mediated dilation and maturation44. Selection of poorly compliant 
or “stiff” arterial vessels due to vascular calcification and arteriosclerosis associated with diabetes, 
hypertension and chronic kidney disease mineral and bone disorder may further compromise 
remodelling and maturation43,46. 
Arteriovenous graft failure  
The most common cause of AVG failure is a venous outflow stenosis near the graft-vein 
anastomosis site caused by neointimal hyperplasia47. Progression of neointimal hyperplasia to a 
flow-limiting stenosis eventually leads to thrombosis and AVG failure. The pathogenesis is similar 
to neointimal hyperplasia formation in AVFs but, histologically, the prominence of macrophages 
indicates an additional inflammatory response likely due to the foreign graft material43,48. Further 
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distinct histological features of stenotic graft lesions include an abundance of extracellular matrix 
within the neointima, neovascularization and macrophage infiltration in the adventitia and 
periadventitial region, which may further compromise vascular function48. 
Neointimal hyperplasia and remodelling 
The mechanistic pathways that may lead to neointimal hyperplasia and maladaptive vascular 
remodelling in HD access are best characterised as a cascade of ‘upstream’ and ‘downstream’ 
events, as first described by Roy-Chaudhury et al.43. ‘Upstream’ events describe factors 
responsible for endothelial and smooth muscle cell injury, such as haemodynamic shear stress, 
surgical manipulation, repeat cannulation, angioplasties and the use of bioincompatible graft 
material. These events may initiate a complex cascade of ‘downstream’ events characterised by 
the interplay of pro-inflammatory mediators, such as cytokines, chemokines, metalloproteinases 
and adhesion molecules. These in turn result in cell activation, proliferation and migration with 
neointimal hyperplasia formation and unfavourable vascular remodelling (Figure 1-3). Other 
factors that may modulate these changes include the uraemic milieu characterised by 
inflammation, oxidative stress and endothelial dysfunction49-51, and genetic pre-dispositions to 
neointimal hyperplasia formation, vasoconstriction, inflammation and thrombosis36,52-55.  
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Figure 1-3: Pathogenesis of vascular access failure 
This figure illustrates the different pathogenic mechanisms that result in vascular access failure. 
Haemodynamic and surgical stressors, inflammatory stimuli (such as bioincompatible graft material), 
uraemia and recurrent needling, as well as genetic predisposition, trigger off a cascade of pro-
inflammatory mediators that promote inadequate outward remodelling, migration and transformation of 
smooth muscle cells and fibroblasts with resulting neointimal hyperplasia, luminal narrowing and 
thrombus formation.  
1.6 Systemic medical therapies to prevent arteriovenous access failure: Rationale 
and clinical trial outcomes 
Considering the pathogenesis of access failure, the most effective therapeutic interventions to 
improve vascular access outcomes would ideally target the prevention of neointimal hyperplasia 
and thrombosis and the promotion of maturation by optimising haemodynamic factors and 
compensatory mechanisms, such as vasodilation and remodelling56.  
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The following sections provide a summary of the biological effects (Figure 1-4) and clinical trials, 
which have studied the effect of systemic medical therapies on arteriovenous access outcomes.
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Figure 1-4: Biological effects of antiplatelet agents, omega-3 polyunsaturated fatty acids, statins and renin-angiotensin-aldosterone 
system blockers with the potential to improve haemodialysis vascular access failure 
Figure 1-4 presents the pleiotropic biological effects of antiplatelet agents (red), omega-3 polyunsaturated fatty acids (blue), statins (yellow) and 
renin-angiotensin-aldosterone-system blockers (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; purple) 
that may be beneficial in preventing vascular access failure. 
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Biological rationale for using antiplatelet agents to improve vascular access outcomes 
Platelets are key components of coagulation initiation and propagation, and provide targets for 
inhibition, as exemplified by the benefits of antiplatelet agents in the management of arterial 
atherothrombosis. Hence, the effect of antiplatelet agents (i.e. aspirin, dipyridamole, ticlopidine 
and clopidogrel) on platelet aggregation and function, which varies by agent, was considered to be 
a potentially effective means of reducing the occurrence of access thrombosis and patency loss.  
Clopidogrel and ticlopidine are thienopyridines and inhibit platelet adenosine diphosphate (ADP)-
induced platelet activation. Once bioactivated to their active metabolites, they irreversibly inhibit 
ADP P2Y12 receptors on platelets and thereby reduce platelet aggregation
57. 
Dipyridamole impairs platelet aggregation by increasing cyclic adenosine monophosphate 
(cAMP) levels in platelets by inhibiting of cAMP phosphodiesterase, blocking cellular re-uptake 
of adenosine and enhancing the biosynthesis and anti-aggregatory effect of prostacyclin58. It may 
also decrease adhesion of platelets to the injured vessel wall by increasing endothelial production 
of 13-hydroxyoctadecadienoic acid59. In addition to its antiplatelet effects, dipyridamole may 
reduce neointimal hyperplasia formation by inhibiting platelet derived growth factor (PDGF) and 
basic fibroblast growth factor (bFGF)-induced vascular smooth muscle cell proliferation60, and 
promote vasodilation by inhibiting cyclic guanosine monophosphate (cGMP) phosphodiesterase 
in vascular smooth muscle cells61. Dipyridamole exerts additional anti-oxidative and anti-
inflammatory effects mediated through attenuation of nuclear factor(NF)-kB and reactive oxygen 
species61.  
Aspirin is a well-established antiplatelet agent whose action is mediated through irreversible 
inhibition of platelet cyclooxygenase 1, resulting in decreased synthesis of thromboxane A2. 
Aspirin reduces endothelial cell damage via the NO-cGMP pathway and anti-inflammatory effects, 
as shown in experimental and clinical models62,63.  
Clinical trials of antiplatelet agents and vascular access outcomes in HD patients 
Table 1-1 summarises randomised controlled trials (RCTs) that have investigated the effect of 
antiplatelet agents on HD access failure. A meta-analysis of 21 RCTs using any type of antiplatelet 
agent to prevent vascular access complications reported a 51% reduction in thrombosis or patency 
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loss in AVF (6 trials, 1,222 participants; relative risk [RR], 0.49; 95% CI, 0.30-0.81), but uncertain 
effects on AVG patency (3 trials, 374 events, 956 participants; RR, 0.94, 95% CI 0.80-1.10)64. 
Aspirin: Conflicting results were found in RCTs investigating the effect of aspirin therapy on 
access outcomes with two trials showing a marked reduction in thrombosis65,66 and one trial 
reporting an increase in thrombosis compared to placebo67. Based on a meta-analysis of these 
trials, the summary effect of aspirin on access thrombosis remained uncertain (odds ratio [OR] 
0.40, 95% CI 0.07-2.25, p=0.3)68.  
Dipyridamole: In a single parallel group RCT including 84 patients with a new AVG, dipyridamole 
therapy led to a significant 65% risk reduction of graft thrombosis at 18 months compared to 
placebo (21% versus 42%), whereas the combination of aspirin and dipyridamole had no additional 
benefits (25%)67.  
Ticlopidine: The effect of ticlopidine was studied in three RCTs69-71 and meta-analysis of these 
trial results suggested a reduction in access thrombosis (OR 0.45, 95% CI 0.25- 0.82)68.  
Clopidogrel: In the largest randomised vascular access trial of 877 patients undergoing AVF 
creation, the short-term use of clopidogrel reduced early access thrombosis compared with placebo 
(12.2% versus 19.5%, p=0.018), but did not increase the proportion of AVFs suitable for HD 
assessed over a 1-month period (61.8% versus 59.5%, p=0.40)72. A smaller RCT including 93 
patients confirmed the reduced risk in early thrombosis (22% versus 5%, p=0.03) and reported a 
significant improvement in the first successful dialysis73 with clopidogrel compared to placebo. 
In summary, results suggest that inhibition of platelet function can reduce early AVF thrombosis, 
although the longer-term effects on clinically important end points, including the usability of the 
vascular access for HD, remain unclear and warrant further study.  
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Table 1-1: Randomised placebo controlled trials on antiplatelet agents and vascular access outcomes in haemodialysis patients 
Trial Intervention Control 
Access 
type 
na 
Treatment 
duration 
(months) 
Primary 
outcome 
(antiplatelet 
agent(s) versus 
placebo) 
Major secondary 
outcome 
(antiplatelet agent(s) 
versus placebo) 
Adverse events 
(antiplatelet agent(s) 
versus placebo) 
Andrassy et 
al. 1974 
Aspirin 1000 
mg alternate 
days 
Placebo  AVF 92 1 
Thrombosis at 
28 days 
4% versus 23%, 
p<0.05 
NR 
Gastric pain: 11% 
versus 4% 
Epistaxis:11% versus 
4% 
Melaena: 4% versus 
4% 
Wound hematoma: 4% 
(greater severity) 
versus 4% 
Harter et al. 
1979 
Aspirin 160 mg 
daily 
Placebo  
AV 
shunt 
44 4  
Thrombosis at 
study end 
(mean 5 
months) 
32% versus 
72%, p<0.01 
Rate of thrombosisb 
0.16 versus 0.46, 
p<0.005 
Transfusion: 26% 
versus 52% 
Kaufmann 
et al. 2003 
Aspirin 325 mg 
+ Clopidogrel 
75 mg daily 
Placebo AVG 200 NR 
Cumulative 
incidence of 
thrombosis: 
HR 0.81, 95% 
CI 0.49-1.40, 
p=0.45 
Cumulative incidence 
of first graft thrombosis 
for patients with grafts 
without previous 
thrombosis (n=111): 
HR 0.52, 95% CI 0.22-
1.26, p=0.14 
Bleeding: 42% versus 
24%, p=0.006 
HR 1.98, 95% CI 1.19-
3.28, p=0.007 
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Trial Intervention Control 
Access 
type 
na 
Treatment 
duration 
(months) 
Primary 
outcome 
(antiplatelet 
agent(s) versus 
placebo) 
Major secondary 
outcome 
(antiplatelet agent(s) 
versus placebo) 
Adverse events 
(antiplatelet agent(s) 
versus placebo) 
Sreedhara 
et al. 1994c 
Aspirin 
325 mg daily 
 
 
Dipyridamole 
225 mg + 
Aspirin 325 mg 
daily 
 
Dipyridamole 
225 mg daily 
Placebo  
 
 
 
Placebo 
 
 
 
 
Placebo 
AVG 
107  
(84 
Type 
Id and 
23 
Type 
IIe) 
18 
Thrombosis at 
18 months 
50% versus 
32%d 
50% versus 
80%e 
 
23% versus 
32%d 
100% versus 
80%e 
 
 
 
17% versus 
32%d 
83% versus 
80%e 
RR of thrombosisd 
Aspirin 1.99, 95% CI 
0.88-4.48, p=0.18 
 
 
 
 
 
 
Dipyridamole 0.35, 
95% CI 0.15-0.80, 
p=0.02 
Gastrointestinal events 
(including bleeding)d,e, 
NS 
Aspirin 15% versus 
11% 
Aspirin and 
dipyridamole 23% 
versus 11% 
Dipyridamole 22% 
versus 11% 
 
Cardiac eventsd,e, NS 
Aspirin 10% versus 
11% 
Aspirin and 
dipyridamole 14% 
versus 11% 
Dipyridamole 9% 
versus 11% 
Fisker-
strand et al. 
1984 
Ticlopidine 
250 mg twice 
daily 
Placebo AVF 18 1 
Thrombosis at 4 
weeks 
25% versus 
50% 
ADP-induced platelet 
aggregation 
Clotted versus non-
clotted AVF, NS 
Rash: 13% versus 0% 
Grontoft et 
al. 1985 
Ticlopidine 
250mg twice 
daily 
Placebo AVF 36 1 
Thrombosis at 4 
weeks 
11% versus 
47%, p<0.05 
NR 
Bleeding: 11% versus 
12% 
Dyspepsia: 0% versus 
6% 
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Trial Intervention Control 
Access 
type 
na 
Treatment 
duration 
(months) 
Primary 
outcome 
(antiplatelet 
agent(s) versus 
placebo) 
Major secondary 
outcome 
(antiplatelet agent(s) 
versus placebo) 
Adverse events 
(antiplatelet agent(s) 
versus placebo) 
Grontoft et 
al. 1998 
Ticlopidine 
250 mg twice 
daily 
Placebo 
AVF 
AVG 
 
242 1 
Thrombosis at 4 
weeks 
12% versus 
19%, p=0.10  
Predictors of access 
occlusion including 
biochemical markers 
(urea, haemoglobin and 
cholesterol levels), 
vessel condition, age 
and gender.  
Gastrointestinal:11% 
versus 13% 
Haemostatic: 4% 
versus 7% 
Dember et 
al. 2008 
Clopidogrel 
300 mg loading 
dose followed 
by 75 mg daily 
Placebo AVF 877 1.5 
Thrombosis 6 
weeks after 
fistula creation 
12% versus 
20%, RR 0.63, 
95% CI 0.46- 
0.97, p=0.018 
Failure to attain 
suitability for dialysis 
62% versus 60%, RR 
1.05, 95% CI 0.94-1.17, 
p=0.40 
 
Bleeding: 3% versus 
3%, p>0.9 
Hospitalisations: 15% 
versus 18%, p=0.16 
Ghorbani et 
al. 
2009 
Clopidogrel 
75 mg daily 
Placebo AVF 75 1.5 
Primary AVF 
failure at 8 
weeks 
5% versus 22%, 
p=0.03, HR 
0.72, 95% CI 
0.41-1.01 
Successful HD within 6 
months of AVF 
creationg: 92% versus 
71%, p=0.008 
Non-gastrointestinal 
bleeding: 5% versus 
4%, p=0.6 
Gastrointestinal 
bleeding: 3% versus 
4%, p=0.6 
anumber of participants analysed for primary outcome; bnumber of thrombotic events per patient month, cparallel group study; dpatients with new AVG; epatients 
with thrombosed AVG requiring new AVG; fsubgroup of participants randomised to aspirin or placebo; gParticipants requiring haemodialysis within 6 months.  
Abbreviations: ADP – adenosine diphosphate; AV –arteriovenous; AVF – arteriovenous fistula; AVG – arteriovenous graft; CI – confidence interval; HD – 
haemodialysis; HR – hazard ratio; NR – not reported; NS – not significant; RR – relative risk. 
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Biological rationale for using fish oil to improve vascular access outcomes 
Omega-3 PUFAs are commonly found in fish and fish oils. These polyunsaturated fatty acids, 
particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been shown to 
decrease blood viscosity and improve red blood cell deformability74,75, promote vasodilation76-78, 
inhibit smooth muscle proliferation79 and platelet aggregation80-83, and reduce inflammation84-88, 
all of which have the potential to improve vascular access maturation and reduce access stenosis 
and thrombosis (Figure 1-4). Omega-3 PUFA supplementation promotes a shift in eicosanoid 
production towards an anti-aggregatory, anti-inflammatory, anti-proliferative and vasodilatory 
direction by reducing the availability of omega-6 fatty acid-derived arachidonic acid and 
competing with arachidonic acid for the enzymes, cyclooxygenase and lipoxygenase89. The anti-
thrombotic and antiplatelet effects are likely mediated through reduced production of thromboxane 
A2, a potent vasoconstrictor and aggregator, and increased production of prostaglandin-I3, which 
inhibits platelet aggregation and promotes vasodilation equipotent to prostaglandin-I2 
(prostacyclin)80-83.  
The anti-inflammatory and immunomodulatory effects of omega-3 PUFAs are mediated through 
a number of mechanisms, including reduction in pro-inflammatory cytokines (such as tumour 
necrosis factor α and interleukins-1 and -6), formation of leukotriene B4 and attenuation of 
leucocyte chemotaxis, adhesion molecule expression and leucocyte-endothelial adhesive 
interactions84,86-88. In addition, DHA- and EPA-derived resolvins and DHA-derived protectins and 
maresins promote resolution of inflammation76,87. The inhibition of neointimal smooth muscle cell 
proliferation may be explained by alterations in cell membrane phospholipid composition, and 
decreased production of endothelial-derived paracrine growth factors79. Omega-3 PUFAs improve 
blood flow dynamics by reducing blood viscosity, increasing erythrocyte deformability and 
promoting vasodilation75,76. Data from experimental animal models and human studies have shown 
that omega-3 PUFA supplementation improves flow-mediated vasodilation via endothelium-
dependent and independent vasodilation76-78, but this effect may be dose-dependent requiring 
omega-3 PUFA doses of ≥ 1.83 gram/day for effectiveness90. In addition, omega-3 PUFAs may 
improve cardiovascular health in patients with chronic kidney disease through modification of 
lipids, especially lowering of triglycerides, and reductions in blood pressure and heart rate89,91,92.  
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Clinical trials of omega-3 polyunsaturated fatty acid supplementation and vascular access 
outcomes in haemodialysis patients 
Omega-3 fatty acid supplementation and AVG outcomes 
Table 1-2 summarises RCTs that have investigated the effect of omega-3 PUFA supplementation 
on HD vascular access failure. Three RCTs have assessed their effect on AVG patency93-95. The 
largest study showed a notable but non-significant reduction in the proportion of participants 
experiencing either AVG thrombosis or radiological or surgical intervention during 12 months of 
follow-up (48% in participants randomised to daily omega-3 PUFAs compared to 62% in 
participants randomised to placebo, p=0.06). However, participants treated with omega-3 PUFAs 
had significantly lower event rates with respect to the secondary outcomes of loss of graft patency 
(incident rate ratio [IRR] 0.58, 95% CI 0.44-0.75), radiological or surgical interventions (IRR 0.59, 
95% CI 0.44-0.78) and thrombotic events (IRR 0.5, 95% CI 0.35-0.72). In addition, significant 
cardiovascular benefits were observed in omega-3 PUFA-treated participants, including an 
increase in cardiovascular event-free survival, blood pressure lowering and a reduction in 
antihypertensive medications93. A small RCT of 24 participants receiving omega-3 PUFAs or 
placebo reported a dramatic improvement in graft thrombosis at 12 months (14.9% versus 75.6%, 
respectively, p<0.03)95. However, these findings were not replicated in a subsequent trial of 29 
patients undergoing new forearm loop graft formation in which patients randomised to receive 
over-the-counter omega-3 PUFAs had almost identical primary graft patency duration (254 ± 52 
days) compared to the placebo group (254 ± 35 days) during an 8 months follow-up period94.  
The variability of these results may have been due to differences in study sample size, outcome 
definitions, and dose and duration of therapy. For example, small sample size and low doses of 
EPA and DHA may have contributed to the negative findings reported in the latter study75 and 
measuring event rates, as opposed to proportion of participants with an event, may be a more 
sensitive metric for detecting statistically significant differences in outcomes74 (Table 1-2).  
The effect of omega-3 PUFA supplementation on AVF outcomes will be assessed in this thesis 
with a large multicentre international randomised placebo-controlled trial (Chapters 2 to 5). In 
addition, a meta-analysis of all RCTs examining the effect of omega-3 PUFAs on arteriovenous 
access outcomes using standardised outcome definitions will be performed (Chapter 6). 
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Table 1-2: Randomised controlled trials on omega-3 polyunsaturated fatty acid supplementation and vascular access outcomes in 
haemodialysis patients 
Trial Intervention Control 
Access 
type 
na 
Treatment 
duration 
(months) 
Primary 
outcome 
(omega-3 PUFA 
versus placebo) 
Major secondary outcome 
(omega-3 PUFA versus placebo) 
Adverse 
events 
(omega-3 
PUFA versus 
placebo) 
Schmitz 
et al. 
2001 
4x1g omega-
3 PUFA 
(44% EPA, 
24% DHA) 
Placebo 
(corn 
oil) 
AVG 24 12  ‘Primary 
patency’ 
(thrombosis-free) 
proportion at 12 
months 75.6% 
versus 14.9%, 
p<0.05 
Mean venous pressure at 12 months 
88 ± 7 mmHg versus 112 ± 10 mmHg 
Reduction in BP compared to placebo: 
systolic BP 30mmHg; diastolic BP 
15mmHg, p<0.05 
Bleeding 
events 0% in 
both groups 
 
Gastrointestinal 
side effects 
25% versus 0% 
Bowden 
et al. 
2007 
6x1g omega-
3 PUFA 
(16% EPA, 
10% DHA) 
Placebo 
(canola 
oil) 
AVG 29 8  Primary patency 
loss (thrombosis 
or venous 
outflow stenosis 
of >50% 
requiring 
angioplasty) 
254.2 days (SEM 
51.8) days versus 
254.1 days (SEM 
34.6), NS 
NR 
Gastrointestinal 
side effects 
36% versus 
13% 
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Trial Intervention Control 
Access 
type 
na 
Treatment 
duration 
(months) 
Primary 
outcome 
(omega-3 PUFA 
versus placebo) 
Major secondary outcome 
(omega-3 PUFA versus placebo) 
Adverse 
events 
(omega-3 
PUFA versus 
placebo) 
Lok et 
al. 
2012 
4x1g omega-
3 PUFA 
(48% EPA, 
25% DHA) 
Placebo 
(corn 
oil) 
AVG 196 12  Proportion of 
subjects with loss 
of AVG patency 
(thrombosis or 
intervention to 
maintain 
patency) within 
12 months 48% 
versus 62%, RR 
0.78 (95% CI 
0.60 to 1.03), 
p=0.06 
Rate of patency lossb 3.43 versus 5.95, 
IRR 0.58, 95% CI 0.44-0.75, p<0.001 
Rate of thrombosisb 1.71 versus 3.41, 
IRR 0.50, 95% CI 0.35-0.72, p<0.001 
Rate of interventions to maintain 
patencyb 2.89 versus 4.92, IRR 0.59, 
95% CI 0.44-0.78), p<0.001 
Cardiovascular event rateb 0.39 versus 
0.95, IRR 0.41, 95% CI 0.20-0.85, 
p=0.02 
Cardiovascular event free at 12 
months 0.88 versus 0.75, HR 0.43, 
95% CI 0.19-0.96, p=0.04 
Mean change in systolic BP -3.61 
versus 4.49 mmHg, difference -8.1 
mmHg, 95% CI -15.4-0.85, p=0.01 
Bleeding 
events 9% 
versus 8%, 
p>0.99 
Abbreviations; DHA - docosahexaenoic acid; HR – hazard ratio; IRR – incidence rate ratio; NS – not significant; RR – relative risk; SEM – standard error of the 
mean; omega-3 PUFA - omega-3 polyunsaturated fatty acids 
anumber of participants analysed; bper 1000 access days. Abbreviations: AVG – arteriovenous graft; BP – blood pressure; CI – confidence interval; EPA - 
eicosapentaenoic acid; 
 22 
 
Biological rationale for using statins to improve vascular access outcomes 
Statins have pleiotropic actions beyond lipid lowering that could reduce vascular access stenosis 
and thrombosis (Figure 1-4). In a murine HD vascular access model, statins reduced neointimal 
hyperplasia and promote outward remodelling by decreasing vascular endothelial growth factor-
A (VEGF-A) and MMP-9 and 2 expression96. Statins may also promote vasodilation by increasing 
endothelial-derived NO and reducing endothelin-1 release97. Multiple anti-inflammatory effects 
(including reduction of C-reactive protein levels, proinflammatory cytokines (interleukins-6 and 
8) and adhesion molecules) and antithrombotic effects could reduce stenosis and thrombosis97.  
Clinical trials of statin therapy and vascular access outcomes in haemodialysis patients 
The evidence for benefits of statin use on vascular access complications in HD patients is based 
on observational trial data and post-hoc analysis of RCT. Exploratory analyses of 2352 participants 
with a pre-existing vascular access from the Study of Heart and Renal Protection (SHARP) trial 
showed a 13% reduction in vascular access occlusive events in participants treated with 
simvastatin (20 mg) plus ezetimibe (10 mg) compared to placebo (RR 0.87, 95% CI 0.75-1.00; 
p=0.05). This finding was not replicated in a post-hoc analysis of a RCT of 2439 dialysis patients 
where 29% receiving rosuvastatin had an occlusive vascular access event versus 28% in the 
placebo group (RR 1.06, 95% CI 0.91-1.23)98. A case-control study of 60 incident dialysis patients 
suggested a treatment benefit of folic acid and/or statin on primary patency loss of AVF compared 
to non-use99. Several retrospective analyses suggested no significant benefits of statin use on 
primary or secondary patency of AVF or AVG100, access maturation101, stenosis formation102, time 
to recurrent angioplasties102 or cumulative access survival (after excluding primary failure)100,101. 
In summary, there is insufficient trial evidence to suggest a benefit of statin therapy on HD vascular 
access outcomes and RCTs investigating statin effects on newly created arteriovenous access are 
needed.  
Biological rationale for using ACEI/ARB to improve vascular access outcomes 
The RAAS plays an important role in vascular proliferation via induction of extracellular matrix 
and smooth muscle cell proliferation103. Based on predominantly pre-clinical studies, RAAS 
blockade by ACEI or ARB has been shown to reduce intimal hyperplasia formation, promote 
vasodilation and prevent platelet activation and adhesion104 (Figure 1-4). 
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Clinical trials of ACEI/ARB therapy and vascular access outcomes in haemodialysis patients 
Clinical evidence for beneficial treatment effects of ACEI and/or ARB on arteriovenous access 
outcomes is based on retrospective analyses104-108, including data of large registries from Taiwan 
(37,771 AVF, 4,473 AVG)109 and the United States (900 AVF, 1,944 AVG)100. Treatment benefits 
with use of ACEI and/or ARB have been reported for primary and secondary fistula and graft 
patency with conflicting results across trials depending on medication type (ACEI versus ARB) 
and access type (AVF versus AVG) as summarised in Table 1-3. These findings require 
confirmation in RCTs due to the limitations inherent in retrospective analyses, such as unadjusted 
or residual confounding.  
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Table 1-3: Retrospective analyses on ACEI and ARB use and vascular access outcomes in haemodialysis patients 
Study 
Numbers 
per access 
type 
Inter-
vention 
AVF outcomes 
(ARB/ACEI use versus non-use) 
AVG Outcomes 
(ARB/ACEI use versus non-use) 
   Primary patency loss 
Secondary 
patency loss 
Primary patency loss 
Secondary 
patency loss 
Chen et 
al. 2016 
37771 AVF 
4473 AVG 
ACEI 
ARB 
HR 0.59, 95% CI 0.56-0.62, p<0.05 
HR 0.53, 95% CI 0.51-0.56, p<0.05 
NR 
HR 0.56, 95% CI 0.48-0.64, p<0.05 
HR 0.54, 95% CI 0.47-0.61, p<0.05 
NR 
Jackson 
et al. 
2011 
212 AVF 
120 AVG 
ARB 
HR 0.35, 95% CI 0.16 to 0.76a, 
p=0.008 
NR HR 0.41, 95% CI 0.18-0.95, p=0.04 NR 
Saran et 
al. 2002 
900 AVF 
1944 AVG 
ACEI 
ARB 
RR 0.77, p=0.09 
RR 1.45, p=0.06 
RR 0.56, 
p=0.01 
RR 1.33, 
p=0.31 
RR 1.02, p=0.85 
RR 1.09, p=0.63 
RR 1.16, 
p=0.13 
RR 1.30, 
p=0.17 
Sajgure 
et al. 
2007 
87 AVF 
179 AVG 
ACEI 
 
Primary patency duration (mean ± 
SEM) 530 ± 80 days versus 501 ± 
76 days, p=0.45 
 
NR 
Primary patency duration (mean ± 
SEM) 672±68 days versus 460±48 
days, p=0.01 
HR 0.48, 95% CI 0.31- 0.73 
NR 
Gradzki 
et al. 
2001 
121 AVG ACEI NR NR RR 0.32, p=0.003 NR 
Diskin et 
al. 1998 
1126 AVF 
and AVG 
ACEI 
Access survival estimated from 
Figure: ~295 days versus ~280 
days, NS 
NR 
Access survival estimated from Figure: 
~255 days versus ~110 days, p<0.05  
NR 
Abbreviations: ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin II receptor blocker; AVF – arteriovenous fistula; AVG – arteriovenous 
graft; CI – confidence interval; HR –hazard ratio; NR – not reported; NS – not significant; RR – relative risk ratio; SEM – standard error of the mean. asubgroup 
analysis revealed a treatment benefit of ARB on AVF patency only in combination with antiplatelet therapy (HR 0.16; 95% CI 0.05 to 0.52). 
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1.7 Local treatment strategies  
Previous clinical research has largely focused on using systemic pharmacological treatment 
approaches to reduce arteriovenous access failure. Considering the complex interplay of 
‘upstream’ and ‘downstream’ events that occur predominantly at the site of vascular access 
creation, perhaps systemic therapies alone are insufficient to provide effective drug concentrations 
at the anastomotic or stenotic sites. Applying local interventions which reduce vascular injury, 
improve shear stress-induced vasodilation, promote outward remodelling and inhibit neointimal 
hyperplasia formation may be more innovative and effective. Such interventions include the use 
of new surgical techniques to alter wall shear stress110-112, endovascular access creation113, far-
infrared therapy114,115, paclitaxel-coated balloon angioplasty116,117, and perivascular application of 
recombinant elastase118,119, endothelial loaded gel foam wrap (Vascugel)120-122 or antiproliferative 
agents such as sirolimus (Coll-R)123. Table 1-4 provides an overview of mode of action and 
expected outcomes of these local and novel interventions that predominantly prevent vascular 
injury, modulate the response to vascular injury and/or promote outward remodelling rather than 
targeting thrombosis prevention. 
Table 1-4: Mode of action and expected effects of local interventions studied to improve 
haemodialysis vascular access outcomes 
Intervention Mode of action 
Expected effect on 
haemodialysis vascular access 
PRT-201 
 
(recombinant human type-1 
pancreatic elastase) 
Vasodilation by fragmentation 
of elastin in blood vessel wall 
Inhibition of adventitial 
myofibroblast migration to the 
intima 
Improvement of access patency 
Improvement of access 
maturation 
Far infrared therapy 
Inhibition of vascular smooth 
muscle cell proliferation 
Inhibition of platelet aggregation 
Vasodilation 
Reduction in oxidative stress 
Improvement of access patency 
Improvement of access 
maturation 
Reduction in access thrombosis 
Vascugel 
 
Inhibition of thrombus 
formation 
Reduction in negative 
remodelling following vascular 
Reduction in access thrombosis 
Improvement of access patency 
Improvement of access 
maturation 
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Intervention Mode of action 
Expected effect on 
haemodialysis vascular access 
(Perivascular placement of 
implants containing allogeneic 
aortic endothelial cells) 
injury (reduction in matrix 
metalloproteinase-2 expression, 
neovascularization and 
adventitial fibrosis) 
Paclitaxel-coated balloon 
angioplasty 
Inhibition of vascular smooth 
muscle cell proliferation 
Reduction in access re-stenosis 
Improvement of access patency 
Coll-R 
(Drug-eluted combination 
product of collagen membrane 
and sirolimus) 
Inhibition of vascular smooth 
muscle cell proliferation 
Improvement of access patency 
Improvement of access 
maturation 
Optiflow device 
Optimizing flow and shear stress  
by fixation of anastomotic angle 
of AVF at 60 degrees  
Shielding of peri-anastomotic 
region  
Improvement of access patency 
Improvement of access 
maturation 
Endovascular AVF creation 
(endovascular creation of an 
arteriovenous anastomosis 
using a radiofrequency 
magnetic catheter-based 
system) 
Reduction in vessel trauma and 
resulting triggers for neointimal 
hyperplasia formation.  
Improvement in access patency 
Improvement of access 
maturation 
Reduction in access 
interventions 
 
In conclusion, vascular access failure is common and poses great challenges in caring for patients 
in need of HD. Despite our increased understanding of the pathogenesis of arteriovenous access 
failure and the development of multiple systemic medical therapies (e.g. antiplatelet agents, 
omega-3 PUFA supplementation, RAAS inhibition and statins) that have theoretical appeal in 
promoting vascular access maturation and reducing access stenosis and thrombosis through anti-
proliferative, anti-aggregatory, anti-inflammatory and vasodilatory effects, trial-based evidence to 
support these therapies remains insufficient. Common limitations of these clinical trials include 
small sample sizes, short durations of treatment and follow-up, and a focus on short-term outcomes 
such as early thrombosis. An additional important barrier to discovering new interventions to 
improve arteriovenous access outcomes is the lack of consensus on clinically meaningful trial 
endpoints and consistent use of vascular access outcome definitions.  
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1.8 Standardisation of haemodialysis vascular access outcome definitions 
Since the early 2000s, multiple efforts have been made to standardise arteriovenous access 
outcomes, with initial definitions mostly proposed by single-stakeholder groups of vascular access 
surgeons124 and interventional radiologists125. The expert focus is exemplified by the various 
definitions to assess arteriovenous access patency as summarised in Figure 1-5: Primary patency 
begins at the time of arteriovenous access creation and ends when the access thromboses and/or 
requires any additional procedures to maintain patency (e.g. angioplasty or surgical revision of a 
stenosis). Cumulative (secondary) patency usually refers to the time period from access creation 
to access abandonment, including any interventions or procedures to maintain patency. In addition 
to primary and cumulative patency, the term assisted primary patency refers to “thrombosis-free” 
patency. Following the same concept, postintervention access patency describes the time frame 
between an index procedure (e.g. angioplasty for an access stenosis) and the next intervention 
(postintervention primary patency), access thrombosis (postintervention assisted primary patency), 
or abandonment of the access (postintervention cumulative patency).  
 
Figure 1-5: Arteriovenous access patency definitions after primary access placement and after an 
index intervention/procedure (postintervention patency) modified from Shenoy S et al.126 
In 2011, the North American Vascular Access Consortium (NAVAC), a multidisciplinary working 
group of HD vascular access experts including nephrologists and interventional nephrologists, 
published a comprehensive proposal for standardised definitions for arteriovenous access and 
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CVC-related complications. In addition to patency definitions, this report focused on clinically 
important outcome definitions for vascular access maturation, dialysis suitability and cannulation 
failure127. Table 1-5 summarises some of the commonly encountered arteriovenous access 
outcome definitions related to patency, maturation and usability, as suggested by the NAVAC, and 
additional comments to point out potential controversies and issues.  
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Table 1-5: Definitions for arteriovenous haemodialysis access (AVF and AVG) as suggested by the North American Vascular Access 
Consortium127 
Outcome NAVAC Definitions Comments 
Access patency  
Primary (unassisted) 
patency 
Time from access creation to any first endovascular or 
surgical intervention to maintain or restore blood flow, 
first access thrombosis or reaching a censored event†. 
Many studies exclude primary AVF failure in the analysis 
of patency, other studies report patency at various time 
points instead of time to event (Kaplan-Meier analysis).  
Loss of primary patency, expressed as proportion or rate is 
often reported instead.  
Primary patency may also be calculated from ‘first use’ of 
the access (also called ‘functional’ patency). 
Various other parameters have been used to assess patency 
including clinical assessment (presence of bruit/thrill), a 
minimum pump speed or a maximum resistive index etc.  
Cumulative survival 
(or secondary patency) 
Time from access creation to access abandonment‡ or 
achievement of a censored event† 
Commonly used in the clinical trial setting: Access 
abandonment‡ expressed as proportion or rate. 
Post intervention 
primary patency 
Time from index procedure until the next access 
thrombosis or further intervention or reaching a 
censored event 
Often reported as post interventional primary patency at 
various time points instead of standard time to event 
(Kaplan-Meier analysis).  
Vascular access (maturation) failure  
Immediate vascular 
access failure 
A vascular access with either no appearance of or loss 
of bruit or thrill within 72 hours of creation as 
determined by skilled healthcare provider or a vascular 
access lost for iatrogenic reasons such as ligation due 
to steal syndrome.  
Usually caused by technical issues such as intra- or 
immediate post-operative thrombosis. 
Early dialysis 
suitability failure 
A vascular access that cannot be used successfully for 
dialysis§ by the 3rd month following its creation despite 
radiological or surgical intervention.  
May be problematic for incident dialysis patients, if dialysis 
is not necessary within the first 3 months of access creation. 
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Outcome NAVAC Definitions Comments 
Late dialysis 
suitability failure 
A vascular access that cannot be used successfully for 
dialysis§ by the 6th month following its creation despite 
radiological or surgical intervention. 
This definition allows for time for further maturation 
following facilitating interventions. 
Fistula Used 
Successfully for 
Haemodialysis 
(FUSH) 
A fistula, that can be used with two-needle cannulation 
for 2/3 or more of all dialysis runs for 1 month and that 
delivers the prescribed dialysis within the prescribed 
time frame¶.  
The aforesaid criterion also applies for AVG if the 
patient is dialysed catheter-free for at least 1 month 
after catheter removal.  
A common clinical approach for maturation assessment is 
the rule of 6s (draining vein diameter > 6 mm, < 6 mm 
deep, blood flow > 600 mL/min, 6 weeks post-surgery)21. 
Performance of blood flow and cephalic vein diameter in 
predicting AVF maturity: 600 mL/min and 6 mm: 
Sensitivity 74%, specificity 93%; ~ 500mL/min and ~ 
5mm: sensitivity 84%, specificity 93%128.  
Prescribed dialysis may alter depending on other adequacy 
criteria applied. 
Cannulation Failure The inability of an expert cannulator to place and 
secure two adequately sized dialysis needles to provide 
prescribed dialysis. 
 
Cannulation Injury An injury that results in bleeding, infiltration and 
swelling. 
Minor: can be managed conservatively with rest and 
ice for 1-2 days and the access should be successfully 
recannulated with two needles in ≤ 7 days. 
Major: requires recovery for >7 days 
Severe: significant injury that requires any one of the 
following: blood transfusion, emergency room visit, 
hospitalisation, radiological or surgical intervention. 
Cannulation injury may also result in thrombus and stenosis 
formation and catheter use129,130. 
†Censored event: Death, transfer to another HD unit, transfer to peritoneal dialysis, transplantation or end of study period127. ‡Access abandonment as defined by 
NAVAC: This access can no longer be used with one or two needles for prescribed dialysis as it may be unable to provide adequate flows and⁄ or is deemed unsafe 
for the patient, and the associated problem cannot be corrected by any intervention, including medical, surgical, or radiological interventions or rest127.  
¶Flow rates, dialysis frequency and duration may vary to achieve a target single pool-Kt/V (indicator of dialysis clearance) of 1.2127. §Defined as a vascular access 
that can be used with two-needle cannulation for 2/3 or more of all dialysis runs for 1 month and that delivers the prescribed dialysis within the prescribed time 
frame72,127.  
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The Kidney Health Initiative 
In March 2018, the Kidney Health Initiative (KHI), a public-private partnership between the 
American Society of Nephrology and the US Food and Drug Administration (FDA), published a 
four-paper series on clinical trial endpoints for HD vascular access126,131-133. The KHI Clinical Trial 
Endpoints for Dialysis Vascular Access project aimed to improve the consistency of trial endpoints 
and outcome definitions related to HD vascular access. It was established from evidence-based 
consensus of a multidisciplinary team of nephrologists, interventional nephrologists, surgeons, 
radiologists, nurses and industry representative with input from the KHI Patient and Family 
Partnership Council and regulatory representatives of the FDA and Centres for Disease Control 
and Prevention (CDC). To facilitate the development of effective interventions and products to 
improve vascular access outcomes, this series of publications provided a lexicon of vascular access 
outcome definitions, grouped these outcome into categories aimed to reflect the goal of an 
intervention being tested (e.g. pharmacological, biologic or device) and suggested primary and 
secondary trial endpoints to go with each of these categories. For example, trial endpoints for 
arteriovenous access were categories into 5 phases that reflected the life cycle of an arteriovenous 
access: (1) Creation, (2) maturation, (3) initial clinical use, (4) sustained clinical use and (5) 
dysfunction. Pragmatic outcome definitions for each of these development steps were provided. 
Primary and secondary outcomes tailored to the different stages of the arteriovenous lifecycle and 
goal of the clinical trial intervention were also suggested. A visual summary of these outcome 
categories, definitions and trial endpoints is provided in Figure 1-6.  
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Figure 1-6: Phases and timeline of the arteriovenous access life cycle including trial endpoints, 
diagnostic criteria, potential complications and clinical significance modified from Hurst et al.44 
Abbreviations: AV – arteriovenous; HD – haemodialysis; QoL – quality of life.  
 
The KHI vascular access project incorporated patient perspectives on these trial endpoints. 
Feedback for CVC and arteriovenous access trial endpoints was based on up to ten patients, 
caregivers and/or patient organisation representatives. Patients’ perspectives were often very 
different from that of health professionals and focused on the incorporation of measures of quality 
of life and patient satisfaction and the need for lay summaries of clinical studies in HD access to 
enhance recruitment. The clinical endpoints proposed by the KHI provide an important framework 
for clinical studies aimed to develop interventions and devices to improve vascular access 
outcomes.  
 
One of the great challenges remains the successful uptake of these trial endpoints in future studies 
and consistent and reliable reporting of these outcome measures regardless of whether the 
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intervention studied showed a positive or negative effect upon the outcome (to avoid reporting 
bias).  
Core outcome sets  
This challenge has prompted large-scale efforts to establish core outcome sets across many medical 
specialties. Core outcome sets are defined as an agreed standardised set of outcomes for a specific 
clinical area that should be reported as a minimum in all trials in this area134. Core outcomes are 
selected because they are considered to be critically important for decision making by all relevant 
stakeholders including patients, health professionals and policy makers. Core outcome sets 
typically include three to five outcomes and are not designed to be comprehensive or exclusive. 
Core outcomes may or may not be selected as the primary outcome of any given trial. Researchers 
may select the primary outcome and add other trial-specific outcomes for reasons including 
responsiveness to the intervention or feasibility to achieve adequate statistical power. The use of 
core outcome sets has been recognised as an effective strategy to enhance the consistency and 
relevance of outcome reporting, minimise reporting bias and ensure global implementation in 
clinical trials135.  
The standardised outcomes in nephrology initiative 
In parallel and complementary to the KHI, the Standardised Outcomes in Nephrology (SONG) 
initiative was launched in 2014 to develop core outcome sets across the spectrum of kidney disease 
based on the shared priorities of patients, caregivers and family members, health professionals, 
researchers, policy makers, regulatory bodies and industry. These core outcome sets are identified 
through an evidence- and consensus-based multistep process to ensure they are considered 
critically important by all relevant stakeholders, including patients, caregivers and health 
professionals. Based on a World Health Organisation (WHO)-endorsed framework developed by 
the Outcome Measures in Rheumatology (OMERACT) group136-138, the SONG initiative follows 
a 5-phase approach139 (Figure 1-7) in identifying the most critically important outcome domains 
(i.e. core outcome sets) across the different areas of nephrology including but not limited to HD, 
peritoneal dialysis and transplantation9,140,141.  
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Figure 1-7: The 5-phase process of SONG to develop core outcome domains139 
For HD, this process involved a comprehensive systematic review of all outcomes reported in 
clinical trials on HD-related interventions142, focus groups using nominal group technique with 
patients and caregivers to identify and rank outcomes for HD research143, stakeholder interviews 
to elicit values and perspectives on HD outcomes, a 3-round Delphi survey to generate a priority 
list of outcomes based on consensus144 and a multistakeholder consensus workshop to endorse the 
core outcome set and discuss implementation strategies. Based on the contributions of 1,376 
participants from 73 countries, the four core outcome domains included (1) vascular access, (2) 
fatigue, (3) cardiovascular disease, and (4) mortality11,143,144. For each of these core outcome 
domains, the most critically important outcome measure will be developed following a similar 
multi-step process including a systematic review, international survey, consensus workshop, pilot 
and validation study to ensure successful implementation139,145. This thesis will describe the 
process and outcomes of establishing a core outcome measure for vascular access.  
1.9 Thesis aims and structure 
This research program aimed to establish strategies to improve vascular access outcomes that are 
relevant to patients, their caregivers and health professionals with a special focus on increasing the 
usability of AVFs. This thesis is presented in two parts (Figure 1-8): Part 1 focuses on systemic 
medical interventions to improve arteriovenous access outcomes and comprises the methodology, 
baseline characteristics, primary, secondary and ancillary outcomes of the omega-3 fatty acids 
(Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study, an 
international, multicentre placebo-controlled RCT of omega-3 PUFA supplementation and aspirin 
use to improve outcomes of newly created AVF (Chapters 2 to 5). PART 1 concludes with a meta-
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analysis of all RCTs on omega-3 PUFAs supplementation to determine the efficacy and safety of 
omega-3 PUFA supplementation in preventing arteriovenous fistula and graft failure (Chapter 6). 
PART 2 describes the identification of a core outcome measure for vascular access as part of the 
SONG-HD initiative and includes a systematic review of all vascular access outcomes reported in 
contemporary RCTs in HD (Chapter 7), an international survey to prioritise vascular access 
outcomes (Chapter 8), and a multistakeholder consensus workshop to establish a core outcome 
measure for the most critically important vascular access outcome (Chapter 9) based on the shared 
priorities of patients, caregivers and health professionals. The thesis concludes with a discussion 
of key findings, strengths and limitations of the research program and implications for clinical 
practice and future research. The thesis structure and specific aims of each chapter are summarised 
in the following Figure 1-8.  
The thesis is built on peer-reviewed publications. This format was selected for its many benefits 
including timely dissemination of research findings to a broad audience, facilitation of 
international collaborations, enhancement of track record and associated increased chances of 
securing research grants to fund ongoing and future research of the candidate. Chapters 1 to 9 are 
based on peer-reviewed research publications. Copyright permission has been obtained to 
reproduce these manuscripts. Each of these chapters is introduced with a chapter overview, details 
of the included publication(s) and a description of the candidate’s contribution to the included 
publication(s). Each chapter concludes with a chapter summary. Tables and figures have been 
embedded within the text. References are presented at the end of the thesis. Figure and table 
numbers, headings, page numbers and general stylistic specifications have been adjusted to align 
with the guidelines set out by the University of Queensland to maintain consistency throughout 
the thesis. Australian English has been used throughout.  
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Figure 1-8: Thesis structure and aims 
Abbreviations: AVF – arteriovenous fistula; FAVOURED - Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in REnal 
Disease; HD – haemodialysis; PUFA – polyunsaturated fatty acid; SONG – Standardised Outcomes in Nephrology 
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1.10 Chapter summary 
A functioning vascular access is the lifeline for patients requiring HD and vascular access dysfunction 
remains a major challenge in caring for these patients. An arteriovenous access, preferentially in the 
form of a native AVF is the access of choice due to its longevity and lower complication rate. In order 
to increase the use of an arteriovenous access for HD as opposed to a CVC, it is critical to (i) identify 
interventions that target the complex pathogenesis of arteriovenous access failure; and (ii) establish 
and implement standardised vascular access outcome measures that are relevant to patients, their family 
and healthcare providers and can be implemented across all HD trials to enhance the applicability, 
comparison and interpretation of study results. This will help guide clinical practice in a meaningful 
way. 
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Chapter 2   
FAVOURED study protocol and rationale of post-
initiation trial modifications 
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2.1 Chapter overview 
The previous chapter has highlighted the high failure rates of AVFs due to early thrombosis and 
maturation failure and the urgent need for effective interventions to increase the usability of AVFs. 
Based on the complex pathophysiology of maturation failure, omega-3 PUFA supplementation may be 
a promising intervention to promote AVF maturation and reduce early thrombosis through pleiotropic 
effects on the vascular biology but clinical trials in AVFs are lacking. While antiplatelet agents may 
be beneficial in reducing early thrombosis based on evidence from relatively small RCTs, it remains 
unknown whether the use of low dose aspirin is effective in improving the usability of newly created 
AVFs. PART 1 of this thesis addresses these knowledge gaps with an international, multicentre 
randomised placebo-controlled trial that examined whether omega-3 PUFA supplementation with or 
without low-dose aspirin use is effective in reducing complications of newly created AVFs. This 
chapter will provide an overview of the study methodology and rationale for post-initiation protocol 
modifications of the FAVOURED trial. 
2.2 Included publication 
The following chapter was published as peer reviewed original research: 
 
Viecelli AK, Pascoe E, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Heritier S, 
Kerr PG, Mori TA, Robertson A, Hooi SL, Irish AB. The Omega-3 fatty acids (Fish Oils) and Aspirin 
in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol 
and rationale of post-initiation trial modifications. BMC Nephrol. 2015;16:89-97. Copyright 
permission has been obtained to reproduce this manuscript 
Contribution of the candidate: The candidate was the lead author of this peer reviewed research article. 
The FAVOURED study was originally concepted and designed in 2007. The candidate joined the trial 
management committee in 2014 and made a substantial contribution to concept and design of ancillary 
analyses, assisted with the statistical analysis plan, data analysis and interpretation, and served as an 
independent outcome adjudicator.  The candidate wrote the first draft for this publication and revised 
the manuscript following feedback from co-authors, journal reviewers and editor.  
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2.3 Abstract 
Background: The FAVOURED study is an international multicentre, double-blind, placebo-
controlled trial which commenced recruitment in 2008 and examines whether omega-3 PUFAs either 
alone or in combination with aspirin will effectively reduce primary access failure of de novo AVF in 
patients with stage 4 and 5 chronic kidney disease. Publication of new evidence derived from additional 
studies of clopidogrel and a high screen failure rate due to prevalent aspirin usage prompted an updated 
trial design.  
Methods/design: The original trial protocol published in 2009 has undergone two major amendments, 
which were implemented in 2011. Firstly, the primary outcome ‘early thrombosis’ at 3 months 
following AVF creation was broadened to a more clinically relevant outcome of ‘AVF failure’; a 
composite of thrombosis, AVF abandonment and cannulation failure at 12 months. Secondly, 
participants unable to cease using aspirin were allowed to be enrolled and randomised to omega-3 
PUFAs or placebo. The revised primary aim of the FAVOURED study is to test the hypothesis that 
omega-3 PUFAs will reduce rates of AVF failure within 12 months following AVF surgery. The 
secondary aims are to examine the effect of omega-3 PUFAs and aspirin on the individual components 
of the primary end-point, to examine the safety of study interventions and assess central venous catheter 
requirement as a result of access failure.  
Discussion: This multicentre international clinical trial was amended to address the clinically relevant 
question of whether the usability of de novo AVF at 12 months can be improved by the early use of 
omega-3 PUFAs and to a lesser extent aspirin. This study protocol amendment was made in response 
to a large trial demonstrating that clopidogrel is effective in safely preventing primary AVF thrombosis, 
but ineffective at increasing functional patency. Secondly, including patients taking aspirin will enrol 
a more representative cohort of HD patients, who are significantly older with a higher prevalence of 
cardiovascular disease and diabetes which may increase event rates and the power of the study.  
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12607000569404). 
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2.4 Background 
Increases in the incidence and prevalence of ESKD associated with aging of the population and diabetes 
mellitus pose challenges to health providers and patients. Haemodialysis remains the most common 
treatment for ESKD worldwide and requires a functioning permanent vascular access for optimal 
patient outcomes. Vascular access dysfunction is associated with significant morbidity and mortality 
and presents a major economic burden for healthcare providers7,146,147. A native AVF is the preferred 
type of vascular access due to lower rates of thrombosis, infection, interventions to maintain patency 
and overall mortality when compared with synthetic AVGs or CVCs19,24,33. However, native AVF take 
longer to establish and have a higher risk of failure to mature. Primary failure rates of AVF range 
between 20 – 60% and usually occur as a result of early thrombosis or failure of maturation28,72. 
Strategies to improve early access survival by reducing thrombosis include short-term antiplatelet 
therapy and the pre-operative identification of unsuitable anatomy by ultrasound.  
Although several small RCTs have assessed the effect of short-term post-operative use of antiplatelet 
agents such as aspirin, sulphinpyrazone, and ticlopidine65,69-71,148 on early AVF thrombosis, these trials 
had many limitations including inadequate power, variable drug dosing and variable timing of drug 
administration. Omega-3 polyunsaturated fatty acids derived from fish and fish oils not only inhibit 
platelet aggregation but are anti-inflammatory, anti-proliferative and promote vasodilatation by 
reducing the availability of arachidonic acid, leukotriene and cytokine production as well as increasing 
prostaglandin-I3 production 
80. The original aim of the FAVOURED trial was therefore to examine the 
potential effects of aspirin and omega-3 PUFAs in preventing early thrombosis in newly created AVF 
using a large, randomised, double-blind, placebo-controlled factorial trial design. Details of the 
rationale and original study design of FAVOURED were published in 2009149.  
Since commencement of the FAVOURED study, an unexpectedly high screen failure rate due to 
prevalent aspirin usage together with the publication of new data from a large RCT assessing 
clopidogrel in AVF72 prompted a review of the trial design. While the clopidogel RCT demonstrated a 
significant reduction of ‘early thrombosis’ by post-operative use of clopidogrel, this did not translate 
into an increased proportion of usable AVF72. As such the FAVOURED Trial Management Committee 
(TMC) decided that it was appropriate to amend the primary outcome to a more clinically relevant 
outcome – AVF failure, defined as a composite of any or all of thrombosis, AVF abandonment and 
cannulation failure. In addition, the TMC revised the protocol and included additional endpoints to 
broaden the clinical applicability and generalisability of the FAVOURED trial, whilst also addressing 
the unexpectedly high screen failure due to aspirin use. This updated publication describes the details 
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and rationales of the study protocol amendments and outcome assessments, which were made and 
implemented in June 2011.   
2.5 Methods 
Ethics approval for the FAVOURED trial was obtained from local Human Research Ethics Committees 
in all participating centres prior to study initiation and participant enrolment. The study has been 
performed in accordance with the 2000 Edinburgh, Scotland Revision of the Declaration of Helsinki, 
the National Health and Medical Research Council (NHMRC) Statement on Human Experimentation, 
Joint NHMRC/AVCC Statement and Guidelines on Research Practice, applicable ICH guidelines and 
the Therapeutic Goods Administration (TGA). The trial is registered with the Australian New Zealand 
Clinical Trials Registry (ACTRN12607000569404). 
Participant population 
The trial included patients with Stage 4 or 5 chronic kidney disease who were on HD or planned to 
start HD within 12 months. Participants underwent AVF surgery in the upper or lower arm as their 
primary HD access. Inclusion and exclusion criteria remained largely unchanged to the original 
protocol. However, patients who were taking aspirin and unable to cease were eligible to be enrolled 
into the expanded protocol of open-label aspirin.  
Inclusion criteria  
1. Stage 4 or 5 chronic kidney disease 
2. Currently on HD or HD is planned to start within 12 months (including patients currently on 
peritoneal dialysis) 
3. Planned AVF will be the primary HD access mechanism 
4. Surgery to create an AVF in the upper or lower arm is planned 
5. Aged over 19 years 
6. Treating team agreeable to patient's involvement in the trial and the patient has given informed 
written consent 
Exclusion criteria  
1. Revision of existing AVF rather than de novo AVF 
2. Medical indication for anticoagulants or antiplatelet agents with the exception of aspirin (eligible 
for expanded protocol using open-label aspirin)* 
3. Known intolerance of agents including hypersensitivity to aspirin, allergy to any other NSAIDs 
or fish 
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4. Current use of aspirin within two weeks of commencing the trial, or of omega-3 PUFAs within 
4 weeks of commencing the trial (eligible for the expanded protocol using open-label aspirin)* 
5. Pregnancy, lactation or intention to fall pregnant during the time course of the study 
6. Known bleeding disorder or established diagnosis of active or suspected bleeding 
7. History of gastrointestinal ulcers or bleeding within the last 3 months 
8. Platelet count less than 100 × 109 /L 
9. Known active peptic ulcer disease 
10. Severe hepatic insufficiency 
11. Already receiving anti-coagulation therapy such as warfarin 
12. Receiving regular non-steroidal anti-inflammatory drugs (NSAIDS) for another indication such 
as arthritis 
13. Syndrome of asthma, rhinitis and nasal polyps if uncontrolled on usual therapy 
14. Plan to have other (non-access) surgery within 2 weeks of trial medication period where in the 
opinion of the investigator aspirin or omega-3 PUFAs would be contraindicated for the planned 
procedure. 
15. Potential non-compliance with treatment regimen in the view of the treating clinicians 
16. Involved in another clinical trial where the intervention being trialled is likely to confound the 
outcome of this trial 
17. Previously randomised to this trial. 
*Changed in the expanded protocol  
Study design and procedure 
This is an international, multi-centre RCT designed by vascular access experts including nephrologists, 
vascular access surgeons, and radiologists, that initially recruited patients from private and public 
hospital renal units performing vascular access procedures in Australia and New Zealand. Following 
review of the protocol and in order to address slow recruitment and improve generalisability, the trial 
began recruiting patients from sites in Malaysia and the UK. Patients that met all inclusion and no 
exclusion criteria and were planned to receive a de novo AVF were eligible for randomisation. 
Participant consent forms were approved by the HREC at each participating site prior to the beginning 
of the trial. Participants were not randomised until a signed consent form was filed at site.  
The original protocol was a 2x2 factorial-design trial, where participants were randomised to one of 
four treatment groups formed by aspirin or matching placebo and omega-3 PUFAs or matching 
placebo. Patients who were not taking aspirin or who were able to cease taking aspirin were consented 
and randomised to one of the 4 groups. The study protocol was amended in June 2011 to include 
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suitable patients who were on aspirin at the time of screening and were unable to cease. In this expanded 
study protocol, participants were allowed to continue with open-label aspirin and were randomised to 
omega-3 PUFAs or matched placebo only (Figure 2-1). The rationale behind this study amendment 
will be described further in the discussion. Randomisation was achieved using a minimisation method 
to balance treatments over two stratification factors: study site and AVF location (upper versus lower 
arm).  
 
Figure 2-1: Amended study protocol 
With the exception of open label aspirin, the two antiplatelet agents were studied using matching 
placebo in order to maintain a double-blind trial. Effectiveness of blinding was assessed by asking 
participants and investigators at the completion of treatment what they believed the participant had 
received.  
Participants were randomised as close as possible to the time of the scheduled procedure and not more 
than 7 days before the planned procedure. The study medication was commenced on the day prior to 
the scheduled surgery. If the procedure was rescheduled, and the patient had already started trial 
medication, it was immediately withheld and then recommenced the day before the rescheduled 
surgery.  
Outcome Measures  
Primary outcome measures 
 
 
 Original Study Protocol Expanded Study Protocol 
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The amended primary outcome measure is AVF failure at 12 months after AVF creation. AVF failure 
is a composite of the following three clinical outcomes:  
1. Thrombosis: This is defined as the absence of a thrill or bruit by clinical assessment and/or the 
requirement of rescue interventions including medical thrombolysis or surgical thrombectomy to 
restore patency for thrombosis or occlusion for the study AVF between AVF surgery and the 
month 12 visit.  
2. AVF abandonment: This is defined as the permanent abandonment of study AVF between AVF 
surgery and months 12 visit. Events that may indicate AVF abandonment include thrombosis of 
the study AVF, imaging showing that the study AVF is unusable or not amenable to any 
intervention for its improvement, insertion of another dialysis access (new AVF, AVG, CVC or 
peritoneal dialysis access) or ligation of the study AVF.  
3. Cannulation failure: This is defined as the failure to successfully cannulate the study AVF with 2 
needles (or with 1 needle if using a single needle dialysis method) during 8 or more out of 12 HD 
sessions during the Cannulation Assessment Period (CAP) (Table 2-1).  
Table 2-1: Cannulation assessment period 
Start of maintenance 
haemodialysis 
Beginning of CAP Duration of CAP 
Prior to week 12 visit 
First haemodialysis session 
after week 12 visit 
First 12 consecutive 
haemodialysis sessions 
Between week 12 and 
month 12 visit 
First haemodialysis session 
First 12 consecutive 
haemodialysis sessions 
After month 12 visit No CAP No CAP 
 
AVF failure was assessed independently by two observers, each unaware of the participant’s treatment 
assignment, treatment course or medical history. 
Secondary outcome measures 
1. Thrombosis: 
1.1. Thrombosis of the study AVF between AVF surgery and the 12 month visit as outlined above. 
1.2. Primary patency at various time points: This is defined as the presence of an audible bruit over 
the site of the arterio-venous anastomosis at time points of within 24 hours post-surgery, and 
visits in weeks 1, 6, and 12 and months 6 and 12 (unchanged from the original protocol).  
1.3. Number and type of intervention: This is defined as the number and type of interventions the 
study AVF requires between AVF surgery and the 12 month visit. Interventions include rescue 
(medical thrombolysis or surgical thrombectomy) and non-rescue procedures (surgical or 
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radiological revision or dilatation of the AVF from or proximal to the anastomosis to the 
ipsilateral central vein, dilatation of central venous stenosis, ligation of tributaries, 
superficialisation of AVF or ligation of fistula or salvage by DRIL [distal reconstruction and 
interval ligation] due to distal ischaemia). 
1.4. Time to first rescue intervention: this is defined as the time from AVF creation to first occasion 
of rescue intervention up to the 12 month visit (unchanged from the original protocol). 
2. Permanent AVF abandonment: 
2.1. AVF Abandonment as defined under the primary outcome. 
2.2. Time to AVF abandonment: This is defined as the time from AVF surgery to permanent 
abandonment of study AVF up to the 12 month visit (unchanged from the original protocol).  
3. Cannulation: 
3.1. Cannulation failure as defined under the primary outcome. 
3.2. Time to first successful cannulation: This is defined as the time taken from the AVF surgery 
until the first successful attempt at access cannulation up to the 12 month visit (unchanged 
from the original protocol).  
4. Central venous catheter requirement: 
4.1. CVC requirement between visits week 12 and month 12: This is defined as the use of a CVC 
on any occasion to provide vascular access for HD between week 12 and the 12 month visits. 
4.2. CVC requirement during CAP: This is defined as the use of a CVC on any occasion to provide 
vascular access for HD during the CAP.  
4.3. CVC requirement after CAP: This is defined as the use of a CVC on any occasion to provide 
vascular access for HD after the CAP to month 12 visit. 
4.4. Days of CVC: This is defined as the number of days a CVC is present in situ between week 
12 and month 12.  
5. Adverse events: All serious adverse events and adverse drug reactions will be collected. The 
analysis of this secondary outcome will focus particularly on bleeding events (unchanged from the 
original protocol).  
Tertiary outcome measures 
1. CVC requirement at any occasion: This is defined as the use of a CVC on any occasion to provide 
vascular access for HD between AVF surgery and the 12 month visit. 
2. Long-term outcome of AVF: This is defined as the rate of permanent abandonment at the 24 and 
36 month visits and the time to permanent abandonment up to the 36 month visit.  
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No changes were made to the three sub-studies (pre-surgical vascular assessment by duplex ultrasound, 
red blood cell fatty acid levels as a compliance measure of omega-3 PUFA intake and dietary and 
physical questionnaire for assessment of interactions between lifestyle/dietary factors and omega-3 
PUFA supplementation) as reported in the original trial methods and protocol 
(http://www.aktn.org.au/index.php). 
Treatment plan and modifications 
Study treatment was commenced on the day prior to the AVF surgery and continued for 12 weeks. All 
participants received 4 g of omega-3 PUFAs (2 g twice daily) in the form of 4 Omacor capsules (46% 
EPA and 38% DHA) or 4 matching placebo capsules supplied by Abbott Products. For participants not 
taking open-label aspirin, 100 mg of oral aspirin daily or matching placebo was supplied by Bayer 
Healthcare. Participants that were taking aspirin and unable to cease continued with their open-label 
aspirin dose. Any changes in use or dosage of aspirin in these participants during the treatment period 
(12 weeks) were recorded.  
Compliance was monitored by capsule/tablet count at the week 12 visit. Centres in Australia and New 
Zealand additionally collected blood samples to test erythrocyte fatty acids levels to assess omega-3 
fatty acids compliance. 
All centres performed routine biochemical and haematological analysis as part of participant 
monitoring.  
Statistical considerations 
Sample size calculation for the primary outcome 
The amended study was powered to detect a clinically relevant difference between omega-3 PUFA and 
control groups (arms A, B and E combined versus C, D and F combined) on the primary composite 
outcome of AVF failure. The 12- month post-surgery event rate for AVF failure estimated to be at least 
30% in the control group. It is expected that the reduction in AVF failure due to omega-3 PUFAs will 
be 30% (an absolute reduction in risk of 9%). To detect a 30% relative risk reduction with 80% power 
and a significance level of 5%, 734 participants will be required (367 per group). To allow for a 5% 
drop-in from control to omega-3 PUFAs and a 5% drop-out from omega-3 PUFAs to placebo, the total 
number of participants was increased to 906 (453 per group). Allowing for a 5% loss to follow-up, a 
total of 954 participants need to be recruited (Table 2-2). The assumed 30% event rate for AVF failure 
is conservative when compared to the 60% event rate reported by the US clopidogrel Trial72 and other 
recently published studies150,151. However, the vascular access practices and AVF outcomes in the USA 
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differ from those in Australasia. Moreover, the report to the FAVOURED Data and Safety Monitoring 
Board in December 2011 showed a 38% blinded pooled event rate among the first 184 participants, 
indicating that a vascular access failure rate of 30% is a reasonable assumption.   
While the study is not adequately powered to detect a clinically important difference between the 
combination of aspirin and omega-3 PUFAs and either treatment alone, it will provide preliminary 
outcome and adverse event data. 
Table 2-2: The enrolment target with increasing event rates 
Event rate 
    Sample size 
           not adjusted                           adjusted 
30% 734 954 
40% 488 634 
50% 340 442 
 
Analysis 
Analysis of the primary composite outcome will be on an intent-to-treat basis. That is, all randomised 
participants who had an AVF surgery attempted will be analysed in the group to which they were 
allocated. The primary analysis of AVF failure will compare omega-3 PUFAs (combined arms A, B 
and E) to control (combined arms C, D and F) using logistic regression with the intervention group as 
a predictor variable. The logistic model will be adjusted for differences in aspirin use (no aspirin, 
randomised to aspirin, open-label aspirin). Additional efficacy analyses will compare AVF failure rates 
in the active aspirin (arms A and C) and aspirin placebo (arms B and D) groups from the original design 
and the omega-3 PUFASs (arm E) and omega-3 placebo (arm F) from the new design. These and other 
comparisons of binary outcomes will be performed using logistic regression with the intervention 
group as a predictor variable in the models. The log-rank test will be used to compare groups on time-
to-event outcomes. 
Screening log data 
Recruitment for the FAVOURED trial started on the 21st of August 2008. As shown in Figure 2-2, a 
total of 4242 patients were screened. Of the 2334 patients that were screened prior to the study protocol 
amendment in June 2011, 1842 were excluded, mainly due to the use of anticoagulants or antiplatelet 
agents including use of aspirin or fish oil (39%, exclusion criteria 2 [26%] and 4 [13%]). Of the 492 
patients deemed suitable, 184 (37%) were enrolled. The two main reasons the remaining 308 patients 
were not enrolled were patient disinterest (37%) and unknown reasons (28%). After introduction of the 
updated study protocol in June 2011 with the inclusion of open-label aspirin use for those taking aspirin 
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and unable to cease, almost half of patients screened (909 out of 1908 participants) were deemed 
suitable and of these 384 were enrolled in the trial. Only 10% of the patients screened after the protocol 
amendments (197 out of 1908) were excluded due to use of anticoagulants or antiplatelet agents 
including aspirin and fish oil.  
 
Figure 2-2: Screening log data 
2.6 Discussion 
This international, multicentre, randomised controlled trial was originally designed to determine 
whether the use of omega-3 PUFAs and/or aspirin will effectively improve postsurgical outcomes for 
patients with de novo AVF. Vascular access failure occurs frequently and poses a considerable health 
risk for patients receiving HD. Effective therapies to prevent primary AVF failure would therefore not 
only improve patient outcomes but also reduce economic costs of the increased hospitalisations arising 
from inadequate or artificial vascular access, rescue interventions and prolonged treatments of infective 
complications. Omega-3 PUFAs and aspirin, used in the FAVOURED study are widely available and 
inexpensive. It is expected that omega-3 PUFAs may have additive benefits to aspirin by improving 
vascular endothelial function and smooth muscle relaxation, which could potentially enhance AVF 
maturation and increase functional patency.  
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Justification for change in primary outcome 
The original FAVOURED trial was designed before the pivotal study examining the effect of 
clopidogrel in AVF was published72. This large RCT demonstrated for the first time that 6 weeks of 
clopidogrel compared to placebo was associated with a reduction in early AVF thrombosis (12.2% 
compared to 19.5%, RR: 0.63; 95% CI 0.46 – 0.97, p=0.018) but without concurrent improvement in 
the usability of newly created AVF for dialysis at 6 months (61.8% [clopidogrel] and 59.5% [placebo], 
respectively, RR 1.05; CI 0.94 – 1.17, p=0.4). This important finding suggests that preventing 
thrombosis (and loss of patency), whilst a pre‐requisite for usability, is not by itself a valid surrogate 
for maturation (usability) of the fistula. In other words, early thrombosis may not be a good clinical 
marker for AVF usability. The FAVOURED TMC therefore decided that this original primary outcome 
(early thrombosis) should be amended to a more clinically relevant outcome – AVF failure, defined as 
a composite of early thrombosis, AVF abandonment and cannulation failure at 12 months. Each 
occurrence of the components of AVF failure can result in multiple adverse clinical consequences such 
as hospitalisation, diagnostic tests, surgical or radiological interventions, insertion of CVCs, inadequate 
dialysis and even death. By increasing the follow-up duration from 3 months to 12 months, the revised 
study will inform clinicians and policy makers about the longer-term effects of omega-3 PUFAs and 
aspirin. Thus, the revised primary outcome is a clinically valid hard endpoint associated with increased 
patient morbidity and mortality as well as health care costs. 
Justification for the inclusion of patients taking aspirin 
The decision to update and implement a revised study protocol in order to allow the inclusion of 
patients taking aspirin was based on two important observations. Firstly, the recruitment rate in June 
2010 was only about one ninth of the expected rate. Analysis of screening logs revealed a high rate of 
screening failure with 1,180 (73%) out of 1,619 screened patients excluded.  The most common reason 
for exclusion from the trial was current use of aspirin in 37% of patients. Despite repeated attempts 
over a 12 month period to educate the participating centres on the lack of evidence about benefits of 
aspirin for secondary prevention in this population, recruitment rates did not improve. As shown by 
Ethier et al. 41% of HD patients in Australia and New Zealand take aspirin152. These data strongly 
support our findings that aspirin usage was a major barrier to recruitment and allowing inclusion of 
patients on aspirin would significantly improve the recruitment rate. Secondly, interim analysis of 
baseline characteristics of the recruited participants revealed an unrepresentative selection of healthy 
participants with a mean age of 55 years and an ischaemic heart disease rate of only 4%. Haemodialysis 
patients who are taking aspirin are significantly older and have a higher prevalence of cardiovascular 
disease and diabetes than those who are not taking aspirin152-154. Thus, high aspirin usage precluded 
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entry to many patients, often those at the highest risk of AVF failure, thereby potentially diluting the 
trial’s ability to detect a true benefit of omega-3 PUFAs and aspirin. Not surprisingly, a blinded analysis 
of primary patency failure rate at 12 weeks in June 2010 was much lower than expected (5% versus 
25%) which was attributed to the relatively young and healthy population as outlined above. Hence, 
with inclusion of patients on aspirin, the study sample is more likely to represent the current dialysis 
population and therefore increase the external validity of the study. Furthermore, the updated study 
inclusion criteria, allowing participation of patients already receiving aspirin, is anticipated to increase 
event rates and hence the power of the study.  
Clinical implication of the study 
If this trial reveals a positive effect of either or both agents, the routine use of these can be 
recommended in clinical practice and lead to improvement in AVF survival by reducing the frequency 
of early thrombosis, shortening time to dialysis access use, and decreasing the need for additional 
surgery. This has significant patient benefits by reducing morbidity and mortality and will lead to a 
decrease in health costs associated with repeat hospitalisations, rescue interventions and artificial 
access creation. If the trial demonstrates no benefit of these agents, this may suggest that platelet 
aggregation is not the major mechanism for early thrombosis and AVF maturation, or that inhibition 
of platelet aggregation merely salvages otherwise unsuitable AVFs as suggested by the US clopidogrel 
trial72. Further research could then focus, for example, on better selection or modification of the 
vasculature used to create the anastomosis. Even if the intervention proves not to be beneficial 
substantial additional clinical data about the natural history of AVFs, use of CVCs and long-term 
outcomes of AVF surgery will inform clinical practice. 
2.7 Chapter summary 
This chapter highlights study protocol adjustments that were undertaken to enhance the study endpoint 
and recruitment of a more representative study cohort. This international RCT was amended to address 
the clinically relevant question of whether the frequency of AVF failure can be reduced within the first 
12 months of access creation by the early use of omega-3 PUFAs and to a lesser extent aspirin. This 
amendment was made in response to a large RCT demonstrating that clopidogrel is effective in safely 
preventing early AVF thrombosis, but ineffective at increasing the usability of AVF for HD. 
Furthermore, inclusion of patients taking aspirin is expected to result in a more representative cohort 
of HD patients, who are significantly older with a higher prevalence of cardiovascular disease and 
diabetes, which may increase event rates and the power of the study. The effects of these protocol 
amendments will be explored in the following chapter.   
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Chapter 3   
Baseline characteristics of FAVOURED trial 
participants 
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3.1 Chapter overview   
The previous chapter outlined two major study amendments. First, the primary outcome, ‘thrombosis 
at 3 months’ was changed to a more clinically meaningful composite outcome of ‘AVF failure’, defined 
as AVF thrombosis, AVF abandonment, and/or cannulation failure within 12 months of AVF creation 
in response to a large RCT suggesting that reduction in early thrombosis using clopidogrel may not 
translate into improved usability of the AVF for HD. Second, the exclusion of patients taking aspirin 
was removed to overcome the high screening failure rate driven predominantly by the exclusion of 
participants taking antiplatelet agents including aspirin and the associated selection of a relatively 
younger and healthier study cohort compared to the average dialysis population based on interim 
analyses. In addition, recruitment was expanded to centres from Malaysia and the UK. This chapter 
investigates whether these post-initiation study protocol amendments successfully increased 
recruitment of a broader and more representative haemodialysis cohort, including patients already 
receiving aspirin to enhance the external generalisability. It also aimed to explore differences in 
participant characteristics between recruiting countries to inform the renal community about 
international differences in patient characteristics and clinical practices.  
3.2 Included publications 
This chapter is based on the following publications: 
Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson 
DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED study team. Baseline 
characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal 
Disease (FAVOURED) study. Nephrology (Carlton). 2016;21(3):217-28. Copyright permission has 
been obtained to reproduce this manuscript 
Contribution of the candidate: The candidate was lead- and corresponding author of the publication 
and developed the concept and design for the comparison of baseline characteristics, interpreted the 
study results, designed the tables, wrote the first draft and revised the manuscript.  
Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson 
DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED study team. Updates on 
baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes 
in REnal Disease (FAVOURED) study. Nephrology (Carlton). 2017;22(10):823-824. Copyright 
permission has been obtained for reproduction. 
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Following publication of the original manuscript, some additional baseline data became available and 
a randomisation error was identified (a randomisation was performed without an identifiable patient) 
resulting in minor changes to the descriptive statistics and a revised total number of 567 rather than 
568 enrolled study participants. Analysis of the final data set with two minor changes to the original 
statistical programs showed that the resulting changes were small and did not alter the conclusions of 
the original article.  
Contribution of the candidate: The candidate identified the data discrepancy and initiated reanalysis of 
the data set. The candidate drafted and submitted a letter to the editor including updated tables of the 
baseline characteristics. This chapter contains the updated baseline characteristics.  
3.3 Abstract 
Aim: The FAVOURED trial investigated whether three months of omega-3 PUFAs, either alone or in 
combination with aspirin, will effectively reduce primary access failure of de novo AVFs. This report 
presents the baseline characteristics of all study participants, examines whether study protocol 
amendments successfully increased recruitment of a broader and more representative haemodialysis 
cohort, including patients already receiving aspirin, and contrasts Malaysian participants with those 
from Australia, New Zealand and the UK. 
Method: This international, randomised, double-blind, placebo-controlled trial included patients older 
than 19 years with stage 4 or 5 chronic kidney disease currently receiving, or planned within 12 months 
to receive HD.  
Results: Participants (n=567) were overweight (28.6 ± 7.3kg/m2), relatively young (54.8 ± 14.3 years), 
and predominantly male (63%) with a high prevalence of diabetes mellitus (47%) but low rate of 
ischaemic heart disease (11%). Sixty one percent were planned for lower arm AVF creation. Malaysian 
participants (n=155) were younger (51.9 ± 13.6 years versus 57.1 ± 14.2 years, p<0.001) with a higher 
prevalence of diabetes mellitus (67% versus 44%, p<0.001) but less ischaemic heart disease (5% versus 
19%, p<0.001) compared with the combined Australian, New Zealand and UK cohort (n=228). 
Protocol modifications allowing for inclusion of patients receiving aspirin increased the prevalence of 
co-morbidities compared with the original cohort.   
Conclusions: The FAVOURED study participants, whilst mostly similar to patients in contemporary 
national registry reports and comparable recent clinical trials, were on average younger and had less 
ischaemic heart disease. These differences were reduced as a consequence of including patients already 
receiving aspirin. 
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3.4 Background 
The importance of vascular access for improving clinical care and outcomes in HD patients is the focus 
of many quality initiatives around the world (e.g. The National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (NKF-KDOQI) guidelines21, Kidney Health Australia - Caring for 
Australasians with Renal Impairment (KHA-CARI) guidelines155, Canadian Society of Nephrology14, 
Fistula First Breakthrough Initiative156). The benefits of a native AVF compared with synthetic AVG 
or CVC include lower rates of thrombosis, infection, interventions to maintain patency and overall 
mortality19,24,33. However, native AVF are more difficult to establish and take longer to mature, 
resulting in a greater need to maintain CVC and a higher primary access failure rate (ranging between 
20–60%). Early and late failure has been attributed to early thrombosis and a failure of maturation28,72. 
Vascular access dysfunction is associated with significant morbidity and mortality and is a major 
economic burden for health care providers and therefore an important target for therapeutic 
interventions7,146,147.  
Although the short-term post-operative use of antiplatelet agents may reduce early thrombosis rates65,69-
72,148, no intervention has been shown to significantly improve the proportion of fistulas that achieve 
the requirement for sustained regular dialysis, defined as the “usability” of AVF. Omega-3 PUFAs 
derived from fish and fish oils not only inhibit platelet aggregation but are anti-inflammatory, anti-
proliferative and promote vasodilatation all of which may have a favourable impact on the usability of 
a de novo AVF80. 
The FAVOURED trial investigated whether omega-3 polyunsaturated fatty acids either alone or in 
combination with aspirin will effectively reduce primary access failure of de novo AVF in patients 
with stage 4 or 5 chronic kidney disease and, by doing so, increase the proportion that achieve usability.  
In this paper, the baseline characteristics of the FAVOURED trial patients recruited in Malaysia, the 
UK, Australia and New Zealand (ANZ) are described. Characteristics of participants recruited before 
and after introduction of study protocol amendments designed to increase recruitment of a broader and 
more representative dialysis patient group, including recruitment of patients already receiving aspirin, 
are compared to evaluate the success of the protocol amendments. The Malaysian participants are 
compared and contrasted with the combined ANZ and UK cohort.  
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3.5 Methods 
Participants 
The trial included patients with stage 4 or 5 chronic kidney disease aged over 19 years and currently 
receiving, or planned within 12 months to receive HD. Participants underwent AVF surgery in the 
upper or lower arm as their primary HD access. Patients were excluded if they received a revision of 
an existing AVF rather than a de novo AVF, had an increased bleeding risk (bleeding disorder, recent 
or active GI ulcer, platelet count < 100×109 /L, hepatic insufficiency or anti-coagulation therapy), were 
taking NSAIDs, anticoagulants or anti-platelet agents with the exception of low-dose aspirin (eligible 
for the expanded protocol using open-label aspirin), had contra-indications for taking the study agents 
(planned surgery that would require cessation of the study medication, treatment-resistant syndrome of 
asthma, rhinitis and nasal polyps or a known allergy to the study agents), or were female patients who 
were breastfeeding, pregnant or intended to fall pregnant during the study period. Local ethics 
committees approved the study and all enrolled patients provided written informed consent. 
Study design  
FAVOURED is an international double-blind, randomised placebo-controlled trial conducted in 35 HD 
centres of ANZ, the UK and Malaysia. This trial is designed to assess the effect of omega-3 PUFAs 
(Omacor capsules, 2g twice daily, Abbott Products Pty Ltd, Allschwil, Switzerland) and/or aspirin 
(100mg daily, Bayer HealthCare, Wuppertal, Germany) on ‘AVF access failure’, defined as a 
composite of thrombosis, AVF abandonment or cannulation failure at 12 months following de novo 
AVF creation. The original protocol was a 2x2 factorial-design trial, whereby participants were 
randomised to one of four treatment groups formed by aspirin or matching placebo and omega-3 
PUFAs or matching placebo. Patient recruitment started in August 2008 and finished in February 2014. 
Recruitment to the amended protocol started in June 2011 and included suitable patients receiving 
aspirin and unable or unwilling to cease. In this expanded protocol, participants were allowed to 
continue with open-label aspirin at their current dose and were randomised to omega-3 PUFAs or 
matched placebo only. This amendment was implemented in response to the high prevalence of aspirin 
use and screen failure with selection of a relatively younger and healthier patient cohort. Including 
patients taking aspirin was expected to enrol a more representative cohort of older patients with a higher 
prevalence of cardiovascular disease and diabetes. A full discussion of the changes to the study protocol 
are described in detail elsewhere157 (Chapter 2).  
Statistical analysis 
Results are expressed as mean ± standard deviation (SD) or median with interquartile range (IQR) 
depending on distribution characteristics for continuous variables and number (percentage) for 
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categorical variables. Comparisons for continuous data were performed using independent-samples t-
tests and Wilcoxon rank sum tests, as appropriate. Comparisons for binary measures were performed 
using Pearson’s chi-square tests. Baseline characteristics independently associated with AVF site 
(upper versus lower arm) were determined using multivariable logistic regression. A p-value less than 
0.05 was considered statistically significant. The calculations were performed using SAS version 9.3 
(SAS Institute Inc., Cary, NC, USA). 
3.6 Results 
Patient enrolment  
The first FAVOURED study patient was enrolled on the 21st of August 2008, and recruitment 
concluded on the 28th of February 2014 with a total of 4242 subjects screened from 35 clinical sites. 
Prior to the start of recruitment to the amended study protocol in June 2011, 21% of patients screened 
(492 out of 2334) were deemed eligible, with the remaining patients excluded mainly due to the use of 
anticoagulants or anti-platelet agents such as aspirin (39%). Of the 492 patients deemed eligible, 184 
(37%) were enrolled. Following extension of the study protocol to allow inclusion of patients receiving 
open-label aspirin, 48% of patients screened (909 out of 1908 participants) were deemed eligible and, 
of these, 383 (42%) were enrolled. Only 10% of the patients screened after the protocol amendments 
(197 out of 999) were excluded due to concurrent use of other anti-platelet agents or anti-coagulants. 
In ANZ, 403 participants were randomised from 25 different sites of which 184 were included pre- and 
219 post-protocol amendment. Following the protocol amendment, an additional 155 participants were 
enrolled from 8 Malaysian sites and 9 from a single centre in the UK.  
Baseline characteristics of all participants 
Baseline characteristics of all 567 participants are shown in Table 3-1. Participants were predominantly 
male and Caucasian or Asian. The proportion of Indigenous participants was similar to that of the 
general incident HD population of ANZ158. Their mean age was 54.8 ± 14.3 years. Most were 
overweight or obese; almost half had diabetes mellitus and half were former or current smokers, 
although only a minority had ischaemic heart disease (IHD, 10%) or congestive heart disease (4%). 
The majority of trial participants had systolic hypertension. The most common causes of chronic 
kidney disease were diabetic nephropathy (39%), glomerulonephritis (14%), and hypertensive 
nephropathy (13%) and. Half of the participants were not receiving renal replacement therapy and had 
no other dialysis access at the time of AVF creation, which was predominantly planned for the lower 
arm. Forty two percent of participants were receiving HD via a CVC at the time of AVF creation. The 
mean haemoglobin was 108 ± 19g/L. Platelet counts and coagulation profiles were normal in the vast 
majority of participants.  
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Table 3-1: Baseline characteristics of all participants 
 
Total 
N=567 
Region 
ANZ 
(N=403) 
Malaysia 
(N=155) 
UK 
(N=9) 
Demographics     
Gender, n (%)†     
     Male  359 (63%) 264 (66%) 92 (59%) 3 (33%) 
     Female 208 (37%) 139 (35%) 63 (41%) 6 (67%) 
Age (years; mean ± SD)† 54.8 ± 14.3 55.8 ± 14.4 51.9 ± 13.6 61.0 ± 12.9 
Ethnicity, n (%)†     
     Aboriginal or Torres Strait Islander 22 (4%) 22 (6%) 0 0 
     Asian 181 (32%) 26 (7%) 155 (100%) 0 
     Caucasoid 298 (53%) 289 (72%) 0 9 (100%) 
     MPI 44 (8%) 44 (11%) 0 0 
     Other 20 (4%) 20 (5%) 0 0 
Clinical history     
Height (cm; mean ± SD)‡ 166.6± 10.2 169.1 ± 10.0 160.2 ± 7.9 166.6 ± 4.6 
Weight (kg; mean ± SD)† 79.7 ± 23.1 85.0 ± 23.3 66.1 ± 16.3 77.7 ± 20.9 
Waist measurement (cm; mean ± SD)§ 99.1 ± 19.4 102.6 ± 18.4 91.0 ± 19.1 93.8 ± 20.7 
Hip measurement (cm; mean ± SD)§ 101.9 ± 18.2 105.2 ± 16.7 93.7 ± 19.4 107.1 ± 16.0 
Waist/hip ratio (mean ± SD)§ 0.98 ± 0.17 0.98 ± 0.10 1.00 ± 0.28 0.87 ± 0.09 
Systolic blood pressure (mm Hg; mean ± SD)† 146 ± 23 145 ± 23 149 ± 24 152 ± 19 
Diastolic blood pressure (mm Hg; mean ± 
SD)† 
82 ± 13 81 ± 14 81 ± 13 83 ± 16 
Heart rate (beats per minute; mean ± SD)‡ 76 ± 13 75 ± 13 79 ± 13 78 ± 19 
Smoking status, n (%)†     
     Never 275 (49%) 179 (45%) 89 (57%) 7 (78%) 
     Former 212 (38%) 162 (40%) 48 (31%) 2 (22%) 
     Current 78 (14%) 60 (15%) 18 (12%) 0 
Diabetes mellitus, n (%)†     
     Type 1 or Type 2  264 (47%) 156 (39%) 104 (67%) 4 (44%) 
     Type 1 25 (10%) 19 (12%) 5 (5%) 1 (25%) 
     Type 2 239 (91%) 137 (88%) 99 (95%) 3 (75%) 
Ischaemic heart disease, n (%)† 58 (10%) 50 (13%) 7 (5%) 1 (11%) 
Congestive heart disease, n (%)† 22 (4%) 17 (5%) 5 (3%) 0 
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Total 
N=567 
Region 
ANZ 
(N=403) 
Malaysia 
(N=155) 
UK 
(N=9) 
Aetiology of renal disease, n (%)†     
     Diabetic nephropathy 221 (39%) 122 (30%) 96 (62%) 3 (33%) 
     Glomerulonephritis 77 (14%) 68 (17%) 7 (5%) 2 (22%) 
     Hypertension/vascular 75 (13%) 46 (12%) 29 (19%) 0 
     Polycystic kidney disease 40 (7%) 36 (9%) 4 (3%) 0 
     Reflux nephropathy 26 (5%) 25 (6%) 1 (1%) 0 
     Other 126 (22%) 104 (26%) 18 (12%) 4 (44%) 
AVF location, n (%)†     
     Upper arm 223 (39%) 137 (34%) 81 (52%) 5 (56%) 
     Lower arm 344(61%) 266 (66%) 74 (48%) 4 (44%) 
     Transplant 10 (2%) 10 (3%) 0 0 
     Peritoneal dialysis 35 (6%) 35 (9%) 0 0 
     Haemodialysis 240 (43%) 145 (36%) 93 (60%) 2 (22%) 
     Not currently receiving renal replacement 
therapy 
280 (50%) 211 (53%) 62 (40%) 7 (78%) 
Principal access currently in use for dialysis, n 
(%)† 
    
     No access currently in use 290 (51%) 221 (55%) 62 (40%) 7 (78%) 
     Arteriovenous fistula 7 (1%) 4 (1%) 2 (1%) 1 (11%) 
     Arteriovenous graft - artificial graft 1 (0.2%) 1 (0.2%) 0 0 
     Central venous catheter (cuffed) 138 (25%) 129 (32%) 8 (5%) 1 (11%) 
     Central venous catheter (non-cuffed) 94 (17%) 11 (3%) 83 (54%) 0 
     Peritoneal dialysis catheter 35 (6%) 35 (9%) 0 0 
Dialysis duration (months; median [IQR])††† 4 (2 - 18) 6 (2- 26) 2 (1 - 5) 21 (2 - 39) 
Laboratory investigations for predialysis and dialysis participants combined 
Haemoglobin (g/L; mean ± SD)† 108 ± 19 113 ± 16 97 ± 19 104 ± 12 
Platelets (109/L; mean ± SD)† 247 ± 79 241 ± 79 262 ± 77 253 ± 88 
White blood cells (109/L; mean ± SD)† 7.9 ± 3.2 7.6 ± 2.3 8.8 ± 4.9 6.0 ± 0.7 
INR (mean ± SD)§ 1.1 ± 0.3 1.0 ± 0.1 1.1 ± 0.5 0.9 ± 0.1 
APTT (seconds; mean ± SD)§ 33.7 ± 17.5 33.2 ± 19.6 35.0 ± 10.7 31.4 ± 3.1 
Fibrinogen (g/L; mean ± SD)¶ 5.0 ± 4.0 4.8 ± 1.4 5.9 ± 8.0 3.4 ± 0.7 
Sodium (mmol/L; mean ± SD)† 138 ± 4 139 ± 3 137 ± 5 138 ± 3 
Albumin (g/L; mean ± SD)‡ 36.0 ± 6.2 36.3 ± 5.7 35.5 ± 7.4 30.3 ± 5.1 
Fasting glucose (mmol/L; mean ± SD)¶ 6.8 ± 3.6 6.5 ± 3.1 7.9 ± 4.6 5.5 ± 3.5 
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Total 
N=567 
Region 
ANZ 
(N=403) 
Malaysia 
(N=155) 
UK 
(N=9) 
HbA1C (%; mean ± SD)§ 6.2 ± 1.4 6.1 ± 1.23 6.7 ± 1.8 6.0 ± 1.3 
Parathormone (pmol/L; mean ± SD)§ 37.2 ± 35.4 37.8 ± 37.9 36.0 ± 28.3 17.1 ± 6.6 
Triglyceride (mmol/L; mean ± SD)‡ 2.0 ± 1.2 2.0 ± 1.1 2.0 ± 1.4 2.1 ± 0.6 
HDL cholesterol (mmol/L; mean ± SD)§ 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 1.6 ± 1.0 
LDL cholesterol (mmol/L; mean ± SD)§ 2.6 ± 1.1 2.4 ± 1.0 3.0 ± 1.2 2.8 ± 1.6 
Laboratory investigations for predialysis participants  
Creatinine (μmol/L; mean ± SD)† 504 ± 212 468 ± 188 642 ± 241 394 ± 154 
Urea (mmol/L; mean ± SD)† 25.4 ± 7.8 26.1 ± 7.8 23.4 ± 7.7 21.9 ± 5.7 
Potassium (mmol/L; mean ± SD)† 4.7 ± 0.7 4.8 ± 0.6 4.5 ± 0.7 5.1 ± 0.9 
Bicarbonate (mmol/L; mean ± SD)‡ 20.9 ± 4.1 21.7 ± 3.3 18.3 ± 5.4 20.0 ± 3.3 
Total calcium (mmol/L; mean ± SD)‡ 2.2 ± 0.2 2.3 ± 0.2 2.2 ± 0.1 2.2 ± 0.1 
Phosphate (mmol/L; mean ± SD)‡ 1.6 ± 0.4 1.6 ± 0.5 1.7 ± 0.4 1.6 ± 0.4 
Laboratory investigations for dialysis participants  
Creatinine (μmol/L; mean ± SD)† 719 ± 271 730 ± 273 703 ± 265 464 ± 238 
Urea (mmol/L; mean ± SD)† 19.0 ± 7.7 20.3 ± 7.5 16.4 ± 7.6 14.9 ± 1.6 
Potassium (mmol/L; mean ± SD)† 4.5 ± 0.9 4.7 ± 0.9 4.2 ± 0.8 5.1 ± 0.0 
Bicarbonate (mmol/L; mean ± SD)§ 23.9 ± 3.7 24.6 ± 3.6 21.9 ± 3.4 25.0 ± 1.4 
Total calcium (mmol/L; mean ± SD)‡ 2.2 ± 0.2 2.3 ± 0.2 2.2 ± 0.3 2.3 ± 0.2 
Phosphate (mmol/L; mean ± SD)‡ 1.7 ± 0.6 1.7 ± 0.6 1.7 ± 0.5 1.2 ± 0.2 
Abbreviations: APTT - activated partial thromboplastin time; AVF – arteriovenous fistula; BMI – body mass index; ESAs 
– erythropoietin stimulating agents; HDL – high-density lipoprotein; IQR – interquartile range; LDL – low-density 
lipoprotein; MPI – Maori & Pacific Islanders. 
†missing data in <1% of patients 
‡missing data in 1-4.9% of patients 
§missing data in 5-9.9% of patients 
¶missing data in 10-19.9% of patients 
††Dialysis patients only (n=275 for all participants on dialysis, n=180 for ANZ cohort, n=93 for Malaysian cohort, and n=2 
for UK cohort)   
Comparison of Australian and New Zealand participants pre- and post-amendment of the study 
protocol  
Following protocol modifications to allow for open-label aspirin use in patients committed to aspirin, 
an additional 219 ANZ participants were enrolled and compared with the 184 participants from the 
original protocol (Table 3-2). The average age of the ANZ cohort increased from 54.6 years to 56.9 
years. The proportion of Indigenous participants increased (from 13 to 19 %) and that of Caucasians 
decreased (from 74% to 71%, p=0.07). Diabetes mellitus was present in 44% of post-modification 
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participants compared with the original 33% (p=0.03), IHD and congestive heart disease increased to 
19% and 7%, respectively, compared with 4% (p<0.001) and 1% (p<0.01), respectively. The mean 
body mass index (BMI) and waist-to-hip ratio (WHR) but not blood pressure were significantly higher 
following protocol amendments and diabetic nephropathy as a cause of ESKD was more prevalent 
post-protocol modification (38% versus 22%).  
There was an increase in planned creation of lower arm AVF (72% compared with 59%, p<0.01) but 
no significant variation in renal replacement modality or type of dialysis access prior to AVF creation 
compared with the pre-modification trial cohort.  
Whilst the average HbA1C was significantly higher in the post-modification cohort (6.6% compared 
to 6%, p<0.05), total cholesterol and LDL-cholesterol levels were reduced.  
Table 3-2: Comparison of Australian and New Zealand participants pre- and post-study protocol 
amendment 
 ANZ 
pre-protocol 
change 
(N=184) 
ANZ 
post-protocol 
change 
(N=219) 
P-value 
Demographics    
Gender, n (%)†   0.60 
     Male 118 (64%) 146 (67%)  
     Female 66 (36%) 73 (33%)  
Age (years; mean ± SD)† 54.6 ± 14.4 56.9 ± 14.3 0.11 
Ethnicity, n (%)†   0.07 
     Aboriginal or Torres Strait Islander 6 (3%) 16 (7%)  
     Asian 17 (9%) 9 (4%)  
     Caucasoid 136 (74%) 153 (71%)  
     MPI 18 (10%) 26 (12%)  
     Other 7 (4%) 13 (6%)  
Clinical history    
Height (cm; mean ± SD)† 169.5 ± 10.3 168.7 ± 9.7 0.47 
Weight (kg; mean ± SD)† 82.9 ± 24.6 86.8 ± 22.0 0.10 
BMI (kg/m2; mean ± SD)† 28.7 ± 7.2 30.6 ± 7.7 0.01 
Waist measurement (cm; mean ± SD)§ 99.2 ± 17.8 105.6 ± 18.5 <0.001 
Hip measurement (cm; mean ± SD)¶ 103.5 ± 16.8 106.7 ± 16.5 0.07 
Waist/hip ratio (mean ± SD)¶ 0.96 ± 0.09 0.99 ± 0.11 <0.01 
……WHR male 0.99 ± 0.07 1.01 ± 0.12  
……WHR female 0.90 ± 0.08 0.95 ± 0.08  
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 ANZ 
pre-protocol 
change 
(N=184) 
ANZ 
post-protocol 
change 
(N=219) 
P-value 
Use of ESAs, n (%)† 112 (61%) 112 (51%) 0.06 
Systolic blood pressure (mm Hg; mean ± SD)† 145 ± 23 145 ± 22 0.83 
Diastolic blood pressure (mm Hg; mean ± SD)† 83 ± 13 80 ± 14 0.10 
Heart rate (beats per minute; mean ± SD)‡ 76 ± 13 74 ± 13 0.06 
Smoking status, n (%)†   0.12 
     Never 92 (50%) 87 (40%)  
     Former 69 (38%) 93 (43%)  
     Current 23 (13%) 37 (17%)  
Diabetes mellitus, n (%)†    
     Type 1 or Type 2  61 (33%) 95 (44%) 0.03 
     Type 1 7 (12%) 12 (13%)  
      Type 2 54 (89%) 83 (87%) 
Ischaemic heart disease, n (%)† 8 (4%) 42 (19%) <0.001 
Congestive heart disease, n (%)† 2 (1%) 15 (7%) <0.01 
Aetiology of renal disease, n (%)†   <0.01 
     Diabetic nephropathy 40 (22%) 82 (38%)  
     Glomerulonephritis 39 (21%) 29 (13%)  
     Hypertension/vascular 22 (12%) 24 (11%)  
     Polycystic kidney disease 22 (12%) 14 (7%)  
     Reflux nephropathy 12 (7%) 13 (6%)  
     Other 49 (27%) 55 (25%)  
AVF location, n (%)†   <0.01 
     Upper arm 75 (41%) 62 (28%)  
     Lower arm 109 (59%) 157 (72%)  
Renal replacement therapy at time of AVF creation, n 
(%)† 
  0.81 
     Transplant 5 (3%) 5 (2%)  
     Peritoneal dialysis 17 (9%) 18 (8%)  
     Haemodialysis 67 (36%) 78 (36%)  
     Not currently receiving renal replacement therapy 95 (52%) 116 (54%)  
Principal access currently in use for dialysis, n (%)†   0.78 
     No access currently in use 100 (54%) 121 (56%)  
     Arteriovenous fistula 1 (1%) 3 (1%)  
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 ANZ 
pre-protocol 
change 
(N=184) 
ANZ 
post-protocol 
change 
(N=219) 
P-value 
     Arteriovenous graft - artificial graft 0 1 (0.5%)  
     Central venous catheter (cuffed) 61 (33%) 68 (31%)  
     Central venous catheter (non-cuffed) 5 (3%) 6 (3%)  
     Peritoneal dialysis catheter 17 (9%) 18 (8%)  
Dialysis duration (months; median [IQR])†‡‡ 6 (2 - 28) 7 (2 - 25) 0.96 
Laboratory investigations for predialysis and dialysis participants combined 
Haemoglobin (g/L; mean ± SD)† 112 ± 17 113 ± 16 0.52 
Platelets (109/L; mean ± SD)† 246 ± 86 238 ± 72 0.33 
White blood cells (109/L; mean ± SD † 7.6 ± 2.2 7.6 ± 2.3 0.78 
INR (mean ± SD)§ 1.0 ± 0.1 1.0 ± 0.1 0.64 
APTT(seconds; mean ± SD)§ 34.7 ± 23.7 32.1 ± 15.5 0.21 
Fibrinogen (g/L; mean ± SD)¶ 4.8 ± 1.4 4.8 ± 1.4 0.92 
Sodium (mmol/L; mean ± SD)† 139 ± 3 139 ± 3 <0.05 
Albumin (g/L; mean ± SD)‡ 36.8 ± 5.5 35.9 ± 5.9 0.12 
Fasting glucose (mmol/L; mean ± SD)¶ 6.1 ± 2.5 6.7 ± 3.5 0.06 
HbA1C (%; mean ± SD)§ 6.0 ± 1.2 6.2 ± 1.3 0.03 
Parathormone (pmol/L; mean ± SD)§ 36.7 ± 35.5 38.8± 39.8 0.59 
Cholesterol (mmol/L; mean ± SD)‡ 4.5 ± 1.2 4.2 ± 1.2 0.01 
Triglyceride (mmol/L; mean ± SD)‡ 2.0 ± 1.0 2.0 ± 1.2 0.83 
HDL cholesterol (mmol/L; mean ± SD)§ 1.1 ± 0.4 1.1 ± 0.4 0.99 
LDL cholesterol (mmol/L; mean ± SD)¶ 2.6 ± 1.1 2.2 ± 0.9 <0.001 
Laboratory investigations for predialysis participants     
Creatinine (μmol/L; mean ± SD)† 470 ± 205 467 ± 174 0.93 
Urea (mmol/L; mean ± SD) † 25.2 ± 7.0 26.9 ± 8.4 0.12 
eGFR (ml/min/1.73m2; mean ± SD)† 12.4 ± 6.8 12.0 ± 5.3 0.62 
Potassium (mmol/L; mean ± SD)† 4.8 ± 0.6 4.8 ± 0.7 0.99 
Bicarbonate (mmol/L; mean ± SD)‡ 21.3 ± 3.3 22.0 ± 3.3 0.14 
Total calcium (mmol/L; mean ± SD)‡ 2.2 ± 0.2 2.3 ± 0.2 0.53 
Phosphate (mmol/L; mean ± SD)‡ 1.6 ± 0.5 1.6 ± 0.4 0.84 
Laboratory investigations for dialysis participants     
Creatinine (μmol/L; mean ± SD)† 732 ± 288 729 ± 261 0.95 
Urea (mmol/L; mean ± SD)† 21.1 ± 7.0 19.7 ± 8.0 0.22 
Potassium (mmol/L; mean ± SD)† 4.7 ± 0.9 4.7 ± 0.8 0.97 
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 ANZ 
pre-protocol 
change 
(N=184) 
ANZ 
post-protocol 
change 
(N=219) 
P-value 
Bicarbonate (mmol/L; mean ± SD)‡ 24.3 ± 4.0 24.9 ± 3.2 0.36 
Total calcium (mmol/L; mean ± SD)‡ 2.2 ± 0.2 2.3 ± 0.2 0.74 
Phosphate (mmol/L; mean ± SD)‡ 1.7 ± 0.7 1.7 ± 0.6 0.96 
Abbreviations: APTT - activated partial thromboplastin time; AVF – arteriovenous fistula; BMI – body mass index; 
eGFR – estimated glomerular filtration rate; ESAs – erythropoietin stimulating agents; HDL – high-density lipoprotein; 
IQR – interquartile range; LDL – low-density lipoprotein; MPI – Maori & Pacific Islanders. 
†missing data in <1% of patients 
‡missing data in 1-4.9% of patients 
§missing data in 5-9.9% of patients 
¶missing data in 10-19.9% of patients 
‡‡Dialysis patients only (n=84 for pre-protocol amendment cohort, n=96 for post-protocol amendment cohort) 
Comparison of combined ANZ and UK participants with Malaysian participants post-protocol 
amendment 
Baseline data comparing the Malaysian cohort (n=155) with the combined ANZ (n=219) and UK (n=9) 
participants (ANZUK n=228) recruited after protocol modifications are presented in Table 3-3. 
Malaysian participants were significantly younger, shorter and had a lower BMI, but had a similar 
WHR when compared with the ANZUK group.  
Although diabetes mellitus was significantly more prevalent in the Malaysian cohort (67% versus 44%, 
p < 0.001), IHD (5% versus 19%, p<0.001) and smoking (current or former = 43% versus 58%, p<0.01) 
were less common than in the ANZUK cohort. At the time of enrolment, Malaysian participants had a 
significantly lower rate of aspirin use (29%) than ANZUK participants (49%, p<0.001).  
A lower arm AVF was planned in 48% of Malaysian participants compared to 71% in the combined 
group. Multivariable regression analysis adjusted for relevant potential confounders indicate that the 
likelihood of undergoing lower arm AVF surgery was strongly associated with male gender, younger 
age, and country (ANZUK), but not BMI or diabetes status (Table 3-4). Sixty percent of the Malaysian 
cohort required HD prior to AVF surgery, predominantly via a non-cuffed CVC (83 out of 93 
participants). This was in contrast to 35% of ANZUK participants undergoing HD, primarily via cuffed 
CVC (69 out of 80), and 43% requiring renal replacement therapy at the time of access surgery. 
The average haemoglobin level was significantly lower in the Malaysian cohort compared with 
ANZUK (97g/L ± 19g/L versus 113 ± 16g/L, p<0.001). The proportion of patients using erythropoietin 
stimulating agents (ESAs) was 25% in Malaysia compared with 51% in ANZUK (p<0.001). Malaysian 
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participants had a significantly greater white cell count (8.8 versus 7.5×109/L, p<0.001) and platelet 
count (262 versus 238×109/L, p<0.01) suggestive of inflammation. Fasting blood glucose, cholesterol 
and LDL-cholesterol levels were significantly higher in the Malaysian cohort compared to participants 
from ANZUK. 
 
Table 3-3: Comparison of Australian, New Zealand and UK participants to Malaysian participants 
post-study protocol amendment 
 
 
Post-protocol 
ANZ and UK 
cohort 
combined 
(N=228) 
Malaysian 
cohort (N=155) 
P-value 
Demographics    
Gender, n (%)†   0.23 
     Male 149 (65%) 92 (59%)  
     Female 79 (35%) 63 (41%)  
Age (years; mean ± SD) † 57.1 ± 14.2 51.9 ± 13.6 <0.001 
Ethnicity, n (%)†   <0.001 
     Aboriginal or Torres Strait Islander 16 (7%) 0  
     Asian 9 (4%) 155 (100%)  
     Caucasoid 162 (72%) 0  
     MPI 26 (12%) 0  
     Other 13 (6%) 0  
Clinical history    
Height (cm; mean ± SD)‡ 168.7 ± 9.6 160.2 ± 7.9 <0.001 
Weight(kg; mean ± SD) † 86.5 ± 22.0 66.1 ± 16.3 <0.001 
BMI (kg/m2; mean ± SD)‡ 30.5 ± 7.7 25.7 ± 5.7 <0.001 
Waist measurement (cm; mean ± SD)§ 105.1 ± 18.7 91.0 ± 19.1 <0.001 
Hip measurement(cm; mean ± SD)§ 106.8 ± 16.4 93.7 ± 19.4 <0.001 
Waist/hip ratio (mean ± SD)§ 0.98 ± 0.11 1.00 ± 0.28 0.53 
……WHR male 1.01 ± 0.11 1.02 ± 0.27  
……WHR female 0.94 ± 0.08 0.96 ± 0.28  
Use of aspirin, n (%)† 111 (49%) 45 (29%) <0.001 
Use of ESAs, n (%)† 115 (51%) 39 (25%) <0.001 
Systolic blood pressure (mm Hg; mean ± SD) † 146 ± 22 149 ± 24 0.22 
Diastolic blood pressure (mm Hg; mean ± SD) † 81 ± 14 81 ± 13 0.52 
Heart rate (beats per minute; mean ± SD)‡ 74 ± 13 79 ± 13 <0.001 
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Post-protocol 
ANZ and UK 
cohort 
combined 
(N=228) 
Malaysian 
cohort (N=155) 
P-value 
Smoking status, n (%)†   <0.01 
     Never 94 (42%) 89 (57%)  
     Former 95 (42%) 48 (31%)  
     Current 37 (16%) 18 (12%)  
Diabetes mellitus, n (%)†    
     Type 1 or Type 2  99 (44%) 104 (67%) <0.001 
     Type 1 13 (13%) 5 (5%)  
      Type 2 86 (87%) 99 (95%) 
Ischaemic heart disease, n (%)† 43 (19%) 7 (5%) <0.001 
Congestive heart disease, n (%)† 15 (7%) 5 (3%) 0.14 
Aetiology of renal disease, n (%)†   <0.001 
     Diabetic nephropathy 85 (38%) 96 (62%)  
     Glomerulonephritis 31 (14%) 7 (5%)  
     Hypertension/vascular 24 (11%) 29 (19%)  
     Polycystic kidney disease 14 (6%) 4 (3%)  
     Reflux nephropathy 13 (6%) 1 (1%)  
     Other 59 (26%) 18 (12%)  
AVF location, n (%)†   <0.001 
     Upper arm 67 (29%) 81 (52%)  
     Lower arm 161 (71%) 74 (48%)  
Renal replacement therapy at time of AVF creation, n 
(%)† 
  <0.001 
     Transplant 5 (2%) 0  
     Peritoneal dialysis 18 (8%) 0  
     Haemodialysis 80 (35%) 93 (60%)  
     Not currently receiving renal replacement therapy 123 (54%) 62 (40%)  
Principal access currently in use for dialysis, n (%)†   <0.001 
     No access currently in use 128 (57%) 62 (40%)  
     Arteriovenous fistula 4 (2%) 2 (1%)  
     Arteriovenous graft - artificial graft 1 (0.4%) 0  
     Central venous catheter (cuffed) 69 (31%) 8 (5%)  
     Central venous catheter (non-cuffed) 6 (3%) 83 (54%)  
     Peritoneal dialysis catheter 18 (8%) 0  
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Post-protocol 
ANZ and UK 
cohort 
combined 
(N=228) 
Malaysian 
cohort (N=155) 
P-value 
Dialysis duration (months; median [IQR]) §‡‡ 7 (2 - 25) 2  (1 - 5) <0.001 
Laboratory investigations    
Haemoglobin (g/L; mean ± SD) † 113 ± 16 97 ± 19 <0.001 
Platelets (109/L; mean ± SD) † 238 ± 73 262 ± 77 <0.01 
White blood cells (109/L; mean ± SD) † 7.5 ± 2.3 8.8 ± 4.9 <0.001 
INR (mean ± SD)§ 1.0 ± 0.1 1.1 ± 0.5 0.06 
APTT(seconds; mean ± SD) § 32.1 ± 15.2 35.0 ± 10.7 0.04 
Fibrinogen (g/L; mean ± SD)†† 4.8 ± 1.4 5.9 ± 8.0 0.14 
Sodium (mmol/L; mean ± SD) † 139 ± 3 137.3 ± 4.5 <0.01 
Albumin (g/L; mean ± SD)‡ 35.7 ± 5.9 35.5 ± 7.4 0.85 
Fasting glucose (mmol/L; mean ± SD)¶ 6.7 ± 3.5 7.9 ± 4.6 <0.01 
HbA1C (%; mean ± SD) ¶ 6.2 ± 1.3 6.7 ± 1.8 <0.01 
Parathormone (pmol/L; mean ± SD) § 38.4 ± 39.5 36.0 ± 28.3 0.54 
Cholesterol (mmol/L; mean ± SD) ‡ 4.2 ± 1.2 5.1 ± 1.5 <0.001 
Triglyceride (mmol/L; mean ± SD)§ 2.0 ± 1.1 2.0 ± 1.4 0.60 
HDL cholesterol (mmol/L; mean ± SD)§ 1.1 ± 0.4 1.1 ± 0.4 0.37 
LDL cholesterol (mmol/L; mean ± SD) § 2.3 ± 0.9 3.0 ± 1.2 <0.001 
Laboratory investigations for predialysis 
participants  
   
Creatinine (μmol/L; mean ± SD) † 463 ± 173 642 ± 249 <0.001 
Urea (mmol/L; mean ± SD) † 26.6 ± 8.3 23.4 ± 7.7 0.01 
eGFR‡‡ (ml/min/1.73m2; mean ± SD) † 12.0 ± 5.2 8.1 ± 3.3 <0.001 
Potassium (mmol/L; mean ± SD) † 4.8 ± 0.7 4.5 ± 0.7 0.01 
Bicarbonate (mmol/L; mean ± SD) § 21.9 ± 3.3 183 ± 5.4 <0.001 
Total calcium (mmol/L; mean ± SD) ‡ 2.3 ± 0.2 2.2 ± 0.2 <0.01 
Phosphate (mmol/L; mean ± SD) ‡ 1.6 ± 0.4 1.7 ± 0.4 0.80 
Laboratory investigations for dialysis participants     
Creatinine (μmol/L; mean ± SD) † 724 ± 263 703 ± 265 0.59 
Urea (mmol/L; mean ± SD) † 19.6 ± 7.9 16.4 ± 7.6 <0.01 
Potassium (mmol/L; mean ± SD) † 4.7 ± 0.8 4.2 ± 0.7 <0.001 
Bicarbonate (mmol/L; mean ± SD) †† 24.9 ± 3.2 21.9 ± 3.4 <0.001 
Total calcium (mmol/L; mean ± SD) ‡ 2.3 ± 0.2 2.2 ± 0.3 0.25 
Phosphate (mmol/L; mean ± SD) § 1.7 ± 0.6 1.7 ± 0.5 0.35 
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Abbreviations: APTT - activated partial thromboplastin time; AVF – arteriovenous fistula; BMI – body mass index; 
eGFR – estimated glomerular filtration rate; ESAs – erythropoietin stimulating agents; HDL – high-density lipoprotein; 
IQR – interquartile range; LDL – low-density lipoprotein; MPI – Maori & Pacific Islanders. 
†missing data in <1% of patients 
‡missing data in 1-4.9% of patients 
§missing data in 5-9.9% of patients 
¶missing data in 10-19.9% of patients 
††missing data in 20-29.9% of patients 
‡‡Dialysis patients only (n=98 for combined ANZ and UK cohort, n=93 for Malaysian cohort)  
 
 
Table 3-4: Multivariable regression analysis for AVF location and covariates post-protocol 
amendment  
Covariates Odds ratio† (95% CI) p-value 
Country (ANZUK) 2.06 (1.34 to 3.17) <.001 
Gender (male) 2.55 (1.77 to 3.66) <.0001 
Age (years) 0.98 (0.97 to 0.99) 0.02 
Body mass index (kg/m2) 1.01 (0.99 to 1.04) 0.35 
Diabetes mellitus 0.91 (0.62 to 1.33) 0.80 
†Odds ratio shows likelihood of undergoing lower arm arteriovenous fistula (AVF). 
 
 
Comparison between FAVOURED and two recent anti-platelet trials of vascular access 
outcomes 
To date, there has only been one large RCT evaluating the impact of fish oil supplementation on access 
survival, which was performed in North America and Canada (FISH study)93. This study was 
conducted in participants receiving a de novo arteriovenous graft as opposed to a native arteriovenous 
fistula93. With regards to native AVF, access failure has so far only been evaluated with short-term (6 
weeks) post-operative use of clopidogrel or placebo in a large North American RCT72. Patient baseline 
characteristics of the FAVOURED study, although generally similar to these two North 
American/Canadian studies, did have some important differences (Table 3-5). The average age and 
male predominance was similar in the FAVOURED and the clopidogrel trial, but the average age was 
higher and gender distribution equal in the FISH study. The prevalence of diabetes mellitus was highest 
in participants undergoing AVG surgery (53%) compared to participants receiving an AVF (47% and 
48% in the FAVOURED and clopidogrel trial, respectively). The rate of IHD was considerably higher 
in the North American/Canadian studies (34-48%) compared to that of the FAVOURED trial (10%). 
 
Table 3-5: Comparison of demographic and clinical characteristics: FAVOURED versus two recent 
anti-platelet trials of vascular access outcomes 
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Characteristics FAVOURED Clopidogrel Trial72 FISH93 
Regions ANZ, UK, Malaysia North America 
North America and 
Canada 
Sample size, n 567 877 201 
Access type AVF AVF AVG 
Anti-platelet agent (dose) 
Fish oil (4 g, 46% 
EPA, 38% DHA) 
Clopidogrel  
(300 mg day 1, 75 
mg maintenance) 
Fish oil (4 g, 48% 
EPA, 25% DHA) 
Starting date of anti-platelet agent  
1 day prior to 
surgery 
1 day after surgery 
7 – 10 days after 
surgery 
Age, years 55 54 63 
Female, % 37 38 50 
Ethnicities, %    
      White 53 NA 63 
      Black NA 48 16 
      Asian 32 NA 14 
      Others 15† NA 7 
BMI, kg/m2 29 30  
Aetiology of renal disease, %  NA  
      Diabetes 39  45 
      Hypertension 13‡  19 
      Glomerulonephritis 14  25 
      Polycystic kidney disease 7  4§ 
      Others 27  7¶ 
Co-morbidities    
      Diabetes mellitus, % 47 48 53 
      Hypertension, % NA NA 86 
      Systolic/diastolic BP, mmHg 146/82 141/79 NA 
      Ischaemic heart disease, % 10 48 34 
      Congestive heart disease, % 4 NA 20 
Current or former smoking 51 20†† 55 
Access location, %    
      Lower arm 61 54 56 
      Upper arm 39 46 39 
      Leg 0 0 5 
Abbreviations: BP – blood pressure; DHA - docosahexaenoic acid; EPA - eicosapentaenoic acid; FAVOURED indicates 
The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUcomes in Renal Disease; FISH indicates Fish oil 
Inhibition of Stenosis in Haemodialysis grafts; NA – not assessed. 
Mean values averaged for placebo and treatment arms, respectively.  
†includes Aboriginal, Torres Strait Islander and Maori & Pacific Islander and others 
‡includes hypertensive and vascular  
§includes cystic and other hereditary disorders 
¶includes tubulointerstitial disorders and other/unknown 
††includes only current smokers 
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3.7 Discussion 
FAVOURED is the first RCT designed to determine whether the use of omega-3 PUFAs with or 
without aspirin will improve the usability of de novo AVF. Patients enrolled in FAVOURED were 
overweight with a male predominance, a high prevalence of diabetes mellitus and current or past 
smoking history. However, trial participants were on average younger and had lower rates of IHD and 
congestive heart failure compared with the general HD population and comparable study 
cohorts72,93,159-161. The trial design was modified in response to concerns about slow recruitment due to 
widespread prevalent aspirin use in order to facilitate recruitment and improve generalizability. 
Examination of the baseline data confirms that the modified trial protocol was consistent with the 
intended aims to recruit a more representative trial population by including a broader demographic 
with participants from Malaysia, Australia, New Zealand and the UK.  
The original study protocol had excluded patients that were unable to cease aspirin, which resulted in 
an unexpectedly high screening failure rate and slow recruitment of a relatively young and healthy 
study cohort. Following protocol amendments to allow for open-label aspirin use, screening failure 
rates due to treatment with anticoagulants and antiplatelet agents halved, the proportion of diabetic 
patients increased by almost one third, the prevalence of IHD more than 4-fold and that of congestive 
heart disease by almost eight times. This is consistent with international data on patients from ANZ, 
Europe, Japan and North America showing that diabetes mellitus and IHD were significantly more 
prevalent in patients taking aspirin compared with those not taking aspirin154. Post-protocol 
amendment, diabetes prevalence (44%) in this study was similar to that reported in incident HD patient 
in ANZ (50%)162. In contrast, the prevalence of IHD in the trial cohort remained considerably lower 
(19%) than that reported in incident HD populations of ANZ (42%)162. This may in part reflect 
physicians’ concern or patient preference regarding the risk and benefit of participating in 
FAVOURED based upon their baseline cardiovascular risk.  
Patients recruited from Malaysia represent one third of the final trial population and had significant 
baseline differences compared with participants from the combined ANZ and UK cohort. Malaysians, 
whilst on average younger and slimmer, had a greater prevalence of diabetes and diabetic nephropathy 
but lower rates of IHD and aspirin use. These findings are consistent with contemporary data from the 
Malaysian Dialysis and Transplant Registry reports where diabetes mellitus accounted for 57-61% of 
primary renal disease and IHD was present in 13% of HD patients160. The mean haemoglobin 
concentration was significantly lower in the Malaysian cohort (97g/L) compared with the ANZUK 
cohort (113g/L), which may be attributed to variations in the use of ESAs. In Malaysia, 25% of 
participants were on ESA at enrolment as opposed to 51% of the ANZUK group. This may reflect 
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regional differences in prescribing patterns and funding models. The lower haemoglobin concentration 
and/or the prevalence of ESA use may influence thrombosis risk and therefore impact on the study 
outcomes. Use of darbepoetin in the TREAT study was associated with a higher risk of venous and 
arterial thrombosis compared with no darbepoetin163, and targeting higher haemoglobin concentrations 
with epoetins significantly increased the risk of vascular access thrombosis164. The haemoglobin levels 
of the Malaysian cohort are likely to increase following initiation of HD given that the average 
haemoglobin of prevalent HD patients reported by the Malaysian Dialysis and Transplant Registry 
(111g/L) is similar to that reported by the Australian and New Zealand Dialysis and Transplantation 
Registry (112g/L) and use of ESA is higher (91% compared to 81-87% in ANZ)159,160,165. Malaysian 
participants had a significantly higher white cell and platelet count suggestive of inflammation. 
Whether this may be due to a higher prevalence of non-cuffed CVC use compared with the ANZUK 
cohort (54% versus 3%) or due to other environmental factors is uncertain.  
Whilst the average age and male preponderance of FAVOURED participants was comparable to that 
of the clopidogrel trial72, the cohort of the FISH study93 was older with an equal proportion of female 
participants. This may be explained by differences in patient selection for an AVF as opposed to an 
AVG and regional differences in practice patterns. Older patients with smaller vessels may still be 
suitable for an AVG but not for a native AVF. Whilst the proportions of patients with diabetes mellitus 
were comparable across the three studies, the rates of ischaemic and congestive heart disease were 
considerably lower in the FAVOURED cohort suggesting differences in patient selection. In North 
America, 47-50% of prevalent HD patients were reported to have ischaemic heart disease compared 
with 13% of HD patients in Malaysia, and 42% of incident and 51% of prevalent HD patients in 
ANZ160-162,165-167. The clopidogrel trial72 and FISH study93 are the only two RCTs of interventions 
targeting HD access failure of comparable size to date and were conducted in North America and 
Canada. The FAVOURED trial therefore adds important information on clinical features of patients 
with ESKD undergoing de novo vascular access surgery in Malaysia, Australia, New Zealand and the 
UK. 
Comparison of baseline characteristics between the study population and registry data was limited by 
differences in data collection. Whilst ANZDATA collects information on incident and prevalent HD 
patients separately, Malaysia focuses mainly on characteristics of incident HD patients and the US 
registry reports on the entire population with chronic kidney disease and those with ESKD, 
respectively. 
In conclusion, the FAVOURED study successfully enrolled a large number of participants undergoing 
de novo AVF creation with baseline characteristics that, for the most part, were similar to contemporary 
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registry reports and comparable clinical trials of such individuals. The initial issue of selecting a 
relatively healthy cohort was managed by modifying the study protocol to allow for open-label aspirin 
use in patients unable to cease aspirin therapy and did result in enrolment of a more representative 
cohort of ESKD patients. The enrolment of Malaysian participants enhances the generalisability of this 
trial whilst providing important information on variations in baseline characteristics of HD patients 
and differences in clinical practices.  
3.8 Chapter summary 
Analyses of the FAVOURED study baseline data confirms, that protocol amendments undertaken to 
allow for inclusion of patients taking aspirin led to enrolment of a more representative study cohort 
with a significantly higher comorbid burden including higher prevalence of diabetes mellitus, BMI and 
IHD. Recruitment of participants from Malaysia has further enhanced the diversity of the study 
population and highlighted significant differences in patient characteristics. Of note, Malaysian 
participants were younger with a higher prevalence of diabetes but lower prevalence of IHD. Inclusion 
of Malaysian participants and exclusion of any patients taking anticoagulants or antiplatelet agents 
other than aspirin have likely contributed to the overall lower prevalence of IHD compared to 
contemporary registry data and comparable trial populations. This may impact on the overall AVF 
complication rates given that cardiovascular disease is a known risk factor for AVF failure. The 
following chapter will describe the frequency of AVF failure and whether omega-3 PUFA 
supplementation and low-dose aspirin are effective treatment strategies to improve AVF outcomes.  
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Chapter 4   
 Effect of fish oil and aspirin on arteriovenous fistula          
failure in haemodialysis – a randomised controlled 
trial 
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4.1 Chapter overview 
The previous chapter has outlined that post-initiation protocol amendments led to successful 
recruitment of 567 participants from 35 dialysis centres across Australia, New Zealand and the UK. By 
adding an open-label aspirin arm for participants unable to cease aspirin therapy, the trial population 
has become more representative of the HD population. The high primary failure rate of newly formed 
AVF remains a major impediment to increasing the use of AVF and reducing CVC dependence, 
particularly in the incident HD population. Omega-3 PUFA supplementation may be beneficial in 
reducing AVF stenosis and thrombosis formation via anti-inflammatory, anti-aggregatory, anti-
proliferation and vasodilatory effects. In addition, aspirin may reduce AVF thrombosis by inhibiting 
platelet aggregation. This chapter addresses the primary and main aim of the FAVOURED study, 
namely whether three months of 4 g daily omega-3 PUFA supplementation or low-dose aspirin therapy 
will decrease the proportion of AVF failure or any of the individual components of AVF failure 
including access thrombosis, abandonment, or cannulation failure within 12 months of AVF creation.  
4.2 Included publication 
This chapter is based on the following publications: 
Irish AB*, Viecelli AK*, Hawley CM, Hooi LS, Pascoe EM, Paul-Brent PA, Badve SV, Mori TA, 
Cass A, Kerr PG, Voss D, Ong LM, Polkinghorne KR, for the Omega-3 Fatty Acids (Fish Oils) and 
Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group. 
The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease 
(FAVOURED) study – a randomized placebo-controlled trial. JAMA Int. Med. 2017;177(2):184-193. 
*Equal first authors. Copyright permission has been obtained to reproduce this manuscript 
Contribution of the candidate: The candidate was co-lead author of the publication, acted as one of the 
outcome adjudicators, assisted with the concept and design of additional analyses, interpreted the data 
under supervision of ABI, CMH, EMP, and KRP, designed the figures and tables, drafted the 
manuscript and integrated feedback and revisions made by all co-authors.  
4.3 Abstract  
Importance: Vascular access dysfunction is a leading cause of morbidity and mortality in dialysis 
patients. Arteriovenous fistulas are preferred over synthetic grafts and central venous catheters due to 
superior long-term outcomes and lower health care costs, but increasing their use is limited by early 
thrombosis and maturation failure. Omega-3 PUFAs (fish oils) have pleiotropic effects on vascular 
biology and inflammation and aspirin impairs platelet aggregation, which may reduce access failure. 
  
76 
 
Objective: To determine whether fish oil supplementation (primary objective) or aspirin use 
(secondary objective) is effective in reducing AVF failure. 
Design, setting, and participants: The FAVOURED study was a randomised, double-blind, 
controlled clinical trial that recruited participants with stage 4 and 5 chronic kidney disease from 2008 
to 2014 at 35 dialysis centres across Australia, Malaysia, New Zealand, and the UK. Participants were 
observed for 12 months after arteriovenous fistula creation. 
Intervention: Participants were randomly allocated to receive fish oil (4 g/d) or matching placebo. A 
subset of participants (n=406) was also randomised to receive aspirin (100 mg/d) or matching placebo. 
Treatment started one day prior to surgery and continued for 12 weeks.  
Main outcome measure: Fistula failure, a composite of fistula thrombosis and/or abandonment and/or 
cannulation failure at 12 months.  
Results: Of 1,415 eligible participants, 567 were randomised (359 [63%] male, 298 [53%] white, 264 
[47%] with diabetes, mean [SD] age 54.8 [4.3] years). The same proportion of fistula failures occurred 
in the fish oil and placebo arms (128 of 270 [47%] versus 125 of 266 [47%], RR adjusted for aspirin 
use 1.03, 95% CI 0.86-1.23, p=0.78). Fish oil did not reduce fistula thrombosis (60 [22%] versus 61 
[23%], RR 0.98, 95% CI 0.72-1.34, p=0.90), abandonment (51 [19%] versus 58 [22%], RR 0.87, 95% 
CI 0.62-1.22, p=0.43) or cannulation failure (108 [40%] versus 104 [39%], RR 1.03, 95% CI 0.83-
1.26, p=0.81). The risk of fistula failure was similar between the aspirin and placebo arms (87 of 194 
[45%] versus 83 of 194 [43%], RR 1.05, 95% CI 0.84-1.31, p=0.68).  
Conclusion: Neither fish oil supplementation nor aspirin use reduced failure of new arteriovenous 
fistulas within 12 months of surgery.  
4.4 Introduction 
Haemodialysis is the commonest renal replacement modality worldwide and requires a functioning 
permanent vascular access. Vascular access dysfunction is associated with substantial morbidity and 
mortality and presents a major health economic burden24,147. Arteriovenous fistulas are recommended 
as the preferred vascular access by international clinical practice guidelines13,14,18 because of their 
longevity and lower complication rates compared with synthetic arteriovenous grafts (AVGs) and 
central venous catheters24-26. However, AVFs require a longer maturation time before use and have a 
significantly higher risk of early failure compared to AVGs27. Early primary failure occurs in 20 to 
50% of AVFs as a result of either thrombosis or maturation failure19,28. Although anti-platelet agents 
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can reduce early thrombosis of AVFs, this has not translated into significant improvements in the 
proportion of AVF that become suitable for dialysis64,72.  
Supplementation of omega-3 PUFAs found in fish oil may be beneficial in promoting vascular access 
maturation and reducing thrombosis by not only inhibiting platelet aggregation83,168, but also 
decreasing blood viscosity, improving red blood cell flexibility74,75, promoting vasodilation90, 
inhibiting smooth muscle cell proliferation79, and reducing inflammation76,84. Fish oil has been shown 
to increase patency rates in AVGs but it has not been assessed in AVFs93,95. Low-dose aspirin is an 
effective anti-platelet agent in the secondary prevention of vascular disease169 and has been used safely 
in patients with advanced kidney disease170; however, it has not been adequately evaluated in the 
prevention of AVF failure.  
The primary aim of the FAVOURED trial was to test the hypothesis that fish oil supplementation will 
reduce AVF failure after AVF creation in patients with stage 4 or 5 chronic kidney disease. A secondary 
aim was to examine the efficacy of aspirin use in preventing failure of new AVF. 
 
4.5 Methods 
Study design  
FAVOURED is an investigator-initiated, international, double-blind, randomised, placebo-controlled 
trial conducted in 35 HD centres across Australia, Malaysia, New Zealand and the UK. Recruitment 
began on August 21, 2008 and ended on February 28, 2014 with the last follow-up on February 28, 
2015. The original study, which commenced with a 2 by 2 factorial design, was amended in June 2011. 
First, the primary outcome of “early thrombosis” at 12 weeks following AVF creation was broadened 
to the more clinically relevant “AVF access failure”, a composite of thrombosis and/or AVF 
abandonment and/or cannulation failure at 12 months. Second, eligibility criteria were broadened so 
that patients who were previously ineligible due to medically indicated aspirin use were eligible and 
randomised to fish oil or matching placebo with continuation of open-label aspirin. As a result of the 
second amendment, the primary objective of FAVOURED was to assess the efficacy of fish oil 
supplementation on AVF failure at 12 months and the efficacy of aspirin was assessed as a secondary 
objective. Details of the original and amended study protocols have been published previously157,171,172. 
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Study oversight 
The study was approved by HRECs at participating centres. All patients provided written consent prior 
to study enrolment.  A Trial Management Committee comprising clinicians and a statistician had sole 
responsibility for the design and conduct of the study, analysis of data and manuscript preparation. An 
independent Data and Safety Monitoring Board reviewed accumulating data. Two interim efficacy 
analyses using the Haybittle-Peto rule were planned after one-third and two-thirds of patients had been 
recruited and followed for at least 12 months. Due to early cessation of recruitment, only the first 
interim analysis was performed, after which the study continued as planned until terminated because 
of slower than anticipated accrual, funding issues and lack of ongoing availability of trial medications. 
FAVOURED is registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12607000569404). 
Study population 
Adults (age >19 years) with stage 4 or 5 chronic kidney disease receiving or planned to receive HD 
within 12 months and scheduled for AVF surgery in the arm were eligible for inclusion. Participants 
were excluded if they had an increased bleeding risk (bleeding disorder, recent or active gastrointestinal 
ulcer, platelet count < 100×109 /L, hepatic insufficiency), were taking aspirin within 2 weeks or fish 
oil within 4 weeks of trial commencement, were taking NSAIDs, anticoagulants or antiplatelet agents, 
or had contraindications for taking the study agents. In June 2011, the exclusion criterion of current 
use of aspirin was removed so that patients currently taking aspirin were eligible for recruitment. 
Randomisation and study intervention  
Randomisation of participants was dependant on aspirin-taking status: (1) not taking aspirin or able to 
cease; (2) taking aspirin and unable to cease (open-label aspirin). Within each group, participants were 
randomly assigned in a 1:1 ratio to receive either 4 g of fish oil (2 g twice daily) in the form of 4 vanilla-
flavoured Omacor capsules (46% eicosapentaenoic acid and 38% docosahexaenoic acid) or 4 matching 
vanilla-flavoured placebo capsules (olive oil) (BGP Products Pty Ltd, trading as Mylan EPD). 
Participants not taking aspirin or able to cease were further randomised in a 1:1 ratio to receive 100 mg 
of oral aspirin daily or matching placebo (Bayer Healthcare). Randomisation was performed by a 
central, web-based system (Flexetrials) using an adaptive minimisation algorithm with study site and 
planned location of the AVF (upper versus lower arm) as minimisation variables. Randomisation 
occurred up to 7 days prior to scheduled AVF surgery. Treatment commenced on the day before 
scheduled AVF surgery and continued for 12 weeks. Participants, care givers, treating physicians and 
surgeons, laboratory staff and members of the study team were blinded to treatment allocation.  
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Outcomes 
The primary outcome was “AVF access failure” at 12 months after fistula creation and defined as a 
composite of any one of AVF thrombosis, AVF abandonment and cannulation failure. Thrombosis was 
defined as the absence of a thrill or bruit by clinical assessment and/or requirement for rescue 
intervention (medical thrombolysis or surgical thrombectomy). Arteriovenous fistula abandonment 
was defined as no further use of, or attempt to intervene on, the study AVF. Cannulation failure was 
defined as failure to successfully cannulate the study AVF during 8 or more of 12 consecutive HD 
sessions during the cannulation assessment period157. Secondary outcomes included components of the 
primary outcome, and safety outcomes. 
Sample size 
The study was designed to detect a 30% relative reduction in AVF access failure assuming 30% AVF 
failure in control groups (an absolute risk reduction of 9%). At 80% power and a two-sided significance 
level of 5%, 734 participants would be required (367 per group). Assuming a 5% drop-in from control 
to fish oil and a 5% drop-out from fish oil to placebo and a 5% loss to follow-up, a total of 954 
participants needed to be recruited.  
Statistical analysis 
Log binomial regression (to enable calculation of RRs173) was used to compare fish oil with matching 
placebo on the composite outcome of AVF access failure, adjusted for differences in aspirin use 
(randomised to aspirin, randomised to placebo aspirin, open-label aspirin). The treatment effect is 
expressed as a RR and 95% CI. The robustness of the fish oil treatment effect was assessed by 
additional analyses that adjusted for pre-specified baseline characteristics and study region. All pre-
specified subgroup analyses were performed using log binomial regression models adjusted for 
differences in aspirin use. Tests of treatment-by-subgroup variable interactions informed the 
interpretation of subgroup results. Secondary outcomes were analysed using log binomial regression 
models as per the primary outcome. Single imputation was used to replace missing values on the 
separate components of the primary outcome as follows: participants with missing data were randomly 
allocated a value (1=event, 0=no event) such that the proportion of imputed events was the same as the 
proportion of events in participants with observed data for the component; for example, if the overall 
frequency of AVF thrombosis for participants with available data was 20%, then a patient with a 
missing value for AVF thrombosis would be randomly assigned an event in 20% of cases.  A range of 
pre-specified sensitivity analyses for imputation of missing values were performed, including a 
complete case analysis. Comparisons of aspirin with matching placebo were performed using the same 
statistical models. 
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Analyses were based on participants’ randomised treatment. Participants who did not receive AVF 
creation surgery or died within 12 months of surgery and were not assessed on any of the three 
components of the primary outcome before their death were excluded. A two-sided p-value less than 
0.05 was considered statistically significant. Statistical analyses were performed using SAS version 
9.4 (SAS Institute) and Stata version 13.1 (Stata Corporation). 
4.6 Results 
Study participants 
Of the 4242 patients assessed for eligibility, 1,415 were deemed eligible, 567 were randomised to fish 
oil (n=284) or placebo (n=283), and 536 included in the analysis (Figure 4-1). There were 406 
participants randomised to aspirin (n=203) or matching placebo (n=203). Participant demographic and 
clinical characteristics were well balanced between each of the two treatment groups (Table 4-1).  
 
Figure 4-1: CONSORT Diagram: Study enrolment and follow-up 
Abbreviations:  AVF – arteriovenous fistula; HD – haemodialysis; NSAIDs – non-steroidal anti-inflammatory drugs. 
  
81 
 
aFollowing the protocol amendment in 2011, participants unable to discontinue aspirin were eligible for randomisation 
to fish oil or matching placebo with continuation of open-label aspirin. 
bNumber of participants whose primary outcome was determined by imputation; fish oil n=62 (23%), placebo n=60 
(23%).  
 
Table 4-1: Patient demographics and baseline characteristics for fish oil versus placebo and separately 
for the subset of aspirin versus placebo 
Characteristics 
Fish oil 
(n=284) 
Placebo 
(n=283) 
Aspirin 
(n=203) 
Placebo 
(n=203) 
Age, (years, mean ± SD) 54.1 ± 14.0 55.6 ± 14.5 52.3 ± 14.5 53.8 ± 14.9 
Male, n (%) 180 (63) 179 (63) 125 (62) 131 (65) 
Country, n (%)     
  Australia and New Zealand 202 (71) 201 (71) 150 (74) 147 (72) 
  Malaysia 79 (28) 76 (27) 53 (26) 53 (26) 
  United Kingdom   3 (1) 6 (2) 0 3 (2) 
Ethnicity, n (%)     
  Asian 92 (32) 89 (32) 68 (34) 61 (30) 
  White 144 (51) 154 (55) 107 (53) 119 (59) 
  Indigenousa 39 (14) 27 (10) 24 (12) 15 (7) 
  Other 9 (3) 11 (4) 4 (2) 7 (4) 
Body mass index,  (kg/m2; mean ± 
SD) 
28.8 ± 7.4  28.4 ± 7.2 27.9 ± 6.9  28.3 ± 7.7 
Blood pressure, (mm Hg; mean ± 
SD) 
    
  Systolic 146 ± 23 146 ± 23 145 ± 22 146 ± 24 
  Diastolic  82 ± 14 81 ± 13 81 ± 13 83 ± 14 
Comorbid conditions            
  Diabetes mellitus, n (%) 139 (49) 125 (45) 83 (41) 75 (37) 
  Ischaemic heart disease, n (%) 30 (11) 28 (10) 9 (4) 3 (2) 
  Congestive heart disease, n (%) 10 (4) 12 (4) 6 (3) 3 (2) 
  Peripheral vascular disease, n (%) 14 (5) 10 (4) 6 (3) 5 (3) 
  Cerebrovascular disease, n (%) 6 (2) 11 (4) 2 (1) 2 (1) 
  Hypertension, n (%) 247 (87) 255 (91) 183 (90) 179 (89) 
  Current or prior smoking, n (%) 155 (55) 135 (48) 99 (49) 95 (47) 
Medications           
  Aspirin, n (%) 78 (28) 78 (28) N/A N/A 
  Statin, n (%) 152 (54) 143 (51) 85 (42) 93 (46) 
  ESA, n (%) 125 (44) 141 (50) 104 (51) 92 (46) 
  Beta-blocker, n (%) 130 (46) 133 (47) 94 (46) 82 (41) 
  ARB/ACEI, n (%) 118 (42) 122 (43) 91 (45) 82 (41) 
  CCB, n (%) 158 (56) 159 (56) 118 (58) 110 (55) 
  Intravenous iron, n (%) 49 (17) 49 (17) 39 (19) 43 (21) 
  Xanthine-oxidase inhibitor, n (%) 50 (18) 38 (13) 32 (16) 28 (14) 
Aetiology of renal disease, n (%)     
  Diabetic nephropathy 124 (44) 97 (35) 70 (35) 56 (28) 
  Glomerulonephritis 38 (13) 39 (14) 29 (14) 33 (16) 
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Characteristics 
Fish oil 
(n=284) 
Placebo 
(n=283) 
Aspirin 
(n=203) 
Placebo 
(n=203) 
  Hypertension/vascular 37 (13) 38 (14) 16 (8) 37 (18) 
  Polycystic kidney disease 18 (6) 22 (8) 20 (10) 18 (9) 
  Reflux nephropathy 15 (5) 11 (4) 11 (5) 14 (7) 
  Other 52 (18) 74 (26) 57 (28) 44 (22) 
Planned study AVF location, n 
(%)b 
    
  Upper arm 113 (40) 110 (39) 84 (41) 82 (40) 
  Forearm 171 (60) 173 (61) 119 (59) 121 (60) 
Renal replacement therapy at time 
of AVF creation, n (%) 
    
  Peritoneal dialysis 15 (5) 20 (7) 17 (8) 11 (5) 
  Haemodialysis 122 (43) 118 (42) 82 (40) 92 (46) 
  Not currently receiving dialysis  147 (52) 143 (51) 104 (51) 99 (49) 
Principal access currently in use for 
participants receiving dialysis, n 
(%) 
    
  Arteriovenous fistula 5 (4) 2 (2) 2 (2) 1 (1) 
  Arteriovenous graft 0 1 (1) 0 0 
  Central venous catheter (cuffed 
and non-cuffed) 
117 (85) 115 (83) 80 (81) 91 (88) 
  Peritoneal dialysis catheter 15 (11) 20 (15) 17 (17) 11 (11) 
Dialysis duration (months; median 
[IQR])c  
3.8 [1.8, 18.2] 4.2 [1.9, 17.7] 4.2 (2.0, 16.3) 3.9 (1.8, 
15.4) 
Haemoglobin (g/L; mean ± SD) 109 ± 18  108 ± 19 109 ±19 108 ± 19 
Albumin (g/L; mean ± SD) 36.0 ± 6.2 36.0 ± 6.3 36.1 ± 6.3 36.3 ± 6.0 
eGFR (ml/min/1.73m2; mean ± 
SD)c 
11.2 (6.3) 11.4 (5.1) 9.4 (4.9) 9.6 (6.2) 
Abbreviations: ACEI – angiotensin-converting enzyme inhibitor; AVF – arteriovenous fistula; ARB – angiotensin 
receptor blocker; CCB – calcium channel blocker; eGFR – estimated glomerular filtration rate; ESAs – erythropoietin 
stimulating agents; HDL – high-density lipoprotein; IQR – interquartile range; LDL – low-density lipoprotein; N/A – 
not applicable; SD – standard deviation. aAboriginal, Torres Strait Islanders, Maori and Pacific Islanders 
bActual AVF location upper arm versus forearm: fish oil n=117 (42%) versus n=162 (58%); placebo n=110 (40%) versus 
n=163 (60%); aspirin n=83 (41%) versus n=118 (59%); placebo n=82 (41%) versus n=116 (59%). 
cFor pre-dialysis participants only (fish oil n=147 and placebo n=143; aspirin n=104 and placebo n=99) 
 
 
AVF failure 
Arteriovenous fistula failure occurred in 128 of 270 (47%) participants assigned to fish oil and 125 of 
266 (47%) assigned to placebo (RR adjusted for aspirin use 1.03, 95% CI 0.86-1.23, p= 0.78). The 
proportion of events in the fish oil and placebo groups was similar for each of the three individual 
components of AVF failure: thrombosis (69 [22%] versus 61 [23%], adjusted RR 0.98, 95% CI 0.72-
1.34, p=0.90); AVF abandonment (51 [19%] versus 58 [22%], RR 0.87, 95% CI 0.62-1.22, p=0.43); 
cannulation failure during the cannulation assessment period (108 [40%] versus 104 [39%], RR 1.03, 
95% CI 0.83-1.26, p=0.81) (Table 4-2A). In the assessment of the pre-specified subgroups, a significant 
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difference in the effect of fish oil on AVF failure was observed in participants with diabetes mellitus 
compared with those without diabetes (interaction p=0.03; RR 1.30, 95% CI 0.99-1.71 versus 0.85, 
95% CI 0.67-1.08), but not in other pre-specified subgroups (Figure 4-2A).  
In participants randomised to aspirin or matching placebo, the risk of AVF failure was similar (87 of 
194 [45%] versus 83 of 194 [43%], RR 1.05, 95% CI 0.84-1.31, p=0.68). Aspirin compared to placebo 
did not reduce the risk of AVF thrombosis (38 [20%] versus 35 [18%], RR 1.09, 95% CI 0.72-1.64, 
p=0.70), AVF abandonment (46 [24%] versus 35 [18%], RR 1.31, 95% CI 0.89-1.95, p=0.17) or 
cannulation failure (73 [38%] versus 74 [38%], RR 0.99, 95% CI 0.76-1.27, p=0.92) (Table 4-2B). 
There were no statistically significant subgroup effects involving the aspirin groups (Figure 4-2B). The 
fish oil by aspirin interaction test was not statistically significant for the composite outcome (p=0.12); 
however, results for comparisons of fish oil plus aspirin with fish oil and aspirin alone and double 
placebo are included in Table 4-3. 
 
 
 
Table 4-2: Primary and secondary outcomes for fish oil versus placebo (A) and aspirin versus placebo 
(B) 
A Primary and secondary outcomes for fish oil versus placebo 
Outcomesa  
Fish Oil Placebo Relative risk 
(95% CI) 
P Value 
Primary outcome 
AVF failure (composite of thrombosis, 
AVF abandonment, and cannulation 
failure), n/total (%)  
 
128/270 (47) 
 
125/266 (47) 
 
1.03 (0.86, 1.23) 
 
0.78b 
Secondary outcomes 
AVF abandonment within 12 months, 
n/total (%) 
 
51/270 (19) 
 
58/266 (22) 
 
0.87 (0.62, 1.22) 
 
0.43 
Thrombosis of study AVF within 12 
months, n/total (%) 
60/270 (22) 61/266 (23) 0.98 (0.72, 1.34) 0.90 
Cannulation failure within 12 months, 
n/total (%) 
108/270 (40) 104/266 (39) 1.03 (0.83, 1.26) 0.81 
B Primary and secondary outcomes for aspirin versus placebo 
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Outcomes 
Aspirin Placebo Relative risk 
(95% CI) 
P Value 
Primary outcome 
AVF failure (composite of thrombosis, 
AVF abandonment, and cannulation 
failure), n/total (%)  
 
87/194 (45) 
 
83/194 (43) 
 
1.05 (0.84, 1.31) 
 
0.68 
Secondary outcomes 
AVF abandonment within 12 months, 
n/total (%) 
 
46/194 (24) 
 
35/194 (18) 
 
1.31 (0.89, 1.95) 
 
0.17 
Outcomes 
Aspirin Placebo Relative risk 
(95% CI) 
P Value 
Thrombosis of study AVF within 12 
months, n/total (%) 
38/194 (20) 35/194 (18) 1.09 (0.72, 1.64) 0.70 
Cannulation failure within 12 months, 
n/total (%) 
73/194 (38) 74/194 (38) 0.99 (0.76, 1.27) 0.92 
Abbreviations: AVF – arteriovenous fistula; CAP – cannulation assessment period: CI – confidence interval. 
aAdjusted for differences in aspirin use (no aspirin, randomised to aspirin, open-label aspirin) 
bInteraction p=0.12 for additivity of fish oil and aspirin effect on composite outcome.  
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Figure 4-2: Forest plot for pre-specified subgroup analysis on AVF failure for fish oil versus placebo 
(A) and aspirin versus placebo (B) 
Abbreviations:  AVF – arteriovenous fistula; CI – confidence interval; P – p-value for treatment by 
subgroup interaction; RR –relative risk  
Cardiovascular disease included any one or more of peripheral vascular disease, ischaemic heart disease 
and cerebrovascular disease. Dialysis at baseline: no [pre-dialysis/transplant], yes [haemodialysis or 
peritoneal dialysis]. 
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Table 4-3: Primary and secondary outcomes for treatment combinations of participants randomised 
to the 2x2 factorial design (n=388) 
A Primary and secondary outcomes for fish oil  + aspirin versus fish oil + placebo 
Outcomes  
Fish oil  + 
aspirin 
Fish oil + 
placebo 
Relative risk 
(95% CI)  
P 
Value 
Primary outcome 
AVF failure (composite of thrombosis, AVF 
abandonment, and cannulation failure), n/total 
(%)  
 
48/99 (48) 
 
37/99 (37) 
 
1.30 (0.94, 1.80) 
 
0.12 
Secondary outcomes 
AVF abandonment within 12 months, n/total 
(%) 
 
26/99 (26) 
 
15/99 (15) 
 
1.73 (0.98, 3.07) 
 
0.06 
Thrombosis of study AVF within 12 months, 
n/total (%) 
19/99 (19) 15/99 (15) 1.27 (0.68, 2.35) 0.45 
Cannulation failure within 12 months, n/total 
(%) 
41/99 (41) 35/99 (35) 1.17 (0.82, 1.67) 0.38 
B Primary and secondary outcomes for fish oil  + aspirin versus aspirin + placebo 
Outcomes 
Fish oil  + 
aspirin 
Placebo + 
aspirin   
Relative risk 
(95% CI) 
P Value 
Primary outcome 
AVF failure (composite of thrombosis, AVF 
abandonment, and cannulation failure), n/total 
(%)  
 
48/99 (48) 
 
39/95 (41) 
 
1.18 (0.86, 1.62) 
 
0.30 
Secondary outcomes 
AVF abandonment within 12 months, n/total 
(%) 
 
26/99 (26) 
 
20/95 (21) 
 
1.25 (0.75, 2.08) 
 
0.40 
Thrombosis of study AVF within 12 months, 
n/total (%) 
19/99 (19) 19/95 (20) 0.96 (0.54, 1.70) 0.89 
Cannulation failure within 12 months, n/total 
(%) 
41/99 (41) 32/95 (34) 1.23 (0.85, 1.77) 0.27 
C Primary and secondary outcomes for fish oil  + aspirin versus placebo + placebo 
Outcomes Fish oil  + 
aspirin 
Placebo + 
placebo 
Relative risk 
(95% CI) 
P Value 
Primary outcome 
AVF failure (composite of thrombosis, AVF 
abandonment, and cannulation failure), n/total 
(%)  
 
48/99 (48) 
 
46/95 (48) 
 
1.00 (0.75, 1.34) 
 
0.99 
Secondary outcomes 
AVF abandonment within 12 months, n/total 
(%) 
 
26/99 (26) 
 
20/95 (21) 
 
1.25 (0.74, 2.08) 
 
0.40 
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Outcomes Fish oil  + 
aspirin 
Placebo + 
placebo 
Relative risk 
(95% CI) 
P Value 
Thrombosis of study AVF within 12 months, 
n/total (%) 
19/99 (19) 20/95 (21) 0.91 (0.52, 1.60) 0.75 
Cannulation failure within 12 months, n/total 
(%) 
41/99 (41) 39/95 (41) 1.01 (0.72, 1.41) 0.96 
Abbreviations: AVF – arteriovenous fistula; CI – confidence interval  
P values for interaction tests: AVF Failure composite p=0.12; AVF thrombosis p=0.45; AVF abandonment p=0.06; 
Cannulation failure p=0.38 
 
Analyses based on complete cases and secondary analyses adjusting for pre-specified baseline 
characteristics and/or geographic region demonstrated results comparable to those of the primary 
analyses for both fish oil and aspirin (Figure 4-3). The amounts of missing data (23% for fish oil and 
placebo; 22% for aspirin and 21% for placebo) and number of imputed events were similar between 
treatment groups (Table 4-4). The majority of “missing” data were due to 81 of 122 (66%) participants 
who did not start dialysis within 12 months of surgery and thus could not be assessed for cannulation 
failure.
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Figure 4-3: Forest plot for sensitivity analysis fish oil versus placebo (A) and aspirin versus placebo (B) 
A: aThe complete case analysis is adjusted for aspirin use; Abbreviations:  
CI – confidence interval; RR –relative risk ratio n=201 for participants 
taking fish oil and n=201 for participants taking placebo.  
B: aThe complete case analysis includes 149 participants taking aspirin 
149 participants taking placebo.   
Pre-specified baseline characteristics included planned AVF site (lower arm, upper arm), diabetes mellitus, age group (quartiles), cardiovascular comorbidity, 
including any one or more of peripheral vascular disease, ischaemic heart disease and cerebrovascular accidents, and renal replacement therapy at baseline (no 
[pre-dialysis/transplant], yes [hemodialysis or peritoneal dialysis]). Regions included Australia and New Zealand, Malaysia and the United Kingdom.  
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Table 4-4: Summary of missing data and single imputation across components and the composite 
outcome for n=536 participants 
 AVF 
abandonment 
AVF 
thrombosis 
Cannulation 
failure 
AVF failure 
composite 
Missing data 50 (9%) 49 (9%) 111 (21%) 122 (23%) 
     Fish oil 28 28 58 62 
     Placebo 22 21 53 60 
Observed events 110 99 168 198 
Observed proportion of events 0.2263 0.2033 0.3953 0.4783 
Imputed number of events 11 10 44 55* 
     Fish oil 8 5 26 32* 
     Placebo 3 5 18 23* 
*Not directly imputed and dependent on at least one imputed event across the components 
Post-hoc analyses examining the timing of first cannulation (Table 4-5), the time from fistula creation 
to initiation of HD (Table 4-6) and the timing of renal replacement therapy initiation in pre-dialysis 
participants (Table 4-7) showed no differences between treatment groups. 
Table 4-5: First cannulation by treatment groups 
Treatment Groups 
Within 12 weeks 
of AVF creation, 
n (%) 
>12 weeks – 12 
months after AVF 
creation, n (%) 
Not within 12 
months of AVF 
creation, n (%) 
P-value 
Fish oil (n=270) 94 (35) 74 (27) 102 (38) 0.99 
Fish oil placebo (n=266) 93 (35) 72 (27) 101 (38)  
Aspirin subset (n=194) 66 (34) 57 (29) 71 (37) 0.48 
Aspirin placebo subset (n=194) 76 (39) 48 (25) 70 (36)  
Abbreviation: AVF – arteriovenous fistula 
 
Table 4-6: Months to haemodialysis initiation for pre-dialysis participants by treatment groups 
Treatment Groups Median (IQR) Mean (± SD) P-value 
Fish oil (n=82) 3.0 (1.0, 6.0) 4.2 (3.5) 0.66 
Fish oil placebo (n=76) 3.5 (2.0, 7.0) 4.4 (3.3)  
Aspirin subset (n=59) 3.0 (1.0, 5.0) 4.0 (3.5) 0.41 
Aspirin placebo subset (n=53) 3.0 (1.0, 8.0) 4.6 (3.7)  
Abbreviations: IQR – interquartile range; SD – standard deviation 
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Table 4-7: Timing of first renal replacement therapy for pre-dialysis participants by treatment 
groups 
Time 
point of first RRT 
RRT 
modality 
Fish oil  
n (%) 
Fish oil Placebo 
n (%) 
Aspirin  
n (%) 
Aspirin Placebo  
n (%) 
Within first 12 
weeks of AVF 
creation 
HD 43 (31) 38 (28) 32 (32) 28 (29) 
PD 10 (7) 7 (5) 4 (4) 7 (7) 
Transplant 0 (0) 1 (1) 0 (0) 1 (1) 
2 weeks – 12 months 
after AVF creation 
HD 39 (28) 38 (28) 27 (27) 25 (26) 
PD 5 (4) 5 (4) 3 (3) 4 (4) 
Transplant 4 (3) 3 (2) 4 (4) 2 (2) 
Abbreviations: AVF – arteriovenous fistula; HD – haemodialysis; PD – peritoneal dialysis; RRT – renal replacement 
therapy 
 
 
Adverse events  
Adverse drug events, including bleeding events (16 [6%] versus 10 [4%], p=0.23) and gastrointestinal 
adverse effects (15 [5%] versus 14 [5%], p=0.86), were similar for the fish oil and placebo groups. 
Death occurred in 8 participants allocated to fish oil and 9 allocated to placebo (Table 4-8). Aspirin 
use was not associated with an increase in adverse drug events or serious adverse events (Table 4-8).  
 
 
Table 4-8: Adverse events fish oil versus placebo (A) and aspirin versus placebo (B) 
A: Adverse events fish oil versus placebo 
Adverse eventsa Fish oil (n=284) Placebo (n=283) P value 
Adverse drug events, n (%)    
..Bleeding event 16 (6) 10 (4) 0.23 
..Gastrointestinal event 15 (5) 14 (5) 0.86 
..Other event 8 (3) 6 (2) 0.59 
Severe adverse events, n (%)    
..Death 8 (3) 9 (3) 0.80 
..Life-threatening event 2 (1) 4 (1) 0.41 
..Hospitalisation 108 (38) 109 (39) 0.91 
..Disability 1 (<1) 1 (<1) 1.00 
..Other important medical event  2 (1) 6 (2) 0.15 
B: Adverse events aspirin versus placebo  
Adverse eventsa Aspirin (n=203) Placebo (n=203) P value 
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Adverse eventsa Aspirin (n=203) Placebo (n=203) P value 
Adverse drug event, n (%) 26 (13) 26 (13) 1.00 
..Bleeding event 12 (6) 12 (6) 1.00 
..Gastrointestinal event 13 (6) 10 (5) 0.52 
..Other event 6 (3) 4 (2) 0.52 
Severe adverse events, n (%)    
..Death 7 (3) 4 (2) 0.36 
..Life-threatening event 2 (1) 3 (2) 0.65 
..Hospitalisation 81 (40) 72 (36) 0.36 
..Disability 0 1 (1)  
..Other important medical event  4 (2) 3 (2) 0.70 
aAdverse events included events occurring within 6 months of arteriovenous fistula creation (i.e. those 
plausibly related to study intervention). 
 
Adherence 
After 6 and 12 weeks of treatment, the percentage of eicosapentaenoic acid and docosahexaenoic acid 
incorporated in erythrocytes (measured in Australian and New Zealand participants taking fish oil) 
doubled, but it remained at baseline levels for those taking placebo, confirming adherence to study 
treatment and providing evidence that the fish oil formulation was sufficient to modify lipid 
composition of erythrocytes (Figure 4-4). For all participants, the median number of returned capsules 
was comparable for both the fish oil and placebo groups (47 versus 45 of 360 dispensed capsules) and 
the aspirin and placebo groups (7 of 90 dispensed tablets for both groups).  
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Figure 4-4: Erythrocyte fatty acid composition by study visit and treatment: Eicosapentaenoic acid 
(EPA; Panel A), docosahexaenoic acid (DHA; Panel B), and EPA and DHA combined (Panel C) 
Abbreviations: DHA - Docosahexaenoic acid; EPA -Eicosapentaenoic acid; FA – Fatty acids.  
Erythrocyte fatty acids composition of Australian and New Zealand participants treated with fish oil (triangle) 
or placebo (square) at baseline, week 6 and 12 of fish oil supplementation shown as mean percentage of total 
erythrocyte fatty acids and standard deviation (error bars) for EPA (Panel A), DHA (Panel B), and 
EPA+DHA (Panel C).  
*The difference in erythrocyte fatty acid composition at study visits 6 and 12 for Panel A-C was statistically 
significant between fish oil and placebo treated participants (p<0.0001).   
4.7 Discussion 
In patients with chronic kidney disease undergoing creation of an AVF, three months’ treatment with 
fish oil at a dose of 4 g per day did not reduce the composite primary outcome of AVF failure nor any 
of the individual components which included AVF abandonment, thrombosis and cannulation failure, 
assessed at 12 months. The trial finished before reaching the planned recruitment target but was able 
to show that fish oil is unlikely to reduce the risk of AVF failure by 30%; results were consistent with, 
at best, a 14% RR reduction. In a smaller subset of patients, the use of low dose aspirin was similarly 
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ineffective in improving AVF outcomes. This large, international trial confirmed the high AVF failure 
of nearly 50% at 12 months after surgery and emphasises the pressing need to improve AVF outcomes.  
Previous studies regarding the benefits of fish oil supplementation in vascular access outcomes have 
been confined to AVGs in which the results are conflicting. Lok and colleagues93 found no significant 
difference in the primary outcome measure, proportion of patency loss of newly created AVGs within 
12 months, in 201 patients treated with 4 g of fish oil or placebo. However, the study demonstrated 
improvements in secondary outcomes including rates of patency loss, interventions and thrombosis in 
addition to cardiovascular benefits.  One small randomised clinical trial of 24 participants treated with 
4g of fish oil or placebo had a 12-month patency of 76% in the fish oil treated group compared with 
15% in the placebo group95 which was not confirmed in another small randomised trial using lower 
doses of eicosapentaenoic and docosahexaenoic acids94. Variability in these results may be due to 
differences in sample size, and dose and duration of therapy. 
Whilst participants receiving fish oil during the FAVOURED trial had increased erythrocyte omega-3 
PUFAs, supporting medication adherence, a clinically relevant effect of fish oil on AVF failure was 
not demonstrated. It remains unknown whether the lack of efficacy is due to achieved levels of 
eicosapentaenoic and docosahexaenoic acids being insufficient to promote adequate vasodilatory, anti-
proliferative, anti-aggregatory, and anti-inflammatory effects at the site of the AVF formation to 
improve clinical outcomes. However, the doses of eicosapentaenoic and docosahexaenoic acids used 
in the FAVOURED trial were higher than doses used in studies assessing AVG outcomes and studies 
in patients with chronic kidney disease using a comparable dose of fish oil achieved significant 
reductions in blood viscosity, platelet aggregation, and blood pressure consistent with biological 
effects74,91,168. Three months of therapy was selected because it corresponds with the expected 
maturation time and early failure of AVF37,127. However, the possibility that a longer duration of 
treatment may have resulted in a delayed benefit on maturation and usability cannot be excluded. It is 
also possible that risk factors such as age, diabetes mellitus, cardiovascular disease and peripheral 
vascular disease that affect characteristics of the conduit vessel30,46, may limit any beneficial effects of 
fish oil supplementation on AVF failure. Although there was no difference in AVF failure between the 
fish oil and placebo groups, participants with diabetes mellitus had a higher risk of AVF failure when 
treated with fish oil than those without diabetes mellitus. The biological plausibility of this finding is 
uncertain, although differences in lifestyle factors associated with diabetic status or a type I statistical 
error are possible explanations. 
Aspirin is a well-established anti-platelet agent with wide clinical efficacy in preventing vascular 
thrombotic events169. One small randomised clinical trial had previously shown a beneficial effect of 
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aspirin use on early AVF thrombosis using 1g of aspirin every other day for 28 days65. In our study, 
three months of low dose aspirin did not reduce AVF failure or thrombosis. In contrast, six weeks of 
clopidogrel bisulfate therapy reduced early access thrombosis from 20% to 12% although this did not 
increase the proportion of usable AVF72. The lower dose of aspirin used in FAVOURED may have 
been inadequate for thrombosis prevention.  
Consistent with contemporary international studies,27,72,174,175 we report 47% AVF failure. Both 
thrombosis and failure to mature were unaffected by the interventions at 12 months, suggesting that 
modifying vascular conduit function to improve vascular access outcomes requires additional research 
focus.  This high failure rate remains the most important impediment to successful HD and is 
considered a critical priority by patients and clinicians10. A substantial proportion of patients 
undergoing fistula creation with the expectation of requiring HD did not commence dialysis within 12 
months of surgery. This uncertainty in predicting dialysis commencement and timing of AVF surgery 
in patients with advanced chronic kidney disease may have implications for both resource use and 
future trial considerations176. 
To our knowledge, FAVOURED is the first trial evaluating fish oil supplementation and the largest 
trial evaluating aspirin use and AVF outcomes. Relevant clinical end points to define vascular access 
failure were included, and participants were from diverse health care settings and geographic regions. 
Treatment groups were well balanced with respect to baseline characteristics. However, the study has 
some limitations that should be considered. The trial population was younger with less vascular disease 
than anticipated because we excluded patients with medical requirements for anti-platelet agents or 
anticoagulants. There were missing data on the primary outcome, mainly because patients had not 
commenced dialysis and therefore could not be assessed for the outcome; however, the proportion of 
missing values was balanced across treatment groups (23% for fish oil and placebo; 22% for aspirin 
and 21% for placebo) and imputation is unlikely to have biased the results.  
In conclusion, the proportion of new AVFs that failed within 12 months of surgery was nearly 50% 
and was not reduced by 12 weeks of fish oil supplementation or low-dose aspirin therapy. This study 
suggests that neither fish oil nor aspirin can be recommended for the prevention of AVF failure and 
that additional strategies to reduce the high AVF failure rate are required.   
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4.8 Chapter summary 
In patients with stage IV or V chronic kidney disease undergoing creation of an AVF, three months of 
omega-3 PUFA supplementation at a daily dose of 4 g (46% EPA and 38% DHA) did not reduce the 
binary composite primary outcome of AVF failure nor any of the individual components which 
included AVF abandonment, thrombosis and cannulation failure, assessed at 12 months. The 
FAVOURED trial did not reach the planned recruitment target but was able to show that fish oil is 
unlikely to reduce the risk of AVF failure by 30%; results were consistent with, at best, a 14% RR 
reduction based on the CI of the point estimate of the effect. In a smaller subset of patients, the use of 
low dose aspirin was similarly ineffective in improving AVF outcomes. This large, international trial 
confirmed the high frequency of AVF complications; nearly half of the newly created AVFs failed 
within 12 months of surgery, 23% thrombosed, 20% were abandoned, and 40% were unable to be 
cannulated reliability once considered usable for HD. The following chapter describes additional 
important vascular access outcomes, including primary patency loss, AVF-related interventions and 
procedures, and CVC requirements and determines whether these complications can be reduced by the 
use of omega-3 PUFAs or aspirin.  
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Chapter 5   
Effect of omega-3 fatty acids on central venous catheter 
use, dialysis suitability and need for interventions 
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5.1 Chapter overview 
The previous chapter demonstrated that in the FAVOURED study cohort almost 50% of patients 
undergoing AVF creation will experience at least one of the following complications: AVF thrombosis, 
AVF abandonment or inability to cannulate the AVF for at least two-thirds of 12 consecutive dialysis 
sessions. These complications usually require alternative access placement and further vascular access 
interventions. For patients depending on HD, vascular access failure can be distressing given that this 
is their lifeline. Vascular access interventions are invasive, often painful and time consuming for 
patients and costly for the health care system. Often, AVF failure results in several interventions, for 
example a non-maturing AVF may require a CVC placement while maturation-enhancing procedures 
such as an angioplasty or ligation of tributary veins are undertaken. Once the AVF is usable for HD, 
the CVC will have to be removed again, which means an additional procedure for the patient. These 
outcomes are important to patients and clinicians and are therefore addressed in this thesis. This chapter 
summarises secondary and exploratory outcomes of the FAVOURED trial including the effects of 
omega-3 PUFA supplementation and low-dose aspirin therapy on AVF intervention rates, CVC 
exposure, late dialysis suitability failure, and times to primary patency loss, abandonment and 
successful cannulation  
5.2 Included publication 
The content of this chapter is based on a manuscript that is currently undergoing peer review. 
Viecelli AK, Polkinghorne KP, Pascoe EM, Paul-Brent P, Hawley CM, Badve SV, Cass A, Hooi LS, 
Kerr PG, Mori TA, Ong LM, Voss D, Johnson DW, Irish AB for the Omega-3 Fatty Acids (Fish Oils) 
and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative 
Group. Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the 
randomised FAVOURED trial. 
Contribution of the candidate: The candidate was lead- and corresponding author of this submitted 
manuscript and contributed to concept and design of axillary outcomes analysis, interpreted the data, 
drafted the manuscript and integrated feedback and revisions made by co-authors into a final version.  
5.3 Abstract  
Background: Arteriovenous fistulas for HD often experience early thrombosis and maturation failure 
requiring intervention and/or CVC placement. This secondary and exploratory analysis of the 
FAVOURED study determined whether omega-3 PUFAs (fish oils) or aspirin affected AVF usability, 
intervention rates and CVC requirements.   
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Methods: In 567 adult participants planned for AVF creation, all were randomised to fish oil (4 g/d) 
or placebo, and 406 to aspirin (100 mg/d) or placebo, starting one day pre-surgery and continued for 
three months. Outcomes evaluated within 12 months included AVF intervention rates, CVC exposure, 
late dialysis suitability failure, and times to primary patency loss, abandonment and successful 
cannulation.  
Results: Final analyses included 536 participants randomised to fish oil or placebo (mean age 55 years, 
64% male, 45% diabetic) and 388 randomised to aspirin or placebo. Compared with placebo, fish oil 
reduced intervention rates (0.82 vs 1.14/1000 patient-days, IRR 0.72, 95% CI 0.54-0.97), particularly 
interventions for acute thrombosis (0.09 vs 0.17/1000 patient-days, IRR 0.53, 95% CI 0.34-0.84). 
Aspirin significantly reduced rescue intervention rates (IRR 0.45, 95% CI 0.27-0.78). Neither agent 
significantly affected CVC exposure, late dialysis suitability failure or time to primary patency loss, 
AVF abandonment or successful cannulation.  
Conclusion: Although fish oil and low-dose aspirin given for 3 months reduced intervention rates in 
newly created AVF, they had no significant effects on CVC exposure, AVF usability and time to 
primary patency loss or access abandonment. Reduction in access interventions benefits patients, 
reduces costs and warrants further study. 
5.4 Introduction 
A functioning vascular access is essential for patients requiring HD. A native AVF has the best long-
term outcomes although this advantage is frequently limited by early thrombosis, maturation failure, 
the need for access interventions and/or placement of a CVC26,27. Vascular access interventions are 
burdensome for patients and incur significant health care costs147. Patients and health professionals 
consider the need for interventions to maintain the use of a vascular access for HD the most important 
adverse outcome of a vascular access177, yet treatments to reduce intervention rates and to increase the 
usability of AVF have not been a major focus of randomised trials in patients requiring HD178. The 
inhibitory effects of omega-3 polyunsaturated fatty acids (fish oils) on platelet aggregation83,168, 
inflammation84,87, and neointimal hyperplasia79, and of aspirin on platelet inhibition could be beneficial 
in reducing the need for interventions for acute thrombosis and maturation-enhancing procedures.  Fish 
oil supplementation has been shown to reduce intervention and thrombosis rates in arteriovenous 
grafts93 but has not previously been studied in AVF.  
The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease 
(FAVOURED) trial found that neither fish oil nor aspirin reduced the primary outcome ‘AVF failure’, 
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a binary composite outcome comprising AVF thrombosis and/or AVF abandonment and/or cannulation 
failure assessed at 12 months following AVF creation179. The current analysis of secondary and 
exploratory outcomes of the FAVOURED trial aimed to determine whether fish oil or low-dose aspirin 
could reduce the need for access interventions and CVC exposure and/or increase the usability of newly 
created AVF for HD. 
5.5 Methods  
Design and population 
The design and results of the main outcomes of the FAVOURED study have been 
published157,171,172,179,180. FAVOURED was a prospective, double-blind, randomised controlled trial 
conducted in Australia, New Zealand, the UK and Malaysia involving 567 adults with stage 4 or 5 
chronic kidney disease who were receiving or expected to receive HD within 12 months and scheduled 
for AVF surgery. Participants were randomly allocated in a 1:1 ratio to receive either fish oil (4 g/d, 
46% EPA and 38% DHA) or matching placebo (olive oil). A subset of 406 participants either not taking 
aspirin or able to cease it prior to enrolment were further randomised in a 1:1 ratio to receive 100 mg 
of oral aspirin daily or matching placebo. Treatment commenced one day prior to surgery and 
continued for 12 weeks. The study was approved by HRECs at participating centres. The study was 
performed in accordance with the Declaration of Helsinki and written consent was obtained from all 
participants. FAVOURED was registered with the Australian New Zealand Clinical Trials Registry 
(ACTRN12607000569404). 
Outcomes 
Pre-specified secondary157 and exploratory outcomes included the number and type of interventions 
from AVF creation to 12 months, and the time to the first intervention. Interventions comprised rescue 
procedures designed to restore patency of the AVF (medical thrombolysis or surgical thrombectomy) 
and non-rescue procedures (surgical or radiological revision or dilation of the AVF from or proximal 
to the anastomosis to the ipsilateral central vein, dilation of central venous stenosis, ligation of 
tributaries, superficialisation of the AVF, ligation of the AVF or salvage by distal reconstruction and 
interval ligation due to distal ischemia. Additional secondary outcomes encompassed the time to first 
successful cannulation (the time between surgery and first of three consecutive successful 
cannulations), time to primary patency loss (first thrombosis or need for rescue intervention), time to 
permanent AVF abandonment, time to abandonment or primary patency loss, and CVC exposure for 
HD (binary and count [duration in situ] outcome). Exploratory analyses included the binary outcomes 
of primary patency loss within the first 12 months and late dialysis suitability failure127 (inability to 
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cannulate the study AVF for at least 8 out of 12 consecutive HD sessions or access abandonment by 6 
months post-surgery). Table 5-1 provides a summary of the outcomes and definitions.  
Table 5-1: Outcomes including measurement definition, metrics and method of aggregation 
Outcome Definition 
Metric(s)/Method of 
aggregation 
Interventions Medical, surgical or radiological 
interventions performed on the study AVF 
within the first 12 months of creation 
including:  
Proportion of participants with 
at least 1 intervention 
Rate of interventions (number 
of interventions per 1000 
patient-days) 
Time to first intervention 
- Rescue 
interventions 
Medical thrombolysis or surgical   
thrombectomy 
- Non-rescue 
interventions 
Surgical or radiological revision or 
dilation of the AVF from or proximal to 
the anastomosis to the ipsilateral central 
vein, dilation of central venous stenosis, 
ligation of tributaries, superficialisation of 
AVF, ligation of AVF or salvage by distal 
reconstruction and interval ligation due to 
distal ischemia [DRIL] 
First successful 
cannulation 
First of three consecutive successful 
cannulations 
Proportion of participants with 
successful cannulation 
Time to event 
Primary patency loss First thrombosis or need for rescue 
intervention (i.e. medical thrombolysis or 
surgical   thrombectomy) 
Proportion of participants with 
primary patency loss 
Time to event 
Permanent AVF 
abandonment  
No further use of, or attempt to intervene 
on, the study AVF 
Time to event 
CVC exposure CVC requirement  
CVC in situ  
Proportion of participants 
requiring at least 1 CVC 
Median number of days in situ 
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Outcome Definition 
Metric(s)/Method of 
aggregation 
Late dialysis 
suitability failure 
Inability to cannulate the study AVF for at 
least 8 out of 12 consecutive HD sessions 
or permanent access abandonment within 
the first 6 months post-surgery 
Proportion of participants with 
late dialysis suitability failure 
Abbreviations: AVF – arteriovenous fistula; CVC – central venous catheter 
 
Statistical analysis 
Continuous variables were expressed as mean (± SD) or median (IQR) depending on the distribution 
and categorical variables as numbers and percentages.  Pearson’s Chi-square test or Fisher’s exact test 
were used to compare categorical data as appropriate. Treatment effects for binary outcomes were 
determined by log-binomial regression and expressed as RR and 95% CI. Incidence rate ratios from 
Poisson regression were used for treatment comparisons on count outcomes. Cox proportional sub-
distribution hazards models were used to compare treatment effects on time to first intervention, first 
successful cannulation and AVF abandonment treating death and transplantation as competing events. 
The proportional hazards assumption was tested by adding an interaction between treatment and time 
to each model. As there were few competing risks (<1% to 2.4%), survival results were displayed as 
Kaplan-Meier curves with 95% CI and competing events censored. All outcome comparisons of fish 
oil with placebo were adjusted for differences in aspirin use (randomised to aspirin, randomised to 
placebo aspirin, open-label aspirin). The robustness of the fish oil effect was assessed by additional 
analyses that adjusted for pre-specified baseline characteristics (planned AVF site, diabetes mellitus, 
age, cardiovascular comorbidities, and renal replacement therapy at baseline) and study region 
(Australia and New Zealand, Malaysia and the UK). The same statistical methods were used for the 
comparison of aspirin with matching placebo. A two-sided p-value less than 0.05 was considered 
statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute). 
5.6 Results  
The FAVOURED study randomised 567 participants to fish oil or placebo from August 21, 2008 to 
February 28, 2014, of which 536 were included in the final analysis179. Table 5-2 shows the baseline 
characteristics of the 536 participants; 31 participants were excluded because they either died prior to 
being assessed on any outcome (n=5 in each of the fish oil and placebo groups) or did not have an AVF 
created (n=9 randomised to fish oil, n=12 randomised to placebo)179. Participants had a mean age of 
55 years and 64% were male. Baseline characteristics were generally well balanced although more 
participants treated with fish oil compared to placebo were diabetic (48% versus 43%) or smokers 
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(53% versus 48%). At study initiation, 49% were on dialysis with 84% dialysing through a CVC. At 
study end, 83% received dialysis with 61% using the study AVF (167 [62%] randomised to fish oil, 
159 [60%] randomised to placebo).  
Table 5-2: Patient demographics and baseline characteristics for fish oil versus placebo and separately 
for the subset of aspirin versus placebo 
Characteristics 
Fish oil 
(n=270) 
Placebo 
(n=266) 
Aspirin 
(n=194) 
Placebo 
(n=194) 
Age, (years, mean ± SD) 54.2 ± 14.1 55.9 ± 14.7 52.4 ± 14.6 54.2 ± 14.9 
Male, n (%) 171 (63) 171 (64) 120 (62) 126 (65) 
Country, n (%)     
  Australia and New Zealand 192 (71) 191 (72) 150 (74) 147 (72) 
  Malaysia 75 (28) 69 (26) 53 (26) 53 (26) 
  United Kingdom   3 (1) 6 (2) 0 3 (2) 
Ethnicity, n (%)     
  Asian 88 (33) 81 (31) 66 (34) 56 (29) 
  White 139 (52) 150 (56) 102 (53) 117 (60) 
  Indigenousa 34 (13) 25 (9) 22 (11) 15 (8) 
  Other 9 (3) 10 (4) 4 (2) 6 (3) 
Body mass index, (kg/m2; mean ± 
SD) 
28.8 ± 7.4  28.3 ± 7.0 27.7 ± 6.6  28.4 ± 7.7 
Blood pressure, (mm Hg; mean ± 
SD) 
    
  Systolic 146 ± 23 146 ± 23 145 ± 22 146 ± 24 
  Diastolic  82 ± 14 81 ± 13 81 ± 13 83 ± 14 
Comorbid conditions            
  Diabetes mellitus, n (%) 130 (48) 113 (43) 79 (41) 70 (36) 
  Cardiovascular disease, n (%) 39 (14) 40 (15) 14 (7) 10 (5) 
  Hypertension, n (%) 234 (87) 241 (91) 174 (90) 172 (89) 
  Current or prior smoking, n (%) 144 (53) 128 (48) 92 (47) 93 (48) 
Medications           
  Aspirin, n (%) 71 (26) 72 (27) NA NA 
  Statin, n (%) 143 (53) 132 (50) 79 (41) 87 (45) 
  ESA, n (%) 119 (44) 134 (50) 99 (51) 90 (46) 
  Beta-blocker, n (%) 123 (46) 124 (47) 91 (47) 77 (40) 
  ARB/ACEI, n (%) 108 (40) 116 (44) 85 (44) 80 (41) 
  CCB, n (%) 150 (56) 149 (56) 113 (58) 103 (53) 
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Characteristics 
Fish oil 
(n=270) 
Placebo 
(n=266) 
Aspirin 
(n=194) 
Placebo 
(n=194) 
Planned study AVF location, n 
(%)b 
    
  Upper arm 104 (39) 103 (39) 84 (41) 82 (40) 
  Forearm 166 (62) 163 (61) 119 (59) 121 (60) 
Renal replacement therapy at time 
of AVF creation, n (%) 
    
  Peritoneal dialysis 14 (5) 19 (7) 16 (8) 10 (5) 
  Haemodialysis 115 (43) 111 (42) 79 (41) 88 (45) 
  Not currently receiving dialysis  141 (52) 136 (51) 99 (51) 96 (50) 
Principal access currently in use 
for participants receiving dialysis, 
n (%) 
    
  AVF 5 (4) 2 (2) 2 (2) 1 (1) 
  AVG 0 1 (1) 0 0 
  CVC (cuffed and non-cuffed) 110 (85) 108 (83) 77 (81) 87 (89) 
  Peritoneal dialysis catheter 14 (11) 19 (15) 16 (17) 10 (10) 
Dialysis duration (months; 
median [IQR])c  
3.8 [1.8, 18.2] 4.2 [1.9, 16.1] 4.6 (2.0, 16.3) 4.0 (1.7, 15.1) 
Abbreviations: ACEI – angiotensin-converting enzyme inhibitor; AVF – arteriovenous fistula; ARB – angiotensin receptor 
blocker; CCB – calcium channel blocker; CVC – Central venous catheter; eGFR – estimated glomerular filtration rate; 
ESAs – erythropoietin stimulating agents; IQR – interquartile range; N/A – not applicable; SD – standard deviation. 
aAboriginal, Torres Strait Islanders, Maori and Pacific Islanders 
bActual AVF location upper arm versus forearm: fish oil n=110 (41%) versus n=160 (59%); placebo n=107 (40%) versus 
n=159 (60%);  aspirin n=79 (41%) versus n=115 (59%); placebo n=79 (41%) versus n=115 (59%). 
cFor pre-dialysis participants only (fish oil n=141 and placebo n=136; aspirin n=99 and placebo n=96) 
 
Of the 406 participants not taking aspirin or able to cease it prior to enrolment, 203 were randomised 
to aspirin and 203 to matching placebo179 of which 388 (194 in each group) were included in the 
analysis (Figure 5-1). The remaining 18 participants were excluded because they either did not undergo 
AVF creation (n=5 randomised to aspirin, n=8 randomised to placebo) or died before they could be 
assessed on any outcome (n=4 randomised to aspirin, n=1 randomised to placebo). As outlined in Table 
5-1, this subset of 388 participants had a lower prevalence of cardiovascular disease (7% randomised 
to aspirin, 5% randomised to placebo) compared to the full set of 536 participants randomised to fish 
oil (14%) or matching placebo (15%).  
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Figure 5-1: Patient demographics and baseline characteristics for fish oil versus placebo and separately 
for the subset of aspirin versus placebo 
Arteriovenous fistula interventions 
Figure 5-2 and Table 5-3 present the frequency and type of AVF interventions by treatment arms for 
fish oil versus placebo (A) and aspirin versus placebo (B). Overall, 22% of participants receiving fish 
oil supplementation required at least one AVF intervention compared to 27% treated with placebo 
(Table 5-3). Of those, 17% treated with fish oil and 28% treated with placebo required more than one 
intervention. The majority of interventions occurred within the first 6 months of AVF creation (Figure 
5-2). Neither fish oil nor aspirin reduced the risk of needing at least one rescue- or non-rescue 
intervention compared to their matching placebo. Similarly, the time to first intervention was not 
significantly reduced by fish oil or aspirin (Figure 5-3A and B; HR 0.85, 95% CI 0.57, 1.26, p=0.41 
for fish oil versus placebo; HR 0.81, 95% CI 0.51, 1.29, p=0.38 for aspirin versus placebo). As shown 
in Figure 5-4A, intervention rates were significantly reduced by fish oil compared to placebo, driven 
by a significant reduction in rescue procedures (IRR 0.53 95% CI 0.34, 0.84, p=0.005). The effect size 
remained similar when adjusting for pre-specified baseline characteristics and geographical regions. 
Of note, there was a significant reduction in the number of rescue interventions with fish oil during the 
active treatment period, i.e. the first 3 months, compared with placebo (p=0.009) (Figure 5-2A). 
Similarly, the rate of rescue interventions was reduced in the participants treated with low-dose aspirin 
compared to matching placebo (Figure 5-4B). The fish oil by aspirin interaction test was not 
statistically significant for rescue or non-rescue interventions (p = 0.12). 
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Figure 5-2: Number of rescue- and non-rescue interventions by time period for fish oil versus placebo 
(A) and aspirin versus placebo. (B) *p=0.009 (Fisher’s Exact Test) for comparison of rescue intervention 
during first 3 months (active treatment phase) and beyond.  
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Table 5-3: Type and frequency of AVF interventions for fish oil versus placebo (A) and aspirin versus 
placebo (B) 
A | AVF interventions for fish oil versus placebo 
Outcomes 
Fish oil 
(n=270) 
Placebo 
(n=266) 
RR 
(95% CI)d 
P value 
Patients with ≥ 1 intervention, n (%)a 
- 1 intervention 
- 2 interventions 
- 3 interventions 
- 4 interventions 
60 (22) 
50 (19) 
8 (3) 
2 (1) 
0 
72 (27) 
52 (20) 
14 (5) 
3 (1) 
3 (1) 
0.82  
(0.61, 1.11) 
0.20 
Patients with ≥ 1 rescue intervention, n (%)b 
- 1 intervention 
- 2 interventions 
8 (3) 
8 (3) 
0 
13 (5) 
11 (4) 
2 (1) 
0.60  
(0.25, 1.42) 
0.24 
Patients with ≥ 1 non-rescue intervention, n (%)c 
- 1 intervention 
- 2 interventions 
- 3 interventions 
- 4 interventions 
55 (20) 
48 (18) 
5 (2) 
2 (1) 
0 
66 (25) 
52 (20) 
9 (3) 
4 (2) 
1 (<1) 
0.82  
(0.60, 1.12) 
0.22 
B | AVF interventions for aspirin versus placebo 
Outcomes 
Aspirin 
(n=194) 
Placebo 
(n=194) 
RR 
(95% CI) 
P value 
Patients with ≥ 1 intervention, n (%)a 
- 1 intervention 
- 2 interventions 
- 3 interventions 
- 4 interventions 
44 (23) 
34 (18) 
7 (4) 
2 (1) 
1 (1) 
49 (25) 
36 (19) 
9 (5) 
2 (1) 
2 (1) 
0.9  
(0.63, 1.28) 
0.55 
Patients with ≥ 1 rescue intervention, n (%)b 
- 1 intervention 
- 2 interventions 
5 (3) 
4 (2) 
1 (1) 
12 (6) 
11 (6) 
2 (1) 
0.42  
(0.15, 1.16) 
0.58 
Patients with ≥ 1 non-rescue intervention n (%)c 
- 1 intervention 
- 2 interventions 
- 3 interventions 
- 4 interventions 
42 (22) 
34 (18) 
6 (3) 
2 (1) 
0 
43 (22) 
36 (19) 
3 (2) 
3 (2) 
1 (1) 
0.98  
(0.67, 1.42) 
0.12 
Abbreviations:  AVF – arteriovenous fistula; CI – confidence interval; n – number; RR – relative risk. 
aSurgical or radiological revision or dilatation of the AVF from or proximal to the anastomosis to the ipsilateral central 
vein, dilation of central venous stenosis, ligation of tributaries, superficialisation of AVF, thrombolysis or thrombectomy, 
ligation of fistula, salvage by distal reconstruction and interval ligation, others. 
bThrombolysis or thrombectomy.  
cSurgical or radiological revision or dilatation of the AVF from or proximal to the anastomosis to the ipsilateral central 
vein, dilation of central venous stenosis, ligation of tributaries, superficialisation of AVF, ligation of fistula or salvage 
by distal reconstruction and interval ligation. 
dAdjusted for differences in aspirin use (no aspirin, randomized to aspirin, open-label aspirin). 
  
107 
 
 
 
Figure 5-3: Time to first AVF intervention for fish oil versus placebo (A) and aspirin versus placebo 
(B).  
Kaplan-Meier curve for active therapy (solid line with 95% confidence interval in light grey) and matching 
placebo (dashed line with 95% confidence interval in dark grey). 
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Figure 5-4: AVF intervention rates for fish oil versus placebo (A) and aspirin versus placebo (B).  
Overall interventions: Surgical or radiological revision or dilatation of the AVF from or proximal to the 
anastomosis to the ipsilateral central vein, dilation of central venous stenosis, ligation of tributaries, 
superficialisation of AVF, thrombolysis or thrombectomy, ligation of fistula or salvage by distal 
reconstruction and interval ligation, others. Rescue interventions: Thrombolysis or thrombectomy. Non-
rescue interventions: Surgical or radiological revision or dilatation of the AVF from or proximal to the 
anastomosis to the ipsilateral central vein, dilation of central venous stenosis, ligation of tributaries, 
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superficialisation of AVF, ligation of fistula or salvage by distal reconstruction and interval ligation. Regions 
included Australia and New Zealand, Malaysia and the United Kingdom. Pre-specified baseline 
characteristics included planned AVF site (lower arm, upper arm), diabetes mellitus, age group (quartiles), 
cardiovascular comorbidity, including any one or more of peripheral vascular disease, ischaemic heart 
disease and cerebrovascular accidents, and renal replacement therapy at baseline (no [pre-dialysis/transplant], 
yes [haemodialysis or peritoneal dialysis]). aAdjusted for differences in aspirin use (no aspirin, randomised 
to aspirin, open-label aspirin).  
Primary patency loss and AVF abandonment 
The proportion of participants with primary patency loss within 12 months of their AVF creation was 
not significantly reduced by fish oil (70/270 [26%] participants) compared to placebo (81/266 [31%]; 
RR 0.85, 95% CI 0.65, 1.12, p=0.25). Similarly, the time to primary patency loss was not significantly 
improved in the fish oil treated group compared to placebo (HR 0.81, 95% CI 0.51, 1.29, p=0.38), as 
shown in Figure 5-5A. In participants treated with aspirin or matching placebo, primary patency loss 
occurred in 27% of participants in both treatment arms and the time to primary patency loss was similar 
for aspirin and placebo treated participants (Figure 5-5B; HR 1.01, 95% CI 0.69, 1.47, p=0.98). Figure 
5-6 shows that neither fish oil (A) nor aspirin (B) led to a significant prolongation in the time to AVF 
abandonment. Similarly, time to either primary patency loss or AVF abandonment was not altered by 
fish oil (HR 0.92, 95% CI 0.69-1.21, p=0.53) or aspirin (HR 1.01, 95% CI 0.73-1.42, p=0.94).  
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Figure 5-5: Time to primary AVF patency loss for fish oil versus placebo (A) and aspirin versus placebo 
(B).  
Kaplan-Meier curve for active therapy (solid line with 95% confidence interval in light grey) and matching 
placebo (dashed line with 95% confidence interval in dark grey).  
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Figure 5-6: Time to AVF abandonment for fish oil versus placebo (A) and Aspirin versus Placebo (B).  
Kaplan-Meier curve for active therapy (solid line with 95% confidence interval in light grey) and matching 
placebo (dashed line with 95% confidence interval in dark grey).  
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Central venous catheter requirements 
Half of the participants required at least one CVC within the first 12 months of AVF creation and this 
was not reduced by fish oil (RR 1.00, 95% CI 0.84, 1.19, p=0.97) or aspirin (RR 0.93, 95% CI 0.76, 
1.14, p=0.48) compared to their matching placebos. The median number of days CVCs stayed in situ 
was comparable in the fish oil and placebo groups (101 days, IQR 56-175 versus 101 days, IQR 57-
176, IRR 0.96, 95% CI 0.76, 1.21, p=0.73). No significant difference in CVC exposure time was found 
between participants treated with aspirin or matching placebo (103 days, IQR 63-154 versus 87 days, 
IQR 54-157, IRR 0.91 95% CI 0.69, 1.19, p=0.48). 
Arteriovenous fistula usability 
Of the 356 participants who required HD within 6 months of AVF surgery, 36% on fish oil and 34% 
on placebo were unable to use the AVF for HD (RR 1.05, 95% CI 0.79, 1.39, p=0.73). Aspirin was 
similarly ineffective in reducing late dialysis suitability failure compared to placebo (47/135 [35%] 
versus 38/124 [31%], RR 1.14, 95% CI 0.80, 1.61, p=0.48). By 12 months following AVF surgery, 
444 participants received dialysis and 74% of participants in the fish oil group and 73% of those in the 
placebo group had three consecutive successful cannulations of their AVF. Neither fish oil (HR 1.03, 
95% CI 0.83-1.28, p=0.77) nor aspirin (HR 0.89, 95% CI 0.69-1.15, p=0.37) reduced the time to first 
successful cannulation of the study AVF (Figure 5-7A and B).  
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Figure 5-7: Time to first successful cannulation for fish oil versus placebo (A) and aspirin versus 
placebo (B).  
Kaplan-Meier curve for active therapy (solid line with 95% confidence interval in light grey) and matching 
placebo (dashed line with 95% confidence interval in dark grey).  
5.7 Discussion 
Secondary and exploratory outcome analyses of the FAVOURED trial showed that a quarter of 
participants required at least one AVF intervention within the first year of AVF creation, almost 30% 
experienced primary patency loss and 50% required at least one CVC. Three months of fish oil 
supplementation reduced the rate of AVF interventions, principally driven by a 47% relative reduction 
in rescue procedures for acute thrombosis. Similarly, low-dose aspirin reduced the incidence of rescue 
interventions by 55%. However, neither fish oil nor aspirin was effective in reducing the frequency 
and duration of CVC use, the frequency of late dialysis suitability failure or the time to first successful 
cannulation. Similarly, the time to first AVF intervention, primary patency loss or AVF abandonment 
did not differ significantly between treatment groups.  
Fish oil had no effect on the primary composite outcome of AVF failure179, defined as the proportion 
of participants with AVF thrombosis, AVF abandonment and/or cannulation failure within 12 months 
of access creation. However, these secondary outcome analyses suggested a significant treatment 
benefit of fish oil in reducing the rate of AVF interventions. Similar findings were reported in 
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arteriovenous grafts by Lok and colleagues93, whereby fish oil did not significantly reduce the 
proportion of AVG thrombosis or interventions to maintain patency but did lead to a clinically 
meaningful reduction in rates of thrombosis and access interventions. These observations suggest that 
count outcomes (i.e. rates) are more sensitive to the detection of changes by interventions compared to 
binary outcomes (i.e. proportions). In addition, a reduction in intervention rates but not in either the 
proportion of AVFs requiring intervention or time to first intervention suggests that fish oil may be 
beneficial in reducing recurrent interventions. Interventions, such as angioplasties, thrombectomies 
and revisions, can increase the risk of recurrent thrombosis and stenosis due to disruption of the 
endothelial layer and subsequent vasoconstrictive, pro-inflammatory and pro-coagulative responses43. 
The vasodilatory90, anti-inflammatory84,87, anti-aggregatory83,168, and anti-proliferative effects79 of fish 
oil may be beneficial in reducing this risk and hence the need for recurrent interventions. Additional 
studies might further explore the potential benefit of fish oil supplementation in secondary prevention 
of AVF interventions. 
High-dose aspirin given as 1000 mg every other day has previously been shown to reduce access 
thrombosis within the first 28 days of AVF creation65. To minimize the risk of bleeding complications, 
a lower dose of aspirin (100 mg) was used in the FAVOURED trial.  Low-dose aspirin, while not 
associated with increased bleeding, did not reduce the frequency of access thrombosis during the first 
12 months of AVF creation as previously shown179. However, similar to fish oil there may be a potential 
role for low-dose aspirin to reduce intervention rates for access thrombosis that warrants confirmation 
in larger trials.   
Vascular access function is the most frequently reported vascular access outcome but is very 
heterogeneous with almost 900 measures used to assess the usability and function of an access5. These 
additional analyses from the FAVOURED study provide novel information across a broad range of 
outcomes related to dysfunction of a newly created AVF including patency loss, need for interventions, 
CVC exposure, cannulation failure and access abandonment.  Patients, caregivers and health 
professionals all consider the need for access interventions the most important clinical outcome 
measure of the function of a vascular access181. From a patient’s perspective, the number of 
interventions and intervention-free time have a dramatic impact on their quality of life and well-being 
because access procedures are burdensome and time-consuming8,181. Financial costs associated with 
AVF procedures account for more than half of the expenditure in the first year of AVF creation even 
without accounting for secondary expenditure for prolonged hospitalisation or procedure-related 
complications147.  
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More than a third of participants were unable to use their study AVF for dialysis by 6 months after 
access creation. This is comparable to the national average of AVF use of 36% in prevalent HD patients 
of the US182 and 39% reported in the US Haemodialysis Fistula Maturation study183. Of note, in the 
North American study investigating the effect of clopidogrel on early fistula thrombosis and dialysis 
suitability failure72, 61% of participants were unable to use their fistula reliably for HD. The higher 
prevalence of cardiovascular disease (25%) and participants of black ethnicity (50%), and the use of a 
more stringent definition that included a minimum machine blood flow rate of 300 mL/min may have 
contributed to the higher frequency of dialysis suitability failure in the clopidogrel trial. Neither fish 
oil nor aspirin in our study, or clopidogrel in the North American study72, were effective in improving 
dialysis suitability despite reducing rescue intervention rates and early thrombosis, respectively. 
Dialysis suitability, while a clinically meaningful and relevant outcome, is multifaceted and not only 
the result of a complex fistula maturation process but also that of a multidisciplinary team effort 
comprising different surgical techniques, variations in fistula care and cannulation skills. A single 
treatment agent may therefore not be sufficient to alter such a complex outcome. Multipronged health 
service intervention studies that include pharmacological, patient- (e.g. vein preservation, AVF care) 
and clinician-directed (e.g. surgical technique, cannulation skills, access surveillance) interventions to 
improve AVF outcomes may be required and warrant further exploration.   
Our study addresses multiple clinically meaningful and relevant outcomes to assess AVF function, 
particularly the need for intervention. However, the study has some limitations that should be 
considered. The FAVOURED study was not powered for these secondary and exploratory outcomes. 
Considering the 95% CI, the treatment benefits of fish oil in reducing intervention rates might have 
been as low as 16% or as large as 76% and a reduction in late dialysis suitability failure by up to 21% 
cannot be excluded. For enhanced precision in treatment estimates, a larger study would be required. 
It is possible that fish oil supplementation or aspirin use beyond the first three months may have had 
prolonged benefits in reducing the need for access interventions or CVCs. Three months of therapy 
were selected because early thrombosis and physiologic maturation (i.e. AVF flow and vein diameter) 
typically occur within the first few weeks of AVF creation37,184. However, there is significant 
variability in the time to successful clinical maturation. Studies have shown a range in median time 
from AVF creation to cannulation of 25 days in Japan to 98 days in the U.S. based on the Dialysis 
Outcomes and Practice Patterns Study185. These observations reflect differences in case-mix, care 
processes, AVF complications (e.g. infiltrations), and AVF procedures183 and are not expected to be 
influenced by fish oil or aspirin use.  
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In conclusion, secondary outcomes of the FAVOURED study suggest that three months of fish oil 
supplementation or low-dose aspirin use may be beneficial in reducing intervention rates for acute 
thrombosis in newly formed AVF. However, neither fish oil nor aspirin was effective in reducing CVC 
exposure, decreasing dialysis suitability failure or prolonging the time to primary patency loss, access 
abandonment, first successful cannulation or first access intervention. Given the importance of access 
interventions to patients and health professionals and associated costs, we consider further studies to 
explore benefits of ongoing fish oil supplementation or low-dose aspirin use, particularly for secondary 
prevention of access interventions to be warranted.  
5.8 Chapter summary 
Secondary and exploratory outcome analyses of the FAVOURED trial showed that within 12 months 
of AVF creation, half of the study participants required at least one CVC for a median duration of 100 
days, almost 30% experienced primary patency loss and a quarter of participants required at least one 
AVF intervention. Of the 66% of participants requiring HD within the first 6 months of AVF creation, 
over one-third was unable to use their AVF reliability for HD. Neither fish oil nor aspirin was effective 
in reducing the frequency and duration of CVC use, the frequency of late dialysis suitability failure or 
the time to first successful cannulation. Similarly, the time to first AVF intervention, primary patency 
loss or AVF abandonment did not differ significantly between treatment groups. However, three 
months of fish oil supplementation reduced the rate of AVF interventions, predominantly driven by a 
47% relative reduction in rescue procedures for acute thrombosis. The reduction in AVF interventions 
was particularly evident in the first 3 months following surgery when fish oil was supplemented. Low-
dose aspirin was similarly effective and reduced the rate of interventions for AVF thrombosis by 55%.  
Fish oil effects observed in AVFs are similar to those reported in AVGs: While fish oil had no 
significant effect on the proportion of AVF failure, thrombosis or need for at least one intervention, 
the rate of interventions for thrombosis was reduced. Similarly, fish oil did not significantly reduce the 
proportion of AVG thrombosis or interventions to maintain patency in the FISH trial93 but did lead to 
a significant reduction in rates of thrombosis and access interventions. These observations may indicate 
a potential treatment benefit of fish oil to reduce recurrent thrombosis or interventions. It may also 
suggest that count outcomes (i.e. rates) are more sensitive to the detection of changes by interventions 
compared to binary outcomes (i.e. proportions), particularly when the sample size is restricted. The 
latter will be addressed in the next chapter by performing a meta-analysis of available RCTs on the 
effects of fish oil in preventing arteriovenous access complications.  
  
  
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6   
Systematic review and meta-analysis on omega-3 fatty 
acids in preventing arteriovenous access failure 
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6.1 Chapter overview 
The results of the FAVOURED trial indicated that fish oil was not effective in reducing the proportion 
of AVF failure including thrombosis, AVF abandonment and cannulation failure at 12 months but may 
be beneficial in reducing the rate of interventions for acute thrombosis. Similarly, the largest RCT of 
fish oil use in AVGs was unable to detect a statistically significant reduction the proportion of graft 
thrombosis or radiological/surgical interventions within 12 months of access creation but found a 
significant reduction in the rate of thrombosis and AVG interventions, raising the question of whether 
a reduction in arteriovenous access thrombosis or patency loss may have been missed due to the choice 
of the metric for the primary outcome, i.e. a binary (proportion) rather than a count outcome (rate) that 
may be less sensitive to detect a difference in treatment impact combined with inadequate sample sizes 
of the studies. To address this question, a systematic review and meta-analysis of all available evidence 
of the efficacy omega-3 fatty acid supplementation in preventing arteriovenous access failure was 
performed. Standardised outcome definitions were used to ensure reliable and meaningful comparison 
of treatment effects across different studies. Several clinically important efficacy and safety outcome 
were explored including primary patency loss, dialysis suitability failure, access abandonment, 
interventions to maintain patency or assist maturation, bleeding events, gastrointestinal side effects, 
hospitalisation, mortality, and treatment adherence.  
6.2 Included publication 
The content of this chapter is based on the following peer-reviewed publication: 
Viecelli AK, Irish AB, Polkinghorne KR, Hawley CM, Johnson DW, Mori TA, Pascoe EM, Strippoli 
GFM, Lok CE, and Palmer SC. Omega-3 polyunsaturated fatty acid supplementation to prevent 
arteriovenous fistula and graft failure: Systematic review and meta-analysis of randomized controlled 
trials. Am J Kidney Dis. 2018;72(1):50-61. Copyright permission has been obtained to reproduce this 
manuscript. 
The candidate developed the concept and design for this meta-analysis, wrote and registered the study 
protocol including the statistical analysis plan and performed the literature search. The candidate 
extracted all the data together with SCP as the second independent adjudicator, performed bias 
assessment and GRADE assessment with SCP as second independent adjudicator, carried out the 
statistical analyses and interpreted the data, created the included figures and tables, drafted the 
manuscript and integrated comments and revisions from co-authors into a final version.   
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6.3 Abstract 
Background: Arteriovenous access failure frequently occurs in people on HD and is associated with 
morbidity, mortality and healthcare expenditure. Omega-3 polyunsaturated fatty acids (omega-3 
PUFA) may improve outcomes via pleiotropic effects on access maturation and function, but may 
cause bleeding complications.  
Study design: Systematic review with meta-analysis. 
Setting & population: Adults requiring HD via arteriovenous fistula, graft or shunt. 
Selection criteria: Trials evaluating omega-3 PUFA for arteriovenous access outcomes identified by 
searches in CENTRAL, MEDLINE, and Embase to 24 January 2017. 
Intervention: Omega-3 PUFA. 
Outcomes: Primary patency loss, dialysis suitability failure, access abandonment, interventions to 
maintain patency or assist maturation, bleeding, gastrointestinal side-effects, all-cause and 
cardiovascular mortality, hospitalisation, and treatment adherence. Treatment effects were summarized 
as relative risks (RR) and 95% confidence interval (CI). Evidence was assessed using GRADE. 
Results: Five eligible trials (833 participants) compared omega-3 PUFA supplementation with 
placebo, commenced perioperatively, with median follow-up of 12 months. One trial (n=567) 
evaluated treatment for fistulas and four (n=266) for grafts. Omega-3 PUFA supplementation 
prevented primary patency loss with moderate certainty (761 participants, RR 0.81, CI 0.68-0.98). Low 
quality evidence suggested, that omega-3 PUFA may have had little or no effect on dialysis suitability 
failure (536 participants, RR 0.95, CI 0.73-1.23), access abandonment (732 participants, RR 0.78, CI 
0.59-1.03), need for interventions (732 participants, RR 0.82, CI 0.64-1.04), or all-cause mortality (799 
participants, RR 0.99, CI 0.51-1.92). Bleeding risk (793 participants, RR 1.40, CI 0.78-2.49) or 
gastrointestinal side-effects (816 participants, RR 1.22, CI 0.64-2.34) were uncertain. There was no 
evidence of different treatment effects for grafts or fistulas.  
Limitations: Small number and methodological limitations of included trials. 
Conclusions: Omega-3 PUFA supplementation probably protects against primary loss of 
arteriovenous access patency, but may have little or no effect on dialysis suitability failure, access 
interventions or abandonment. Potential treatment harms are uncertain.  
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6.4 Introduction 
Haemodialysis is the most common renal replacement therapy worldwide and ideally requires a 
functioning arteriovenous vascular access. Establishing and maintaining a functional arteriovenous 
access remains one of the greatest challenges for dialysis care28,186,187. Arteriovenous fistula and graft 
dysfunction lead to prolonged use of CVCs and repeated hospitalisation and procedures, which are 
associated with higher rates of complications and mortality24-26. Patients, caregivers, and health care 
professionals consider vascular access outcomes a critical priority11. Strategies to improve the usability 
of HD vascular access are required.  
The pathogenesis of arteriovenous access failure is complex and not fully understood188. Pathogenic 
processes that may contribute to patency loss, impaired maturation, and dialysis suitability failure 
include neointimal hyperplasia formation and impaired vascular remodelling with insufficient 
vasodilation and vessel wall thickening in response to the increased pressure, shear stress and oxygen 
tension resulting from redirected arterial inflow4,188,189.  
Randomised controlled trials have evaluated various local and systemic therapies to improve 
arteriovenous access maturation and function4. Most trials have focused on antiplatelet agents to 
prevent access thrombosis and maintaining vascular access patency. While antiplatelet agents may be 
effective in reducing early arteriovenous access thrombosis65,69-72,148, they have not been shown to 
improve long-term patency and dialysis suitability64,72. Given the complexity of processes involved in 
dialysis vascular access failure, an agent with pleotropic vascular effects may provide a more durable 
and effective therapeutic strategy for favourably influencing vascular remodelling, neointimal 
hyperplasia formation, and thrombotic risk in newly formed vascular access. Omega-3 PUFA show 
promise because they inhibit platelet aggregation168 and exert anti-inflammatory84,87, anti-
proliferative79,190 and vasodilatory effects90 on vascular structures. These actions may improve 
maturation and function of a newly created arteriovenous access. Conversely, while previous small 
studies did not show an increased risk of bleeding in dialysis patients taking omega-3 PUFA191,192, the 
antiplatelet effects of omega-3 PUFA may continue to pose a concern given the already increased 
bleeding diathesis in this population170,193-195.  
The aim of this systematic review and meta-analysis was to evaluate the benefits and harms of omega-
3 PUFA supplementation for arteriovenous access complications in people with ESKD requiring HD.  
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6.5 Methods 
Study design 
This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines for 
reporting of systematic reviews of interventions and a pre-specified, registered protocol196,197. Research 
ethics committee approval was not required for this study.  
Search strategy and selection criteria 
We searched MEDLINE (1946 through January 24, 2017), Embase (1980 through January 24, 2017) 
and CENTRAL (through Issue 11 of 12, 2016) without language restriction using search strategies 
designed by a specialist information manager (Table S6- 1). All randomised controlled and quasi-
randomised controlled trials comparing omega-3 PUFA with placebo or no treatment for prevention of 
AVF or AVG failure were eligible. Adults with ESKD receiving or planning to receive HD via an 
AVF, AVG or arteriovenous shunt in the upper or lower limb were included.  
Study selection and data extraction 
Two authors (AV, SP) independently screened the titles and abstracts of all retrieved citations and 
reviewed the full text of potentially relevant records to identify trials that fulfilled the review eligibility 
criteria using the Population, Intervention, Comparison, Outcomes (PICO) framework198. Baseline 
characteristics, study design, interventions, and outcome definitions were extracted independently by 
the same authors (AV, SP).  
Outcomes 
Standardised definitions for outcomes related to HD vascular access were used127. The primary efficacy 
outcome was loss of primary vascular access patency (first thrombosis or need for surgical or 
endovascular intervention to restore patency) and the primary safety outcome was bleeding. Secondary 
outcomes included: need for surgical or radiological intervention(s) to maintain dialysis vascular access 
patency or to assist maturation, dialysis vascular access abandonment (defined as an AVF/AVG that 
could no longer be used for HD and the associated access problem was not correctable by any further 
intervention), early dialysis suitability failure (defined as an access that, despite radiological or surgical 
interventions, could not be used successfully for dialysis by three months following access creation), 
late dialysis suitability failure (defined as an access that, despite radiological or surgical interventions, 
could not be used successfully for dialysis by six months following access creation), gastrointestinal 
side-effects, all-cause mortality, cardiovascular mortality, hospitalisation, and treatment adherence. 
For each outcome, the number of events and number of people at risk in each treatment arm of included 
studies were extracted to calculate an individual study RR and 95% CI.  To reduce heterogeneity and 
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increase certainty in the review findings, outcome measures from contributing studies were only used 
in meta-analyses, if consistent with the pre-specified outcome definitions reported in the protocol for 
this systematic review. Additional outcome data consistent with the outcome definitions in the protocol 
were requested from study investigators in writing (including re-analyses of patient-level data) and 
included in meta-analyses when provided.  
Evidence quality assessment 
Risks of bias in included studies were adjudicated independently by two review authors (AV, SP) using 
Cochrane methodology199 for: random sequence generation, allocation concealment, blinding of 
participants and investigators, blinding of outcome assessment, attrition, selective reporting of 
outcomes, and other sources of bias. Discrepancies were resolved by discussion. The certainty of the 
overall evidence related to each main outcome was assessed by two authors (AV and SP) using the 
GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (GRADE 
2008)200,201 to ensure accurate interpretation of effect estimates taking into consideration the certainty 
of available evidence (i.e. a non-significant effect estimate may be interpreted as “uncertain” if the 
certainty of available evidence is very low and a significant effect estimate as “probable” if the 
available evidence is moderate).  
Statistical analysis 
Random-effects pairwise meta-analysis was used to estimate treatment effects. Summary effect 
estimates were expressed as RRs and the associated 95% CIs. Statistical heterogeneity was quantified 
using the Cochran Q test and the I2 metric202. An I² value >75% was considered to indicate substantial 
heterogeneity202. Pre-specified subgroup analyses were planned to explore potential sources of 
heterogeneity: age (<65 years versus ≥65 years), gender, diabetes mellitus, peripheral vascular disease, 
risk of bias, vascular access type, vascular access location, and duration of intervention. Funnel plots 
to assess the potential existence of small study bias were planned if more than ten studies were 
included. Statistical analyses were performed using Review Manager 5, Version 5.3 (The Cochrane 
Collaboration, http://ims.cochrane.org/revman).  
6.6 Results 
Study characteristics 
Description of included studies 
Six trials involving 865 participants93-95,179,203,204 met eligibility criteria (Figure 6-1 and Table 6-1). The 
number of participants allocated to treatment in each study ranged between 7 and 567. Treatment was 
administered for 12179 to 52 weeks93,95 and the study follow-up time ranged between five204 and 12 
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months93,95,179 (median 10 months [IQR 6.5 to 12 months]). The timing of treatment initiation was 
reported in four studies: within seven days of access creation in two trials93,94, two weeks after access 
creation in one trial95, and one day before access creation in one trial179. The dose of omega-3 PUFA 
varied from 3 grams three times weekly203 to 6 grams daily94, and varied in contents of the two main 
biologically active components (EPA [0.96-3 grams] and DHA [0.6-1.52 grams]). Four studies 
investigated the effect of omega-3 PUFA on arteriovenous graft outcomes93-95,203, one on AVF 
outcomes179, and one on shunt outcomes204. The latter study was a crossover trial without extractable 
outcome data reported at the end of the first study phase and it was therefore not possible to include 
data in meta-analyses204. The definitions of the trial outcomes varied across trials (Table S6- 2). Re-
analyses of individual patient level data to conform with standardised definitions for outcomes127 were 
available from two studies93,179 Table S6- 3.  
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Figure 6-1: Identification process for eligible trials 
Abbreviations: AVF – arteriovenous fistula; AVG – arteriovenous graft. 
ano non-English citations were identified.  
 
128 citations identified in databases through 
January 24, 2017 
   14 Cochrane CENTRAL  
   78 Embase  
   36 MEDLINE  
34 citations screened by title and abstracta 
15 full text articles assessed for eligibility 
6 randomised trials (865 people) included in 
systematic review 
Primary patency loss 
     AVF: 1 trial (n=144 events, 536 participants) 
     AVG: 2 trials (n= 121 events, 225 participants) 
   
Dialysis suitability failure 
     AVF: 1 trial (n=159 events, 536 participants)      
   
Interventions to maintain patency or assist maturation 
     AVF: 1 trial (n=98 events, 536 participants) 
     AVG: 1 trials (n= 86 events, 196 participants) 
   
Access abandonment 
     AVF: 1 trial (n=109 events, 536 participants) 
     AVG: 1 trial (n= 58 events, 196 participants) 
   
Bleeding 
     AVF: 1 trial (n=26 events, 567 participants) 
     AVG: 3 trials (n= 18 events, 227 participants) 
   
1 trial not included in meta-analyses because of no 
extractable outcome data 
9 citations excluded 
   3 abstract only 
   3 study protocols 
   3 irrelevant outcomes    
94 duplicate citations removed 
19 citations excluded 
    4 not haemodialysis population 
    3 not fish oil trials 
    12 non-randomized trials 
Gastrointestinal side-effect 
     AVF: 1 trial (n=29 events, 567 participants) 
     AVG: 3 trials (n= 22 events, 249 participants) 
   
All-cause mortality 
     AVF: 1 trial (n=17 events, 567 participants) 
     AVG: 3 trials (n=17 events, 232 participants) 
   
Cardiovascular mortality 
     AVF: 1 trial (n=13 events, 536 participants) 
     AVG: 3 trials (n= 9 events, 232 participants) 
   
Hospitalisation 
     AVF: 1 trial (n=217 events, 567 participants) 
     AVG: 1 trial (n=1 event, 7 participants) 
   
Treatment adherence 
     AVF: 1 trial (n=92 events, 720 tablets) 
     AVG: 2 trials (n= 30 events, 130 participants) 
5 randomised trials (833 people) included in meta-analysis 
AVF: 1 trial (567 people); AVG: 4 trials (266 people) 
 
Number of trials by outcome 
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Table 6-1: Characteristics of populations and interventions in the included trials 
Study Country Participantsa 
Vascular 
access 
Inclusion criteria Intervention Control 
Study 
durationb 
Agec Male DM PVD 
Bowden 
et al 
(2007) 
North 
America  
34 
PTFE 
graft 
 
Adult (≥ 18 y) long-
term HD patients with 
new PTFE graft. And 
unable to have an 
AVF  
Fish oil 
(0.96g EPA, 0.6g 
DHA) daily for 8 
months, starting 
within 7 days 
following access 
creation 
Placebo 
(canola 
oil) 
8 mo 62 y 
13 
(45%)d 
20 
(69%)d 
NR 
De Fijter 
et al 
(1995) 
Nether-
lands 
32 Shunt HD patients 
Fish oil 
(3g EPA + DHA) 
daily for 5 mo  
Placebo 
 
5 mo NR NR NR NR 
Diskin et 
al 
(1990) 
North 
America 
7 
PTFE 
graft 
Long-term HD 
patients with > 3 
episodes of graft 
thrombosis within the 
12 preceding months 
Fish oil 
(3g EPA) trice 
weekly during 
HD 
Placebo 
 
6 mo NR NR NR NR 
Irish et 
al 
(2017) 
Australia, 
NZ, 
Malaysia, 
UK 
567 AVF 
Patients >19 y with 
CKD stage 4 or 5 on 
dialysis or planned to 
start within 12 
months. Planned de 
novo AVF of in the 
upper or lower arm is 
planned 
Fish oil 
(1.84g EPA, 
1.52g DHA) 
daily for 12 
weeks starting 1 
day prior to 
access creation 
Placebo 
(olive 
oil) 
12 mo 55 y 
359 
(63%) 
264 
(50%) 
24 
(5%) 
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Study Country Participantsa 
Vascular 
access 
Inclusion criteria Intervention Control 
Study 
durationb 
Agec Male DM PVD 
Lok et al 
(2012) 
North 
America,  
201 
PTFE 
Graft 
Individuals aged ≥ 18 
years with end-stage 
renal disease who 
require a new 
synthetic graft for 
chronic HD. The 
patient may or may 
not have initiated 
dialysis at the time of 
enrolment.  
Fish oil 
(1.6g EPA, 0.8g 
DHA) daily for 
12 months, 
starting 7 days 
after access 
creation 
Placebo 
(corn 
oil) 
12 mo 63 y 
49 
(50%) 
103 
(53%) 
29 
(15%) 
Schmitz 
et al 
(2002) 
North 
America 
24 
PTFE 
graft 
Patients close to the 
initiation of chronic 
HD or on chronic HD 
who required 
placement of a new 
PTFE graft.  
Fish oil 
(1.76g EPA, 
0.96g DHA) 
daily for 12 
months, starting 2 
weeks after 
access creation 
Placebo 
(corn 
oil) 
 
12 mo 53 y 
11 
(46%) 
NR NR 
Note: Unless otherwise indicated, values are given as number (percentage). 
Abbreviations: AVF – Arteriovenous fistula; CKD – chronic kidney disease; DHA – Docosahexanoic acid; EPA – Eicosapentaenoic acid; mo – months; n – number; HD – 
haemodialysis NR – not reported; NZ – New Zealand; PTFE – Polytetrafluorethylene; UK – United Kingdom; y – years (mean).  
aNumber of randomised people; bStudy duration equals time of outcome assessment; cValues are means; dTotal number analysed = 29; eTotal number analysed = 196. 
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Risk of bias 
Studies were at low risk of bias for most domains (Figure 6-2). Reported methods for 
generating the randomisation sequence were low risk in 3 studies and unclear in the remainder. 
Allocation concealment was low risk in 2 studies and methods were unclear in 4 studies. 
Participants and investigators were masked to treatment allocation in 5 studies while outcome 
assessment was blinded in 2 trials for the primary outcome and was unclear in 3 trials. Three 
of the included RCTs were not strictly conducted by intention-to-treat principle93,94,179,, 
however, risks of bias from attrition were considered to be low in these studies as the numbers 
of participants and the reasons for exclusion were well balanced between treatment groups. 
Incomplete outcome data reporting was adjudicated as low risk for four studies because there 
were either no missing data94 or numbers were well balanced between treatment groups93,95,179, 
unclear for one203 and high risk for the cross-over study without available outcome data at the 
end of the first study phase204.  Selective reporting was low risk for the two studies that reported 
all the major efficacy and safety outcomes as outlined in the published study protocol and 
unclear for those without available protocols. None of the studies appeared to have other 
sources of bias. 
 
Figure 6-2: Risk of bias summary: review authors’ judgements about each risk of bias item for 
each included study. 
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Outcomes 
A summary of the findings is shown in Table 6-2. The outcome definitions that were used in 
meta-analyses are described in Table S6- 3. Treatment estimates for trials evaluating omega-3 
PUFA for AVF and AVG were combined when there was no evidence of statistical 
heterogeneity between subgroups (Figure 6-3). 
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Table 6-2: Summary of findings 
Outcome 
Illustrative comparative 
risksa 
RR 
(95% CI) 
No of 
patients 
(studies) 
Certainty of 
evidence 
(GRADE)b 
Comments regarding downgrading of evidence quality Assumed  Corresponding  
Placebo Omega-3 
PUFA 
Primary 
patency 
failure 
384 73 fewer (123 
fewer to 8 
fewer)  
0.81  
(0.68, 0.98) 
761 (3) ⊕⊕⊕1 
moderate 
 
1Directness: data derived from small number of studies in 
different settings which may not be generalizable (treatment 
duration variable, access type variable). 
Bleeding 46 18 more (10 
fewer to 68 
more) 
1.40  
(0.78, 2.49) 
794 (4) ⊕1,2 
very low 
 
1Severe Imprecision (2 downgrades): risk estimates include null 
effect and estimate consistent with both appreciable benefit and 
harm. 
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, dose variable, co-administration of anti-
platelet agents variable). 
Dialysis 
suitability 
failure  
305 15 fewer (82 
fewer to 70 
more) 
0.95  
(0.73, 1.23) 
536 (1) ⊕⊕1,2 
low 
 
1Imprecision: risk estimate includes null effect  
2Directness: data derived from only 1 study in specific setting 
which may not be generalizable (AVF, 3 months of treatment). 
Interventions 
to maintain 
patency or 
assist 
maturation 
275 50 fewer (99 
fewer to 11 
more) 
0.82  
(0.64, 1.04) 
732 (2) ⊕⊕1,2 
low 
 
1Imprecision: risk estimate includes null effect  
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, access different – interventions may differ). 
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Outcome 
Illustrative comparative 
risksa 
RR 
(95% CI) 
No of 
patients 
(studies) 
Certainty of 
evidence 
(GRADE)b 
Comments regarding downgrading of evidence quality Assumed  Corresponding  
Placebo Omega-3 
PUFA 
Access 
abandonment  
256 56 fewer (105 
fewer to 8 more) 
0.78  
(0.59, 1.03) 
732 (2) ⊕⊕1,2 
low 
 
1Imprecision: risk estimate includes null effect  
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, access different – interventions may differ) 
GI side-
effects 
57 12 more (20 
fewer to 76 
more) 
1.22 (0.64, 
2.34) 
816 (4) ⊕⊕1 
Low 
1Severe imprecision (2 downgrades): risk estimates include null 
effect and estimate consistent with both appreciable benefit and 
harm. 
All-cause 
mortality 
43 1 fewer (21 
fewer to 37 
more) 
0.98 (0.51, 
1.86) 
799 (4) ⊕1,2 
very low 
 
1Severe Imprecision (2 downgrades): risk estimates include null 
effect and estimate consistent with both appreciable benefit and 
harm. 
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, dose variable, co-administration of anti-
platelet agents variable). 
CV mortality 37 17 fewer (29 
fewer to 13 
more) 
0.55 (0.22, 
1.35) 
768 (4) ⊕1,2 
very low 
 
1Severe Imprecision (2 downgrades): risk estimates include null 
effect and estimate consistent with both appreciable benefit and 
harm. 
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, dose variable, co-administration of anti-
platelet agents variable). 
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Outcome 
Illustrative comparative 
risksa 
RR 
(95% CI) 
No of 
patients 
(studies) 
Certainty of 
evidence 
(GRADE)b 
Comments regarding downgrading of evidence quality Assumed  Corresponding  
Placebo Omega-3 
PUFA 
Hospitalisati
on 
381 4 fewer (72 
fewer to 84 
more) 
0.99 (0.81, 
1.22) 
574 (2) ⊕⊕1,2 
low 
 
1Imprecision: risk estimate includes null effect  
2Directness: data derived from small number of studies in 
specific settings which may not be generalizable (treatment 
duration variable, access different – interventions may differ) 
Abbreviations: CI - Confidence interval; CV – cardiovascular; GI – gastrointestinal; GRADE – Grading of Recommendations Assessment, Development and Evaluation 
(Working Group grades of evidence);  
High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to have an important impact on our confidence in the estimate 
of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate. aThe basis for the assumed risk (e.g. the average control group risk 
across studies, per 1,000 patients treated for 12-52 weeks) was calculated from data in the meta-analyses. The corresponding risk (per 1,000 patients treated for 12-52 weeks; 
values in parentheses are 95% CI) is based on the assumed risk in the comparison group and the relative risk of the intervention (and its 95% CI). bIt was not possible to assess 
or downgrade for small-study effects.  
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Figure 6-3: Summary of overall treatment effects of omega-3 polyunsaturated fatty acids on 
arteriovenous vascular access outcomes and potential adverse events.  
Abbreviations: AVF – arteriovenous fistula; AVG – arteriovenous graft; CI – confidence interval; 
NA – not assessable; PUFA – polyunsaturated fatty acids.  
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Primary patency loss 
Overall, 265 people experienced primary patency loss due to thrombosis or requiring an 
intervention to restore patency in three trials (761 people at risk)93,94,179. Moderate certainty 
evidence suggested that omega-3 PUFA treatment prevented primary patency loss (RR 0.81, 
95% CI 0.68 - 0.98) using 1.6 to 3.4 grams of EPA and DHA for 12 to 52 weeks (Table 6-2, 
Figure 6-3 and Figure  a of Item S6- 1). There was no evidence of significant heterogeneity in 
treatment effects. Treatment effects on vascular access patency loss did not differ significantly 
between access type (p [for subgroup difference] = 0.87).  
Bleeding 
Forty-four people experienced at least one bleeding event (794 people at risk)93,95,179,203. Very 
low certainty evidence suggested an uncertain risk of bleeding associated with omega-3 PUFA 
supplementation (RR 1.40, 95% CI 0.78- 2.49) (Table 6-2, Figure 6-3 and Figure  b of Item 
S6- 1) No data were provided on the severity or nature of the bleeding episodes with the 
exception of one participant allocated to omega-3 PUFA treatment (3 grams of EPA three times 
weekly) who required hospitalisation for a gastrointestinal bleed203.  
Dialysis suitability failure 
A single trial reported data on late dialysis suitability failure179, defined as an AVF that was 
unable to be cannulated for at least 8 of 12 consecutive dialysis sessions or abandoned within 
six months of access surgery (Table 6-2, Figure 6-3 and Figure  c of Item S6- 1). Meta-analysis 
was not possible. In the single trial, the RR determined by log-binomial regression analysis and 
adjusted for aspirin use was not statistically different between the omega-3 PUFA (3.4 grams 
of EPA and DHA daily for 12 weeks) and placebo arm (78/270 [29%] versus 81/266 [30%], 
RR 0.95, 95% CI 0.73- 1.24). 
Surgical or radiological interventions to restore patency or assist maturation 
One trial179 reported on the need for interventions to restore patency or assist maturation in 
newly created AVF (536 people) and one trial93 in AVG (196 people). Low certainty evidence 
suggested, that omega-3 PUFA treatment (2.493 to 3.495 grams of EPA and DHA daily) may 
have had little or no effect on the need for access interventions, such as thrombolysis or 
thrombectomy, angioplasty, revision, stent insertion or ligation of tributaries (RR 0.82, 95% 
CI 0.64-1.04) to maintain patency (Table 6-2, Figure 6-3 of Item S6- 1). There was no evidence 
that treatment effects were different for AVF and AVG (p = 0.64, Figure  e of Item S6- 1).  
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Vascular access abandonment 
Based on low certainty evidence, omega-3 PUFA supplementation (2.493 to 3.495 grams of EPA 
and DHA daily) may have had little or no effect on arteriovenous access abandonment (RR 
0.78, 95% CI 0.59-1.03) (Table 6-2, Figure 6-3 and Figure  e of Item S6- 1). There was no 
evidence of different treatment effects according to arteriovenous access type (p = 0.30). 
Gastrointestinal side-effects 
Four studies93-95,179 (816 people) reported gastrointestinal side-effects, including bloating, gas 
or “fishy” aftertaste. Based on low certainty evidence, omega-3 PUFA treatment (1.694 to 3.4179 
grams of EPA and DHA daily) had an uncertain risk of gastrointestinal symptoms (RR 1.22, 
95% CI 0.64-2.34) (Table 6-2, Figure 6-3 and Figure  f of Item S6- 1). 
All-cause and cardiovascular mortality 
Omega-3 PUFA had uncertain effects on all-cause mortality93,94,179,203 (RR 0.98, 95% CI 0.51-
1.86) (Table 6-2, Figure 6-3 and Figure  g of Item S6- 1). Cardiovascular mortality was reported 
in 4 trials93,94,179,203 (22 events in 768 people). Omega-3 PUFA supplementation (3 grams of 
EPA 3 times weekly203 to 3.4 grams of EPA and DHA daily179) may not have reduced risks of 
death due to cardiovascular causes (RR 0.55, 95% CI 0.22-1.35) (Figure 6-3 and Figure  h of 
Appendix A). There was no evidence that this treatment effect differed according to whether 
people had an AVF or AVG (p for subgroup difference = 0.93 for cardiovascular- and 0.78 for 
all-cause mortality, Figure 6-3, Figure  g and Figure  h of Item S6- 1).  
Hospitalisation 
Data on hospitalisation were provided in 2 studies179,203 (574 people). Omega-3 PUFA 
treatment (3 grams of EPA 3 times weekly38 to 3.4 grams of EPA and DHA daily39) may have 
had little or no effect on risks of hospitalisation (RR 0.99, 95% CI 0.81- 1.22). There was no 
evidence that treatment effects differed between people with an AVF or AVG (p = 0.55, Figure 
6-3 and Figure  i).  
Treatment adherence 
Treatment adherence was assessed in 4 trials using various methods38,93,95,179. Three 
studies93,95,179 measured changes in the fatty acid composition of whole blood cells93, platelets95 
or erythrocytes179, and confirmed adherence by showing a significant increase in DHA and 
EPA in people prescribed omega-3 PUFA. Omega-3 PUFA was not associated with treatment 
non-adherence based on the median number of returned capsules179, the number of people who 
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did not take the study treatment (as reported by study coordinators or evident from returned 
capsules)93 or people who were ‘noncompliant’ based on pill counts94 (Figure  j of Item S6- 1).  
Subgroup analysis and assessment of small study effects 
Prespecified subgroup analyses and funnel plots could not be performed due to insufficient 
data observations.   
6.7 Discussion  
Moderate certainty evidence suggests that omega-3 PUFA therapy commenced around the time 
of dialysis vascular access surgery and continued for 12 to 52 weeks prevents primary patency 
loss. Based on an assumed event rate of 40 per 100 patients experiencing primary patency loss 
within one year28,205, treatment of 100 patients with omega-3 PUFA started perioperatively 
might be expected to prevent 8 patients experiencing primary patency loss (95% CI 1 to 13) 
within 12 months of access creation, although effects of omega-3 PUFA treatment on dialysis 
suitability failure, access interventions, access abandonment or treatment harms (bleeding and 
gastrointestinal side-effects) are uncertain. There is no robust evidence that omega-3 PUFA 
supplementation lowers all-cause or cardiovascular mortality in people with ESKD requiring 
HD as studies were not specifically designed to examine these outcomes.  
This review adds to the existing literature by summarising current evidence for the effects of 
omega-3 PUFA supplementation on a number of clinically important vascular access and safety 
outcomes, and by including the largest and only trial examining the effect of fish oil on AVF. 
The findings contrast with those of a well-conducted meta-analysis of medical adjuvant 
therapies to increase patency of arteriovenous dialysis access in people with ESKD undergoing 
HD68: Random-effects pairwise meta-analysis of two trials (220 people)93,95 showed no 
significant treatment effect on the frequency of graft thrombosis (odds ratio 0.24, 95% CI 0.03 
to 1.95). The lack of treatment benefit on graft thrombosis reported in this meta-analysis may 
be attributed to the low number of events resulting in imprecise treatment estimates or the 
difference in the chosen outcome (i.e. graft thrombosis as opposed to primary patency loss 
which additionally includes the need for interventions to restore patency).  This assumption is 
supported by findings of a more recent meta-analysis of omega-3 PUFA examining a range of 
clinical outcomes (cardiovascular events, depression, protein malnutrition, dyslipidaemia, 
secondary hyperparathyroidism, AVG thrombosis) in people on long-term HD206: Significant 
treatment benefit of omega-3 PUFA (1.6 to 3.4 grams of EPA and DHA daily) on graft 
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thrombosis was found using random-effects pairwise meta-analysis on data from four trials 
(n=287, RR 0.71, 95% CI 0.52 to 0.97). While this result accords with the protective effects of 
omega-3 PUFA on primary patency loss shown in the current study, it should be interpreted 
with caution because outcomes other than graft thrombosis were also included in the meta-
analysis by He et al.206 including graft infection207 and angioplasty for significant stenosis94. 
Reduction in thrombosis and patency loss may be explained by inhibitory effects on platelet 
aggregation168, smooth muscle cell proliferation79 and inflammation87, reduction in serum 
viscosity74 and promotion of vasodilation90. 
There was no high certainty evidence that omega-3 PUFA treatment prevents all-cause 
mortality in the present study. This finding was consistent with the meta-analysis by He and 
colleagues206 that included 4 trials (n= 353) and showed a RR of 0.83 (95% CI 0.36 to 1.90) 
using fixed-effect meta-analysis. The same authors, however, reported a significant benefit of 
omega-3 PUFA supplementation on fatal and non-fatal cardiovascular events in 334 
participants of 5 studies (RR 0.41; 95% CI 0.26 to 0.66) which was not observed in the present 
study. The interpretability and meaningfulness of this result were limited by the inclusion of 
different composite outcome definitions. By restricting the definition to cardiovascular death, 
a cardiovascular mortality benefit was not ascertained in the present meta-analysis. Thus far, 
cardiovascular benefits of omega-3 PUFA in people with chronic kidney disease have largely 
been shown by surrogate outcome measures, including lipid modulation, heart rate and blood 
pressure lowering effects91,92 which may not translate into patient-centred clinical outcomes, 
such as cardiovascular death. The latter outcome of omega-3 PUFA supplementation has not 
been addressed in adequately powered studies to date. However, a large international 
multicentre RCT (Protection against Incidences of Serious Cardiovascular Events Study with 
daily fish oil supplementation in dialysis patients [PISCES]) is ongoing to assess the effect of 
omega-3 PUFA supplementation on serious fatal and non-fatal cardiovascular events in people 
on long-term HD208.  
People treated with HD are at increased risk of bleeding due to uraemia-induced platelet 
dysfunction and requirements for anticoagulation during dialysis. The addition of low intensity 
anticoagulation with warfarin or antiplatelet agents exacerbates bleeding194,195, yet the safety 
profile of omega-3 PUFA therapy in this population is uncertain. This systematic review 
observed few bleeding events (among 44 participants) leading to imprecise treatment estimates. 
In addition, the frequencies of minor (i.e. bleeding that ceases without intervention other than 
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compression) versus major bleeding events (i.e. bleeding that requires blood products, hospital 
admission and/or interventions) were not specified.  
Effective treatments to reduce arteriovenous access complications are highly valued by patients 
and mandate the need for larger, adequately powered RCTs addressing patient-centred, 
clinically important outcomes, such as dialysis suitability, need for interventions, mortality and 
risk of severe bleeding events to improve our confidence in the effectiveness and safety of 
omega-3 PUFA supplementation in dialysis patients. In addition, implementation of 
standardised outcome definitions for vascular access outcomes would facilitate meta-analysis 
of treatment effects arising from new trials. An international, multi-stakeholder initiative 
(SONG) is currently underway to establish core outcome measures for vascular access 
complications based on shared priorities of patients and health professionals11. This initiative 
will enhance the quality and relevance of outcome reporting of interventional trials in HD. 
The present review was conducted according to methods outlined by Cochrane, including a 
systematic search designed by a specialist trial information manager, and data extraction and 
assessments of risks of bias and evidence certainty using the GRADE approach by two 
independent authors. Patient-level data analysis was performed by the original authors where 
possible to ensure reliable comparison and meta-analysis of outcomes aligned with previously 
published standardised outcome definitions127. Although this review included a broad range of 
clinically relevant efficacy and safety outcomes, the key findings were limited by several 
factors. First, risk estimates were imprecise and the certainty of evidence was low for most 
outcomes due to the small numbers of trials and events. Only one trial was conducted in people 
undergoing AVF creation, which limited the generalisability of its results to this clinical setting. 
Moreover, data for vascular access suitability for dialysis, access abandonment and need for 
interventions were limited to the two most recently conducted trials93,179. Second, the ability to 
detect a significant treatment effect difference between AVG and AVF may have been limited 
by the small number of trials and potential confounding due to differences in patient and access 
characteristics could not be excluded. Third, the findings are based on dichotomous outcomes 
and may not be applicable to more sensitive metrics such as rate or time to event as evident 
from the trial by Lok and colleagues41, whereby the rate of access interventions but not the 
number of participants requiring AVG intervention was reduced by omega-3 PUFA 
supplementation. Fourth, the dose effects of omega-3 PUFA treatment were unable to be 
determined due to large variations in the dosages, the compositions of omega-3 PUFA and 
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different methods used to assess adherence. Fifth, the optimal timing and duration of omega-3 
PUFA supplementation could not be determined due to differences in study designs. Finally, 
unpublished studies may have been missed despite a highly sensitive search that included hand-
searching and conference abstracts.  
In conclusion, omega-3 PUFA supplementation started at the time of arteriovenous access 
surgery probably prevents primary patency loss within 12 months but may have little or no 
effect on access interventions, dialysis suitability failure or access abandonment and treatment 
harms are uncertain. Larger RCTs are required to determine the efficacy and safety of omega-
3 PUFA supplementation in patients requiring HD and to assess novel putative interventions 
to improve dialysis vascular outcomes. Based on the available evidence, recommendations on 
the routine use of omega-3 PUFA for safely preventing arteriovenous access complications 
cannot be made. 
6.8 Chapter summary 
Early arteriovenous access failure due to stenosis and thrombosis is burdensome for patients 
and costly because it usually requires additional interventions and placement of a temporary 
CVC, which in turn exposes the patient to an increased risk of infection. This meta-analysis 
shows that omega-3 PUFA supplementation given for 12 to 52 weeks following arteriovenous 
access creation reduces primary patency loss by 19% within 12 months based on moderate 
quality evidence from 3 RCTs including 761 participants. Further research is therefore 
warranted to ascertain this treatment benefit and to explore additional clinically meaningful 
outcomes including the effects of omega-3 PUFA supplementation on dialysis suitability 
failure, access interventions, access abandonment or potential adverse treatment effects 
(bleeding and gastrointestinal side-effects), which remain uncertain based on the available 
evidence from 5 RCTs including a total of 833 participants. Furthermore, there is currently no 
robust evidence to suggest that omega-3 PUFA supplementation lowers all-cause or 
cardiovascular mortality in people with ESKD requiring HD but PISCES, an ongoing 
international multicentre RCT of 1200 adults HD patients is expected to fill this evidence gap 
by assessing the effect of omega-3 PUFA supplementation on serious fatal and non-fatal 
cardiovascular events in people on long-term HD208.  
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7.1 Chapter overview 
Improving vascular access outcomes is a high priority for patients, their caregivers and health 
professionals. Based on the contribution of 1,376 participants from 73 countries including 
patients and caregivers, vascular access was identified as one of the critically important core 
outcome domains in HD along with fatigue, cardiovascular disease, and mortality11. PART 2 
of this thesis describes the identification and establishment of the most important vascular 
access outcome and how to measure this outcome consistently across all future trials in HD. 
Implementation of core outcome measures in all HD trials will (i) ensure consistent reporting 
of outcomes that are considered important and meaningful by all stakeholders, including 
patients and clinicians; (ii) reduce reporting bias; and, (iii) provide clinicians with useful 
outcome measures for assessing and improve their practice.  
The core outcome measure for vascular access is established through a multistep evidence and 
consensus-based process including a systematic review, international survey and consensus 
workshop followed by a pilot and validation study prior to its global implementation in 
research. This chapter described the findings of a systematic review on outcomes and outcome 
measures used to assess vascular access complications in contemporary RCTs in HD. It 
outlined the substantial heterogeneity and inconsistency in reported outcomes and highlighted 
the pressing need for establishing and implementing core outcome measures for vascular access 
and more broadly for HD that are reported consistently across trials and are meaningful to 
patients and their treating team. 
7.2 Included publication 
The content of this chapter is based on the following peer reviewed publication:  
Viecelli AK, O'Lone E, Sautenet B, Craig JC, Tong A, Chemla E, Hooi LS, Lee T, Lok C, 
Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Irish AB, Mori TA, Pascoe 
EM, Johnson DW, Hawley CM. Vascular Access Outcomes Reported in Maintenance 
Hemodialysis Trials: A Systematic Review. Am J Kidney Dis. 2018;71(3):382-391. Copyright 
permission has been obtained to reproduce this manuscript. 
The candidate developed the concept and design of the review with input from EO, AT, BS, 
and JCC. The candidate performed the literature search with the assistance of specialist 
information managers Gail Higgins and Christine Dalais, extracted all the data, grouped 
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outcome measures into outcome categories with BS as second independent assessor, performed 
all data analysis and interpreted data with feedback from BS, AT, CH, EO, JC. The candidate 
generated all figures and tables, drafted the manuscript and integrated comments and revisions 
from co-authors into a final version. 
7.3 Abstract 
Background: Many RCTs have been performed with the goal of improving outcomes related 
to HD vascular access. If the reported outcomes are relevant and measured consistently to allow 
comparison of interventions across trials, such trials can inform decision making. This study 
aimed to assess the scope and consistency of vascular access outcomes reported in 
contemporary HD trials. 
Study design: Systematic review. 
Setting & population: Adults requiring maintenance HD. 
Selection criteria: All RCTs and RCT protocols reporting vascular access outcomes identified 
from ClinicalTrials.gov, Embase, MEDLINE and the Cochrane Kidney and Transplant 
Specialised Register from January 2011 to June 2016. 
Interventions: Any HD-related intervention. 
Outcomes: The frequency and characteristics of vascular access outcome measures were 
analysed and classified.  
Results: From 168 relevant trials, 1426 access-related outcome measures were extracted and 
classified into 23 different outcomes. The three commonest outcomes were function (136 
[81%] trials), infection (63 [38%]), and maturation (31 [18%]). Function was measured in 489 
different ways, but most frequently reported as “mean access blood flow (mL/min)” (37 [27%] 
trials) and “number of thromboses” (30 [22%]). Infection was assessed in 136 different ways 
with “number of access-related infections” being the commonest measure. Maturation was 
assessed in 44 different ways, at 15 different time points, and most commonly characterized by 
vein diameter and blood flow. Patient-reported outcomes, including pain (19 [11%]) and 
quality of life (5 [3%]), were reported infrequently. Only a minority of trials used previously 
standardised outcome definitions.   
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Limitations: Restricted sampling frame for feasibility and focus on contemporary trials. 
Conclusions: The reporting of access outcomes in HD trials is very heterogeneous with limited 
patient-reported outcomes and infrequent use of standardised outcome measures. Efforts to 
standardise outcome reporting for vascular access are critical to optimising the comparability, 
reliability and value of trial evidence to improve outcomes for patients requiring HD.  
7.4 Introduction 
A reliably functioning vascular access is associated with improved health outcomes and overall 
well-being of patients treated by maintenance HD, but establishing and maintaining such a 
vascular access without major complications and the need for recurrent interventions remains 
challenging28,186,187. Vascular access related complications account for ~ 20% of hospital 
admissions of patients with ESKD annually, and are associated with increased morbidity, 
mortality, and healthcare costs25,147. As such, vascular access is often referred to as both the 
“lifeline” and “Achilles’ Heel” of HD3. From a patient’s perspective, the experience and 
anticipation of vascular access surgery and complications, particularly pain during cannulation, 
bleeding, and access failure, are key sources of stress and anxiety8,209.  Improving vascular 
access outcomes is a high priority for patients, their caregivers and health professionals10,11.  
During the last two decades, numerous interventions have been trialled in an attempt to improve 
vascular access outcomes with little success4,64,68. This is in the context of increasing 
recognition across many health conditions that outcomes used in clinical trials are measured 
inconsistently and may not be relevant to end-users including patients, caregivers, and health 
professionals8,186,209-211. In addition, reporting bias due to selective publication of outcomes 
with favourable results makes interpretation and comparison of research output 
unreliable212,213. The lack of consensus on outcome selection (i.e. what to measure, such as 
“infection” or “pain”) and outcome measures (i.e. how and when to measure the outcome, such 
as “number of access interventions within 12 months of access creation”) has been identified 
as an additional source of research waste214-217. The comparability, value and reliability of trial 
evidence are compromised by the selection of outcomes with limited clinical or policy 
relevance, under-reporting of patient-centred outcomes and inconsistent use of outcome 
measures. There have been efforts to standardise outcome definitions for vascular access by 
various working groups, with the most recent publication released in 201113,124,125,127; however, 
these may not have been widely adopted. 
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This study aimed to describe the scope and consistency of vascular access outcomes and 
outcome measures used in contemporary HD trials and to assess the use of previously published 
standardised outcome definitions. A secondary, longer-term aim is to underpin strategies to 
prioritise outcomes, improve outcome reporting for vascular access complications, increase the 
value of future trials to inform evidence-based practice and ultimately, to help improve patient 
outcomes.   
7.5 Methods 
Selection criteria 
An electronic search using Embase, the Cochrane Kidney and Transplant Specialised Register, 
and MEDLINE databases without language restriction was conducted using search strategies 
developed in collaboration with a specialist information manager to identify trials reporting on 
vascular access outcomes in adult (aged 18 years or older) patients requiring maintenance HD 
(Table S7- 1). Trials in patients with acute kidney injury undergoing temporary HD were 
excluded. All RCTs including protocols and post-hoc analyses of RCTs published between 1st 
of January 2011 and 16th June 2016 were included. This time frame was chosen to provide an 
assessment of contemporary outcome measures of recently published and ongoing trials 
allowing for implementation of previously published standardised outcome 
measures13,124,125,127. Systematic reviews and meta-analyses were screened to identify 
additional RCTs published within the same time frame. In addition, the clinicaltrials.gov 
registry was searched for unpublished protocols of RCTs using the same inclusion criteria to 
ensure that current and ongoing trials were included. Trials of registered protocols that had 
completed recruitment prior to January 2011, terminated recruitment due to poor enrolment, 
had been withdrawn, suspended, published or had not yet started recruitment were excluded. 
Research ethics committee approval was not required for this study. 
Data extraction 
For each trial, one reviewer (AV) extracted the following trial characteristics if available: first 
author, year of publication (for published trials) and year of registration with clinicaltrials.gov 
(for unpublished trials), participating countries, sample size, study duration, intervention type, 
access type, and all vascular access-related outcomes. All levels of specification of outcome 
measures were collected if reported by one reviewer (AV): outcome (e.g. infection, cannulation 
problems), specific measurement (e.g. catheter-related bacteraemia, successful cannulation at 
first attempt), specific metric (i.e. time to event, change from baseline, mL/min), method of 
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aggregation (i.e. mean, median, proportion), and time point of measurement in line with 
previously published tools215,218. 
Analysis  
Two reviewers independently grouped individual outcome measures assessing a similar aspect 
of vascular access complications into outcomes. Discrepancies were discussed to reach 
agreement (AV, BS). The list of outcomes was reviewed and agreed upon by four additional 
reviewers (AT, CH, EO, JC). Reviewer AV assigned all outcomes to three categories based on 
the majority of outcome measures: clinical (a “direct” medical endpoint based on clinician 
assessment or diagnosis that in itself represents or characterises a meaningful outcome, 
surrogate (a laboratory, imaging-based or physical sign that is used as a substitute for a 
clinically meaningful endpoint and patient-reported (outcomes reported by the patients usually 
relating to quality of life or symptoms), using standard definitions219,220. The classification was 
agreed upon by two reviewers (AT, JC).  
7.6 Results 
Trial characteristics 
We identified 168 relevant trials, involving 29,038 participants Figure 7-1. Two-thirds of trials 
were published and one-third were registered trial protocols Table 7-1. Published trials were 
conducted across 39 countries from North America, Latin America, Europe, Middle East, Asia 
and Oceania. The median trial duration was 12 months (IQR 6 to 24 months) and the median 
sample size was 96 participants (IQR 61 to 196 participants). The most commonly studied type 
of intervention was pharmacologic (47%). Forty-one percent of trials investigated vascular 
access outcomes in AVFs alone, 32% in CVCs, 10 % in AVGs and 17 % of studies included 
various combinations of access types. 
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 Table 7-1: Characteristics of included trials (n=168) 
Trial characteristic Number of trials, n (%) 
Year of publication  
2011-2012 45 (27%) 
2013-2014 45 (27%) 
2015-2016 23 (14%) 
Unpublished (ongoing or completed trial) 55 (33%) 
Country  
Not stated / not reporteda 55 (33%) 
United States 17 (10%) 
Iran 17 (10%) 
Canada  10 (6%) 
United Kingdom 8 (5%) 
Taiwan 7 (4%) 
Italy 6 (4%) 
Turkey 5 (3%) 
Greece  4 (2%) 
Spain 4 (2%) 
Australia 3 (2%) 
China 3 (2%) 
Multinational studies 10 (6%) 
Otherb  19 (11%) 
Sample sizec  
1 to 50 35 (21%) 
51 to 100 54 (32%) 
101 to 150 22 (13%) 
151 to 200 15 (9%) 
>200 38 (23%) 
Not reported 4 (2%) 
Duration of trial (months)  
≤ 3 40 (24%) 
> 3 – 6  32 (19%) 
> 6 – 9  2 (1%) 
     > 9 – 12 48 (29%) 
> 12 37 (22%) 
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Trial characteristic Number of trials, n (%) 
Not reported 9 (5%) 
Intervention type  
Pharmacological 79 (47%) 
Radiological  11 (7%) 
Catheter type 11 (7%) 
Surgical 9 (5%) 
Radiological/pharmacological combined 9 (5%) 
Graft material 7 (4%) 
Anaesthetic 7 (4%) 
Cannulation technique 7 (4%) 
Dialysis delivery 5 (3%) 
Radiation 5 (3%) 
Exercise 3 (2%) 
Otherd 15 (9%) 
Number of outcome measures reported in each trial  
1 to 5 97 (58%) 
6 to 10 31 (18%) 
11 to 15 23 (14%) 
>16 17 (10%) 
Access type  
AVF 69 (41%) 
CVC  53 (32%) 
AVG 17 (10%) 
All  14 (8%) 
AVF and AVG 14 (8%) 
CVC and AVF 1 (1%) 
Abbreviation: AVF – arteriovenous fistula; AVG – arteriovenous graft; CVC – central venous catheter  
aTrials only registered with ClinicalTrial.gov did not report countries(n=55) 
bAsia (n=1), Belgium (n=2), Brazil (n=1), Egypt (n=1), France (n=1), Georgia (n=1), Germany (n=2), 
India (n=1), Israel (n=1), Japan (n=2), Korea (n=1), Pakistan (n=1), Poland (n=2), United Arab Emirates 
(n=2). 
cIncluding estimated numbers for trial protocols according to latest update on ClinicalTrial.gov (June 
2016). 
dAccess location (n=2), access planning (n=1), algorithm (n=3), behavioural (n=2), biological (n=1), 
education (n=1), surgical/interventional combined (n=1), surveillance (n=1), ultrasound (n=3). 
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Figure 7-1: Search results 
aestimated number of enrolment bsample size unknown in four trials 
Outcomes 
In total, 1426 outcome measures were identified (defined by the measurement, metric, method 
of aggregation and time point of measurement), that could be grouped into 23 outcomes, of 
which 15 (65%) were predominantly clinical, four (17%) were surrogate, and four (17%) were 
patient-reported. The three most frequent outcomes were function (136 [81%] trials), infection 
(63 [38%] trials), and maturation (31 [18%] trials). Pain was the most common patient-reported 
outcome and assessed in 19 (11%) trials. Less than 5% of trials reported quality of life (5 [3%] 
trials), satisfaction with the vascular access (2 [1%]), or needle phobia (1 [<1%]). Nineteen 
(11%) trials measured vessel characteristics, which was the most commonly reported surrogate 
outcome (Figure 7-2).  
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Figure 7-2: Percentage of trials reporting each vascular access outcome (total 168 trials, 23 
outcomes) 
Outcome categories: clinical (black); patient-reported (grey); surrogate (white).  
Outcomes reported in less than 2% of trials: venous hypertension (surrogate), procedure related 
complications (clinical), patient satisfaction (patient-reported), erythema (clinical), needle 
phobia/fear (patient-reported), vascular access location (surrogate), and inflammation (surrogate).  
Outcome measures 
The number of outcome measures of the 10 most frequently reported specified vascular access 
outcomes are presented in Figure 7-3.  
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Figure 7-3: Number of outcome measures (with and without time points) for the 10 most 
frequently reported specified vascular access outcomes. 
Function  
Function was measured in 489 different ways and at 46 different time points. Function was the 
most heterogeneous outcome due to the variety of ways it can be assessed (Figure S7- 1 of 
Appendix B). The most frequently used outcome measures for assessing the function of a 
vascular access included mean access blood flow in mL/min (37 trials [27%]) and the number 
of thromboses (30 trials [22%]) (Figure 7-4). Approximately one third of outcome measures 
described patency, thrombosis or stenosis (Figure S7- 1). Of the 134 patency measures reported 
across 64 trials, 17 (13%) were consistent with one or more of the patency definitions as 
proposed by the Society for Vascular Surgery and the American Association for Vascular 
Surgery, the Society of Interventional Radiology Technology Assessment, or the North 
American and Australian Vascular Access Consortium124,125,127.  
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Figure 7-4: Most frequently reported outcome measures (definitions and time points) to assess 
vascular access function (136 trials, 23 of 489 outcome measures) 
Abbreviations: AAVS – American Association for Vascular Surgery; SIR – Society of 
Interventional Radiology; SVS – Society of Vascular Surgery. 
Definitions: Post-intervention primary patency as defined by the Society of Interventional 
Radiology125: interval following intervention until the next access thrombosis or repeated 
intervention. Primary patency as defined by the Society of Vascular Surgery and American 
Association for Vascular Surgery 2002124: the interval from the time of access placement until any 
intervention designed to maintain or re-establish patency, access thrombosis, or the time of 
measurement of patency. 
This figure shows the proportion of trials reporting each outcome measure (bars) and the different 
time points the outcome measure has been reported at (dots).  
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Infection  
Infection was reported in 136 different ways (not including variation in time points) and at 20 
different time points, with 30 (22%) consistent with criteria used by the Centres for Disease 
Control and Prevention (CDC) and/or other published definitions21,221-223. The number of 
access-related infections was the most commonly used outcome measure (10% of trials) 
(Figure 7-5). Ninety different outcome measures were used to assess catheter-related infections 
(excluding time points) of which, 64 referred specifically to systemic catheter-related infection, 
11 to exit site infection and 4 to tunnel infection. The rate (number per 1000 catheter days) and 
type (causative organism) of catheter-related bloodstream infection, as defined by the CDC223, 
were the most frequently used catheter-related outcome measures and each was reported in 
only 8% of trials.  
 
Figure 7-5: Most frequently reported outcomes measures (definitions and time points) to assess 
infection (63 trials, 15 of 136 outcomes measures) 
This figure shows the proportion of trials reporting each outcome measure (bars) and the different 
time points the outcome measure has been reported at (dots).  
Abbreviations: CDC – Centres for Disease Control and Prevention 
Definitions: CDC criteria221,223: Bacteraemia/fungemia in a patient with an intravascular catheter 
with at least one positive blood culture obtained from a peripheral vein, clinical manifestations of 
infections (i.e. fever, chills, and/or hypotension), and no apparent source for the BSI except the 
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catheter.  Definite bloodstream infection: isolation of the same organism from a peripheral blood 
sample and catheter-driven blood sample of a symptomatic patient (fever, chills, hypotension or 
mental confusion) while there is no other probable source of infection. Probable bloodstream 
infection:  infectious symptoms disappear after catheter removal while either blood cultures or 
culture of the catheter tip, but not both, confirm infection in a symptomatic patient in the absence of 
another suspicious source of infection. Possible bloodstream infection: disappearance of infectious 
symptoms in a symptomatic patient with negative blood and catheter tip cultures after catheter 
removal while there is no other probable source of infection224. 
Maturation  
Maturation was measured in 43 different ways, and at 15 different time points (Figure S7- 2), 
with one-quarter of trials referring to previously published criteria21,225. Maturation was most 
commonly defined as the number of fistulas with a vein diameter of 6 mm and a blood flow of 
more than 600 mL/min21 and/or a vein diameter of 4 mm and a blood flow of at least 500 
mL/min225 or as time to first cannulation (n=2 [6%] trials for each outcome measure).  
Pain  
The patient-reported outcome pain was assessed in 19 trials using 29 different outcome 
measures. Two (10%) studies measured procedural pain but the majority of studies (n=15 
[79%]) assessed pain during cannulation using one of 11 different methods to quantify pain 
(Figure S7- 3).  
Bleeding/haematoma  
Access-related haematomas or the occurrence of bleeding from the access site were recorded 
in 26 trials and measured in 29 different ways, at 24 different time points (Figure S7- 4). The 
number of haematomas was the most frequently used outcome measure and recorded by more 
than a quarter of trials (n=7), followed by number of access-related bleeding episodes (n=4 
[15%]). Bleeding after removal of dialysis needles was assessed in 7 different ways including 
bleeding time, number or proportion of bleeding episodes following removal of the dialysis 
needles, and the number of prolonged bleeding episodes (defined as greater than 10 minutes in 
duration, or unspecified).  
The surrogate outcome, vessel characteristics, included measurements of vessel diameter, 
depth and wall thickness, and was evaluated in 26 different ways (Figure S7- 5). The outcome 
measures for cannulation problems, steal syndrome, aneurysms and vascular access-related 
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hospitalisation provided in Figure S7- 6 to Figure S7- 9 were heterogeneous as highlighted by 
the fact that the majority of outcome measures were only used in one or two trials.  
7.7 Discussion 
The vascular access outcomes reported in clinical trials of adult patients requiring HD were 
most frequently clinical, such as function, infection and maturation. Patient-reported outcomes 
including pain, quality of life, satisfaction with the vascular access and fear of cannulation were 
rarely reported. The outcome measures used were extremely numerous and heterogeneous at 
every level; measurement, metric, method of aggregation and time point of measurement, 
making it very difficult to reliably evaluate the comparative effectiveness of different 
interventions designed to improve the lives of people receiving HD. Attempts to standardise 
definitions appear to have been only partially successful with a minority of trials using such 
definitions. 
This study highlights the plethora and broad heterogeneity of vascular access outcome 
measures across trials in HD, with 1,426 outcome measures used to assess 23 different 
outcomes. This inconsistency was observed at all levels of an outcome measure218. 
Consequently, comparative assessments of vascular access outcomes across trials to guide 
evidence-based clinical practice (i.e. meta-analyses) are likely to be problematic. The need for 
standardising outcome measures for vascular access complications has been recognised and 
several proposals have been published by expert committees and societies over the past two 
decades 124,125,127,221-223,226. However, as demonstrated in this study, implementation of 
standardised outcome measures into recent clinical trials and trial protocols is infrequent. Major 
barriers to a global implementation of standardised outcome measures may be the limited 
engagement of stakeholders from all relevant clinical specialties (i.e. vascular access surgery, 
interventional radiology and nephrology), different types of health professionals (e.g. nurses 
and physicians), regulatory bodies and policy makers, and of patients. Feasibility and relevance 
may also be issues, with selected outcome measures being cumbersome to collect and regarded 
as of limited clinical utility for daily practice and quality improvement.  
A potential strategy to overcome these barriers may be the implementation of a “core outcome 
set” incorporating a consensus-based “minimum set of outcomes that should be measured and 
reported in all clinical trials of a specific disease or trial population”214(page 2).  This would ensure 
that results can be compared across trials and that all trials contribute relevant and usable 
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information214. The OMERACT initiative was the first to establish core outcomes for clinical 
trials and has led to improvements in the reporting and relevance of outcomes in 
rheumatology136. A recent analysis demonstrated that reporting and homogeneity of outcomes 
were better in registered trial protocols for rheumatology compared to those for nephrology215. 
There have been increasing efforts to identify and establish core outcomes in nephrology as 
evident from recent work via the SONG initiative9,11,144. Based on the shared priorities of 
patients and their caregivers, clinicians, researchers, and policy makers, vascular access has 
been identified as a core outcome domain in HD. This study, led by the SONG-HD Vascular 
Access expert working group1, further informs the process of establishing and implementing a 
core outcome measure for vascular access that is: (i) considered important and relevant by all 
relevant stakeholders, (ii) feasible across different clinical settings without adding additional 
burden to clinicians or patients, (iii) inexpensive and (iv) relevant to clinical decision-making 
and quality improvement.  
Function was the most commonly reported vascular access outcome in HD trials. Although 
thrombosis and access flow were the most frequently used outcome measures to assess 
function, these outcomes may not capture all relevant contributing aspects of function and 
dysfunction of a vascular access and may therefore lack content validity214. For example, using 
thromboses as an outcome measure may not adequately assess whether an intervention 
improves the function and usability of a vascular access. Results from the largest interventional 
vascular access trial to date showed that despite clopidogrel leading to a reduction in early 
thrombosis rates, this did not translate into a simultaneous improvement in the usability of 
AVFs for HD72, suggesting that other unmeasured outcomes may play a greater role. 
There is increasing interest in using outcome measures considered important by patients.  This 
study showed that patient-reported vascular access problems were measured infrequently in 
HD trials and therefore, the effect of many interventions on patients’ comfort and satisfaction 
with their vascular access remains uncertain. Pain during cannulation has been identified as the 
most commonly reported problem by patients209, yet was assessed in only 11% of trials. 
Cosmetic and lifestyle considerations such as restrictions on showering and swimming with a 
catheter, free-time lost to frequent appointments for access procedures and fear of a potentially 
life-threatening haemorrhage of an aneurysmal access are also important to patients, but these 
outcomes were not reported in any of the studies included in our systematic review8,227.  
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This study addresses an evidence gap by providing a detailed analysis of the scope and 
consistency of vascular access outcome measures and of the implementation of previously 
published standardised outcome definitions across a large selection of contemporary HD trials. 
Limitations of this study include the sampling frame, that was restricted to recently published 
(since January 2011) and ongoing trials, which may have introduced selection bias. However, 
attempts were made to provide a contemporary assessment of outcomes and outcome measures 
and to assess the use of previously published outcome definitions with the most recent 
publication released in 2011127. It is likely that including older trials would only have increased 
the heterogeneity of outcome measures due to less consistency with existing outcome 
definitions, only strengthening the study’s key findings. The quality or risk of bias of included 
trials was not assessed, such that it was not possible to evaluate the association between the 
reliability of trial results and the outcomes reported.  
In conclusion, there is substantial variability and inconsistency in vascular access outcomes 
and outcome measures reported in HD trials, with very little focus on patient-reported 
outcomes, making it difficult for clinicians, patients and policy makers to make informed 
decisions. Clinicians are encouraged to judge current trial outcomes and measures based on the 
relevance to their patients and clinical practice. To improve the relevance and consistency of 
vascular access outcome measures used in clinical trials and day-to-day clinical practice, we 
recommend implementation of trial endpoints tailored to the different types of vascular access 
and time points of their life cycle. These were recently published by the Dialysis Vascular 
Access group of the American Society of Nephrology KHI126,131-133. Complementing the KHI, 
the international SONG Initiative has established a core outcome set for HD that includes 
vascular access as one of four core outcome domains based on the shared priorities of patients 
and health professionals9,11.  
7.8 Chapter summary 
This systematic review of all vascular access outcomes reported in contemporary RCTs in HD 
highlights the substantial inconsistency and heterogeneity of reported vascular access outcome 
measures despite the availability of standardised outcome measures. Insufficient uptake of 
proposed outcome definitions may partially be driven by: (i) the lack global engagement of 
multiple stakeholder groups including patients and their caregivers, (ii) outcomes that are 
cumbersome to measure or of limited importance and (iii) the lack of incentives to use 
standardised outcome definitions. Patient-reported outcome measures were reported in a 
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minority of trials which further strengthens the need for broader engagement of the patients’ 
voice in research from study design to dissemination and implementation. The next chapter 
will outline how to engage patients, caregivers, clinicians, researchers and policy makers 
around the world to determine the most critically important outcome for vascular access to be 
included in the core outcome set for trials in HD.   
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Chapter 8   
International survey on vascular access outcomes 
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8.1 Chapter overview 
The previous chapter has highlighted the substantial variability in vascular access outcomes 
reported across HD trials and infrequent assessment of patient-reported outcomes including 
pain and quality of life. To determine the most critically important outcomes to patients, their 
supporters and health professionals, an international vascular access survey was conducted in 
English, Spanish, Malay, and Chinese. This survey is part of the SONG process of establishing 
a core outcome measure for vascular access and will be described in the following chapter.  
8.2 Included publication 
The manuscript included in this chapter has been submitted for publication and is currently 
undergoing peer review.  
Viecelli AK, Howell, M, Tong, A, Teixeira-Pinto, A, O’Lone, E, Ju A, , Craig JC, Hooi, LS, 
Lee, T, Lok CE, Polkinghorne, KR, Quinn RR, Vachharajani, T, Vanholder, R, Zuo, L, Tordoir, 
J, Pecoits-Filho, R, You, T, Kopperschmidt, T, Smith, R, Irish, AB, Mori, TA, Pascoe, EM, 
Johnson, DW, Hawley, CM. Identifying a core vascular access outcome for trials in 
haemodialysis: an international survey with patients and health professionals (under review).  
The candidate concepted and designed the survey and prepared/coordinated teleconference 
meetings with the SONG-HD vascular access expert working group to gather feedback on the 
survey content. The candidate coordinated survey translations and programming of the online 
survey in all four languages. The candidate developed the statistical analysis plan, performed 
the statistical analysis together with MH, analysed all survey comments thematically under 
supervision of AT, and interpreted data. The candidate drafted the manuscript and integrated 
comments and revisions from co-authors into a final version. 
8.3 Abstract  
Background: A functioning vascular access is the lifeline for patients requiring HD but access-
related complications remain a major challenge. Vascular access outcomes reported across 
trials are numerous, heterogenous, and may not have direct relevance to patients and clinicians. 
This study aimed to identify the most critically important vascular access outcomes for trials 
in HD. 
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Method: Twelve outcomes derived from a systematic review, multidisciplinary expert panel, 
and patient input were included in an online survey conducted in English, Chinese, Spanish 
and Malay. Participants rated the absolute importance of outcomes using a 9-point Likert scale 
(7-9 being critically important). The relative importance was determined by a Best-Worst-Scale 
using multinomial logistic regression. Open text responses were analysed thematically. 
Results: The survey was completed by 873 participants (224 [26%] patients/caregivers and 
649 [74%] health professionals) from 58 countries. Vascular access function was considered 
the most important outcome (mean score 7.8 for patients and caregivers/8.5 for health 
professionals, with 85%/95% rating it critically important, and top ranked on Best-Worst-
Scale), followed by infection (mean 7.4/8.2, 79%/92% rating it critically important, second 
rank on Best-Worst-Scale). Based on mean differences, health professionals rated the 
importance of all outcomes equal or higher than patients/caregivers except for aneurysms, 
which was considered relatively more important by patients/caregivers. We identified six 
themes: necessity for HD; applicability across vascular access types; frequency and severity of 
debilitation; minimizing the risk of hospitalisation and death; optimizing technical competence 
and adherence to best practice; and direct impact on appearance and lifestyle.  
Conclusions: Vascular access function was the most critically important outcome among 
patients/caregivers and health professionals. Consistent reporting of this outcome across trials 
in HD will strengthen their value in supporting vascular access practice and shared decision-
making in patients requiring HD. 
8.4 Introduction 
A functioning vascular access is the lifeline for patients requiring HD, but access-related 
complications, such as infection, vascular access failure, cannulation problems and bleeding, 
are associated with increased morbidity, mortality and health-related costs8,24,147. Importantly, 
vascular access complications are a major stressor for patients on HD8,209,210. Despite increasing 
numbers of trials conducted to improve vascular access-related outcomes, implementation of 
trial results into clinical practice is limited by the highly variable, often selectively reported 
outcomes, which may be of little relevance to end-users, including patients and health 
professionals228.  
Currently, reported vascular access outcomes are highly variable with a recent analysis of 168 
contemporary HD trials showing that 23 different vascular access outcomes were reported and 
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assessed by over 1400 different measures178. Such inconsistency in outcome reporting limits 
the ability to compare and interpret findings across trials68,186. Vascular access outcomes 
important to patients are infrequently reported142. For example, vascular access-related pain 
and bleeding have been identified as highly relevant to patients8,209, yet these outcomes were 
reported in less than 15% of vascular access trials178.  
Consensus-based core outcome sets can help to improve consistent reporting of outcomes that 
are critically important to patients and health professionals136,215,229. Core outcome sets are 
defined as “an agreed standardised set of outcomes that should be measured and reported, as a 
minimum, in all clinical trials in specific areas of health or healthcare”134. The SONG-HD 
initiative aims to identify core outcomes that are critically important to patients with chronic 
kidney disease and health professionals. Through an international multi-phase consensus 
process involving more than 1300 patients, caregivers and health professionals from over 70 
countries, vascular access complications, fatigue, cardiovascular disease and mortality were 
established as core outcome domains for HD11,142,144. This study aimed to identify the most 
critically important vascular access outcome based on the priorities of patients, caregivers and 
health professionals, and the reasons for their priorities11, which will inform the development 
of a standardised core outcome measure for vascular access to be reported in all trials in HD. 
8.5 Methods 
Study design 
This open international survey assessed the absolute and relative importance of vascular access 
outcomes. The survey was available in English, Malay, Chinese, and Spanish and administered 
online. The survey design and process are shown in Figure 8-1. The Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES) was used to report the survey method and 
results230. The survey is provided in Appendix C, Item S8- 1.  
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Figure 8-1: Survey process 
Abbreviations: SONG-HD – Standardised Outcomes in Nephrology – Haemodialysis. 
Participant selection and recruitment 
Participants aged 18 years and older, including patients, caregivers/family members, 
nephrologists, general physicians, radiologists, surgeons, nurses, physiotherapists, social 
workers, psychologists, dieticians, pharmacists, policy makers, researchers, and industry 
representatives with interest or experience in HD and vascular access, were invited to complete 
this survey. Multiple recruitment strategies were used to be broadly inclusive. Patients and 
caregivers were invited via the SONG Initiative database and patient organisations worldwide 
(Item S8- 2) using standardised invitation fliers, and via opt-in snowball sampling, which 
included the use of social media. Health professionals were recruited via professional 
organisations (Item S8- 2) using standardised email invitations or newsletters to their 
membership list, investigator networks, and via the SONG Initiative database. Participants 
registered their email on the SONG website to receive an email invitation with the survey link. 
All participants provided informed voluntary consent and did not receive financial 
reimbursement. The study was approved by the ethics board of The University of Sydney 
(2015-228). 
Data collection 
The 12 outcomes included in the survey were identified from a systematic review of vascular 
access outcomes reported in clinical trials178 and qualitative research227,231, and discussed with 
the SONG Vascular Access Expert working group1 and SONG Executive Committee. 
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Outcomes were accompanied by a plain language definition (Table 8-1). The English survey 
was translated into Malay, Chinese and Spanish by a bilingual health professional and cross-
checked by a second bilingual health professional to ensure that the translation was accurate. 
The survey was piloted among 10 participants for every language included (5 patients, 5 health 
professionals).  
Table 8-1: Outcomes and definitions 
Outcome Definition 
Function 
The ability to use the vascular access for haemodialysis.  
Problems with function are difficulties or the inability to use the 
vascular access for haemodialysis because the access is not 
working well. This includes poor blood flow because of blood 
clots or narrowing of vessels, blocked lines (catheters), needing 
extra procedures (such as surgery for declotting) to try and get the 
access to work properly, and loss of the vascular access with the 
need for a new vascular access. 
Maturation 
Maturation is the time needed for a new fistula or graft to work 
and be used for haemodialysis.  
Problems with maturation include the need for a line (catheter) 
because the fistula or graft is not ready for use or the need to have 
further tests (such as ultrasound) and procedures (such as surgery) 
until the graft or fistula can be used for haemodialysis. 
Bleeding 
Bleeding or bruising where the vascular access is located, 
immediately before, during or after dialysis or a procedure 
(examples include bleeding during needling/cannulation or 
ongoing bleeding after dialysis for fistulas/grafts, or bleeding after 
a line insertion). 
Pain 
Pain (including fear of pain) at or around where the vascular 
access is located (e.g. during needling/cannulation or during or 
after vascular access procedures). 
Infection 
Disease/harm caused by organisms such as bacteria that entered 
the body via the vascular access. This includes blood infection and 
infection in and around the vascular access. 
Reduced blood supply 
(“steal syndrome”) 
Pain, tingling, paleness or coolness of the hand or forearm on the 
side of the vascular access caused by problems with blood supply. 
This can also lead to numbness, weakness in finger/hand/forearm, 
ulcers (dying tissue) or dead (black) tissue. 
Interference with activities  
Problems with or inability to perform activities you wish to do 
because of your vascular access, such as bathing, sports, wheeling 
a wheelchair, being in an uncomfortable position during dialysis 
or unable to do something because of an appointment/procedure 
for your vascular access.  
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Outcome Definition 
Weakening of the vessel 
wall (aneurysm/ 
pseudoaneurysm) 
A balloon-like swelling in the wall of the vessels of the fistula or 
graft. This swelling weakens the vessel wall and can burst/rupture. 
Cannulation (needling) 
problem 
Problems with placing the dialysis needles into the fistula or graft 
or the need for repeated punctures. 
Oedema 
Swelling of the body part where the vascular access is located 
(leg, arm, can also extend to neck or face).    
Hospitalisation 
Need to be in hospital because of vascular access problems such 
as infection, procedures or bleeding. 
Appearance  
Changes in appearance because of the vascular access (e.g. 
bulging veins, scars). 
 
Participants rated the absolute importance of each of the 12 randomly ordered outcomes based 
on a 9-point Likert scale. A score of 7-9 indicated that the outcome was of “critical 
importance”, 4-6 indicated “important but not critical” and 1-3 indicated “limited importance”. 
An option of “unsure” was available. For each outcome, participants had the option to enter 
comments about their choices. Participants could also suggest new outcomes that were not 
included in the survey. The relative importance of the 12 outcomes (i.e. relative to each other) 
was assessed on a Best-Worst-Scale, whereby participants were presented with five blocks 
consisting of 6 of the 12 possible outcomes, randomly selected and ordered. For each block, 
participants were required to choose the most and the least important outcome. Like discrete 
choice experiments, the Best-Worst-Scale is a preference elicitation method that involves less 
cognitive burden and provides better discrimination and greater information retrieval232-234. 
The survey was completed using LimeSurvey from October 2016 to July 2017.   
Data analysis 
The absolute importance of each outcome was assessed by the mean, median and proportion 
of participants who rated the outcome as critically important (scores of 7-9) on the Likert Scale. 
The relative importance was estimated using a multinomial logistic regression model. Utility 
functions containing all outcomes and interaction terms for participant characteristics were 
constructed for the best worst choice task. Following this approach, the mean regression 
coefficients are the relative importance scores for each outcome233. As the regression 
coefficients have the same underlying scale, preference scores can be adjusted to any 
convenient scale to aid interpretation. Absolute importance scores were calculated separately 
for patients/caregivers and health professionals while relative importance scores were 
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calculated using interaction terms in the regression model. Mean differences and 95% CI were 
calculated for absolute (Likert) and relative (Best-Worst-Scale). Analyses were stratified by 
participant group (patients/ caregivers and health professionals) to ensure equal weighting. 
Complete survey responses for the Likert scale and Best-Worst-Scale, respectively, were 
analysed. Stata/SE version 14.0 (StataCorp. College Station, TX) and NLOGIT V6 
(Econometric Software Inc.) were used to analyse the data. Excel (Microsoft Corporation, 
Product version 16.0) and HyperRESEARCH (Version 3.7, Randolph, MA) were used to code 
the text and inductively identify themes focusing on reasons for outcome ratings.  
Definition of consensus for the core outcome 
The core outcome (i.e. the most critically important outcome) was defined as the outcome with 
the highest absolute and relative importance scores on the Likert scale and Best-Worst-Scale 
in both stakeholder groups. A priori cut-off points were not possible because of the unknown 
distribution of scores.  
8.6 Results 
Participant characteristics 
In total, 984 participants commenced the survey, 956 provided demographic details, 873 
completed the rating of each outcome on a Likert scale, and 828 also completed the relative 
importance rating on the Best-Worst-Scale (87% completion rate). Characteristics of included 
participants (total n=224, 26%) are shown in Table 8-2 for patients (n=196, 22%) and 
caregivers (n=28; 4%) and Table 8-3 for health professionals (n=649, 74%).  
Patients/caregivers were from 16 countries including Australia, the US, China, Malaysia, the 
UK and 11 other countries. Most patients had an AVF or CVC as their current (62% AVF and 
8% CVC) and/or previous vascular access (54% AVF, 32% CVC) and the most commonly 
experienced vascular access complications were cannulation problems (40%) and pain (40%). 
Most patients had been on HD for less than 12 months (47%). Health professionals included 
341 (53%) nephrologists, 184 (28%) nurses, 25 (4%) general physicians, 17 (3%) surgeons, 
and 82 (12%) stakeholders in other roles from 56 different countries. 
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Table 8-2: Characteristics of patients and caregivers 
Patients/caregivers, n=224 (26%) 
Characteristics n (%) Characteristics n (%) 
Participant type  Education*  
 Patient 
196 (88) Did not complete high 
school 
52 (25) 
 Caregiver/family member 28 (12)  High school graduate 29 (14) 
 
  Professional 
certificate/diploma 
43 (21) 
Gender   Undergraduate degree 57 (27) 
 Male 109 (49)  Postgraduate degree 27 (13) 
 Female 115 (51)   
  Current type of treatment*  
Age group (years)   In centre haemodialysis 74 (36) 
 18 – 40 53 (24)  Satellite haemodialysis 18 (9) 
 41 – 50 46 (21)  Home haemodialysis 37 (18) 
 51 – 60 52 (23)  Peritoneal dialysis 4 (2) 
 61 – 70 60 (27)  Transplant 67 (32) 
 71 – 80 12 (5)  Not applicable 8 (4) 
 ≥ 81 1 (<1)   
  Years on haemodialysis*  
Marital status*   < 1 85 (47) 
 Single 43 (21)  1-5 38(21) 
 Partner/de-facto 7 (3)  6-10 12 (7) 
 Married 125 (60)  11-15 11 (6) 
 Divorced/separated/widowed  33 (16)  > 15 14 (8) 
   Not applicable 19 (11) 
Number of children*    
 0 85 (41) Current vascular access*  
 1-2 89 (43)  AVF 129 (62) 
 3-4 31 (15)  AVG 6 (3) 
 ≥5 2 (1)  CVC 16 (8) 
   Not applicable 57 (27) 
Employment status*    
 Employed (full-/part-time) 80 (39) Previous vascular access(s)  
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Patients/caregivers, n=224 (26%) 
Characteristics n (%) Characteristics n (%) 
 Unemployed 35 (17)  AVF 111 (54) 
 Retired 71 (34)  AVG 13 (6) 
 Student  2 (1)  CVC 67 (32) 
 Other 19 (9)  Not applicable  16 (8) 
Countries 
 Experienced vascular access 
complications* 
 
 Australia 49 (22)  Bleeding 77 (37) 
 United States 36 (16)  Hospitalisation 42 (20) 
 China  35 (16)  Infection 29 (14) 
 Malaysia 32 (14)  Needling problems 83 (40) 
 United Kingdom 23 (10)  Pain 83 (40) 
 Canada 14 (6)  Dysfunction 72 (35) 
 New Zealand 12 (5)   
 Othera 23 (10) Current type of treatment*  
   In centre haemodialysis 74 (36) 
   Satellite haemodialysis 18 (9) 
   Home haemodialysis 37 (18) 
Abbreviation: AVF – arteriovenous fistula; AVG – arteriovenous graft; CVC – central venous catheter. 
*Total numbers do not add up to total number of participants due to undisclosed responses (excluded). 
aOther includes 9 countries (in descending order of frequency): Brazil, Denmark, South Africa, India, Ireland, 
Spain, Cuba, Greece, Netherlands.  
 
Table 8-3: Characteristics of health professionals 
Health professionals, n=649 (74%) 
Characteristics n (%) Characteristics n (%) 
Participant type  Number of trials as investigator*  
 Nephrologists 341 (53)  0 147 (33) 
 Nurses 184 (28)  1-5 169 (38) 
 General physicians 25 (4)  6-10 45 (10) 
 Surgeons 17 (3)  11-15 9 (2) 
 Trainees  16 (2)  ≥16 27 (6) 
 Social worker 4 (1)  Not applicable 49 (11) 
 Radiologist 2 (<1)   
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Health professionals, n=649 (74%) 
Characteristics n (%) Characteristics n (%) 
 Psychologists 2 (<1) Other roles*  
 Dietitian 3 (<1)  Government, policy 58 (13) 
 Researcher 15 (2)  CPG 140 (31) 
 Pharmacist 1 (<1)  Funding 32 (7) 
 Policy maker 2 (<1)   
 Industry/private sector 7 (1) Countries  
 Other 47 (7)  China 159 (25) 
   Malaysia 109 (17) 
Gender   Australia 88 (14) 
 Male 293 (45)  Spain 27 (4) 
 Female 356 (55)  Canada 27 (4) 
   United Kingdom 26 (4) 
Age group (years)   United States 24 (4) 
 18 – 40 268 (41)  Portugal 18 (3) 
 41 – 50 198 (31)  India 15 (2) 
 51 – 60 138 (21)  Brazil 14 (2) 
 61 – 70 38 (6)  New Zealand 10 (2) 
 71 – 80 6 (1)  Netherlands 9 (1) 
 ≥ 81 1 (<1)  Italy 9 (1) 
Experience with haemodialysis 
(years)* 
  Belgium 8 (1) 
 <11 166 (37)  Othera 106 (16) 
 11 to 20 146 (33)   
 21 to 30 76 (17)   
 >30 40 (9)   
 Not applicable  18 (4)   
Abbreviation: CPG – Clinical Practice Guidelines;  
*Total numbers do not add up to total number of participants due to undisclosed responses (excluded).  
aOther includes 42 countries (in descending order of frequency): Uruguay, Saudi Arabia, Greece, France, 
Romania, Poland, Peru, Germany, Egypt, Colombia, Argentina, Sweden, Chile, Bolivia, Turkey, Slovenia, 
Singapore, Serbia, Russian Federation, Montenegro, Mexico, Lithuania, Israel, Ireland, Croatia, Austria, Vietnam, 
Syria, Switzerland, Sri Lanka, South Africa, Rwanda, Philippines, Paraguay, Nigeria, Morocco, Kosovo, 
Hungary, Finland, El Salvador, Bulgaria, Belarus 
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Absolute importance of outcomes 
Table 8-4 shows the absolute importance scores expressed as the mean, median and proportion 
of participants rating an outcome as 7-9 (critical importance) for each of the 12 vascular access 
outcomes. Both patients/caregivers and health professionals considered function as the most 
critically important outcome for vascular access (Figure 8-2). Based on mean scores, the 3 
outcomes rated highest by patients/caregivers were vascular access function (mean 7.8), 
infection (7.4), and aneurysms (7.2). The top 3 outcomes for health professionals were function 
(8.5), infection (8.2), and maturation (7.4). Patients/caregivers and health professionals 
considered appearance of the vascular access as the least important outcome (mean score 5.2 
and 5.4, respectively). Additional outcomes suggested by survey participants are provided in 
(Table S8- 1). None of these new outcomes were suggested by more than one per cent of all 
participants. 
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Table 8-4: Summary of importance scores for patients/caregivers and health professionals. 
Outcomes 
Median 
Likert score 
Mean 
Likert score 
Proportion critically 
important (7-9) 
Mean 
BWS score 
Patients/ 
Carers 
HP 
Patients/ 
Carers 
HP 
Patients/ 
Carers 
HP 
Patients/ 
Carers 
HP 
Vascular access function* 9 9 7.8 8.5 85 95 6.3 9.0 
Infection 8 8 7.4 8.2 79 92 5.6 7.7 
(Pseudo-)aneurysm 8 7 7.2 7.4 78 70 5.3 4.7 
Cannulation problems 7 7 6.8 7.1 67 69 4.6 5.9 
Steal syndrome 7 8 6.7 7.6 61 80 4.6 6.0 
Hospitalisation 7 8 6.6 7.4 63 76 4.1 6.5 
Oedema 7 7 6.5 6.7 57 55 3.2 4.0 
Maturation 7 8 6.4 7.7 56 79 2.7 5.1 
Bleeding 7 5 6.3 7.0 52 65 3.1 3.8 
Interference with activities 6 6 5.9 6.2 40 45 1.9 2.5 
Pain 6 7 5.9 6.4 42 51 3.1 3.2 
Appearance  5 5 5.2 5.4 33 24 1 (ref) 1 (ref) 
Abbreviations: BWS – Best Worst Scale; HP – Health professionals. *Core outcome (i.e. most critically important outcome) based on highest absolute and 
relative importance scores in both stakeholder groups (i.e. patient/caregiver and health professionals) 
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Figure 8-2: Proportion of patients/caregivers (right) and health professionals (left) considering outcomes as critically important, important or of 
limited importance. 
Note: Critically important (black): 7-9 points on Likert scale; important (dark grey): 4-6 points on Likert scale; limited importance (light grey): 1-3 points 
on Likert scale. 
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Relative importance of outcomes 
Patients/caregivers and health professionals ranked vascular access function highest among the 
12 outcomes (mean Best-Worst-Scale scores 6.3 and 9, respectively), followed by infection 
(mean 5.6 and 7.7, respectively; Table 8-4, Figure 8-3). Patients and caregivers considered 
aneurysms the third most important outcome followed by cannulation problems, steal 
syndrome (i.e. access-induced ischemia) and hospitalisation. Health professionals ranked 
hospitalisation third followed by steal syndrome, cannulation problems and maturation.  
 
Figure 8-3: Mean relative importance scores of patients (light grey) and health professionals 
(dark grey) based on the Best-Worst-Scale. Ordered by the mean importance scores of 
patients/caregivers (bars with 95% confidence intervals). 
Abbreviation: BWS – Best-Worst-Scale 
Differences between stakeholder groups 
Differences in mean rating scores between stakeholder groups are shown in Figure 8-4. 
Compared to patients and caregivers, health professionals rated the following 8 outcomes 
higher on the Likert scale: maturation (mean difference 1.23, 95% CI 0.95-1.51), steal 
syndrome (0.89, 95% CI 0.62-1.16), hospitalisation (0.83, 95% CI 0.54-1.12), infection (0.79, 
95% CI 0.55-1.03), function (0.67, 95% CI 0.45-0.89), bleeding (0.63, 95% CI 0.34-0.92), pain 
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(0.57, 95% CI 0.26-0.87) and cannulation problems (0.31, 95% CI 0.03-0.59).  Mean 
differences between relative importance scores from the Best-Worst-Scale outline clearer 
differences between the two stakeholder groups (Figure 8-4), particularly for function (mean 
difference 2.67, 95% CI 2.40-2.93), hospitalisation (2.37, 95% CI 2.09-2.65), maturation (2.37, 
95% CI 2.09-2.64), and infection (2.11, 95% CI 1.85-2.38). The only outcome that 
patients/caregivers rated higher on the Best-Worst-Scale compared to health professionals was 
aneurysm/pseudoaneurysm (mean difference 0.59, 95% CI 0.36-0.81).   
 
Figure 8-4: Difference in absolute (Likert scale) and relative (Best-Worst-Scale) mean scores 
between patients/caregivers and health professionals. Error bars refer to 95% confidence 
interval. 
Abbreviations: BWS – Best-Worst-Scale (assessment of the relative importance of outcomes); 
Likert – Likert scale (assessment of the absolute importance of outcomes) 
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Differences by language groups 
The majority of participants completed the survey in English (n=518), 191 in Chinese, 131 in 
Malay and 33 in Spanish. Absolute and relative importance scores by different language 
surveys are shown in Figure S8- 1 and Figure S8- 2, respectively. Overall, importance ratings 
were similar across all four languages and vascular access function and infection were 
consistently considered the two most important outcomes.  
 
Themes  
Based on comments from both stakeholder groups, we identified six themes that reflected 
reasons for the rating of vascular access outcomes: necessity for HD; applicability across 
vascular access types; frequency and severity of debilitation; minimising the risk of 
hospitalisation and death; optimising technical competence and adherence to best practice; and 
direct impact on appearance and lifestyle. Supporting quotations are provided in Table 8-5. 
Necessity for HD  
Vascular access function was rated critically important because “no access, no dialysis. Poor 
access, poor dialysis”. A functioning vascular access was described as indispensable for 
surviving and therefore regarded as a key issue to address in research and clinical practice. 
Applicability across vascular access types  
Vascular access function was known to apply to all access types. However, outcomes such as 
infection and interference with activities were predominantly viewed as being more specifically 
related and relevant to CVC and were thus regarded to be of lower importance.  
Frequency and severity of debilitation  
Certain outcomes, such as steal syndrome, bleeding and pain, were prioritised based on the 
severity and overall frequency of the outcome: “Steal [syndrome] is an important complication 
but it occurs in less than 5% of AVF patients. Thus, in relative terms, it is not as important as 
the other complications (e.g. primary failure)”. However, a rare event such as steal syndrome 
was recognised as a severe complication. Similarly, bleeding was considered “important 
because a bleeding fistula can lead to potential mortality and morbidity”, yet downgraded on 
the importance scale in view of the low frequency of occurrence.  
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Minimising the risk of hospitalisation and death: Outcomes, including vascular access 
dysfunction, infection, aneurysm, bleeding and steal syndrome, were prioritised highly if they 
were expected to reduce the risk of death, need for interventions and hospitalisation.  
Optimising technical competence and adherence to best practice  
Participants believed that consistent demonstration of technical competence, adherence to best 
practice and ability to optimise technique skills could help mitigate avoidable complications 
related to maturation, cannulation or aneurysm formation. Cannulation problems were closely 
related to the “competency/skill level of cannulation technician”. Infections were considered 
avoidable with adherence to good clinical practice. Achieving consensus on the optimal timing 
of first cannulation of a mature/maturing vascular access to improve maturation and ensuring 
implementation of protocols for sterile handling of vascular accesses to minimise infection 
risks, were highlighted as two important research priorities.  
Direct impact on appearance and lifestyle  
Some participants gave higher priority to outcomes that had a palpable and severe impact on 
their personal identity, self-esteem, independence and daily life. For example, appearance was 
considered least important overall, however this outcome was ranked highly by patients who 
viewed the vascular access as “ugly” and “unpleasant”, and by patients who had been asked if 
they were victims of domestic abuse due to bruising and scarring. Cannulation problems were 
viewed critically important for home dialysis training units because the inability to cannulate 
the arteriovenous access by patients or their family members was identified as a limiting step 
to dialysing independently at home. 
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Table 8-5: Themes with selected illustrative quotations 
Themes Outcome 
Likert 
score 
Necessity for haemodialysis    
No access, no dialysis. Poor access, poor dialysis. Health Professional Function 9 
Without vascular access that works effectively, patients could either get a less than adequate dialysis dose or have to 
spend more time on dialysis. Health Professional 
Function 9 
Without vascular access there is no haemo! Health Professional Function 9 
血管功能=患者生命。毫无疑问，和血管有关的任何问题都要放在至关重要的位置. Patient. (Vascular function = 
patient's life. There is no doubt that any problems related to blood vessels should be regarded as a key issue)  
Function 9 
Applicability across vascular access types   
Depends on kind of vascular access...per example Catheter versus native AVF. Health professional  Infection 7 
Not applicable as neckline used. Caregiver Pain N/A 
This would relate more to tunnelled CVC than AVF I would think. Health professional 
Interference with 
activities 
7 
Weak evidence that arteriovenous accesses are superior to CVC; therefore, maturation of an arteriovenous access 
should not be the first question to ask. Health professional 
Maturation 1 
Frequency and severity of debilitation   
Although rare, this might be a cause for giving up to that access. Health professional Steal syndrome 7 
Experienced a number periods of hospitalisation due to failed fistulas and emergency measures taken (e.g. a temporary 
line in the groin) to ensure haemodialysis could continue to be performed at scheduled times. Patient 
Hospitalisation 7 
Frequent in the beginning but usually no patient complains after some weeks or months. Health professional Pain 3 
I applied a cream to my site before needling so did not feel any pain. Patient Pain 7 
Importance would depend on the frequency and severity of the bleeding. Health professional Bleeding 6 
No significant problems with bleeding, just odd occasions of incidents when either I or my carer were a little too 
impatient when removing the needle at the end of the session. Patient 
Bleeding 6 
Infective complications in my country is very high. Health professional Infection 8 
Most of my haemodialysis related complications are related to vascular access. Health professional Hospitalisation 9 
Occurs 1-3x/year/patient and lasts 1-2 weeks; cumbersome in practice! Health professional Bleeding 8 
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Frequency and severity of debilitation Outcome 
Likert 
score 
The needling process was my regular nightmare, even after the addition of using an anaesthetic injection it was still a 
treatment that had me in tears. When I had a catheter pre a fistula I had painful episodes of machine alarming, 
blockage, nausea. Patient 
Pain 9 
Steal can be really distressing and it seems very unfair to add this to all the other complications of a dialysis patient's 
life. Health professional 
Steal syndrome 9 
Steal is an important complication but it occurs in less than 5% of AVF patients. Thus, in relative terms, it is not as 
important as the other complications (e.g. primary failure). Health professional 
Steal syndrome 4 
This is the most common reason why our patients are admitted to my hospital ... vascular access patency is a thorny 
issue. Health professional 
Function 9 
Very important if you get it, but fortunately true steal syndrome is uncommon. Health professional Steal syndrome 5 
When/if this happens it is very, very painful. Patient Aneurysm 7 
Minimising the risk of hospitalisation and death   
A serious problem in patients with long standing in dialysis that needs a rapid solution Function 9 
Frequently, the patient will need some intervention over the fistula, or even closing it. It’s very important. Health 
professional 
Steal syndrome 8 
It is a cause of death and has to be prevented by careful disinfection and handling. Health professional Infection 6 
In the meanwhile, the patient will need a catheter, and this fact increases the risk of infection, hospitalisation, etc. Good 
vascular access function is critical. Health professional 
Function 9 
Infection can be life-threatening. Health professional Infection 9 
Important because a bleeding fistula can lead to potential mortality and morbidity e.g. insertion of line with associated 
sepsis risks. Health professional 
Bleeding 6 
This is very important not just because of the morbidity and mortality to the patients, but also because of the burden 
that infection, particularly of temporary [vascular] access, puts on us for hospital beds and other resources. Health 
professional 
Infection 9 
We had 2 patients who died because of this. Health professional Aneurysm 8 
血管壁弱化肯定是病人情况达到了很危险的境地了，而且原因可能有很多，后果也很严重. Patient (The 
weakening of the blood vessel wall is definitely a dangerous situation for the patient, and there may be many reasons 
for this situation and the consequences are severe.) 
Aneurysm 8 
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Minimising the risk of hospitalisation and death Outcome 
Likert 
score 
这个问题是必须放在第一严重的位置的，关系到病人的生命. Patient.  (This problem should be prioritised, it 
affects patients’ life.) 
Infection 9 
Optimising technical competence and adherence to best practice   
Ensuring that the effort that goes into creating an AVF results in a working access is really important. I expect some 
units have better records than ours and I would love to know why. Health professional 
Maturation 6 
This can be a problem sometimes due to the competency/skill level of cannulation technician. Patient Cannulation problems 9 
We need a consensus in time to maturation, needles to use, etc. tackle the maturation time with the same approach in 
every dialysis units. Patient 
Maturation 9 
We need to apply sterile protocols during manipulation of vascular access, in every dialysis units worldwide, in for 
profit and no-profit centres. Patient 
Infection  9 
解决这个问题可能的办法，也许只有“选择一位专业、权威的主刀医生”这一个办法了. Patient. (Perhaps the only 
way to solve this problem is to find a professional key opinion leader surgeon).。 
Maturation 3 
Memerlukan staf yang mahir mencucuk jarum di kawasan akses salur darah. Patient. (Need staff who are expert at 
cannulating with needles in the area of the vascular access) 
Maturation 8 
It may be a serious problem that may imply the need to close the access but it is avoidable. I do not understand why the 
vascular surgeons treat the varicose veins with contention but not the fistulas. All my patients use an elastic brace on 
their fistulas. Health professional 
Aneurysm 3 
向护士提出过进针标准动作的培训，但没有受到重视. Patient (Suggestion that training for nurses for standardised 
needling was ignored)  
Pain 4 
Important but should be avoidable with good clinical practice. Anything that makes it easier for patients and staff to 
minimise the risk of infection would be good. Health professional. 
Infection 8 
This should not happen at all, if it does then bad practices are being adopted. Patient Infection 6 
Direct impact on appearance and lifestyle   
Can't wear my wedding ring do to the change in my hands due to my fistula. Patient Oedema 8 
Due to the bruising and scarring I've been asked many times if my husband has been abusing me. Patient Appearance 9 
I found I was not as active as I was and could not do things I used to do, This I found very frustrating. Patient 
Interference with 
activities 
9 
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Direct impact on appearance and lifestyle Outcome 
Likert 
score 
This is a very ugly side effect of the fistula and the buzzing is also unpleasant. Patient Appearance 9 
Mine looks like a Kiwi fruit. Living on a rural property, mowing, chain sawing, gardening etc. Needs a tie off, but I’m 
a high chance of rejection. Patient 
Appearance 9 
Women seemed more concerned about this but my experience majority of patients understand that access is their 
lifeline. Health professional 
Appearance 7 
This can be an issue for us as we are primarily a home training unit, with the expectation that patients or family 
members will be cannulating the access. Unfortunately, they are training on AVF that are still maturing. Health 
professional 
Cannulation problem 9 
Abbreviation: AVF – arteriovenous fistula. 
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8.7 Discussion 
The most critically important vascular access outcomes identified by patients/caregivers and health 
professionals was vascular access function. This finding was consistent across the two groups whether 
measured as absolute or relative importance. Participants identified the necessity of a functioning 
vascular access to provide adequate dialysis (i.e. the lifeline for HD) and the devastating and costly 
consequences of a failing vascular access, including invasive procedures, hospitalisations and death as 
important reasons for prioritising this outcome. The second highest ranking outcome, vascular access 
related infection was deemed critically important because of the detrimental consequences of 
prolonged hospitalisation and associated increased morbidity and mortality. Infection was considered 
as largely preventable through best clinical practice and to be mostly a consequence of CVC use. It 
was deemed not as relevant to all forms of vascular access whereas function was equally applicable to 
all forms of access. While there was consensus on function and infection as the most critically 
important outcomes across both stakeholder groups, patients and caregivers considered aneurysms to 
be more important and health professionals particularly viewed maturation, steal syndrome and 
hospitalisations to be of greater importance.  
Concordant with our findings, problems with vascular access function have been voiced as the most 
prominent concern by patients on HD. In a survey of 128 patients from a single US dialysis program, 
59% reported vascular access thrombosis as their major concern209. A vascular access survey 
administered to 132 patients on HD in Canada identified that within the domain of dialysis 
complications, concerns regarding vascular access longevity caused the highest level of 
dissatisfaction235. An international study with patients and different health professional groups 
(nephrologists, nurses, and surgeons/radiologists) on priorities for guidelines regarding vascular access 
found that decisions related to vascular access type and site selection, and prevention of vascular access 
infections were the highest priorities to be addressed.  However, while patients’ highest priority was 
how to manage catheter thrombosis, nephrologists, nurses and surgeons/ radiologists considered the 
management of arteriovenous access stenosis and central vein obstruction within their top 10 priorities 
to be covered by international guidelines236.  
Aligned with patients’ concerns, vascular access function has been a major focus of clinical trials in 
patients on HD. In a systematic review of 168 contemporary randomised trials in HD, function was the 
most frequently reported vascular access outcome (81% of trials) followed by infection (38%), yet 
function was the most heterogeneous outcome and measured in nearly 500 different ways178. Based on 
this review, the uptake of standardised outcome definitions has been minimal. Less than 13% of trials 
published or registered between 2011-2016 used standardized definitions to measure vascular access 
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patency and only 22% of trials used standardized definitions to assess vascular access related 
infections178. These findings underpin the need for broader implementation of internationally agreed 
and standardized, patient-important outcome measures to enhance the consistency and relevance of 
outcome reporting in clinical trials and beyond. Recently, the KHI has published a series of papers on 
recommended trial endpoint definitions tailored to the different types of vascular access and time points 
of their life cycle to facilitate the development of effective interventions and products to improve 
vascular access outcomes126,131-133. Complementing this work by KHI, the inclusion of vascular access 
function as part of the core outcome set for HD established through the international SONG initiative 
will help to ensure more consistent reporting of outcomes in HD research that are considered important 
by all relevant stakeholders11,145. 
 
Increasingly, clinical performance measures have been used for quality improvement for enhanced 
transparency through public reporting and calculating payment for services237. The clinical 
performance measures for ESKD used by the Centres for Medicare and Medicaid Services include 
mortality, hospital readmissions, patient experience of care, dialysis adequacy, vascular access type in 
use, blood transfusions, bloodstream infections and hypercalcaemia. Clinical performance measures 
are a powerful tool for quality improvement and have become a driving force to determine care 
delivery. However, current clinical performance measures are largely chosen by health professionals 
and may not reflect what patients and their families care about the most. Adding core outcomes that 
are considered critically important by patients, caregivers and health professionals, like vascular access 
function, may help improve the relevance of performance-based measures to patients.  
For example, monitoring the rate of vascular access interventions needed to maintain its use for HD as 
a measure of function rather than targeting a percentage of AVF and CVC use may be recommended. 
This is a more patient-centred goal of finding the optimal vascular access requiring the least number 
of procedures to provide adequate dialysis238,239. Incentivising a reduction in interventions is 
anticipated to reduce healthcare costs and hospitalisations while simultaneously reducing the burden 
of invasive, often painful and anxiety-provoking procedures that are disruptive to the patients’ 
lives8,181.  
Vascular access infection was the second most important outcome identified by patients/caregivers and 
health professionals. Infections are an important cause of morbidity and death in patients on HD24,32,240. 
Approximately 30% of patients using a CVC experience a bloodstream infection per year and each 
episode costs the healthcare system US$17,000-32,000241. However, infection is less relevant to 
vascular access problems as a whole, because it primarily relates to CVC use with a minimum 9-fold 
higher rate of access-related bloodstream infections compared to AVF use186,242. Survey participants 
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emphasised that infection is a preventable outcome if there is strict adherence to best practice 
guidelines. A Centres for Disease Control and Prevention (CDC) evidence-based quality improvement 
project across 17 HD facilities confirmed that staff training and competence assessment, aseptic 
technique, chlorhexidine use for CVC exit site care, and feedback of performance to staff can reduce 
access-related bloodstream infections by 54%243. For these reasons, infection was deemed less suitable 
as a core outcome to be reported across all trials in HD compared to function181.   
Patients/caregivers rated the importance of aneurysms/pseudoaneurysms third and significantly higher 
compared to health professionals. The responses from patients in our survey and the SONG-HD 
vascular access consensus workshop181 suggest that fear of a catastrophic haemorrhage was a key 
reason for the high importance of this outcome. Other reasons may include pain associated with this 
vascular access outcome, appearance and having to restrict physical activity to reduce the risk of 
complications such as rupture8,227.   
In our international survey, we included a broad group of stakeholders across 58 countries and a large 
proportion of patients/caregivers. Administering the survey in multiple languages allowed for 
recruitment from countries, such as China and Malaysia, that have not been included in previous 
vascular access surveys210,227,236. The large sample size, coupled with a quantitative assessment of the 
absolute and relative importance ratings enabled a detailed and robust assessment of the prioritization 
of outcomes for vascular access. Qualitative data analysis provided further insights into the meaning 
and reasons for outcome prioritization by survey participants. However, there are some potential 
limitations. The survey was administered online to ensure efficient dissemination and minimize data 
transfer errors, which restricted the sampling frame to participants with access to internet and computer 
literacy. This, together with the administration of the survey in only 4 languages, may have led to 
ascertainment bias (e.g. overrepresentation of nephrologists compared to other health profession 
groups, underrepresentation of participants from low-income countries). Differences in 
patient/caregiver experiences with respect to specific access types and their complications may have 
impacted on outcome prioritization. However, these data were generally not disclosed by survey 
respondents, thereby preventing reliable exploratory analysis of this issue. The survey was restricted 
to the 12 most commonly reported outcomes, however, the option to suggest new outcomes ensured 
that additional important outcomes were not missed. A further limitation inherent to all surveys was 
the potential for response bias, including demand bias and neutral or extreme responses.  
In conclusion, function was the most critically important vascular access outcome for 
patients/caregivers and health professionals. The broad applicability of this outcome to all access types, 
the absolute necessity of a functioning vascular access to provide adequate dialysis, and the detrimental 
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consequences of a failing access make this outcome a meaningful and suitable core outcome. A 
definition and metric for vascular access function is currently in development and will be piloted and 
validated in an international, multicentre study to ensure it is a reliable and feasible outcome measure 
to be used in research and routine clinical practice without adding undue burden to researchers and 
health professionals to ensure global implementation1,145,181. Consistent reporting of a validated, 
feasible, robust and meaningful outcome measure for vascular access function in research and 
ultimately in quality improvement projects will help to inform clinical practice and decision making in 
a meaningful way.  
8.8 Chapter summary 
Survey responses provided by 873 participants from 58 countries including 26% patients and 
caregivers in four languages showed that vascular access function was considered the most important 
outcome due to its central role within the domain of vascular access and the necessity to provide 
adequate HD. There is currently striking heterogeneity in the reporting of vascular access function. 
Establishment of a standardised core outcome measure for vascular access function that is based on the 
shared priorities of all relevant stakeholders, meaningful, robust and feasible, will help to ensure future 
trials will report this important outcome consistently. The next chapter will summarise how vascular 
access function should best be assessed and implemented in HD research to inform patient-centred care 
provision.   
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Chapter 9   
Report of the SONG-HD vascular access consensus 
workshop 
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9.1 Chapter overview 
The previous chapter showed that vascular access was considered the most critically important 
outcome for vascular access by patients, caregivers and health professionals. The findings of this 
survey were presented at an international consensus workshop held during the American Society of 
Nephrology Kidney Week 2016 in Chicago with 59 participants including patients, caregivers, health 
professionals, researchers, and policy makers to identify and describe the preferred core outcome 
measure for vascular access, and the rationale for its selection. This workshop report will be 
summarised in this chapter. 
9.2 Included publication 
The content of this chapter is based on the following peer reviewed publication:  
 
Viecelli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla 
E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder 
R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators. Report of the 
Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on 
Establishing a Core Outcome Measure for Hemodialysis Vascular Access. Am J Kidney Dis. 
2018;71(5):690-700. Permission to reproduce this manuscript has been obtained.  
The candidate concepted and designed the workshop. She organised the content and logistics of the 
consensus workshop. This included several teleconferences with the SONG-HD vascular access expert 
working group leading up to the workshop, piloting of the workshop at Princess Alexandra Hospital 
together with CMH as the chair of the SONG-HD vascular access working group, organisation of the 
venue and invitation of key stakeholders with assistance from AT and AJ. The candidate presented the 
findings of the aforementioned systematic review and survey during the workshop, and facilitated one 
of the breakout group discussions. She then performed qualitative data analysis of the workshop 
discussion transcripts under the supervision of AT, generated tables and figures, drafted the manuscript 
and integrated comments and revisions from co-authors into a final version. 
9.3 Abstract  
Vascular access outcomes in HD are critically important for patients and clinicians but frequently are 
neither patient-relevant nor measured consistently in randomised trials. A SONG-HD consensus 
workshop was convened to discuss the development of a core outcome measure for vascular access. 
Thirteen patients/caregivers and 46 health professionals (clinicians, policy makers, industry 
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representatives, researchers) attended. Participants advocated for vascular access function to be a core 
outcome based on the broad applicability of function regardless of access types, involvement of a 
multidisciplinary team in achieving a functioning access, and the impact of access function on quality 
of life, survival, and various access-related outcomes. A core outcome measure for vascular access 
required demonstrable feasibility for implementation across different clinical and trial settings. 
Participants advocated for a practical and flexible outcome measure with a simple, actionable 
definition. Integrating patients’ values and preferences was warranted to enhance the relevance of the 
measure. Proposed outcome measures for function included “uninterrupted use of the access without 
the need for interventions” or “ability to receive prescribed dialysis”, but not “access blood flow”, 
which was deemed too expensive and unreliable. These recommendations will inform the definition 
and implementation of a core outcome measure for vascular access function in HD trials. 
9.4 Background 
A functioning vascular access is a lifeline for patients requiring HD, but has a high risk of 
complications3. Vascular access complications account for approximately 20% to 30% of hospital 
admissions for patients on HD and incur substantial healthcare costs147,244. One in every two AVFs or 
AVGs will fail to function within the first year of creation and necessitate further interventions for 
problems such as inadequate maturation, stenosis or thrombosis27,28,93,179. Central venous catheters are 
often required and may be associated with even higher levels of morbidity, mortality and healthcare 
costs24,245. Infection, bleeding, and pain during arteriovenous access (fistula or graft) cannulation can 
cause further stress to patients and their caregivers8,209. Improving vascular access outcomes is 
therefore, a critical priority for patients requiring HD, their caregivers, and clinicians11. 
Many trials have been conducted in an effort to improve vascular access outcomes, but little success 
has been achieved4,68,179. The interpretation and applicability of trials outcomes are limited by the 
extreme heterogeneity of reported outcome measures, use of outcomes that may not be directly relevant 
to patients or clinical decision-making, and outcome reporting bias9. The ability to assess the 
comparative effects of interventions on vascular access complications has been limited by inconsistent 
outcome reporting28,64,68,186. The need to standardise reporting of critically important outcomes has 
been widely advocated127,131-133 and there is a growing number of initiatives to establish core outcome 
sets, defined as an agreed minimum set of standardised outcomes that should be measured and reported 
in all trials for a specific clinical area136,211,229,246.   
The international SONG initiative aims to establish a set of core outcome measures across the spectrum 
of chronic kidney disease based on the shared priorities of patients, caregivers, clinicians, researchers, 
policy makers, and industry. Consistent reporting of highly relevant core outcomes in clinical trials can 
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help improve the quality, relevance, and comparability of research to inform clinical decision-making, 
inform quality improvement initiatives and help facilitate measurement of clinical outcomes in 
everyday practice. The first and current focus of SONG is on establishing a set of core outcomes for 
HD following established methodology9,11,134,136,211. Based on consensus among almost 1,400 patients, 
caregivers, and health professionals from over 70 countries, vascular access has been identified as one 
of four core outcome domains in HD (i.e. vascular access, fatigue, cardiovascular disease and 
mortality)11,144. The current report focuses on the development of a core outcome measure for vascular 
access.  
The aim of this workshop report is to describe and summarise stakeholder perspectives on the 
identification and implementation of a core outcome measure for vascular access to be used across all 
HD trials. This will help to ensure that the most relevant and meaningful outcome measure is selected, 
address potential challenges, and optimise implementation strategies.  
9.5 SONG-HD vascular access consensus workshop 
Context and scope 
The international SONG-HD vascular access consensus workshop was convened in Chicago during 
the American Society of Nephrology Kidney Week Conference in 2016 for stakeholders to discuss the 
identification and implementation of a core outcome measure for vascular access to be reported in all 
trials in HD. The top prioritised outcomes were vascular access function and infection based on a 
systematic review and interim results from an international survey on vascular access outcomes that 
was completed by patients/caregivers and health professionals.  
Participants and contributors 
Patients, caregivers and health professionals (nephrologists, radiologists, interventionalists, surgeons, 
nursing and allied health professionals, researchers, policy makers) with current or previous experience 
with HD were invited to the workshop. To further enhance successful dissemination and 
implementation of the vascular access core outcome measure, invitations were extended to 
representatives of professional societies (e.g. American Society of Nephrology, Australian and New 
Zealand Society of Nephrology, European Society of Nephrology, and the Asian Pacific Society of 
Nephrology), regulatory agencies (e.g. FDA, Centres for Medicare and Medicaid Services [CMS]), 
nephrology journals, registries, funding organizations (e.g. National Institutes for Health [NIH]), 
industry, and guideline organisations (e.g. Kidney Disease Improving Global Outcomes).  In total, 59 
participants (11 patients, 2 caregivers, and 46 health professionals) from 12 countries attended the 
workshop and 25 workshop contributors provided feedback on the workshop materials and preliminary 
report, but were unable to attend the workshop in person (Table S9- 1, Appendix D). All workshop 
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participants consented to being recorded and listed as investigators and ethics approval was therefore 
not required for this workshop. 
Workshop program and materials 
The two-hour workshop was held on November 18, 2016 at Conference Chicago at University Centre 
in Chicago, United States. The workshop program, background material (including examples of 
outcome measures and validation tools214) and interim results were sent to participants two weeks in 
advance. During the workshop, an overview of the SONG-HD Vascular Access initiative was 
presented including interim results from the aforementioned systematic review of vascular access 
outcome measures and the SONG-HD vascular access survey.  
Participants were allocated to one of five breakout discussion groups. Each group had 10 to 13 members 
and included two to four patients or caregivers and at least one member of the SONG-HD vascular 
access working group. The facilitator of each group (C.M.H, A.K.V., BM, AT, and EO) received a 
briefing session prior to the workshop and were provided with a question guide (Supplementary Item 
S9- 1 of Appendix D). Participants discussed the interim results of the survey (which will be reported 
separately but are referred to in this report when necessary to provide context for specific statements), 
potential core outcomes (i.e. function, infection) and outcome measures. Examples of outcome 
measures, measurement properties and feasibility aspects for the selection of a core outcome 
measure214 were provided as prompts. Participants were also asked to discuss strategies for 
implementing core outcome measures in trials. In the final plenary session, all groups reconvened and 
a member from each group presented key points from their discussion, which was then summarised by 
the chair of the workshop (C.M.H.). 
All breakout and plenary discussions were audio-taped and transcribed. The transcripts were entered 
into HyperRESEARCH (ResearchWare Inc. United States; Version 3.0.) to facilitate coding and data 
analysis. From the transcripts, A.K.V. reviewed and analysed participants’ comments and suggestions 
regarding the development and implementation of a core outcome measure for vascular access in HD. 
Following the workshop, all participants and contributors received a draft workshop report to provide 
feedback within a two-week timeframe. Additional comments were integrated into the final report. 
9.6 Summary of workshop discussion 
Overall, we identified five themes from the discussion: 1) capturing the broad applicability of function; 
2) emphasising experiential relevance and severity; 3) demonstrating feasibility of implementation; 4) 
ensuring robustness and validity; and 5) integrating patients’ values and preferences. Illustrative 
quotations for each theme are shown in Table 9-1 and contributions from breakout groups to the 
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respective themes are listed in  Supplementary Item S9- 2 of Appendix D. Possible outcome measures 
discussed during the workshop are provided in Table 9-2 and recommendations of the consensus 
workshop are summarised in Table 9-3. 
Table 9-1: Selected quotations from the workshop discussions on the identification and 
implementation of a vascular access core outcome measure in haemodialysis 
Theme Quotations 
Capturing the 
broad 
applicability of 
function 
Applicable to all access types 
I was just going to say function is a good one, because it has to apply to all types of 
access, which function clearly does.  It has to be important.  It was important in the 
survey. H2 
Cannulation would be a very important outcome to assess when we get to vascular 
access specific trials, so some trials that only address fistulas and grafts where 
cannulation actually plays an important and crucial role.  If we look at all dialysis trials, 
where catheters don’t have to be cannulated, for example, that may be the reason why 
this didn’t come up as the core outcome, the most important one. H2  
If you look at the three access types that are used for chronic dialysis, function is the 
only one that’s applicable overwhelmingly to all, because we know that infection is 
most prominent in catheters, minimal in fistulas, and then somewhere in between for 
grafts but not to the degree that it is for catheters.  So focusing on infection we’ll 
completely miss the boat if we’re looking at the full scope of access. H5 
Multidisciplinary involvement 
And when I look at function, it’s not just the surgeon that puts it in.  It’s not just the 
patient.  It’s the entire team.  It’s the doctor, it’s the nurse, it’s the technician; it’s 
everybody that’s involved in that patient’s care.  So I want to make sure our prime 
measure gives us a chance to look at the entire team that’s taking care of that patient. 
H5 
Contributing to quality of life 
Keeping the access open is giving you a better quality of life and why wouldn’t they 
want to do that. P1 
That [a functioning access] means to me that I’m getting good health. P1 
What the patients brought up which is very crucial is this concept in terms of function, 
the maintenance of life versus quality of life so you could have poor function but it’s 
maintaining life but, I think, you need to balance that with quality of life and how many 
interventions were they having? H1 
I have one word and that's just the health of the patient (…)That's the most important 
thing, the function of that fistula. P4 
 Capturing important multidimensional aspects 
The intervention is also incorporated into interfering with activity, so having that extra 
visit to the hospital was part of interfering with your daily life and activity so it, kind of, 
also got incorporated into that. H1  
When you’re talking about function, it incorporates to some degree cannulation and 
many other aspects of function, so as a global aggregate outcome measure; it captures 
elements of a number of things that are quite important to everybody. H2 
Preventing subsequent consequences 
The first thing that you want is for the fistula to function properly because if it doesn't 
function properly you're in pain and then you have to go get it redone again and you 
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Theme Quotations 
have to have that catheter stuck back in you and then you run the risk of infection with 
a catheter in. P4 
I'm not surprised that function and infection are the top two because when you have 
issues in those two areas it leads to increased events like hospitalisations, more 
interaction with the health care facility than you might want, more procedures. H4 
[Function is the most important outcome] just because of problems that arise as far as 
the function is concerned. P5 
Emphasizing 
experiential 
relevance and 
severity 
Variability in experiences 
The priority, because of the experience I’ve had from August until now, has been the 
cannulation, the needling, and to me, the experience has not been good. P2 
The issue was for people who hadn’t experienced aneurysms and other things, how do 
you relate to that?  (…) So it’s hard to rate something from one to nine if you haven’t 
experienced it, or didn’t have any sense of how it could happen. P3 
If you don't know what Steal is you might not rank it very high, but I think it has a 
terrible outcome which is very important to avoid. H4 
I just wondered about Steal: if people are thinking of a mild form then it will get a very 
different result.  When I think of Steal I think of severe Steal. H4 
Fear driven prioritisation 
(…) Those needles are a fear thing. P2 
There's a lot of anxiety around potential for infection. C3 
He, as my caregiver, worries more that he’d be responsible for infection.  And I worry 
less about that, I worry more about explosions [rupture of an aneurysm].  Well those 
sorts of things just scare me. P3 
Demonstrating 
feasibility for 
implementation 
Simple requiring minimal resources 
In terms of function I would say blood flow rates, because it’s easily measurable, 
everyone understands it, and you can track it very easily. H3 
I wouldn’t use blood flow rate at all. I would just use a simple definition about being 
able to use the access for dialysis without interruption or problems because it’s simple, 
it covers both, catheters, grafts and fistulas. H3 
One of the keys is simplicity.  If it’s very simple, then both patients can measure it 
easily, can relate to it, and also the units can document very simply as well.  A good 
[counter-] example is measuring blood flow. It requires specialised equipment. It’s out 
for home dialysis, unless you pay for someone to go there and do it.  A lot of units can't 
afford to buy that machine, and don’t use it.  Something that’s simple, easy to use, is 
key. H3 
We think about this in the context of trials and studies and ease of measurement in its 
study, but the extension of that is that we’ll often use for quality of improvement and 
accountability, so how are we doing in day to day life?  And that measure has to be 
something that is easily implementable in everyday practice and easy to measure so you 
don’t end up waiting to come off the machine any longer than you need to. H2 
Pragmatic definition 
(…) Having a robustly pragmatic definition is much, much easier and perhaps more 
meaningful than a certain number of cannulations or a certain number of mls per minute 
flow related definition of access function. H4 
Whether or not you can do somebody’s standard dialysis, or standard prescribed dialysis 
treatment using the access or not. That’s a good definition that would fit all access types, 
and really just encompass the functionality aspect. H3 
What do you do about the marginal one that is still going but has extended dialysis 
duration to reduce flow rates?  As a clinical pragmatist I would say that's functional 
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because we're getting by and we've chosen to accept that because the balance is - that's 
a better outcome than sticking a line back in. That's a very pragmatic definition. H4 
You have to be clear about what you consider to be the prescribed dialysis and you have 
to be clear on what’s an intervention, and whether you have an intervention or not, and 
that has to be recorded in order to answer that question. It’s  a great idea, to have a tick 
box, and in itself, it’s still an easy way to assess an outcome. It doesn’t take any extra 
equipment. H2 
Demonstrating 
feasibility for 
implementation 
(continued) 
Practical across settings internationally 
Across cultures, we do consider adequate dialysis differently. By leaving it at the 
prescribed dialysis, you leave it up to the actual centre or country. H2 
In the eyes of the clinician and the patient, functioning enough to not have to intervene?  
And that’s going to be a little bit different for different people around the world. H5 
Some units operate, they like 400 ml/min flows.  There are units in, particularly Asia, 
where they're quite happy with 200 ml/min. H5 
What if we’re trying to do a universal measure and a lot of places don’t use ultrasound? 
H5 
Flexibility for different trial settings 
It's nice to have one core coherent definition, but for trials evaluating early versus late 
outcomes there's going to be the need for some flexibility because if you're looking at 
trials of early patency for fistulas that by their nature are not going to be used for a 
number of months it may not be practical to have what I would love to see, which is a 
truly pragmatic measure, something along the lines of a fistula is functional if and only 
if it can be used for the purpose for which it was made (…).H4 
For a pragmatic trial a definition that is more real world is fine.  But for a more regulated 
trial then you need something that is FDA approved or whatever and so maybe we 
should be agreeing that it should be an adequate HD and then decide, depending on the 
kind of trial that you're doing, you have to have flexibility.  One size will not fit all for 
trials. H4 
Ensuring 
robustness and 
validity 
Responsiveness to changes over time 
Responsiveness is important. When we’re taking care of our patients and the vascular 
access is worse, and we look at the blood flow and it can only go to 200ml/min, there's 
a very big chance that fistula is failing. H5 
Reliability of the outcome measure 
The only time it (the access blood flow) changes it's a bad stick or a bad cannulation or 
I'm moving around. P4 
I have an issue with flow, because it depends how the needles go in.  It’s not 
reproducible, it’s not reliable; it’s different for different people. H5 
Right, and I don’t agree with the blood flow thing either.  Because I can go and have 
one blood flow on Monday, and not get a good blood flow on Wednesday, and go back 
on Friday.  And I don’t agree with the Kt/V either, only because of the fact that you can 
drop so much and still get enough clearance that you're okay. P5 
 
 
 
Integrating 
patients’ values 
and preferences 
 
Meaningful and important to patients 
Let me ask you; do you care more about how much blood is flowing through that based 
on our machine measurement?  Or how many times you have to go get a procedure 
done?  Which one of those things really matter? H2 - Those doggone procedures (…). 
P2 
We do measure function in a whole pile of different ways.  Time to revision, their 
primary patency, delayed assisted primary, all the various technique definitions.  But 
the most important thing, from a patient’s point of view is how long you actually go 
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Theme Quotations 
 
 
 
 
Integrating 
patients’ values 
and preferences 
(continued) 
without having to do anything with it.  Uninterrupted dialysis where you haven’t had to 
revise, you haven’t had to de-clot it. That’s the most important thing. H5 
What is the most meaningful and important to you when having those discussions about 
treatment? H4 - Time period between interventions. P4 
Informed by shared decision-making 
We have a combined clinician/patient reported outcome; the patient is reporting that 
their access is fine, the clinician is reporting that the access is fine. H4 
Even if the blood flow rate has decreased, but if the doctors and the patient agreed to 
not do intervention but increase the time so that the clearance is better and still avoid 
hospitalisation or intervention that would be a good outcome too. If the patient does not 
want to increase their time then having an intervention would be fine. H4 
(…) At that trial end point there is a collaborative decision between the physician and 
the patients about whether during that period of time and during the period that the 
intervention has been given they agree that the fistula functioned or not and as a 
clinician/patient reported outcome. H4  
The prescription is a matter of practice between the physician and the patient (…) we 
shouldn’t judge what’s in that prescription.H1 
Abbreviations: H - health professional; P – patient; C – caregivers; PL - plenary (summary from individual break out 
discussion groups); number indicated (e.g. H1) refers to the Group ID (1 – 5). 
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Table 9-2: Proposed outcome measures for function 
Proposed outcome measure Advantages Disadvantages 
Proposed metric(s) / 
method of aggregation 
Uninterrupted use of the vascular 
access for haemodialysis without need 
for any access intervention / 
procedures  
Simple to collect as part of routine 
practice 
Patient-centred 
Standardisation of indication for interventions  
Time to event (first/next 
procedure)  
Rate 
Relative change in access blood flow 
Responsive to change 
Can be tracked easily (if 
available) 
Expensive 
May not be available across different settings / 
internationally 
Limited reliability 
Prone to measurement errors  
Not patient-centred 
Time consuming 
Standardisation of measurement challenging 
(expertise, equipment)   
Percentage change over a 
specific time period 
Ability to receive two needle 
cannulation to achieve prescribed 
dialysis without need for any access 
interventions / procedures 
Incorporates cannulation as an 
important aspect of the usability 
of an access for dialysis 
Patient-centred 
Two needle cannulation not applicable to 
catheters 
Standardization of indication for interventions 
Standardisation of what the prescribed dose 
should be to be considered “adequate dialysis”  
Proportion of times within a 
month 
Ability to receive the prescribed 
dialysis  
Simple 
Feasible across different settings 
and internationally  
Inexpensive 
Pragmatic 
Standardisation of what the prescribed dose 
should be to be considered “adequate dialysis”  
Does not capture “at what price” (i.e. need for 
interventions) the access is usable for dialysis  
Proportion of times within a 
month 
Time to event 
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Capturing the broad relevance of function 
Applicable to all access types  
Function was confirmed by workshop participants to be the most important vascular access 
outcome, reflecting the interim results of the international survey. Participants emphasised that 
access function was equally relevant to all access types (i.e. AVF, AVG, and CVC) and 
contributed greatly to the success of HD. In comparison, although infection was commonly 
encountered in catheters, it was less so in AVG and AVF. Therefore, as one health professional 
put it, “by focusing on infection we will completely miss the boat if we are looking at the full 
scope of access”. Similarly, although cannulation problems were considered a very important 
outcome by patients and health professionals, this applied only to AVFs and AVGs and was 
therefore deemed unsuitable as a core outcome. Participants suggested that cannulation 
problems could be a core outcome specifically for trials on arteriovenous access.  
Multidisciplinary involvement  
The involvement of a multidisciplinary team in establishing and maintaining a functioning 
access was identified as another reason for prioritising function as the core outcome. An 
outcome that captured the result of a multidisciplinary team effort, such as the process and 
quality of care of patients requiring HD, was expected to provide valuable information beyond 
the effect of an intervention. As one health professional observed, “it’s not just the surgeon 
that puts it in.  It’s not just the patient.  It’s the entire team.  It’s the doctor, it’s the nurse, it’s 
the technician; it’s everybody that’s involved with that patient’s care. So, I want to make sure 
our prime measure gives us a chance to look at the entire team that’s taking care of that 
patient”. 
Contributing to quality of life  
There was general agreement that a functioning access enables adequate HD that in turn, affects 
patients’ quality of life. Participants drew a distinction between “maintenance of life” versus 
“quality of life” because a malfunctioning access may maintain life, but have a detrimental 
impact on the quality of life due to the need for recurrent interventions and interruption of 
treatments.  
Capturing important multidimensional aspects  
Function incorporated various important impacts on health, well-being and quality of care. For 
example, problems with access function could interfere with daily life due to extra hospital 
visits for necessary corrective or maintenance procedures or for alternate access 
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creation/insertion in case of access failure. Given the potential overlap of function with other 
outcomes, investigators conducting trials with a specific focus on access function may elect to 
untangle the multidimensionality of access function by measuring contributing outcomes 
separately (i.e. type of interventions, needling problems, access replacement, dialysis adequacy 
etc.).  
Preventing subsequent consequences  
Some participants considered function as a “fundamental outcome” that triggered a cascading 
effect on other outcomes; for instance, as one patient described, “if it (the access) doesn't 
function properly you're in pain and then you have to go get it redone again and you have to 
have that catheter stuck back in you and then you run the risk of infection with a catheter in”. 
An intervention that improved the function of a vascular access would therefore, prevent 
further potential complications.   
Emphasising experiential relevance and severity 
Variability in experiences  
Some patients emphasised the importance of cannulation problems, particularly if they had 
experienced a complication. On the other hand, participants acknowledged that some outcomes 
could be regarded to be less important if patients had not experienced the outcome (e.g. severe 
steal syndrome). However, function was recognised as the most important outcome by all 
stakeholders and could be comprehended by all patients.  
Fear-driven prioritisation  
Fear and anxiety were identified as main drivers for prioritising outcomes involving invasive 
and severe complications, such as needling problems, aneurysms or infection. In the interim 
survey results, the only outcome that was rated higher by patients/caregivers than by health 
professionals was aneurysm/pseudoaneurysm and workshop participants suggested that the 
fear of potentially life-threatening bleeding complications may explain this difference.  
Demonstrable feasibility of implementation  
Simple, requiring minimal resources  
For an outcome measure to be implemented across all HD trials, “it needed to be easy to 
measure, readily implemented in everyday practice, and for the purpose of quality 
improvement, and something that wouldn’t be a burden on investigators, and could very easily 
be measured during studies” (plenary discussion, group 2). Participants supported a simple 
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definition such as “ability to use the access for dialysis without the need for interventions” or 
“ability to receive the prescribed dialysis”. While a physician suggested access blood flow to 
be “easily measurable, everyone understands it, and you can track it very easily”, patients and 
the majority of health professionals thought it may be complicated and cumbersome to 
measure, costly, unreliable and difficult to interpret.   
Pragmatic definition  
Participants supported a pragmatic definition for the core outcome that was not too detailed 
and would be applicable to different practice settings and access types. A pragmatic definition 
was expected to capture real-world practice patterns by allowing clinicians and patients to 
decide whether the conditions of the outcome measure such as “prescribed dialysis” were 
fulfilled. However, some were concerned that using a pragmatic definition would consequently 
result in inconsistencies in how the outcome was measured. As voiced by a health professional, 
“but you will see a different doctor the next day who might make a different recommendation, 
and that's what worries me, is the inconsistencies”. Participants concluded that, in the words 
of a health professional, “the definition should be clear, so that even though the concept is 
simple, everybody interprets it the same way”. A proposed solution to overcome the risk of 
inconsistency in outcome reporting was to provide a “tick box” with step-wise instructions on 
how to collect data for the core outcome, as expressed by a health professional, “because as 
everybody knows the devil is in the detail when it comes down to actually measuring it”. 
Practicality across settings internationally  
Participants remarked on the challenges arising from differences in practices and available 
resources across different countries, cultures and practice settings. They considered the 
variability in using an outcome measure for function such as “the ability to receive adequate 
dialysis without the need for interventions” as the threshold to intervene on an access may 
differ between patients and clinicians, and more broadly across centres and regions: “Across 
cultures, we do consider adequate dialysis differently”, observed a health professional, “by 
leaving it at the prescribed dialysis, you leave it up to the actual centre or country”. Thus, the 
differences in defining sufficient flow rates, dialysis adequacy or indication for access 
intervention could be defined locally to allow for differences in practice and global 
implementation.   
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Flexibility for different trial settings  
Some participants mentioned that there should be some flexibility to the outcome measure for 
it to be applicable to different trial settings such as real-life pragmatic trials versus more 
regulated, explanatory trials and trials of short- versus long-term follow-up duration because, 
as expressed by a health professional, “one size will not fit all trials”. For example, “ability to 
use the access for HD” as an outcome measure for function may not be applicable to trials that 
investigated the short-term outcomes of a surgical procedure one month after fistula creation, 
because the fistula is not expected to be usable for dialysis at that time. Participants argued that 
a trial with a follow-up time that was too short to assess the function of an access may not 
address outcomes that are relevant to clinicians and patients. Suggested solutions included 
sufficient flexibility in the outcome measure to suit different trial settings or a paradigm shift 
to promote outcome measures that really matter, as voiced by a health professional: “… 
regardless of ultrasound flow at one month, it's whether they (access) work ultimately”.  
Ensuring robustness and validity 
Responsiveness to changes over time  
To show the potential efficacy of an intervention, it was considered important for the outcome 
measure to be responsive to changes over time. Otherwise, a favourable effect on the vascular 
access could be missed. While the majority of participants considered “the need for 
interventions” a sensitive and meaningful measure of change in access function, others argued 
that “access blood flow” measures may be more responsive to change over time.  
Reliability of the outcome measure 
Participants questioned the reliability of access blood flow recordings as a measure of access 
function because flow rates could be decreased due to malpositioning of the dialysis needles 
or haemodynamic changes rather than a true access-related problem (e.g. thrombosis or 
stenosis). Similarly, the reliability of surrogate markers of adequate dialysis were challenged. 
As one patient explained, “I don’t agree with the blood flow thing either because I can go and 
have one blood flow on Monday, and not get a good blood flow on Wednesday, and go back 
on Friday.  And I don’t agree with the Kt/V either, only because of the fact that you can drop 
so much and still get enough clearance that you're okay”.  
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Integrating patients’ values and preferences 
Meaningful and important to patients 
Access function meant the ability to undergo uninterrupted dialysis without the need for access 
procedures, which was critically important for patients and caregivers. In comparison, access 
flow and surrogate measures of dialysis adequacy such as Kt/V were considered less relevant. 
Some patients described their access function by the number of interventions, or the time frame 
they were able to dialyse without the need for procedures, highlighting the importance of access 
procedures (i.e. angioplasty, thrombectomy, revisions or access replacement) to define access 
function. Defining an outcome measure that was meaningful to all end-users was expected to 
enhance the broad engagement of clinicians and patients and global implementation of the core 
outcome across different clinical and research settings.     
Informed by shared decision-making  
There was detailed discussion about how to further define specific terms used to describe 
access function, such as the ability to receive “prescribed” dialysis without the “need for 
interventions”. “The prescription is a matter of practice between the physician and the 
patient”, argued one health professional; this attitude was also expressed by another health 
professional, “…even if the blood flow rate has decreased, but if the doctors and the patient 
agreed to not do an intervention, but increase the [dialysis] time so that the clearance is better 
and still avoid hospitalisation or intervention that would be a good outcome too.  It comes 
down to if the patient does not want to increase their time then having an intervention would 
be fine”. It was recommended that the definition should be based on shared-decision making 
between patients and clinicians as one size does not fit all.  
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Table 9-3: Workshop recommendations for selecting, defining and implementing a core 
outcome measure for haemodialysis vascular access 
Reasons for selecting function as the core outcome for vascular access: 
• Relevant to all vascular access types 
• Reflects the most important aspect of a vascular access (e.g. vascular access as the “life line”) 
• Critical for clinical decision making and quality improvement in vascular access care 
• Impacts on patient’s overall well-being 
• Reflects the result of a multidisciplinary effort 
• Captures a broad range of inter-related important outcomes and complications (e.g. cannulation, 
dialysis adequacy, pain, procedures) 
A core outcome measure for function: 
• Should be meaningful and important to patients  
• Requires a pragmatic definition 
• May be based on shared decision making between patient and treating team (e.g. threshold to 
intervene on an access, definition for dialysis prescription) 
• Should be established routine clinical practice across different settings and countries 
• Should not be cumbersome or expensive to measure 
A core outcome measure for function: 
• Should not require additional equipment or training (e.g. to measure access flow) 
• Has to be reliable and responsive with content validity  
• Should include the need for interventions, uninterrupted dialysis, and achievement of prescribed 
dialysis 
Implementation of a core outcome measure requires: 
• To be simple and feasible 
• Clear instructions on how to operationalize the outcome measure in clinical practice 
• Endorsement by trial registrations (such as clinicaltrials.gov) and journal authorship policies 
• Engagement of individual trial groups, societies, the international committee of medical journal 
editors, and renal registries 
• Support and endorsement from regulatory agencies and industry 
• Dissemination of incentives associated with the use of standardized outcome measures (i.e. improve 
quality of comparative research, facilitation of trial registration, quality improvement and clinical 
decision making)  
 
9.7 Discussion 
Access function is highly relevant, important and appropriate as the core outcome for vascular 
access because of its applicability to all access types, impact on quality of life and survival of 
patients, and representation of a multidisciplinary team effort. It encapsulates other important 
aspects of a vascular access such as the ability to cannulate and receive adequate dialysis and 
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has implications on potential complications, such as pain, hospitalisation for access procedures 
or access replacement. Other important outcomes, such as infection, steal syndrome, aneurysms 
and cannulation problems, were deemed unsuitable as core outcomes given their restricted 
applicability to specific access types or fear- and/or experience-driven prioritisation. Although 
workshop participants supported an outcome measure that is simple and applicable across 
different clinical and trial settings, concerns were raised about inconsistent interpretation, 
reproducibility and applicability to trials of short duration (Table 9-2).  
To address the concerns of inconsistencies in defining access function, a pragmatic “patient-
clinician-reported” outcome was suggested that would be based on the shared decision-making 
between clinicians and patients, which takes into account differences in clinical practice within 
units and across countries and cultures. For trials with a follow-up time that is too short to 
measure a core outcome, such as access function, participants argued that, in the context of 
clinical decision making, patients and clinicians want to know whether an intervention impacts 
on outcomes that they consider important and meaningful and, as such, one should question 
the usefulness of trials of very limited duration. The increasing popularity of pragmatic clinical 
trials and registry-based randomised clinical trials may further overcome the concern of short 
follow-up times247-251.   
Workshop participants and contributors strongly supported an outcome measure that is relevant 
and meaningful to patients with ESKD to ensure that research in this area addresses outcomes 
that matter to those who are ultimately affected and in need of HD. Patients advocated for 
function to be measured as the ability to receive uninterrupted and adequate dialysis without 
the need for interventions rather than using surrogate markers, such as access blood flow or 
Kt/V. It was considered important to involve patients as partners during all stages in developing 
core outcome measures which is in line with recent recommendations from a recent Outcome 
Measures in Rheumatology (OMERACT)252. The Dialysis Vascular Access group of the 
American Society of Nephrology KHI recently released recommendations for standardised 
clinical trial endpoints tailored to the different types of vascular access and time points of their 
life cycle. The SONG-HD Vascular Access Initiative complements this project by identifying 
a core outcome measure for vascular access that is meaningful to patients and clinicians and 
feasible to be reported consistently across all trials in HD131-133.  
Recommendations from this workshop reflect the consensus of a broad range of international 
stakeholders including patients and caregivers. We acknowledge that most participants were 
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from high-income countries and only patients residing locally in Chicago could participate due 
to limited resources to support travel. However, similar perspectives have been documented 
among patients in other countries209,210,231, suggesting that our findings are broadly 
transferable.  
Specific outcome measures that were proposed and discussed during the workshop (Table 9-2) 
will now be assessed taking into consideration established measurement properties and 
feasibility aspects214 and a core outcome measure for access function will be selected  and 
piloted in different clinical settings to ensure it fulfils the OMERACT criteria of discrimination 
(responsiveness to change and reliability), truth (validity), and feasilbility136, and implemented 
prospectively in clinical trials. The recommendations from this workshop (Table 9-3) will be 
integrated into the finalisation of the core outcome measure for HD vascular access and should 
facilitate better understanding, endorsement and implementation of core outcome measures 
into HD trials and other forms of research. Currently, vascular access outcomes are reported in 
more than 1400 different ways178. Reporting vascular access function consistently across trials 
will improve comparison of the effectiveness of interventions across trials, provide information 
on the performance of vascular access function in different clinical settings, and deliver a useful 
quality improvement tool. Ultimately, this may strengthen the value of trials for decision-
making based on vascular access function – an outcome that is critically important and relevant 
to patients, caregivers, and health professionals. We believe that core outcomes for HD that are 
important to patients and clinicians will optimise shared-decision making and ultimately, lead 
to better patient outcomes. 
9.8 Chapter summary 
This international consensus workshop with patients, caregivers, health professionals, 
researchers, policy makers, regulatory bodies and industry representatives underpins the 
importance of vascular access function in research and clinical practice. Vascular access 
function was deemed suitable as a core outcome for HD trials based on its broad applicability 
to all three vascular access types (i.e. CVC, AVF and AVG), its impact on quantity and quality 
of life, the encompassment of a multidisciplinary team to facilitate and maintain a functioning 
access, and the close interrelatedness with other important outcomes. A key determinant of a 
functioning access for many patients and health professionals was whether a vascular access 
provided the prescribed HD without needing any additional interventions or procedures. Given 
the importance of vascular access interventions for patients but also from a health economic 
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view point, vascular access function would be best measured by the rate of interventions 
required to enable and maintain the use of a vascular access for HD. This would be a pragmatic, 
yet meaningful and truthful core outcome definition and fulfil the key measurement properties 
and feasibility aspects outlined by Prinsen et al.214. An international validation study will be 
conducted to assess the feasibility and reliability of the proposed core outcome measure to be 
measured across different clinical settings and countries to ensure successful global 
implementation in future trials. The following chapter will provide a brief outline of this 
validation study.  
 203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 10   
  Discussion and future directions   
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10.1 Chapter overview 
The overarching goal of this thesis was to explore strategies to improve vascular access 
outcomes for patients requiring HD. The two areas examined in this thesis were: i) the use of 
fish oil and aspirin to reduce arteriovenous access failure, and (ii) identification of vascular 
access outcomes that are most important to patients, caregivers and health professionals to 
improve the relevance, meaningfulness and reliability of future research in HD. This chapter 
summarises the key findings from this body of work. The studies within the thesis are critically 
appraised. Future directions and implications for clinical practice arising from this research are 
described, highlighting how this body of work has contributed to the field of Nephrology. 
10.2 Summary of key findings 
Patients in need of HD depend on a long-lasting, reliable vascular access as their life-line. 
While a native AVF lasts the longest, its early course is often complicated by thrombosis and 
failure to mature into a usable access for HD. For patients, AVF failure often means additional 
vascular access interventions including insertion of a temporary CVC until a more durable 
arteriovenous access can be (re-)established.  Vascular access complications are considered a 
critically important research priority for patients and health professionals and effective 
strategies to improve these outcomes are urgently needed.  
Chapter 1 described the complex and incompletely understood pathology and pathophysiology 
of arteriovenous access failure and outlined multiple treatment targets to optimise vascular 
remodelling and reduce neointimal hyperplasia and early thrombosis. The biological rationale 
for using systemic medical therapies, including antiplatelet agents, omega-3 PUFAs, statins, 
ACEI and ARB to prevent arteriovenous access failure, was outlined. Clinical trial evidence to 
support the routine use of these agents was limited due to the inconsistent use of vascular access 
outcome definitions and reporting of predominantly short-term outcomes that may have been 
of limited importance to end-users including patients and clinicians. Antiplatelet agents may 
have been effective in reducing early AVF thrombosis and patency loss64 and omega-3 PUFA 
may have reduced the rate of thrombosis, patency loss and need for AVG interventions93. 
However, the effect of omega-3 PUFA supplementation on AVF outcomes has not been 
explored and long-term effects of antiplatelet therapies on AVF remain uncertain. PART 1 of 
this thesis therefore aimed to determine whether fish oil or aspirin use is effective in improving 
outcomes of newly created AVFs beyond the early post-operative period. PART 2 of this thesis 
aimed to identify what vascular access outcomes are most important to patients and health 
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professionals in order to improve the consistency, reliability and relevance of research in HD 
vascular access.  
PART 1 – Systemic medical interventions to prevent arteriovenous access failure 
The FAVOURED study was an international, double-blinded, randomised, placebo-controlled 
trial that commenced recruitment in 2008. This investigator-initiated trial examined whether 
three months of omega-3 PUFA supplementation either alone or in combination with low-dose 
aspirin effectively reduced the risk of AVF failure within 12 months of surgery in patients with 
stage 4 and 5 chronic kidney disease. Publication of new evidence72 and a high screening failure 
rate due to prevalent aspirin usage prompted an updated trial design in 2009. Firstly, the 
primary outcome ‘early thrombosis’ at 3 months following AVF creation was broadened to a 
more clinically relevant outcome of ‘AVF failure’: a composite of thrombosis, AVF 
abandonment and cannulation failure at 12 months. Secondly, participants unable to cease 
using aspirin could be enrolled and randomised to omega-3 PUFAs or placebo, as outlined in 
Chapter 2. Chapter 3 showed that these protocol modifications resulted in successful 
recruitment of a more representative study cohort with an increased prevalence of 
comorbidities compared to the original study cohort.  Additional inclusion of participants from 
Malaysia enhanced the diversity of the study cohort and thus generalisability. These 
participants were generally younger with lower cardiovascular burden but more often had 
diabetes mellitus compared to participants from ANZ and the UK. Comparison to 
contemporary national registry data and clinical trial populations revealed that FAVOURED 
study participants were overall similar, although were generally younger with a lower 
prevalence of ischaemic heart disease. This was likely attributable to the exclusion of patients 
taking antiplatelet agents or anticoagulants and may have impacted on the frequency of AVF 
failure. Chapter 4 described the main outcomes of the FAVOURED trial: 12 weeks of omega-
3 PUFA supplementation did not reduce the proportion of AVF failure compared to placebo 
(47% versus 47%, RR adjusted for aspirin use 1.03, 95% CI 0.86-1.23) or its outcome 
components. Low-dose aspirin was similarly ineffective. However, omega-3 PUFAs were 
effective in reducing AVF intervention rates, driven by a significant relative reduction in rescue 
interventions for thrombosis by 47%. Similarly, low-dose aspirin significantly reduced rescue 
intervention rates by 55%. Neither omega-3 PUFAs nor aspirin reduced the frequency or 
duration of CVC requirements compared to placebo, nor did they have significant impacts on 
times to first AVF intervention, primary patency loss, AVF abandonment, or successful 
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cannulation, as outlined in Chapter 5. Of note, AVF complications were common: within the 
first 12 months of AVF creation; 23% thrombosed, 20% were abandoned, and 40% were unable 
to be cannulated reliably once considered usable for HD. Furthermore, 24% of study 
participants required at least one AVF procedure, 50% required at least one CVC for a median 
duration of 100 days, and 35% of those on dialysis by 6 months were unable to use the study 
AVF for HD.  
Chapter 6 included the FAVOURED trial results in a meta-analysis of RCTs to determine the 
efficacy and safety of omega-3 PUFA supplementation to prevent complications of AVFs and 
AVGs using standardised outcome definitions127. Based on meta-analysis of five eligible RCTs 
(833 participants) comparing omega-3 PUFA supplementation with placebo, moderate 
certainty evidence showed that omega-3 PUFAs reduced the risk of primary patency loss by 
19%. In other words, assuming an event rate of 40% within 12 months, treatment of 100 
patients with omega-3 PUFA might be expected to prevent 8 patients experiencing primary 
patency loss within 12 months. Low to very low certainty evidence suggested that omega-3 
PUFA supplementation had little or no effect on other vascular access outcomes or mortality 
and uncertain effects on bleeding risk and gastrointestinal side-effects.  
PART 2 – Establishing a standardised core vascular access outcome for research in HD 
To increase the quality and relevance of trial evidence to guide patient-centred care, it is 
imperative to understand and identify what outcomes are important and relevant to patients. 
Focusing on outcomes that matter to patients can help the shared decision-making process 
between patients and their clinicians. It can also improve care provision and outcomes by 
encouraging adherence to treatment and active patient engagement253. The global SONG 
initiative was launched in 2014 to identify research priorities based on the shared opinions of 
patients, their caregivers and health professionals. For HD, the most critically important 
outcome domains included vascular access along with fatigue, cardiovascular disease and 
mortality11. This core outcome set was established through a robust evidence- and consensus-
based process involving nearly 1,400 patients, caregivers and health professionals from 73 
countries9,11,142-144.  
The second part of this thesis described the identification and establishment of the most 
important outcome measure for vascular access for patients, caregivers and health professionals 
as part of the SONG initiative. This multistep process started with a systematic review to 
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identify the scope and consistency of vascular access outcomes and measures reported in 
contemporary RCTs in HD (Chapter 7). Based on 1,426 access-related outcome measures from 
168 contemporary RCTs, 23 different vascular access outcomes were identified. Vascular 
access function was the most commonly reported outcome, followed by infection and 
maturation. Outcome measures were very heterogeneous. Function was assessed in 489 
different ways, infection in 136 different ways and maturation in 44 different ways and all 
outcomes were assessed at various time points. This review not only highlighted the substantial 
heterogeneity of outcomes but also the infrequent use of previously published standardised 
outcome definitions and limited assessment of patient-reported outcomes, such as pain or 
quality of life. As demonstrated in rheumatology through the OMERACT initiative, more 
consistent outcome reporting can be achieved by implementing “core outcome sets” that 
comprise standardised outcome measures of critical importance to all relevant stakeholders 
including patients136,214,215.  
To identify the most important vascular access outcome, an international survey was designed 
and described in Chapter 8. Twelve outcomes, derived from the aforementioned systematic 
review, multidisciplinary expert panel discussions and patient inputs, were rated and ranked. 
The survey was completed by 873 participants, including 224 (26%) patients/caregivers and 
649 (74%) health professionals, from 58 countries. Vascular access function was considered 
the most important outcome by patients/caregivers and health professionals, followed by 
infection. Participants prioritised vascular access function because of its necessity for HD, its 
applicability to all three access types, and the risks of hospitalisation and death associated with 
loss of access function. Infection was considered important based on the frequency and severity 
of debilitation, hospitalisation and death, but was viewed as predominantly being applicable to 
CVCs and potentially avoidable by adherence to best practice.  
Chapter 9 reported on an international consensus workshop that was convened to discuss the 
development of a core outcome measure for vascular access function. This workshop was 
attended by 13 patients/caregivers and 46 health professionals, including clinicians, policy 
makers, industry representatives and researchers. In line with the findings of the systematic 
review and survey, vascular access function was considered the most important and suitable 
core outcome for research in HD. Participants considered the ability to receive prescribed 
dialysis without the need for access interventions a meaningful outcome definition for vascular 
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access function that would fulfil the key measurement properties and feasibility aspects 
outlined by Prinsen et al.214 
Consistent reporting of this core outcome across all future trials in HD would (i) ensure 
research informs clinical practice and policy in a meaningful and reliable way; (ii) improve the 
comparability of treatment effects across trials; (iii) enhance our ability to discover effective 
interventions to improve vascular access function; and, (iv) provide clinicians with a useful 
outcome measure for assessing and improving their practice. 
10.3 Strengths and limitations of this thesis 
PART 1 – The FAVOURED study 
This thesis reports on the first randomised controlled trial to examine the effect of omega-3 
PUFAs and the largest to examine the effect of aspirin on AVF outcomes. This rigorously 
conducted RCT addressed a broad range of clinically meaningful end points to define vascular 
access failure and included participants from diverse health care settings and geographic 
regions. Treatment groups were well balanced with respect to baseline characteristics. 
Treatment adherence was ascertained by a significant increase in erythrocyte omega-3 PUFA 
concentrations in the treatment group.  However, the FAVOURED study had some limitations 
that should be considered. The trial population was younger with less cardiovascular disease 
than anticipated because patients with medical requirements for anti-platelet agents (except 
aspirin post protocol amendment) or anticoagulants were excluded. As cardiovascular disease 
and older age are known predictors of AVF maturation failure30, this may have had an impact 
on the frequency of events and compromised the external validity of the study. The trial 
finished before reaching the planned recruitment target but was able to show that omega-3 
PUFA supplementation was unlikely to reduce the risk of AVF failure by 30%. Considering 
the 95% CI of the primary outcome, results were consistent with, at best, a 14% RR reduction. 
Conversely, the treatment benefits of omega-3 PUFAs in reducing intervention rates might 
have been as low as 16% or as large as 76%. For enhanced precision in treatment estimates, a 
larger study would be required. There were missing data on the primary outcome, mainly 
because patients had not commenced dialysis and therefore could not be assessed for the 
outcome; however, the proportion of missing values was balanced across treatment groups 
(23% for fish oil and placebo; 22% for aspirin and 21% for placebo) and imputation is unlikely 
to have biased the results. An additional 31 participants were excluded from the analysis 
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because they either had no AVF created or died so early that they could not be assessed on any 
outcome. Again, numbers were balanced between treatment groups and bias was considered 
unlikely. Treatment duration was restricted to the first three months following AVF creation 
because it corresponded with the expected duration of physiologic maturation time (i.e. AVF 
flow and vein diameter) and occurrence of early AVF thrombosis37,184. However, it is possible 
that a longer treatment duration may have resulted in delayed benefits on the usability of AVFs. 
Finally, it remains unknown whether the dose of omega-3 PUFA or aspirin was sufficient to 
affect AVF failure. However, the doses of EPA and DHA used in the FAVOURED trial were 
higher than doses used in studies assessing AVG outcomes and studies in patients with chronic 
kidney disease using a comparable dose of fish oil achieved significant reductions in blood 
viscosity, platelet aggregation, and blood pressure consistent with biological effects74,91,168. 
Furthermore, higher doses of aspirin were avoided to minimise the risk of bleeding in a 
population that is already at increased risk of bleeding. The extent of platelet inhibition by low-
dose aspirin was not examined in this study and warrants further investigation in future studies. 
Part 1 of this thesis concluded with a rigorously performed meta-analysis that followed the 
methods outlined by Cochrane, including data extraction and assessments of risks of bias and 
evidence certainty using the GRADE approach by two independent authors. Patient-level data 
analysis was performed where possible to ensure reliable comparison and meta-analysis of 
outcomes aligned with previously published standardised outcome definitions127. However, the 
small numbers of trials and events resulted in several limitations. Firstly, risk estimates were 
imprecise and the certainty of evidence was low for most outcomes. Secondly, the ability to 
detect a significant treatment effect difference between AVFs and AVGs may have been 
compromised and potential confounding due to differences in patient and vascular access 
characteristics could not be excluded. Thirdly, the small number of trials precluded an adequate 
assessment of publication bias. Fourthly, differences in study designs prohibited a reliable 
assessment of the optimal treatment duration, timing or dose of omega-3 PUFA 
supplementation. Finally, the findings were based on dichotomous outcomes and may not be 
applicable to more sensitive metrics such as rate or time to event.  
PART 2 – The SONG-HD Vascular Access Project 
The SONG-HD vascular access project followed a robust evidence- and consensus-based 
process that involved 3 separate studies with the following key strengths and limitations:  
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1. A systematic review (Chapter 7) providing a detailed analysis of the scope and consistency 
of vascular access outcome measures and of the implementation of previously published 
standardised outcome definitions across a large selection of contemporary HD trials. The 
limitations of this study included the restricted sampling frame (RCTs published since 
January 2011 or ongoing), which may have introduced selection bias. However, including 
older trials and non-RCTs would likely have increased the heterogeneity of outcome 
measures because of less consistency with contemporary outcome definitions. The quality 
or risk of bias of included trials was not assessed, such that it was not possible to evaluate 
the association between the reliability of trial results and the outcomes reported. 
2. An international survey (Chapter 8) that included a diverse and large group of stakeholders 
from 58 countries and a substantial proportion of patients/caregivers. Administering the 
survey in multiple languages allowed for recruitment from countries, such as China and 
Malaysia, that have not been included in previous vascular access surveys210,227,236. The 
large sample size, coupled with quantitative assessments of the absolute and relative 
importance ratings permitted a detailed and robust assessment of the prioritisation of 
vascular access outcomes. Qualitative data analysis gave further insights into the meaning 
of, and reasons for outcome prioritisation by survey participants. The survey was 
administered online to ensure efficient dissemination and minimize data transfer errors, 
which restricted the sampling frame to participants with access to internet and computer 
literacy. This, together with the administration of the survey in only 4 languages, may have 
led to ascertainment bias and restricted generalisability. Differences in patient/caregiver 
experiences with respect to specific access types and their complications may have 
impacted on outcome prioritisation. However, these data were generally not disclosed by 
survey respondents, thereby preventing reliable exploratory analysis of this issue. The 
survey was restricted to the 12 most commonly reported outcomes, however, the option to 
suggest new outcomes ensured that additional important outcomes were not missed. A 
further limitation inherent to all surveys was the potential for response bias, including 
demand bias and neutral or extreme responses.  
3. An international consensus workshop (Chapter 9) brought together a broad range of 
stakeholders, including patients and caregivers, from 12 countries thereby allowing for 
face-to-face discussions regarding the reasons for, and definition of the most important 
vascular access outcome measure. Qualitative analysis of the workshop transcripts enabled 
in-depth understanding of diverse opinions from multiple stakeholder groups and 
consensus on key recommendations for research and clinical practice. Study limitations 
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included restriction of the workshop duration to 2 hours due to competing events. 
Furthermore, most participants were from high-income countries including a large 
proportion of workshop attendees from the USA, and only patients residing locally in 
Chicago could participate due to limited resources to support travel. However, similar 
perspectives have been documented among patients in other countries209,210,231, suggesting 
that study findings are broadly transferable. Finally, only English-speaking participants 
were able to participate in the workshop discussions.  
10.4 Future research directions 
Implementing a core outcome for vascular access in research 
Selecting the right outcomes in research is key to informing policies and clinical practice in a 
meaningful way and thereby reducing research waste. The use of core outcomes can improve 
the consistency and relevance of outcomes in trials. However, without consistent reporting of 
these core outcomes, there is little scope for guideline producers, policy makers, clinicians and 
patients to reap their benefits. Strategies to successfully implement core outcomes in research 
include (i) the engagement of all relevant stakeholders, including patients, in the development 
process; (ii) demonstration of feasibility and validity of proposed core outcomes; and, (iii) 
global dissemination of the reasons for, and type of core outcomes145.  
This thesis has addressed the first point and exemplified how patients and other key 
stakeholders can be involved successfully to prioritise outcomes for vascular access. The 
important next steps include (ii) and (iii) above and the research planning for these steps has 
commenced. Based on the work presented in PART 2 of this thesis and independent assessment 
of key feasibility and measurement properties214 by the SONG vascular access expert working 
group1, the outcome measure for vascular access function has been defined as the need for 
interventions to enable and maintain the use of a vascular access for HD. The feasibility 
and reliability of this outcome measure will now be evaluated in an international multicentre, 
prospective observational study (Appendix E). This study, entitled “Vascular Access outcome 
measure for function: a vaLidation study In haemoDialysis (VALID),” aims to (i) assess the 
feasibility of measuring vascular access function in different HD settings internationally; (ii) 
compare the feasibility of assessing the metric intervention rate versus time to (first) 
intervention; and, (iii) assess the reliability of data collection of vascular access interventions 
(number, types and dates) by clinical staff. VALID includes adult, incident and prevalent HD 
patients from 10 facilities across 6 countries (Australia, Malaysia, China, Canada, US and 
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Europe). Dates and types of access interventions will be collected independently by two 
assessors in each centre via a web-based system (REDcap) over 6 months. Assessor 1 will be 
a clinical staff member (e.g. dialysis nurse) to reflect “real life” conditions. They will only 
extract data required for the vascular access core outcome (i.e. type and date of vascular access 
interventions). Assessor 2, a clinical research assistant, will represent the “gold standard.” They 
will extract the source documents (i.e. procedure notes) and indication for each intervention in 
addition to the date and type of access intervention. Data accuracy will be verified by an 
adjudication committee. Feasibility will be assessed quantitatively (by percentage of data 
completeness, mean duration of data collection, and Likert scale score of feasibility 
questionnaire) and qualitatively (through semi-structured interviews with assessors and 
feasibility questionnaire comments). Study investigators include patients, researchers, vascular 
access surgeons, nurses and nephrologists to ensure broad representation of relevant 
stakeholders in the design and conduct of the study.  
In addition to demonstrating feasibility and robustness of the vascular access core outcome, a 
multipronged approach will be required to socialise the concept and need for core outcomes in 
research and clinical practice. A readily available, clearly defined tool to assess vascular access 
function (e.g. a list of interventions/procedures considered relevant to define vascular access 
function) would facilitate its uptake in clinical practice, renal registries and trials. Once 
validated, all core outcomes established through the SONG initiative will be made publicly 
available on the website (www.songinitiative.org) and registered on the Core Outcome 
Measure in Effectiveness Trials (COMET) database of core outcomes (www.comet-
initiative.org). Dissemination of core outcomes through key stakeholders and organisations 
(i.e. patients, patient organisations, clinicians, professional societies, research/trial registries, 
journals and systematic review organisations, trialists, funders, industry and regulatory bodies) 
will expedite the future uptake of core outcomes134,145. The consistent reporting of vascular 
access function in clinical trials will facilitate the discovery of effective interventions to 
improve vascular access outcomes. 
Further exploration of treatment effects of fish oil and aspirin in a registry-embedded, 
pragmatic RCT 
Implementation of the proposed vascular access core outcome measure for function in renal 
registries would offer a novel approach to investigate treatments to improve vascular access 
outcomes. For example, the potential benefit of fish oil or aspirin in reducing AVF intervention 
rates shown in the FAVOURED trial could be further investigated in a registry-embedded 
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RCT. The Australian and New Zealand Dialysis and Transplant (ANZDATA) registry includes 
annual data on all patients in ANZ who receive renal replacement therapy. Currently, there are 
two studies underway (RESOLVE and BEST Fluids; https://aktn.org.au) using this registry to 
capture data. This pragmatic study design would offer many advantages. Firstly, it would 
reduce data collection burden and associated cost and time. Secondly, it would facilitate 
recruitment of a more representative (“real-life”) study cohort. Thirdly, it would simplify 
selection of “high risk” study populations that may have an increased treatment benefit (e.g. 
patients with previous access interventions or a high cardiovascular disease burden). Finally, it 
would enable recruitment of a larger sample size to increase the precision and certainty of the 
treatment effect size.  
Exploration of mechanistic pathways of AVF failure 
In addition to exploring treatments to improve vascular access function, further research is 
required to improve our understanding of the mechanistic pathway of AVF failure and refine 
the predictability of AVF failure. This will help the development of future treatment targets 
and facilitate optimal vascular access selection. Results from the Haemodialysis Fistula 
Maturation (HFM) study are expected to advance our understanding of anatomical, biological 
and clinical characteristics, as well as processes of care associated with enhanced AVF 
usability254. This study has recruited 602 patients undergoing single-stage AVF surgery in the 
US and already provided information on clinical and post-operative processes of care 
predictors of AVF maturation255,256. Assessment of pre-operative vessel characteristics, 
anaesthetic (e.g. type of anaesthesia), surgical (e.g. surgical experience) and patient 
characteristics (e.g. comorbidities, CVC use) of the FAVOURED trial population will help 
refine the predictability of AVF failure. Comparison of AVF outcomes between FAVOURED 
study participants from ANZ and Malaysia with adjustment of identified predictors of AVF 
may help identify differences in practice patterns, including patient selection, surgical and/or 
cannulation techniques. In addition, a bi-national registry analysis of patient- and centre-level 
predictors of vascular access choice has been designed by the candidate to help identify barriers 
to initiating HD with a functioning arteriovenous access. This study includes 27,123 incident 
HD patients from 61 centres across Australia and New Zealand and results are expected to be 
published mid-2019. 
Given the complexity of AVF failure outlined at the beginning of this thesis, it is unlikely that 
a single intervention will suffice to achieve a clinically meaningful improvement in AVF 
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outcomes. Instead, combining different interventions that target sequential events in the 
pathogenesis of arteriovenous access failure may be more effective257. In particular, the 
combination of interventions that target both the upstream “injury pathways” (e.g. 
haemodynamic changes and vessel injury) and the downstream “response to injury” 
(inflammation, coagulation, proliferation, endothelial dysfunction) might be most effective at 
reducing AVF maturation failure. In this context, it is possible that combining systemic 
approaches, such as omega-3 PUFAs (used as downstream anti-inflammatory, vasodilatory, 
antiproliferative and antiaggregatory therapy) with targeted local therapies that modulate the 
upstream injury (e.g. minimally invasive AVF creation), may be more effective than either 
strategy alone.  
Best vascular access outcomes are likely achieved by optimisation of vascular access choice 
and a multipronged management approach. The former entails a more individualised vascular 
access selection (i.e. “the right access for the right patient at the right time for the right 
purpose”239,258) taking into consideration the patient’s preference and outcome priorities and 
making use of refined prediction tools to better inform the optimal access choice259. The latter 
requires further research and optimisation of integrated care delivery, education, training, 
surgical- and cannulation skills, and surveillance combined with targeted therapies and would 
be best evaluated with innovative adaptive trial designs (e.g. platform trial)260. 
10.5 Contribution to the field of nephrology 
This thesis has contributed to the field of nephrology in several ways. 
First and foremost, this thesis has made a major contribution to closing the gap between 
researchers and end-users (i.e. patients, their caregivers and clinicians). This thesis 
demonstrated that a robust process was used to establish the most critically important vascular 
access outcome for research in HD through comprehensive assessment of currently used 
vascular access outcomes in HD research and global engagement of all relevant stakeholder in 
establishing and defining the core outcome. Working towards a common goal, namely 
improving vascular access function by reducing the rate of interventions required to maintain 
its use for HD, will benefit patients, their treating team and the healthcare system in many 
ways. Used as a clinical performance measure, this core outcome could promote quality 
improvement in patient-centred care delivery. For example, rather than targeting a set 
percentage of AVFs, finding the optimal vascular access with the least anticipated 
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complications including procedures to enable effective and safe HD may serve as more 
individualised, patient-oriented approach238,239. Introduction of vascular access performance 
targets that include a maximum acceptable number of  interventions per access type and a 
maximum acceptable CVC-bacteraemia rate is anticipated to reduce healthcare costs and 
hospitalisations while simultaneously reducing the burden of invasive, often painful and 
anxiety-provoking procedures that are disruptive to patients’ lives8,181.  
Another way in which this thesis has added to the field of nephrology is through building 
evidence for the use of systemic medical therapies to improve vascular access outcomes. While 
neither fish oil nor low-dose aspirin can be recommended for reducing the frequency of AVF 
failure or individual outcome components, including thrombosis, AVF abandonment or 
cannulation failure, secondary outcome analyses suggested a significant benefit in reducing the 
rate of vascular access interventions for thrombosis. In addition, fish oil supplementation can 
be recommended with moderate certainty to reduce primary arteriovenous access patency loss. 
Findings from these studies have already been incorporated in the upcoming KDOQI Clinical 
Practice Guideline for Vascular Access (personal communication with Professor Charmaine 
Lok).  
Another way in which this thesis has added to the field of nephrology is through building 
awareness of the need for consumer engagement to reduce research waste and improve 
outcomes. Via the international SONG initiative (www.songinitiative.org), key stakeholders 
around the globe have been socialised with the concept of core outcomes in nephrology 
including vascular access function. This involved widespread dissemination of findings at 
national and international conferences, workshops and seminars, through publication in 
international peer-reviewed journals, and through dissemination via media (e.g. 
https://www.youtube.com/watch?v=aRvMSFfuYuc, twitter @song_initiative). Furthermore, 
sharing the findings from this research was extended beyond scientific forums to include the 
general public (e.g. Award for 3 Minute Thesis Competition). As a testament of recognition, 
core outcomes for nephrology established via the SONG initiative, including vascular access 
function, have been endorsed by nearly 20 renal societies, networks and service providers 
already (http://songinitiative.org/endorsement/).  
In summary, this thesis has significantly contributed to the field of Nephrology through 
building scientifically robust evidence for interventions to improve vascular access outcomes, 
promoting a paradigm shift by involving patients as partners in research to bridge the gap 
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between research and patient-centred clinical practice, and promoting successful 
implementation through robust evidence establishment and effective dissemination. This 
framework is key to improving patient care delivery and outcomes. 
10.6 Conclusion 
Through the SONG initiative, vascular access function, defined as the rate of interventions 
required to enable and maintain the use of a vascular access for HD, was found to be the most 
important vascular access outcome based on the shared priorities of patients and health 
professionals. Consistent reporting of vascular access function in all HD studies through global 
implementation of the SONG-HD core outcome set will maximize the opportunity to further 
explore and either confirm or refute the possible treatment benefits of fish oil or aspirin in 
improving vascular access function shown in the FAVOURED study. Consistent reporting of 
outcomes will also help the discovery of other effective interventions for improving vascular 
access function in patients receiving dialysis.  
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Appendix A: Supplementary material for Chapter 6  
 Table S6- 1: Search Items  
Database Search Terms 
Database 
EMBASE 
1 Fish Oil/ 
2 Omega 3 Fatty Acid/ 
3 Linolenic Acid/ 
4 Docosahexaenoic Acid/ 
5 Icosapentaenoic Acid/ 
6 ((omega 3 or omega three) adj2 fatty acid*).tw. 
7 (n-3 adj2 fatty acid*).tw. 
8 alpha-linolenic acid*.tw. 
9 docosahexa?noic acid*.tw. 
10 eicosapenta?noic acid*.tw. 
11 or/1-10 
12 Arteriovenous Fistula/ 
13 Kidney Arteriovenous Fistula/ 
14 Arteriovenous Shunt/ 
15 Blood Vessel Graft/ 
16 Blood Vessel Prosthesis/ 
17 Vascular Access/ 
18 (fistula* or graft* or shunt* or AVF or AVG).tw. 
19 access.tw. 
20 or/12-19 
21 Hemodialysis/ 
22 End Stage Renal Disease/ 
23 Renal Replacement Therapy-Dependent Renal Disease/ 
24 Chronic Kidney Disease/ 
25 Chronic Kidney Failure/ 
26 (hemodialysis or haemodialysis).tw. 
27 (kidney failure or kidney disease or renal failure or renal disease).tw. 
28 (CKD or CRD or CKF or CRF or ESKD or ESRD or ESKF or ESRF).tw. 
29 predialysis.tw. 
30 or/21-29 
31 randomized controlled trial/ 
32 crossover procedure/ 
33 double-blind procedure/ 
34 single-blind procedure/ 
35 random$.tw. 
36 factorial$.tw. 
37 (crossover$ or cross-over$).tw. 
38 placebo$.tw. 
39 (double$ adj blind$).tw. 
40 (singl$ adj blind$).tw. 
41 assign$.tw. 
42 allocat$.tw. 
43 or/31-42 
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Database Search Terms 
44 and/11,20,30,43 
MEDLINE 
1 exp Fish Oils/ 
2 fish oil*.tw. 
3 ((omega 3 or omega three) adj2 fatty acid*).tw. 
4 (n-3 adj2 fatty acid*).tw. 
5 alpha-linolenic acid*.tw. 
6 docosahexa?noic acid*.tw. 
7 eicosapenta?noic acid*.tw. 
8 or/1-7 
9 Arteriovenous Fistula/ 
10 Arteriovenous Shunt, Surgical/ 
11 (fistula* or graft* or shunt* or AVF or AVG).tw. 
12 access.tw. 
13 or/9-12 
14 Renal Dialysis/ 
15 Kidney Failure, Chronic/ 
16 (hemodialysis or haemodialysis).tw. 
17 dialysis.tw. 
18 (kidney failure or kidney disease or renal failure or renal disease).tw. 
19 (CKD or CRD or CKF or CRF or ESKD or ESRD or ESKF or ESRF).tw. 
20 predialysis.tw. 
21 or/14-20 
22 and/8,13,21 
23 randomized controlled trial.pt. 
24 controlled clinical trial.pt. 
25 pragmatic clinical trial.pt. 
26 randomized.ab. 
27 placebo.ab. 
28 clinical trials as topic/ 
29 randomly.ab. 
30 (crossover or cross-over).tw. 
31 Cross-over Studies/ 
32 trial.ti. 
33 or/23-32 
34 animals/ not (humans/ and animals/) 
35 33 not 34 
36 and/22,35 
CENTRAL 
1 (fish next oil*):ti,ab,kw   
2 (("omega 3") near/2 (fatty next acid*)):ti,ab,kw   
3 (("omega three") near/2 (fatty next acid*)):ti,ab,kw   
4 (n-3 near/2 fatty acid*):ti,ab,kw   
5 (alpha-linolenic next acid*):ti,ab,kw   
6 (docosahexa*noic next acid*):ti,ab,kw   
7 (eicosapenta*noic next acid*):ti,ab,kw   
8 {or #1-#7}  
9 "arteriovenous fistula":ti,ab,kw   
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Database Search Terms 
10 "arteriovenous shunt":ti,ab,kw   
11 (fistula* or graft or grafts or shunt or shunts or AVF or AVG):ti,ab   
12 "vascular access":ti,ab,kw  
13 {or #9-#12} 
14 dialysis:ti,ab,kw   
15 h*emodialysis:ti,ab,kw   
16 ("kidney failure" or "kidney disease" or "renal failure" or "renal 
disease"):ti,ab,kw  
17 (CKD or CRD or CKF or CRF or ESKD or ESRD or ESKF or 
ESRF):ti,ab,kw  
18 predialysis:ti,ab,kw   
19 {or #14-#18} (Word variations have been searched)  
20 {and #8, #13, #19} in Trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 243 
Table S6- 2 Published primary and secondary outcomes and narrative conclusions reported in 
included studies 
Study Primary Outcome Secondary Outcomes Investigator’s conclusion 
Bowden et al 
2007 
Primary graft patency, 
defined as graft 
thrombosis or 
development of venous 
outflow stenosis of 50% 
as confirmed by 
fistulagram that affected 
blood flow, requiring 
angioplasty per unit 
protocol. 
Not specified ‘Although the present 
study did not support n-3 
as a way to increase 
survival time of access 
primary patency, future 
research should study the 
effects of n-3 on primary 
patency, secondary 
patency, and vascular 
access thrombosis.’ 
De Fijter et al 
1995 
Blood pressure  Thrombogenic events, 
red cell deformability, 
plasma viscosity, fatty 
acid composition of 
plasma phospholipids, 
serum fibrinogen 
levels. 
‘Since hypertension and 
shunt occlusion occurred at 
rates comparable to those 
reported in the literature, 
long-term ingestion of fish 
oil does not appear to 
mitigate the side effects of 
low and slow dose 
rHuEPO’. 
Diskin et al 
1990 
Outflow stenosis Metabolic (glucose, 
urea, creatinine, 
cholesterol), hepatic 
(SGOT, LDH, 
Albumin), and 
haematological 
parameters (viscosity, 
coagulation 
parameters, blood cell 
count) 
‘We found our study a 
promising beginning that 
suggests outflow stenosis 
and intimal hyperplasia 
may be inhibited by EPA 
which may eventually 
result in improved graft 
patency in a larger study.’ 
Irish et al 
2017 
‘AVF access failure’ at 12 
months after fistula 
creation, defined as a 
composite of any of the 
following three outcomes: 
AVF thrombosis, AVF 
abandonment and 
cannulation failurea. 
AVF thrombosis, AVF 
abandonment, 
cannulation failurea, 
bleeding events, 
gastrointestinal side 
effects and severe 
adverse events (death, 
life-threatening events, 
initial or prolonged 
hospitalization, 
disability, important 
medical events). 
‘The proportion of new 
AVFs that failed within 12 
months of surgery was 
nearly 50% and was not 
reduced by 12 weeks of 
fish oil 
supplementation…’ 
Lok et al 
2012 
The proportion of 
arteriovenous grafts with 
loss of native patency 
Rate (events per 1000 
access-days) and 
proportion of 
‘Among patients with new 
synthetic arteriovenous 
hemodialysis grafts, daily 
 244 
Study Primary Outcome Secondary Outcomes Investigator’s conclusion 
within 12 months. Loss of 
native patency was 
defined as the graft 
having a primary event of 
thrombosis or requiring 
radiological or surgical 
intervention to maintain 
patency following its 
creation. 
arteriovenous graft 
thrombosis and 
radiological or 
surgical interventions, 
the time to each event, 
and cumulative graft 
patency, time to loss 
of native patency 
(primary unassisted 
patency). Cumulative 
arteriovenous graft 
patency (defined as the 
time from graft 
creation to 
unsalvageable graft 
loss), minor and major 
bleeding episodes, 
changes in lipid status 
and blood pressure, 
hospitalizations for 
cardiovascular events, 
and death. 
ingestion of fish oil did not 
decrease the proportion of 
grafts with loss of native 
patency within 12 months. 
However, fish oil showed 
beneficial effects on some 
clinically relevant 
secondary outcomes such 
as graft patency and rates 
of thrombosis and 
corrective interventions, 
while the potential benefits 
of fish oil on 
cardiovascular events 
deserve confirmation in 
future studies.’ 
Schmitz et al 
2002 
Incidence of graft 
thrombosis 
Venous outflow 
pressure, urea kinetics, 
changes in fatty acid 
composition of platelet 
membrane, whole-
blood bleeding time, 
serum lipid profile, 
systemic blood 
pressure 
‘…our study supports a 
novel approach for the 
prevention of dialysis 
access thrombosis… given 
the tolerability and limited 
risk associated with 
supplemental fish oil 
ingestion, we think that 
this strategy will prove 
useful for the prevention of 
access thrombosis.’ 
Abbreviations: AVF – arteriovenous fistula; LDH – lactate dehydrogenase; EPA - Eicosapentaenoic acid;  
rHuEPO – recombinant human erythropoietin; SGOT -  serum glutamic oxaloacetic transaminase. 
aCannulation failure defined as failure to cannulate the study fistula for at least 8 of 12 consecutive dialysis 
sessions during the cannulation assessment period. 
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Table S6- 3: Definitions provided by included studies for outcomes included in the meta-analyses  
Outcome Bowden et al. 
2007 
Diskin et al. 
1990 
Irish et al. 
2016 
Lok et al. 
2012 
Schmitz et al. 
2002 
Primary patency 
loss 
Primary graft 
patency, defined as 
graft thrombosis or 
development of 
venous outflow 
stenosis of 50% that 
affected blood flow 
and required 
angioplasty. 
NR Thrombosis, defined as the 
absence of a thrill or bruit by 
clinical assessment and/or need 
for thrombolysis or 
thrombectomy or surgical or 
radiological revision of 
anastomosis or dilation of 
vein/artery. 
A graft having a primary 
event of thrombosis or 
requiring radiological or 
surgical intervention to 
maintain patency following 
its creation. 
NRd 
Late dialysis 
suitability failure  
 
NR NR Failure to successfully cannulate 
the study AVF during 8 or more 
out of consecutive 12 
haemodialysis sessions during 
the cannulation assessment 
perioda or access abandonment 
by 6 months  
NR NR 
Access 
abandonment 
NR NR No further use or intention to 
intervene on the study AVF. 
Unsalvageable access loss 
despite the assistance of 
radiological or surgical 
assistance. 
NR 
Interventions to 
maintain 
patency or assist 
maturation  
 
NR NR Thrombolysis or surgical 
thrombectomy,  surgical or 
radiological revision of 
anastomosis or dilation of vein/ 
artery, dilatation of central 
venous stenosis, ligation of 
tributaries  
Surgical and radiological 
interventions. Radiological 
intervention that alters the 
morphology or content of the 
vessel or graft e.g. 
angioplasty, thrombolysis, 
stent; i.e., NOT an 
angiogram.  
NR 
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Outcome Bowden et al. 
2007 
Diskin et al. 
1990 
Irish et al. 
2016 
Lok et al. 
2012 
Schmitz et al. 
2002 
Bleeding NR Gastrointesti
nal bleeding 
requiring 
hospitalizatio
n 
Bleeding event (not further 
specified) 
Combination of minorb and 
majorc bleeding episodes  
NR 
Hospitalisation NR Hospitalizati
on due to 
gastrointestin
al bleed 
Initial or prolonged 
hospitalization 
NR NR 
Gastrointestinal 
events 
Gastrointestinal 
distress including 
bloating, gas and a 
“fish” aftertaste 
NR Gastrointestinal events (not 
further specified) 
Gastrointestinal events (gas, 
bloating or a “fishy” 
aftertaste) 
Gas, bloating 
or a “fishy” 
aftertaste 
Cardiovascular 
mortality 
NR Fatal 
myocardial 
infarct 
Cardiac or cerebrovascular death Cardiac or cerebrovascular 
death 
NR 
Adherence Noncompliance NR Random pill count and number 
of returned capsules 
Fatty acid composition (EPA, 
DHA) of red blood cells 
Participants refusing to take 
study medications 
consistently or returning 
study medications. 
Fatty acid composition (EPA, 
DHA) of endogenous  cells 
Fatty acid 
composition 
(AA, LA, DPA 
EPA, DHA) of 
red blood cells 
Abbreviations: AA – Arachidonic acid, DPA – Docosapentaenoic acid; DHA – Docosahexanoic acid; EPA – Eicosapentaenoic acid; LA – Linoleic acid; NR – not 
reported 
aInitiation of the cannulation assessment period: first haemodialysis session after week 12 visit  
bMinor bleeding episode: one that requires compression of the bleeding vessel for >30 min for it to cease without other intervention. 
cMajor bleeding episode: one that requires either (a) blood transfusion or (b) correction using other blood products such as fresh frozen plasma or (c) admission 
into hospital to manage the bleeding episode or (d) admission into hospital due to complications of the bleeding episode. 
dData only available for graft thrombosis, not for interventions to maintain or restore patency. Data therefore not included in primary efficacy outcome analysis.
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Item S6- 1: The meta-analysis for each outcome, showing effect of fish oil supplementation 
 
 
Figure  a: Effect of fish oil supplementation on primary patency loss of arteriovenous dialysis 
accesses 
 
 
Figure  b: Effect of fish oil supplementation on bleeding  
 
 
Figure  c: Effect of fish oil supplementation on late dialysis suitability failure 
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Figure  d: Effect of fish oil supplementation on the need for interventions to maintain patency 
or assist maturation of arteriovenous dialysis accesses 
 
 
Figure  e: Effect of fish oil supplementation on arteriovenous dialysis access abandonment 
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Figure  f: Effect of fish oil supplementation on gastrointestinal adverse effects 
 
 
Figure  g: Effect of fish oil supplementation on all-cause mortality 
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Figure  h: Effect of fish oil supplementation on cardiovascular mortality 
 
 
Figure  i: Effect of fish oil supplementation on hospitalisation 
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Figure  j: Effect of fish oil supplementation on adherence 
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Appendix B: Supplementary material for Chapter 7 
  
Table S7- 1: Search terms 
Database Search terms 
Database 
EMABSE 
1. hemodialysis/  
2. dialysis membrane/ or dialysis catheter/ or dialysis pump/ 
or home dialysis/  or dialysis/ or dialysis.mp. or extended 
daily dialysis/ or equilibrium dialysis/ or "dialysis 
equipment and supplies"/ or dialysis encephalopathy/ or 
dialysis fluid/  
3. haemodialysis.mp. or hemodialysis/  
4. hemofiltration/ or continuous hemofiltration/ or 
hemofiltration.mp.  
5. hemodiafiltration/ or continuous hemodiafiltration/ or 
hemodiafiltration.mp. 
6. exp mortality/ or exp hemofiltration/ or exp 
hemodialysis/ or exp renal replacement therapy/  
7. 1 or 2 or 3 or 4 or 5 or 6  
8. exp vascular access/  
9. arteriovenous shunt/ or blood vessel shunt/ or shunt 
failure/ or shunt thrombosis/ or shunt infection/ or shunt 
occlusion/  
10. exp blood vessel graft/ or exp arteriovenous fistula/ or 
vascular access/ or exp arteriovenous shunt/  
11. catheter removal/ or catheter thrombosis/ or dialysis 
catheter/ or catheter infection/ or double lumen catheter/ 
or catheter care/ or exp catheter/ or catheter fracture/ or 
catheter leakage/ or catheter complication/ or catheter 
occlusion/ or catheter migration/ or catheter dislocation/ 
or catheter aspiration/ or central venous catheter/  
12. 8 or 9 or 10 or 11  
13. 7 and 12  
14. limit 13 to randomized controlled trial 
15. limit 14 to (adult <18 to 64 years> or aged <65+ years>) 
16. limit 15 to (human and yr="2011 - 2016") 
MEDLINE 
1. Renal Replacement Therapy/  
2. Renal Dialysis/  
3. Hemodiafiltration/  
4. Hemodialysis, home/  
5. exp Hemofiltration/  
6. dialysis.tw.  
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7. (hemodialysis or haemodialysis).tw.  
8. (hemofiltration or haemofiltration).tw.  
9. (hemodiafiltration or haemodiafiltration).tw.  
10. or/1-9  
11. randomized controlled trial.pt.  
12. 10 and 11  
13. limit 12 to yr="2011 -Current"  
14. exp Mortality/  
15. exp Vascular Access Devices/ae, cl, ct, ec, mi, st, sn, td, 
ut [Adverse Effects, Classification, Contraindications, 
Economics, Microbiology, Standards, Statistics & 
Numerical Data, Trends, Utilization]  
16. Fistula/ or exp Arteriovenous Fistula/ 
17. graft.mp.  
18. exp Catheterization, Central Venous/ or exp Catheter-
Related Infections/ 
19. 14 or 15 or 16 or 17 or 18  
20. 13 and 19 
Cochrane Kidney and 
Transplant 
Specialised Register 
1. Hemodialysis 
2. Vascular access 
3. Areteriovenous fistula* 
4. Arteriovenous graft* 
5. Catheter* 
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Figure S7- 1: Categories of outcome measures used to assess function (163 trials assessing 
function) 
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Figures S7-2 to S7-9 present the proportion of trials reporting each outcome measure (bars) 
and the different time points the outcome measure has been reported (dots). 
 
 
Figure S7- 2: Outcome measures (frequency and time points) used to assess maturation (31 
trials, 43 outcomes measures) 
Abbreviations: BFR – blood flow rate; HD – haemodialysis; NKF-KDOQI – National Kidney 
Foundation - Kidney Disease Outcomes Quality Initiative  
Definitions: NKF-KDOQI21 criteria – rule of 6s: A fistula in general must be a minimum of 6 mm 
in diameter, less than 6 mm deep, with a blood flow >  600 mL/min, and should be evaluated for 
non-maturation if, after 6 weeks from surgical creation, it does not meet these criteria., Robbin et 
al.225: minimum venous diameter of 4 mm with blood flow of ≥ 500 ml/min.  
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Figure S7- 3: Outcome measures (frequency and time points) used to assess pain (19 trials, 
28 outcomes measures) 
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Figure S7- 4: Outcome measures (frequency and time points) used to assess bleeding/ 
hematoma (26 trials, 29 outcomes measures) 
Abbreviations: cc - cubic centimetre 
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Figure S7- 5: Outcome measures (frequency and time points) used to assess vessel 
characteristics (19 trials, 26 outcomes measures) 
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Figure S7- 6: Outcome measures (frequency and time points) used to assess cannulation 
problems (13 trials, 19 outcomes measures) 
Abbreviation: G – gauche; VAS – visual analogue scale 
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Figure S7- 7: Outcome measures (frequency and time points) used to assess vascular access 
related hospitalisation (16 trials, 19 outcomes measures) 
Abbreviations: ICU – intensive care unit 
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Figure S7- 8: Outcome measures (frequency and time points) used to assess “steal syndrome” 
(access induced ischaemia; 13 trials, 8 outcomes measures) 
 
 
Figure S7- 9: Outcome measures (frequency and time points) used to assess aneurysms and/or 
pseudoaneurysm (11 trials, 7 outcomes measures) 
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Appendix C: Supplementary material for Chapter 8  
Item S8- 1: SONG-HD Vascular access survey 
[Page 1] Invitation: Introductory text 
 
The Standardised Outcomes in Nephrology - Haemodialysis (SONG-HD) initiative has 
established “vascular access complications” as a core outcome domain to be reported in research 
(clinical trials) in patients needing haemodialysis (the other core outcome domains are listed at 
www.songinitiative.org/about-us/song-hd/). 
 
Vascular access complications have been defined as problems with a fistula, graft, or catheter 
required for haemodialysis e.g. access infections, bleeding, bruising, pain, discomfort, clotting.  
 
This survey will help to identify which vascular access problems are most important to be 
measured in research for patients needing haemodialysis. 
 
This survey aims to find out which vascular access complications are considered most important 
by patients, caregivers, and healthcare professionals. Your participation is voluntary and you may 
exit the survey at any time. Further information can be found on the <Participant Information 
Sheet>.  
 
Please complete these questions on your own. By clicking submit at the end of the surveys you 
are consenting for your data to be used for research purposes. Responses will be anonymous.  
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[Page 2] Demographics: initial screen 
 
I am a:  
o Patient 
o Caregiver 
o Healthcare professional  
 
[Pages 3-4a] Demographics  
Healthcare professional 
*Gender: □ Male □ Female    
*Age group: □ 18-30 □ 31-40 □ 41-50 □ 51-60 □ 61-70 
 □ 71-80 □ 81 and over    
*City: _____________     
*Country: <dropdown box selection> 
*Primary role: □ Nephrologist □ Surgeon □ 
Radiologist 
□ Nurse □ Psychologist 
 □ Physician 
(other than 
nephrologist) 
□ Researcher □ Policy 
maker 
□ Social 
worker 
□ Participant 
from 
Industry/private 
sector 
 □ Nephrologist in training (e.g. 
trainee, resident, fellow) 
□ Other: 
<free text> 
□ 
Dietician 
□ Pharmacist 
*Experience in 
haemodialysis (years): 
□ ≤10 □ 11-20 □ 21-30 □ >30  
*No. of haemodialysis 
trials as investigator: 
□ 0 □ 1-5 □ 6-10 □ 11-15 □ >15 
Indicate if you have a 
role in any of the 
following 
(haemodialysis-related) 
□ Government, 
policy making  
□ Clinical 
practice 
guidelines  
□ Funding 
(e.g.. 
government, 
charity) 
□ Other 
<free text> 
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[Pages 3-4b] Demographics 
Patient or 
caregiver 
  
*Participant: □ Patient □ Caregiver and/or family member 
*Gender: □ Male □ Female    
*City: <text>     
*Country: <dropdown box selection> 
*Age group 
(years): 
□ 18-30 □ 31-40 □ 41-50 □ 51-60 □ 61-70 
 □ 71-80 □ 81 and over    
Marital status: □ Single □ Married □ Living 
with 
partner/de 
facto      
□ Partner 
(not living 
with) 
□ Widowed 
 □ Divorced □ Separated    
Number of 
children: 
□ 0 □ 1-2 □ 3-4 □ 5 or more  
Employment 
status: 
□ Full Time □ Part time/ 
casual 
□ Student            □ Not 
employed 
□ Retired 
 □ Other: <text>     
Education: □ Did not complete primary school 
□ Completed high/secondary school before 10th grade/GCSE, O level or equivalent 
□ Completed high/secondary school up to 10th grade/GCSE, O level or equivalent 
□ Completed high/secondary school (12th grade/A level or equivalent) 
□ Professional certificate, vocational school e.g. Diploma 
□ Undergraduate/Bachelor’s Degree 
□ Postgraduate Degree (Masters/PhD) 
*Current type of 
treatment (patient): 
□ Haemodialysis at an in-centre unit (hospital) 
□ Haemodialysis at a satellite unit (usually separate to the hospital, may be in the 
community) 
□ Haemodialysis at home 
□ Peritoneal dialysis 
□ Kidney transplant from a living donor 
□ Kidney transplant from a deceased donor (waiting list) 
□ Not applicable 
*Current type of 
vascular access for 
haemodialysis: 
□ Arteriovenous 
fistula (“fistula”) 
□ 
Arteriovenous 
graft (“graft”) 
□ Central venous catheter 
(“line”) 
 
 
  
 
*Previous type(s)  
of vascular access 
used for 
haemodialysis: 
□ Arteriovenous 
fistula (“fistula”) 
 
□ 
Arteriovenous 
graft (“graft”) 
□ Central venous catheter 
(“line”) 
 
 
□ Not 
applicable 
 
 
*Have you 
experienced any of 
the following 
vascular access 
complications at 
least once? 
□ Bleeding 
□ Hospitalisation because of vascular access problems 
□ Infection 
□ Needling problems  
□ Pain 
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□ Problems with vascular access function (difficulties or inability to use the access for 
haemodialysis)  
 
List other vascular 
access problems 
you have 
experienced 
<free text> 
*Years on 
haemodialysis 
(years) in total 
(patient): 
□ Not applicable 
□ less than 1 
□ 1-5 
□ 6-10 
□ 11-15 
□ more than 15 
 
 
[Page 5] Survey: part 1 
 
The following questions will ask you how important different vascular access complications are 
to you. This will help to ensure that the most important vascular access problems will be reported 
in research. The vascular access problems listed in the survey were developed from previous 
research (clinical trials) and have also been identified by patients and caregivers. We have also 
provided a definition for each vascular access problem. 
Please rate the following vascular access outcomes from 1(least important) to 9 (most important):  
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[Pages 6-8] Survey: part 1 
 
No. Outcome 
How important is this outcome to report in research involving people needing 
haemodialysis? 
Vascular access includes fistula, graft and central venous catheter (“line”) 
1 Function 
The ability to use the vascular access for 
haemodialysis.  
 
Problems with function are difficulties or the 
inability to use the vascular access for 
haemodialysis because the access is not working 
well. This includes poor blood flow because of 
blood clots or narrowing of vessels, blocked 
lines (catheters), needing extra procedures 
(such as surgery for declotting) to try and get 
the access to work properly, and loss of the 
vascular access with the need for a new 
vascular access.  
 
Comments: 
2 Maturation  
Maturation is the time needed for a new fistula 
or graft to work and be used for haemodialysis.  
 
Problems with maturation include the need for a 
line (catheter) because the fistula or graft is not 
ready for use or the need to have further tests 
(such as ultrasound) and procedures (such as 
surgery) until the graft or fistula can be used for 
haemodialysis. 
 
Comments: 
 
 
3 Bleeding 
Bleeding or bruising where the vascular access 
is located, immediately before, during or after 
dialysis or a procedure (examples include 
bleeding during needling/cannulation or 
ongoing bleeding after dialysis for 
fistulas/grafts, or bleeding after a line 
insertion). 
 
Comments: 
 
 
4 Pain  
Pain (including fear of pain) at or around where 
the vascular access is located (e.g. during 
needling/cannulation or during or after vascular 
access procedures). 
 
Comments: 
 
5 Infection 
Disease/harm caused by organisms such as 
bacteria that entered the body via the vascular 
access. This includes blood infection and 
infection in and around the vascular access. 
 
Comments: 
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6 Reduced blood supply (“steal syndrome”) 
Pain, tingling, paleness or coolness of the hand 
or forearm on the side of the vascular access 
caused by problems with blood supply. This can 
also lead to numbness, weakness in 
finger/hand/forearm, ulcers (dying tissue) or 
dead (black) tissue.  
 
 
Comments: 
 
 
7 Interference with activities  
Problems with or inability to perform activities 
you wish to do because of your vascular access, 
such as bathing, sports, wheeling a wheelchair, 
being in an uncomfortable position during 
dialysis or unable to do something because of an 
appointment/procedure for your vascular 
access.  
 
 
 
 
Comments: 
 
8 Weakening of the vessel wall 
(aneurysm/pseudoaneurysm) 
A balloon-like swelling in the wall of the vessels 
of the fistula or graft. This swelling weakens the 
vessel wall and can burst/rupture. 
 
 
Comments: 
 
 
9 Needling (cannulation) problem  
Problems with placing the dialysis needles into 
the fistula or graft or the need for repeated 
punctures.  
 
 
Comments: 
 
 
10 Swelling (oedema) 
Swelling of the body part where the vascular 
access is located (leg, arm, can also extend to 
neck or face).    
 
 
Comments: 
 
 
11 Hospitalisation 
Need to be in hospital because of vascular 
access problems such as infection, procedures 
or bleeding. 
 
 
 
Comments: 
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12 Appearance  
Changes in appearance because of the 
vascular access (e.g. bulging veins, scars). 
 
 
Comments: 
 
 
   
Please list any other outcomes you think are important. 
How important is this outcome to report in research involving people needing 
haemodialysis? 
Vascular access includes fistula, graft and central venous catheter (“line”) 
* Other (1):   
 
Comments: 
 
 
* Other (2):  
 
 
 
Comments: 
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[Page 9] Survey: part 2 
 
The next part of the survey is called the Best Worst Scale which is used to compare the level of 
importance across the outcomes. Please choose the most important and least important access 
complication on the next screens. We emphasize that all outcomes are important and understand 
that it may be difficult to choose. However, for the purposes of including a vascular access 
outcome in every trial, we may need to try and work out which one to measure so your choice is 
important. 
NB: these outcomes are the same as those in part 1 (including an abbreviated definition).  
 
[Pages 10-14] Please choose the most important and the least important vascular access 
complications from the below list.  
This type of survey) called the Best Worst Scale) is used to compare the level of importance across 
the outcomes. 
NB: these outcomes are the same as those in part 1.  
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Note: only the first block (B1) of randomly selected outcomes is shown here.  
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[Page 15] Other comments: <free text>  
 
[Page 16] Submission 
 
In submitting my response, I am giving my consent to participate in the survey and I state that: 
✓ I understand the purpose of the study, what I will be asked to do, and any risks/benefits 
involved.  
✓ I have read the <Participant Information Statement> and have been able to discuss my 
involvement in the study with the researchers if I wished to do so.  
✓ The researchers have answered any questions that I had about the study and I am happy with 
the answers. 
✓ I understand that being in this study is completely voluntary and I do not have to take part. 
My decision whether to be in the study will not affect my relationship with the researchers or 
anyone else at the University of Sydney now or in the future 
✓ I understand that I can withdraw from the study at any time. 
✓ I understand that my questionnaire responses cannot be withdrawn once they are submitted, 
as they are anonymous and therefore the researchers will not be able to tell which one is mine.  
✓ I understand that personal information about me that is collected over the course of this project 
will be stored securely and will only be used for purposes that I have agreed to. I understand 
that information about me will only be told to others with my permission, except as required 
by law. 
✓ I understand that the results of this study may be published, and that publications will not 
contain my name or any identifiable information about me. 
 
Submit 
 
Thank you for your participation. 
 
 
 
Note: The survey was presented over 16 pages with ≤ 6 outcomes displayed per page and 
expected to take between 5 to 10 minutes to complete. Adaptive questioning was used where 
appropriate to reduce the number of questions (e.g. pages 3-4 a or b). Incomplete responses 
were highlighted and respondents were able to review and change their answers through a 
back-button option prior to submission. The survey could only be completed once per registered 
user (name and email) to avoid duplication. Identifiable survey data were stored on an 
encrypted server by the University of Sydney. 
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Item S8- 2: Collaborating organisations  
We acknowledge the following patient/consumer and professional organisations that assisted with 
recruitment for the SONG-HD Vascular Access Survey 
International 
Cochrane Kidney and Transplant 
Dialysis Outcomes and Practice Patterns Study (DOPPS) 
International Society of Nephrology (ISN) 
Kidney Disease | Improving Global Outcomes (KDIGO) 
PKD International 
The Transplantation Society (TTS) 
World Transplant Games Federation 
Australia and New Zealand 
Australian and New Zealand Society of Nephrology (ANZSN) 
Australian Kidney Trials Network (AKTN) 
Christchurch Kidney Society 
Caring for Australasians with Renal Impairment Kidney Health New Zealand (KHNZ) 
Kidney Health Australia (KHA) 
PKD Foundation of Australia 
Renal Society of Australasia (RSA) 
Transplant Australia  
Canada 
The Kidney Foundation of Canada (KFOC) 
Canadian Society of Nephrology (CSN) 
Canadian Society of Transplantation (CST) 
Malaysia 
Malaysian Society of Nephrology 
Europe 
British Kidney Patient Association 
British Renal Society (BRS) 
European Kidney Patients Federation (EKPF) 
European Kidney Transplant Association (EKITA) 
European Society of Transplantation (ESOT) 
European Renal Best Practice (ERBP) 
UK National Kidney Federation (NKF) 
PKD Charity 
Société Francophone de Transplantation 
The Renal Association 
America 
American Association of Kidney Patients 
Home Dialysis Central 
National Kidney Foundation Southern California 
Sociedad Latinoamericana de Nefrología e Hipertensión. 
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Table S8- 1: Suggested outcomes by participants (n=873) and reasons for exclusion 
Cause of non-inclusion N (%) 
Outcome already included in survey  
- Function 70 (8) 
- Maturation 5 (0.6) 
- Infection 5 (0.6) 
- Cannulation problems 4 (0.5) 
- Aneurysm/pseudoaneurysm 3 (0.3) 
- Bleeding 2 (0.2) 
- Oedema 1 (0.1) 
Outcome described as an intervention  
- Access surveillance 7 (0.8) 
- Cannulation technique 7 (0.8) 
- Education and training (staff) 6 (0.7) 
- Education and training (patients/caregivers) 6 (0.7) 
- Education and training (general) 4 (0.5) 
- Interventions for thrombosis 1 (0.1) 
Outcome too broad (“access outcomes”) 1 (0.1) 
Outcome suggested by ≤ 1% of participants  
- Access choice (AVF, AVG or CVC) 9 (1) 
- Cost 7 (0.8) 
- Process of care 7 (0.8) 
- Cardiovascular complications 6 (0.7) 
- Cannulation skills 6 (0.7) 
- Access planning 5 (0.6) 
- Access location 4 (0.5) 
- Timing of access creation 4 (0.5) 
- Anxiety 3 (0.3) 
- Access-related mortality 2 (0.2) 
- Allergic reaction 2 (0.2) 
- Appearance 2 (0.2) 
- Quality of Life 2 (0.2) 
- Fluid removal 2 (0.2) 
- Adverse drug effects 1 (0.1) 
- Blood pressure 1 (0.1) 
- Fatigue 1 (0.1) 
- Informed consent 1 (0.1) 
- Nutritional status 1 (0.1) 
- Patient support 1 (0.1) 
- Pruritus 1 (0.1) 
- Psychological health 1 (0.1) 
- Mechanical catheter complication 1 (0.1) 
- Dialysis adequacy 1 (0.1) 
Abbreviations: AVF – arteriovenous fistula; AVG – arteriovenous graft; CVC – central venous catheter 
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Figure S8- 1: Absolute importance scores by survey languages 
 
 
 
 
Figure S8- 2: Relative importance scores by survey languages 
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Appendix D: Supplementary material for Chapter 9 
Table S9- 1: SONG-HD vascular access workshop investigators 
Name  
Affiliation 
(Organisation/Institute) 
Country Main role(s) 
Health Professionals  
Adeera Levin 
University of British 
Columbia 
CA Physician/researcher 
Allison Tonga,b University of Sydney AU 
Social 
scientist/researcher 
Andrea Viecellia,b University of Queensland AU Physician/researcher 
Angela  Wangb 
Queen Mary Hospital, 
University of Hong Kong 
HK Physician/researcher 
Angela  Jua,b University of Sydney AU Researcher 
Anna Porterb 
University of Illinois at 
Chicago 
US Physician/researcher 
Benedicte  Sautenenta,b University Francois Rabelais FR Physician/researcher 
Bharathi Reddyb University of Chicago US Physician/researcher 
Braden Mannsa,b University of Calgary CA Physician/researcher 
Brenda Hemmelgarn University of Calgary CA Physician/researcher 
Brigitte Schiller Satellite Healthcare US Physician/researcher 
Camilla Hansona,b University of Sydney AU Psychologist/researcher 
Carmel Hawleya,b University of Queensland AU Physician/researcher 
Charmaine Loka,b University of Toronto CA Physician/researcher 
David Wheeler University College London UK Physician/researcher 
David Harris Westmead Hospital AU Physician/researcher 
David Johnsona,b University of Queensland AU Physician/researcher 
Dori Schatellb Medical Education Institute US 
Psychologist/medical 
educator 
Eduardo Lacson Jrb Tufts University US Physician/researcher 
Elena Bavlovlenkov 
Centers for Medicare & 
Medicaid Services 
US Policy maker/regulator 
Emma O’Lonea,b University of Sydney AU Physician/researcher 
Eric Chemla 
St George’s University NHS 
Foundation Trust 
UK Surgeon/researcher 
Fergus  Caskeyb University of Bristol UK Physician/researcher 
Giovanni Strippolib University of Bari IT Physician/researcher 
Harold Feldmanb University of Pennsylvania US Physician/researcher 
Ibironke Apatab 
US Centers for Disease 
Control  
US Physician/researcher 
Jan Tordoir Maastricht University NL Physician/researcher 
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Name  
Affiliation 
(Organisation/Institute) 
Country Main role(s) 
Jennifer Flythe University of North Carolina US Physician/researcher 
John Gill 
University of British 
Columbia 
CA Physician/researcher 
John Kusekb National Institutes of Health US Researcher 
Jonathan Craig University of Sydney AU Physician/researcher 
Kevan 
Polkinghornea
,b 
Monash University AU Physician/researcher 
Kevin Abbottb National Institutes of Health US Researcher 
Lai-Seong Hooia,b Hospital Sultanah Aminah MY Physician/researcher 
Laura Demberb University of Pennsylvania US Physician/researcher 
Li Zuoa,b 
Peking University People’s 
Hospital 
CN Physician/researcher 
Lilia Cervantesb University of Colorado US Physician/researcher 
Louise Moistb 
London Health Science 
Centre 
CA Physician/researcher 
Lynn Pooleb  US Nurse 
Marcello Tonellib University of Calgary CA Physician/researcher 
Martin Howell University of Sydney AU Health economist 
Maurizio  Gallienib University of Milano IT Physician/researcher 
Meghan Elliotb University of Toronto CA Physician/researcher 
Michael Klusmeyerb Satellite Healthcare US Nurse 
Michelle Josephsonb University of Chicago US Physician/researcher 
Michelle Robbinb University of Alabama US Radiologist 
Miguel Riella 
Pontificia Universidade 
Católica do Paraná 
BR Physician/researcher 
Nicole Evangelidis The University of Sydney AU 
Social 
scientist/Researcher 
Peter Tugwell University of Ottawa CA Physician/researcher 
Peter Kerrb Monash University AU Physician/researcher 
Pietro Ravani University of Calgary CA Physician/researcher 
Prabir 
Roy-
Chaudhuryb 
University of Arizona US Physician/researcher 
Rajnish Mehrotra University of Washington US Physician/researcher 
Raymond Vanholdera,b Ghent University BE  Physician/researcher 
Robert Quinna,b University of Calgary CA Physician/researcher 
Roberto Pecoits-Filho 
Pontificia Universidade 
Catolica do Paraná 
BR Physician/researcher 
Sally Crowe Crowe Associates Ltd UK Researcher 
Sharrilyn Evered 
Centers for Medicare & 
Medicaid Services 
US Policy maker/regulator 
 278 
Name  
Affiliation 
(Organisation/Institute) 
Country Main role(s) 
Stephan Segerer University of Zurich CH Physician/researcher 
Stephen Fademb Baylor College of Medicine US Physician/researcher 
Stephen McDonaldb University of Adelaide AU Physician/researcher 
Stuart Sprague Northshore University US Physician/researcher 
Suetonia Palmerb University of Otago NZ Physician/researcher 
Tammy Pomab University of Chicago US Nurse 
Timmy Leea,b 
Veterans Affairs Medical 
Center, Birmingham 
US Physician/researcher 
Tushar 
Vachharajania
,b 
W.G. (Bill) Hefner Veterans 
Affairs Medical Center, 
Salisbury 
US Physician/researcher 
Vanja Sikiricab GlaxoSmithKline US 
Pharmacologist/research
er 
Vivek Jhab 
The George Institute for 
Global Health 
IN Physician/researcher 
Wim van Biesen University of Ghent BE Physician/researcher 
Wolfgang Winkelmayer Baylor College of Medicine US Physician/researcher 
Patients   
Alison Mayersb Chicago US Patient 
Barry Bellb Chicago US Patient 
Jane Carterb Chicago US Patient 
Kimberly Hardyb Chicago US Patient 
Mary Ennisb Chicago US Patient 
Metarose Johnsonb Chicago US Patient 
Noah Rouse Jrb Chicago US Patient 
Sarita Wrightb Chicago US Patient 
Tess Harrisb London UK Patient/researcher 
Uthman Muhammadb Chicago US Patient 
Vanessa McNortonb Chicago US Patient 
Caregivers   
David Mayersb Chicago US Caregiver 
David Ennisb Chicago US Caregiver 
Note: Those who were unable to attend in person provided feedback on the pre-workshop material and preliminary 
workshop report. One attendee did not give permission to be named, so is not listed. 
Abbreviation: AU, Australia; BR, Brazil; CA, Canada; CH, Switzerland; CN, China; BE, Belgium; FR, France; HK, 
Hong Kong; IN, India; IT, Italy; MY, Malaysia; UK, United Kingdom; US, United States; NZ, New Zealand; NL, 
The Netherlands;  
aFacilitator or co-facilitator 
bAttended the workshop 
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Supplementary Item S9- 1:Facilitator question guide for break out discussion 
 Opening and introduction: 5 minutes 
- For the next 40 minutes, we would like to hear your feedback on the results of the vascular 
access survey, to talk about how to choose ways to measure these outcomes, and how to 
make sure they are measured and reported in trials. 
- We’ll quickly go around the group and in 30 seconds, please say your name and in one 
sentence, your interest in vascular access outcomes – who would like to go first? (then go 
around)  
- Identify a spokesperson to provide a 2 minute summary 
• Feedback on results: 15 minutes 
- What are your initial thoughts and reflections on results of the survey? [Appendix A 
(Preliminary survey results) - program]   
- Are there any outcomes that you would like to discuss or clarify? 
- Vascular access function and infection were the two top prioritised outcomes. What do 
you think about this? 
- Do you agree that vascular access function should be measured and reported across all 
hemodialysis trials?  
• How to choose a core outcome measure? 15 minutes 
- Function has so far been the top prioritised/most important vascular access outcome. We 
would now like to discuss how to measure access function and what criteria to consider 
when choosing an outcome measure. If time allows we would also like to discuss outcome 
measures for infection, given that this was rated as the 2nd most important outcome.   
- How do you currently measure vascular access function (and infection if time permits) in 
clinical practice or research - why? 
- How do you think function (and infection if time permits) should be measured – why? 
- Let’s look at Appendix C (Examples of vascular access outcome measures). What do you 
think of these examples of outcome measures for function and infection? (see Appendix 
C - program) 
- Do you have other suggestions how to measure the top outcomes (function/infection) – 
why?  
- What considerations or criteria do you think are important for choosing a core outcome 
measure - why? (optional – use Appendix B (measurement properties and feasibility 
aspects) - program as prompts) 
• Implementation: 5 minutes 
- What are the strategies, opportunities and barriers to implementing core outcome measures 
across all trials in haemodialysis? (Examples: regulatory agencies such as the FDA, 
funding organisations such as NIH, guidelines, journals via the ICMJE, professional 
organisations.  
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Supplementary Item S9- 2: Break-out groups that contributed to the respective themes  
Theme Break-out group ID 
Capturing the broad relevance of function 
Applicable to all access types 1, 2, 3, 5  
Multidisciplinary involvement 4, 5 
Contributing to quality of life 1, 3, 4, 5 
Capturing important multidimensional aspects 1, 2, 4 
Preventing subsequent consequences 1, 4, 5 
Emphasizing experiential relevance and severity  
Variability in experiences 1, 2, 3, 4 
Fear driven prioritization 2, 3 
Demonstrating feasibility for implementation  
Simple requiring minimal resources 1, 2, 3, 4 
Pragmatic definition 1, 2, 3, 4, 5 
Practical across settings internationally 1, 2, 4, 5 
Flexibility for different trial settings 4 
Ensuring robustness and validity  
Responsiveness to changes over time 5 
Reliability of the outcome measure 3, 4, 5 
Integrating patients values and preferences  
Meaningful and important to patients 2, 3, 4, 5 
Informed by shared decision-making 1, 4, 5 
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Appendix E:  Study Protocol for “Vascular Access outcome measure for function: a 
vaLidation study In haemoDialysis (VALID)” 
Principal Investigator: Andrea K Viecelli1,2        
Co-Investigator/s: Carmel M Hawley1,2, Veronica Oliver2, David W Johnson1,2, Allison Tong3,4, 
Armando Teixeira-Pinto3,4, Emma O’Lone3,4, Angela Ju3,4, Benedicte Sautenet3,4,5,6,7, Jonathan C 
Craig3,4 , Pascal Kopperschmidt8, Rob Smith9, Lai-Seong Hooi10, Wen-J. Liu10, Jan Tordoir11, 
Timmy Lee12, Charmaine E Lok13,14, Kevan R Polkinghorne15,16,17, Robert R Quinn18, Tushar 
Vachharajani19, Raymond Vanholder20,21, Theodore Yuo22, Li Zuo23, Krishan Madhan24, Martin 
Wilkie25 
1Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia 
2Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia 
3Sydney School of Public Health, University of Sydney, Sydney, Australia 
4Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney, Australia 
5University Francois Rabelais, Tours, France 
6Department of Nephrology and Clinical Immunology, Tours Hospital, Tours, France 
7INSERM, U1246, Tours, France 
8Patient partner, Fresenius Medical Care, Global Research & Development, Schweinfurt, Germany  
9Patient partner, Nightcliff Renal Unit, Darwin, Australia 
10Department of Medicine and Haemodialysis Unit, Hospital Sultanah Aminah, Johor Bahru, Malaysia 
11Department of Surgery, University Hospital Maastricht, Maastricht, Netherlands 
12Department of Medicine and Division of Nephrology, Veterans Affairs Medical Center, Birmingham, Alabama 
13Division of Nephrology, University Health Network, Toronto, Ontario, Canada 
14Department of Medicine, University of Toronto, Toronto, Ontario, Canada 
15Department of Nephrology, Monash Medical Centre, Melbourne, Australia 
16Department of Medicine, Monash University, Melbourne, Australia  
17School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 
18Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada 
19Division of Nephrology, W.G. (Bill) Hefner Veterans Affairs Medical Center, Salisbury, North Carolina 
20Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium 
21Department of Nephrology, Ghent University Hospital, Ghent, Belgium 
22 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania  
23Peking University People’s Hospital, Beijing, China 
24Hervey Bay Hospital, Pialba, Queensland, Australia. 
25Department of Nephrology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom 
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Funding  
Secured funding to date includes a Jacquot Research Establishment Grant (total AUD$90,000, 
50% towards the VALID study) and a Princess Alexandra Research Foundation 2019 Research 
Award (total AUD$100,000, 50% towards the VALID study) to fund salaries of research 
assistants, statistician, and data manager. No member of the research team will receive a personal 
financial benefit from his/her involvement in this research project (other than their ordinary 
wages). 
Ethics  
Institutional Review Board/ethics exemption or submission as a low risk application with waiver 
of consent or opt out consent is preferred but not necessarily guaranteed and will depend on 
jurisdiction of practice. All data required for this study are expected to be collected as part of 
routine clinical practice and will be de-identified. Direct patient involvement is not required and 
there is no intervention or change in care for participants as a result of this validation study. 
Individual consent could introduce a selection bias and impact on the representativeness of 
participating dialysis centers. 
Background 
Vascular access outcomes in haemodialysis (HD) are critically important for patients and health 
professionals but trial-based evidence to improve vascular access-related outcomes is limited by 
the inconsistent and selective reporting of outcomes. Standardised Outcomes in Nephrology 
(SONG) is a global initiative that was formed to identify core outcomes across the spectrum of 
chronic kidney disease that are critically important to patients and health professionals, with the 
expectation that these outcomes would be reported consistently across trials. Through an 
international multi-phase consensus process involving nearly 1,400 patients, caregivers and health 
professionals worldwide, vascular access was identified as one of the most critically important 
outcome domains in HD along with fatigue, cardiovascular disease and mortality11.  
A systematic review of vascular access outcomes reported in trials in HD has identified vascular 
access function to be the most frequently reported outcome178. However, this outcome was 
measured in 489 different ways and most frequently reported as “mean access blood flow” and 
“number of thromboses”. Despite efforts to standardise outcome definitions for vascular access 
by various working groups13,124,125,127, only a minority of HD trials reported these standardised 
definitions. For example, of the 134 patency measures reported across 64 trials, only 13% were 
consistent with 1 or more of the standardised definitions as proposed by national and international 
consortiums and societies178. These findings underpin the need for broader implementation of 
standardised, patient-important outcome measures to enhance the consistency and relevance of 
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outcome reporting in clinical trials. Based on feedback from an international survey and consensus 
workshop involving over 1000 stakeholders including patients, caregivers, clinicians, researchers, 
policy makers and industry from 60 different countries, “vascular access function,” was deemed 
the most critically important outcome based on 1. the broad applicability of function regardless of 
the vascular access type, 2. the involvement of a multidisciplinary team in achieving a functioning 
vascular access, and 3. the impact of vascular access function on quality of life, survival, and other 
vascular access-related outcomes177. The need for interventions to enable and maintain the 
use of a vascular access for HD was considered a simple, pragmatic, and inexpensive measure 
of vascular access function that was meaningful and relevant to patients177. Stakeholders 
considered the frequency (rate) of vascular access interventions and the intervention-free time to 
be key descriptors of a functioning vascular access. For this outcome measure to be reported across 
all HD trials, it should be feasible to collect it reliably across different clinical settings without 
requiring additional resources or expertise in vascular access177.  
Aims of the vascular access validation study  
• To assess the feasibility of measuring vascular access function in different HD settings 
internationally. 
• To compare the feasibility of assessing the metric time to first intervention versus intervention 
rates.  
• To assess the reliability of data collection of vascular access interventions (number, types and 
dates) by clinical staff (e.g. dialysis nurses, technicians). 
Definitions of vascular access function 
• Rate of intervention(s) to enable and maintain the use of a vascular access for HD (alternative 
metric: time to first intervention) 
Study design and participants 
• Inclusion criteria: Adult incident and prevalent patients on chronic HD. 
o Target sample size = 612 patients. Sample size of patients is based on an assumed 
event rate of 2 vascular access interventions / patient-year to achieve 520 events 
within 6 months of follow-up and allowing for 15% drop out. 
o Aiming to include all patients within each dialysis unit to avoid selection bias. 
o Aiming to include sites of different size and practice patterns (i.e. in-centre, satellite, 
home dialysis) 
• Sites: 10 sites across 6 countries: 
o Australia:  
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▪ Princess Alexandra Hospital, Brisbane, Queensland (in centre and home 
dialysis unit) ~ 90 patients 
▪ Hervey Bay Hospital (regional centre in Queensland) – ~60 patients  
o Malaysia  
▪ Haemodialysis Unit, Hospital Sultanah Aminah Johor Bahru ~ 90 patients 
o China – 
▪ Peking University People’s Hospital, Beijing, one additional site TBC ~ 
200 patients 
o Canada  
▪ Toronto General Hospital and one additional site TBC ~ 100-200 patients 
o Europe  
▪ Sheffield Teaching Hospitals, UK, ~ 30 home dialysis patients 
▪ Maastricht University Medical Centre, Netherlands ~ 130 patients 
o United States of America 
▪ University of Pittsburgh Medical Centre ~ 13 patients.  
Data collection 
• Mode: Web-based system (REDcap)  
• Study duration: 6 months with an interim assessment of data entry at 3 months (aiming to 
commence between January and March 2019) 
• Data collectors (assessors): Independent assessment by 
o Assessor 1: Data collection and collector as per local clinical practice (likely to be a 
dialysis nurse).   
o Assessor 2: Clinical Research Assistant (CRA) (alternatively vascular access 
coordinator or doctor) collecting procedure notes (i.e. gold standard) and indication 
of procedures as well as baseline characteristics. 
• Adjudication committee: Members of the SONG-HD Vascular Access Working Group1 and 
VALID study Investigators. 
• Baseline characteristics:  
o Patient characteristics: 
▪ Sex  
▪ Age 
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▪ Setting (in centre, satellite, home HD, in centre nocturnal HD, home 
nocturnal HD)  
▪ Comorbidities (diabetes mellitus, cardiovascular diseases [ischaemic heart 
disease, cerebrovascular accidents, peripheral vascular disease], BMI). 
▪ Dialysis duration (vintage)  
▪ Usual number of dialysis sessions per week 
▪ Usual number of hours of dialysis per week  
▪ Vascular access in use (one or more of: arteriovenous fistula [AVF] fistula, 
arteriovenous graft [AVG], central venous catheter [CVC]) 
▪ Location of AVF/AVG in use (upper arm, lower arm or leg) 
▪ Self-cannulation (AVF/AVG) 
▪ Rope ladder versus button hole (AVF) 
o Assessor 1 
▪ Years of experience in HD 
▪ Research experience (i.e. involvement in clinical trials 0, 1-5, 5-10, >10 
years) 
o Assessor 2 
▪ Research experience (i.e. involvement in clinical trials 0, 1-5, 5-10, >10 
years) 
▪ Years of experience in HD research 
• Outcome: Vascular access interventions to enable or maintain the use of the vascular access 
for HD during the study period. 
o Vascular access Interventions to be collected: 
AVF/AVG 
▪ Open surgical or endovascular creation/placement of AVF/AVG 
▪ Open surgical revision or endovascular intervention of AVG/AVF 
• Thrombolysis or thrombectomy of AVG/AVF  
• Ligation or resection of AV access 
• Repair of aneurysm/pseudoaneurysm 
• Competing/collateral vein ligation 
• Fistulogram (Angiogram) +/- angioplasty +/- stenting (including 
inflow artery, body of AVF/AVG, venous outflow, central vein) 
• Competing/collateral vein embolization 
• Superficialisation/transposition 
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▪ Management of Dialysis Associated Steal Syndrome (DASS)/Access 
Induced Ischaemia. Procedures include: 
• Distal Revascularization, Interval Ligation (DRIL) 
• Proximalisation of the Arterial Inflow (PAI) 
• Revision Using Distal Inflow (RUDI) 
• Banding 
CVC  
▪ CVC insertion  
▪ CVC exchange  
▪ Fibrin sheath removal/disruption 
▪ CVC removal 
o Vascular access interventions NOT to include: 
▪ Repositioning of patient 
▪ Reversing of CVC lines 
▪ Flushes of CVC lines 
▪ Repositioning of dialysis needles in AVG or AVF 
▪ Thrombolytics for CVC lines 
▪ Use of antibiotics for vascular access-related infections 
o Indication for interventions (Appendix E.1). 
Feasibility assessment 
• The feasibility of collecting vascular access interventions as a measure of vascular access 
function will be assessed by 
o A feasibility questionnaire using a 5-point Likert Scale (Appendix E.2) to address 
relevant feasibility aspects as outlined by Prinsen et al214. 
o Face-to-face or video-call semi-structured interviews performed with all assessor 1 and 
2 or until data saturation across all topics is reached (Appendix E.3). All interviews 
conducted in English will be performed by PI AV. If required, interviews will be 
conducted in the assessor’s native language by a bilingual member of the SONG 
vascular access working group1.  The interview serves to further explore assessors’ 
perspectives on the feasibility of measuring vascular access function. The interviews 
will be audio-recorded and transcribed verbatim. 
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Table S10- 1: Data collection timeline  
 Assessor 1 Assessor 2 
Time point of data collection (months) 0 3 6 0 3 6 
Assessor characteristics √   √   
Patient characteristics    √   
Number of vascular access intervention(s)   √ √  √ √ 
Type of vascular access intervention(s)   √ √  √ √ 
Date of vascular access intervention(s)  √ √  √ √ 
Extraction of procedure notes     √ √ 
Indication for vascular access intervention     √ √ 
Time required to collect/enter vascular access 
intervention data 
 √ √  √ √ 
Feasibility questionnaire   √   √ 
Semi-structured interview   √   √ 
Data analysis 
• Assessment of the reliability of data collection: 
o Reliability of vascular access intervention data collection will be assessed 
independently by two members of the adjudication committee (and a third member to 
resolve disagreement) by examining the agreement between Assessor 1 and 2 for 
number of interventions/patient, dates of interventions (allowing for imprecision of ± 
3 days) and type of interventions with a margin of equivalence extending from -10% 
to 10%. The actual difference between the proportions of correctly identified data is 
assumed to be ±5%, with assessors 2 having an expected accuracy of 95%. The intra-
centre correlation is assumed to be 0.010, and the significance level is set at 0.05. Any 
discrepancy between assessor 1 and 2 will be investigated by the adjudication 
committee by verification of the procedure notes. In addition, the adjudication 
committee will check correctness of data entered by assessor 1 and 2 for 10% of 
randomly selected participants.  
o A sample size of 520 records (=vascular access interventions) (obtained by 
sampling 52 records at each of the 10 participant centres) will achieve 80% power to 
detect equivalence between the proportion of correctly identified intervention dates 
between assessors 1 and 2 as outlined above.   
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• Assessment of feasibility of data collection:  
o Quantitative data analysis of feasibility questionnaire scores (Appendix E.2).  
o Semi-structured interviews (Appendix E.3). Thematic analysis of the transcripts will 
be performed to identify, code, group and compare concepts to develop themes that 
describe the perspectives of the data collectors on the feasibility of measuring vascular 
access function in research in HD.  
Table S10- 2: Study timeline  
 Year 1 (2019) Year 2 (2020) Year 3 (2021) 
 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
Ethics approval 
completed by 
individual sites 
√ √           
Submission of study 
protocol for publication 
 √           
Patient enrolment √ √ √ √         
6 months follow-up 
completed 
  √ √ √ √       
Finalization of outcome 
adjudication 
    √ √ √      
Semi-structured 
interviews 
    √ √ √      
Data lock        √     
Data analysis        √ √    
SONG WG meetings √  √  √  √  √    
Manuscript preparation         √ √   
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Appendix E.1: Indication for intervention (to be collected by Assessor 2 only) 
Clinical exam and patient indicators 
Arm swelling 
Chest/breast swelling 
Difficult/painful cannulation 
Prolonged bleeding after decannulation 
Poor maturation of AVF/AVG 
Decreased intra-access flow 
High intra-access flow 
High output congestive heart failure 
Steal syndrome/ischemia 
Aneurysm/pseudoaneurysm 
Access-related infection (local or bloodstream) 
Withdrawal of HD/transfer to PD/transplantation 
Patient preference 
 
Dialysis indicators 
Increased venous pressure 
Worsening negative arterial pressure  
Inadequate clearance (in the absence of other causes (non-vascular access)) 
Increased recirculation 
 
Radiologic indicators 
Central venous stenosis/thrombosis 
Atrial thrombosis 
Vascular access thrombosis 
 
Mechanical indicators 
Removal of CVC 
Replacement of CVC 
Extruded CVC cuff/CVC pulled/fell out 
Cracked hub 
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Appendix E.2: Feasibility assessment questionnaire (adapted from Prinsen et al. Trials, 
2016;17:449) 
Feasibility criteria Response Comments 
I was able to understand the outcome 
measure. 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED 
 
The measure was quick to report.  Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED 
 
It was easy to collect the number of 
vascular access interventions. 
 
 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED 
 
It was easy to collect the type of 
vascular access intervention(s). 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED  
 
It was easy to collect the date of the 
vascular access intervention(s). 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED  
 
I would have measured and reported 
the outcome as part of usual clinical 
care. 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
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Feasibility criteria Response Comments 
 Strongly disagree 
 NOT COMPLETED 
It was easy to apply the outcome to 
different patients (i.e. easy to 
standardise). 
 Strongly agree  
 Agree 
 Neither agree or disagree 
 Disagree 
 Strongly disagree 
 NOT COMPLETED 
 
Collection and data entry of vascular 
access intervention type and date 
should be performed 
 Prospectively (real-time, i.e. at 
the time the intervention 
occurs) 
 Every ___ weeks 
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Appendix E.3: Semi-structured interview guide to describe the assessors’ perspectives on the 
feasibility of measuring vascular access function (adapted from Prinsen et al. Trials, 2016;17:449). 
 
Questions: 
1. How did you go with collecting and entering the data for this study? 
2. What were the most challenging aspects of collecting and entering the data? Would you have 
any suggestions on how to change/improve this? 
3. Did you involve the patients in gathering the data? If so, what information were they providing 
(i.e. whether, when, and what type of vascular access interventions they have had) and did you 
cross-check the accuracy of this information? 
4. In your unit, do you routinely collect this data? If so, are there any differences in the way you 
collected the data for this study (prompts: date of the intervention, type of intervention, 
indication for intervention)? 
5. Why did this data collection require/not require extra time? Would you have any suggestions 
on how to make the data collection more efficient/faster? 
6. Was there any cost involved to collect the data? If so, what for? 
7. Do you think the “rate of intervention required to maintain the use of a vascular access for 
HD” is a meaningful way to assess vascular access function? Per example, patient A required 
3 interventions within a year to keep the access working compared to patient B who did not 
require any interventions. Why or why not? Would you have alternative suggestions?  
8. Do you think measuring vascular access function as “time to the first intervention to maintain 
the use of a vascular access for HD” would be more meaningful than measuring the rate of 
interventions? Why or why not? 
9. Would you be prepared/willing to continue collecting these data for research (e.g. clinical 
trials) conducted in patients on HD in your unit – why/why not? 
10. Would you be prepared/willing to continue collecting these data as part of your routine clinical 
practice (i.e. not just for research purposes) – why/why not?  
 
 
 
